Note: This page contains sample records for the topic concurrent systemic chemotherapy from Science.gov.
While these samples are representative of the content of Science.gov,
they are not comprehensive nor are they the most current set.
We encourage you to perform a real-time search of Science.gov
to obtain the most current and comprehensive results.
Last update: November 12, 2013.
1

Arterial interventional chemotherapy and IMRT with concurrent chemotherapy for nasopharyngeal carcinoma with intracranial involvement  

PubMed Central

The aim of this study was to ensure a high dose of intensity modulated radiation therapy (IMRT) was delivered to tumor tissue with a low dose to normal organs. Seldinger interventional techniques were used to inject chemotherapy drugs for nasopharyngeal carcinoma (NPC). IMRT was conducted 3 weeks after intervention. Primary tumor volume was reduced by 42.76% after 2 doses of interventional chemotherapy and intracranial tumor volume was reduced by 55.63%. All patients presented grade II and above nasopharyngeal mucositis. In the 2 years following radiotherapy, overall survival (OS) was 83.3% and progression-free survival (PFS) was 75%. In conclusion, T4 NPC patients with intracranial extension received induction chemotherapy followed by IMRT and concurrent chemotherapy, which proved to be efficacious and well tolerated.

FEN, XINGLAI; QIN, WEIFENG; BAO, WUAN; JIANG, FENG; LI, BIN; HU, FUJUN; CHEN, XIAOZHONG

2013-01-01

2

Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Locoregionally Advanced Laryngeal and Hypopharyngeal Cancers  

Microsoft Academic Search

Purpose: To perform a retrospective review of laryngeal\\/hypopharyngeal carcinomas treated with concurrent chemotherapy and intensity-modulated radiotherapy (IMRT). Methods and Materials: Between January 2002 and June 2005, 20 laryngeal and 11 hypopharyngeal carcinoma patients underwent IMRT with concurrent platinum-based chemotherapy; most patients had Stage IV disease. The prescription of the planning target volume for gross, high-risk, and low-risk subclinical disease was

Nancy Y. Lee; William O’Meara; Kelvin Chan; Cesar Della-Bianca; James G. Mechalakos; Joanne Zhung; Suzanne L. Wolden; Ashwatha Narayana; Dennis Kraus; Jatin P. Shah; David G. Pfister

2007-01-01

3

Concurrent systems for knowledge processing  

Microsoft Academic Search

Actors have catalyzed the development of a new programming methodology and architecture for ultra-concurrent systems. This sourcebook on the development and impact of the actor paradigm brings together more than 20 milestone contributions on the actor concept and its application to knowledge processing. Each contribution is placed in its historical context and explained. This book is divided into four major

C. Hewitt; G. Agha

1989-01-01

4

Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma  

Microsoft Academic Search

Purpose: This study was performed to evaluate the outcome of patients with gallbladder cancer who received postoperative concurrent chemotherapy and radiation therapy.Methods and Materials: Curative resection followed by adjuvant combined modality therapy with external beam radiation therapy (EBRT) and chemotherapy was attempted in 21 consecutive gallbladder carcinoma (GBC) patients at the Mayo Clinic from 1985 through 1997. All patients received

John J Kresl; Steven E Schild; George T Henning; Leonard L Gunderson; John Donohue; Henry Pitot; Michael G Haddock; David Nagorney

2002-01-01

5

Reirradiation of recurrent breast cancer with and without concurrent chemotherapy  

PubMed Central

Background Treatment options for loco-regional recurrent breast cancer after previous irradiation are limited. The efficacy of chemotherapy might be hampered because of impaired tissue perfusion in preirradiated tissue. Thus, mastectomy or local excision and reconstructive surgery are the preferred treatments. However, in recent years evidence accumulates that a second breast conserving approach with reirradiation as part of the treatment might be feasible and safe and, furthermore, reirradiation might be an option for palliation. Here we report on the experience of a single community centre in reirradiation of recurrent breast cancer. Methods The report is based on 29 patients treated with reirradiation. All data were prospectively collected. The median age was 63 years (range 35 to 82 yrs). The interval between initial diagnosis and diagnosis before start of reirradiation was 11.6 months to 295.5 months. The mean total dose (initial dose and reirradiation dose) was 106.2 Gy (range 80.4 to 126 Gy) and the mean BED3 Gy 168,5 Gy (range 130,6 to 201,6). The mean interval between initial radiotherapy and reirradiation was 92.9 months (range 8.7 to 290.1). Inoperable or incompletely resected patients were offered concurrent chemotherapy with either 5-FU or capecitabine. All patients received 3D-conformal radiotherapy with 1.6 to 2.5 Gy/fraction five times weekly. The treatment volume comprised all visible lesions or lesions detectable on CT/MRI/FDG-PET/CT or the tumour bed or recurrent tumour. Results The local progression-free survival of all patients at one and two years was 81% and 63%. Patients who had no surgery of the recurrence (16/29) had local progression-free survival at one and two years of 72% and 25% with a median progression-free survival time of 17 months. Partial remission and good symptom relief was achieved in 56% (9/16) or complete response of symptoms and/or tumour in 44% (7/16). Patients who had no distant metastases and had at least an R1-resection had a local progression-free survival of 90% after 2 years. The disease-free survival after 2 years was 43% and the median disease-free survival time was 24 months. In four patients a second breast conserving operation was performed and the cosmetic results in all four patients are good to excellent. Acute side effects were mild to moderate with no grade 3 or 4 toxicity. Accordingly, no grade 3 or 4 late effects were observed so far. No grade 3 or 4 plexopathy was observed. Conclusion In this heterogeneous group of patients reirradiation of locoregional recurrences of breast cancer showed low to moderate acute toxicity. In our experience, local control rates are high and palliation is good.

Wurschmidt, Florian; Dahle, Jorg; Petersen, Cordula; Wenzel, Claudia; Kretschmer, Matthias; Bastian, Christoph

2008-01-01

6

EDITORIALS Radiotherapy and Concurrent Chemotherapy: a Strategy That Improves Locoregional Control and Survival in Oropharyngeal Cancer  

Microsoft Academic Search

In this issue of the Journal, Calais et al. (1), representing the French Groupe d'Oncologie Radiotherapie Tete et Cou (GORTEC), report a multicenter randomized comparison of ra- diotherapy and concurrent chemotherapy versus radiotherapy alone in patients with oropharyngeal cancer. Their results add to a growing list of trials that demonstrate superior survival and locoregional control with this combined-modality approach. A

Arlene A. Forastiere; Andy Trotti

2010-01-01

7

Concurrency control algorithms for multiversion database systems  

Microsoft Academic Search

Concurrency control is the activity of synchronizing operations issued by concurrently executing programs on a shared database. The goal is to produce an execution that has the same effect as a serial (noninterleaved) one. In a multiversion database system, each write on a data item produces a new copy (or version) of that data item. This paper presents a theory

Philip A. Bernstein; Nathan Goodman

1982-01-01

8

Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer  

Microsoft Academic Search

BACKGROUND: Despite broad advances in multimodal treatment of locally advanced breast cancer (LABC), 30 to 40% of patients develop loco-regional relapse. The aim of this study was to analyze in a retrospective manner the effectiveness of concurrent chemo-radiotherapy (CCRTh) after neoadjuvant chemotherapy (NCT) in patients with LABC. METHODS: One hundred twelve patients with LABC (stage IIB-IIIB) were treated with NCT

Alberto Alvarado-Miranda; Oscar Arrieta; Carlos Gamboa-Vignolle; David Saavedra-Perez; Rafael Morales-Barrera; Enrique Bargallo-Rocha; Juan Zinser-Sierra; Victor Perez-Sanchez; Teresa Ramirez-Ugalde; Fernando Lara-Medina

2009-01-01

9

Concurrent chemoradiation followed by adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea  

Microsoft Academic Search

Purpose  Concomitant approach using cisplatin and 5-fluorouracil (5-FU) has shown an excellent local control rate and significantly\\u000a reduced distant metastasis in patients with locally advanced nasopharyngeal carcinoma (NPC). However, optimal schedule and\\u000a dosing of chemotherapy still need to be developed to reduce distant metastasis. This retrospective study was conducted to\\u000a evaluate the efficacy, toxicity, and tolerability of a concurrent chemoradiation therapy

Kyong Hwa Park; Jeong Sun Kim; Yong Park; Hee Yeon Seo; Young Je Park; In Keun Choi; Sang Chul Oh; Jae Hong Seo; Chul Yong Kim; Kwang Yoon Jung; Sang Won Shin; Yeul Hong Kim; Jun Suk Kim; Nam Joon Lee

2010-01-01

10

Chemotherapy  

MedlinePLUS

... cancer Next Topic Targeted therapy for thyroid cancer Chemotherapy for thyroid cancer Chemotherapy (chemo) uses anti-cancer drugs that are injected ... vein or muscle, or are taken by mouth. Chemotherapy is systemic therapy, which means that the drug ...

11

Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion  

SciTech Connect

The combined effects of continuous low dose rate irradiation (CLDRI) and concurrent infusion of bleomycin, cyclophosphamide, cis-platinum, 5-fluorouracil, actinomycin D, and mitomycin C were studied in the SCC VII/SF tumor, a squamous cell carcinoma and the jejunal crypt cells in the mouse. For the SCC VII/SF tumor, enhanced cell killing was seen with each of the six drugs when infused concurrently with CLDRI; the greatest enhancement was seen with mitomycin C and cis-platinum. For the jejunal crypt cells, enhanced cell killing was seen primarily with bleomycin. The authors results suggest a therapeutic gain with concurrent CLDRI and chemotherapy infusion for five of the six chemotherapeutic drugs studied with the exception of bleomycin.

Fu, K.K.; Rayner, P.A.; Lam, K.N.

1984-08-01

12

Systematic Review: Generating Evidence-Based Guidelines on the Concurrent Use of Dietary Antioxidants and Chemotherapy or Radiotherapy  

PubMed Central

The risk–benefit ratio for concurrent use of dietary antioxidants with chemotherapy or radiation therapy is a controversial topic. In this review, the medical literature on concurrent antioxidant use with chemotherapy or radiotherapy was assessed and further steps for generating evidence-based guidelines are suggested. The clinical cancer research community should cooperate and focus new studies on the use of a specific combination of antioxidant and chemotherapy or radiotherapy, and determine optimal doses for a specific cancer setting. Mechanistic studies on the interaction between antioxidants and conventional cancer therapy could lead to novel biomarkers for assessing dose adequacy.

Nakayama, Akiko; Alladin, Karen P.; Igbokwe, Obianuju; White, Jeffrey D.

2013-01-01

13

Intensity-Modulated Radiotherapy With Concurrent Chemotherapy for Previously Irradiated, Recurrent Head and Neck Cancer  

SciTech Connect

Purpose: Primary treatment fails in >70% of locally advanced head and neck cancer patients. Salvage therapy has a 30-40% response rate, but few long-term survivors. Intensity-modulated radiotherapy (IMRT) has recently emerged as a new modality for salvage therapy. This retrospective study evaluated our experience using every-other-week IMRT with concurrent chemotherapy. Methods and Materials: Between 2001 and 2006, 41 patients underwent IMRT as repeat RT with concurrent chemotherapy. All but 6 patients received 60 Gy at 2 Gy/fraction. RT was delivered on an alternating week schedule. Results: With a median follow-up time of 14 months, the overall response rate was 75.6%, with a complete response and partial response rate of 58.5% and 17.1%, respectively. The Kaplan-Meier estimate of overall survival, disease-free survival, and progression-free survival at 24 months was 48.7%, 48.1%, and 38%, respectively. Patients who underwent surgery as a part of their salvage therapy had a mean estimated survival of 30.9 months compared with 22.8 months for patients who received only chemoradiotherapy (p = 0.126). Grade 3 or 4 acute toxicities occurred in 31.7% of patients, but all had resolved within 2 months of therapy completion. No deaths occurred during treatment, except for 1 patient, who died shortly after discontinuing treatment early because of previously undiagnosed metastatic disease; 6 patients had long-term complications. Conclusions: Concurrent chemotherapy with repeat radiotherapy with IMRT given every other week appears to be both well tolerated and feasible in patients treated with previous radiotherapy for recurrent head and neck cancer. IMRT represents a reasonable modality for reducing treatment-related toxicities in a repeat RT setting.

Biagioli, Matthew C. [Department of Radiation Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL (United States)], E-mail: MCBiagioli@yahoo.com; Harvey, Mark [Department of Radiation Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL (United States); Roman, Eloy; Raez, Luis E. [Department of Medicine, Division of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL (United States); Wolfson, Aaron H. [Department of Radiation Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL (United States); Mutyala, Subhakar [Department of Radiation Oncology, Albert Einstein Medical Center, New York, NY (United States); Han, Hyo S. [Department of Medicine, Division of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL (United States); Markoe, Arnold [Department of Radiation Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL (United States)

2007-11-15

14

Concurrent Involved-field Radiotherapy and XELOX Versus XELOX Chemotherapy Alone in Gastric Cancer Patients With Postoperative Locoregional Recurrence.  

PubMed

PURPOSE:: To compare the treatment outcomes of concurrent involved-field radiotherapy and XELOX (oxaliplatin and capecitabine) versus XELOX chemotherapy alone in gastric adenocarcinoma patients with locoregional recurrence. MATERIALS AND METHODS:: From 2004 to 2008, 79 patients with recurrent locoregional gastric cancer after curative resection of gastric tumor were enrolled. Among them, 41 patients received involved-field radiotherapy (median dose 50 Gy) by a 3-dimensional conformal radiotherapy technique and concurrent XELOX chemotherapy, and 38 patients were treated with XELOX chemotherapy alone (oxaliplatin 130 mg/m, capecitabine 1000 mg/m, twice daily, 3 wk each cycle). RESULTS:: The concurrent radiochemotherapy group showed better overall response (including complete response and partial response) when compared with the chemotherapy group (87.8% vs. 63.0%, P=0.01). The control rates for pain, bleeding, and dysphagia/obstruction were 89.5% (17/19), 81.8% (9/11), and 80% (8/10), respectively, in the radiochemotherapy group and 58.8% (10/17), 50% (5/10), and 57.1% (4/7), respectively, in the chemotherapy group. The concurrent radiochemotherapy group showed better overall symptom-control rate when compared with the chemotherapy group (55.9% vs. 85%, P=0.006). Patients receiving concurrent radiochemotherapy trended toward a better median overall survival when compared with those receiving chemotherapy alone (13.4 vs. 5.4 mo, P=0.06). In addition, there were no significant differences in the rates of toxicity or adverse reactions between the 2 groups. CONCLUSIONS:: Concurrent involved-field radiotherapy and XELOX showed better responses and overall symptom-control rates compared with XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence. A trend of survival benefit from radiochemotherapy was also observed but needs to be further explored. PMID:23608834

Yuan, Shuanghu Tiger; Wang, Fu-Li; Liu, Ning; Liu, Yu-Hui; Liu, Shu-Guang; Huang, Yong; Li, Yong-Qing; Liu, Xi-Bin; Zhang, Yi; Li, Wan-Hu; Yu, Jinming; Zhang, Jian-Dong

2013-04-19

15

Deadlock Detection in Discrete Concurrent Systems  

Microsoft Academic Search

In this paper a method of deadlock detection in the concurrent discrete systems is given. Sequent automaton is used as a universal model of discrete systems. The method is based on constructing a sub-graph of reach ability graph of the system. It can be considered as a generalization of the stubborn set method for Petri nets.

Mohammad A. Al-Rababah

2007-01-01

16

Phase II Study of Consolidation Chemotherapy After Concurrent Chemoradiation in Cervical Cancer: Preliminary Results  

SciTech Connect

Purpose: Our aim was to determine the efficacy of consolidation chemotherapy after concurrent chemoradiation (CCRT) using high-dose-rate brachytherapy in patients with locally advanced cervical carcinoma. Methods and Materials: Patients with cervical carcinoma (FIGO stage IB2-IVA) were treated with external beam radiation therapy to the whole pelvis (50.4 Gy) and high-dose-rate brachytherapy (24 Gy to point A). Cisplatin 60 mg/m{sup 2} (Day 1) and 5-fluorouracil 1000 mg/m{sup 2} (Days 1-5) were given every 3 weeks starting concurrently with the radiation and followed by 3 more cycles of consolidation for a total of 6 cycles. Results: Thirty patients (94%) received 3 more cycles of post-CCRT consolidation chemotherapy and were evaluable for the toxicity and efficacy of consolidation. The most common toxicities of Grade 2 or higher were nausea or vomiting (47%) and anemia (33%). Late complications of the rectum and bladder occurred in 13% and 6% of the patients, respectively. The clinical complete response rate was 87% (95% CI, 75%-99%). During a median follow-up of 27 months (range, 6-58 months), 5 patients (17%) had recurrence; the sites of failure were 3 (10%) inside the radiation field and 2 (7%) outside the radiation field. The estimated 3-year progression-free survival rate was 83% (95% CI, 67%-99%) and overall survival rate was 91% (95% CI, 79%-100%). Conclusions: Consolidation chemotherapy after CCRT is well tolerated and effective in patients with locally advanced cervical carcinoma. A prospective randomized trial to compare this treatment strategy with standard CCRT seems to be worthwhile.

Choi, Chel Hun [Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Lee, Jeong-Won [Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Kim, Tae-Joong [Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Kim, Woo Young [Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Nam, Hee Rim [Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Kim, Byoung-Gie [Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of)]. E-mail: huna0@naver.com; Huh, Seung Jae [Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Lee, Je-Ho [Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Bae, Duk-Soo [Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of)

2007-07-01

17

Phase I/II study of induction chemotherapy plus concurrent chemotherapy and SMART-IMRT-based radiotherapy in locoregionally-advanced nasopharyngeal cancer  

PubMed Central

This study aimed to evaluate the efficacy, toxicity and tolerability of simultaneous modulated accelerated radiation therapy (SMART)-intensity modulated radiotherapy (IMRT) plus cisplatin and 5-fluorouracil (5-FU) chemotherapy for patients with advanced nasopharyngeal cancer (NPC). Forty-five patients with stage II–IV NPC, determined by the American Joint Committee on Cancer system, were treated with prescribed doses of 72 Gy total to the gross tumor volume, 60 Gy to the clinical target volume and metastatic nodal station, and 54 Gy to the clinically-negative neck region. Before radiotherapy, two cycles of cisplatin (30 mg/m2/day on days 1–3) plus 5-FU (400 mg/m2/day on days 1–5) were delivered every three weeks for two cycles. Patients received two cycles of cisplatin (30 mg/m2 day on days 1–3) every three weeks during radiotherapy. In addition, two cycles of cisplatin and 5-FU were given after radiation. All patients completed the prescribed radiotherapy and all scheduled cycles of chemotherapy. Thirty of the 45 patients (66.6%) had a complete response at the end of treatment. Grade 3 mucositis occurred in 4/45 patients (8.8%) and grade 3 dermatitis occurred in 5/45 (11.1%) during radiotherapy. Grade 3 neutropenia occurred in 6/45 (13.3%) during concurrent chemotherapy. There was no treatment-related mortality. After a median follow-up time of 51 months, only three patients’ treatments had failed. Local and distant failure rates were 1.5 and 3.0%, respectively. SMART-IMRT plus cisplatin and 5-FU chemotherapy showed promising activity with manageable toxicity. It is a feasible regimen and improves locoregional disease control.

FAN, TING-YONG; XING, JUN; LU, JIE; LIU, TONG-HAI; XU, MIN; ZHANG, YING-JIE; SHAO, QIAN; LI, JIAN-BIN; YU, JIN-MING

2013-01-01

18

A simple approach to specifying concurrent systems  

Microsoft Academic Search

Over the past few years, I have developed an approach to the formal specification of concurrent systems that I now call the transition axiom method. The basic formalism has already been described in [12] and [1], but the formal details tend to obscure the important concepts. Here, I attempt to explain these concepts without discussing the details of the underlying

Leslie Lamport

1989-01-01

19

Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Locoregionally Advanced Laryngeal and Hypopharyngeal Cancers  

SciTech Connect

Purpose: To perform a retrospective review of laryngeal/hypopharyngeal carcinomas treated with concurrent chemotherapy and intensity-modulated radiotherapy (IMRT). Methods and Materials: Between January 2002 and June 2005, 20 laryngeal and 11 hypopharyngeal carcinoma patients underwent IMRT with concurrent platinum-based chemotherapy; most patients had Stage IV disease. The prescription of the planning target volume for gross, high-risk, and low-risk subclinical disease was 70, 59.4, and 54 Gy, respectively. Acute/late toxicities were retrospectively scored using the Common Toxicity Criteria scale. The 2-year local progression-free, regional progression-free, laryngectomy-free, distant metastasis-free, and overall survival rates were calculated using the Kaplan-Meier method. Results: The median follow-up of the living patients was 26 months (range, 17-58 months). The 2-year local progression-free, regional progression-free, laryngectomy-free, distant metastasis-free, and overall survival rate was 86%, 94%, 89%, 92%, and 63%, respectively. Grade 2 mucositis or higher occurred in 48% of patients, and all experienced Grade 2 or higher pharyngitis during treatment. Xerostomia continued to decrease over time from the end of RT, with none complaining of Grade 2 toxicity at this analysis. The 2-year post-treatment percutaneous endoscopic gastrostomy-dependency rate for those with hypopharyngeal and laryngeal tumors was 31% and 15%, respectively. The most severe late complications were laryngeal necrosis, necrotizing fascitis, and a carotid rupture resulting in death 3 weeks after salvage laryngectomy. Conclusion: These preliminary results have shown that IMRT achieved encouraging locoregional control of locoregionally advanced laryngeal and hypopharyngeal carcinomas. Xerostomia improved over time. Pharyngoesophageal stricture with percutaneous endoscopic gastrostomy dependency remains a problem, particularly for patients with hypopharyngeal carcinoma and, to a lesser extent, those with laryngeal cancer. Strategies using IMRT to limit the dose delivered to the esophagus/inferior constrictor musculature without compromising target coverage might be useful to further minimize this late complication.

Lee, Nancy Y. [Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)], E-mail: leen2@mskcc.org; O'Meara, William; Chan, Kelvin [Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Della-Bianca, Cesar; Mechalakos, James G. [Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Zhung, Joanne; Wolden, Suzanne L.; Narayana, Ashwatha [Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Kraus, Dennis; Shah, Jatin P. [Department of Surgery, Division of Head and Neck Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Pfister, David G. [Department of Medicine, Division of Head and Neck Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)

2007-10-01

20

Concurrent Cyclophosphamide, Methotrexate, and 5-Fluorouracil Chemotherapy and Radiotherapy for Early Breast Carcinoma  

SciTech Connect

Purpose: The optimal sequencing of adjuvant chemotherapy (CT) and radiation therapy (RT) in patients with early-stage breast cancer remains unclear. Patients and Methods: We retrospectively compared 485 patients treated with conservative breast surgery and postoperative whole-breast RT and six courses of CMF (cyclophosphamide 600 mg/m{sup 2}, methotrexate 40 mg/m{sup 2}, and 5-fluorouracil 600 mg/m{sup 2}) with 300 patients who received postoperative CMF only and with 509 patients treated with postoperative whole-breast RT only. The mean radiation dose delivered was 50 Gy (range, 46-52 Gy) with standard fractionation. The boost dose was 6-16 Gy according to resection margins and at the discretion of the radiation oncologist. Acute and late RT toxicity were scored using respectively the Radiation Therapy Oncology Group and the Late Effects in Normal Tissues Subjective, Objective, Management and Analytic scale. Results: A slightly higher Grade 2 acute skin toxicity was recorded in the concurrent group (21.2% vs. 11.2% of the RT only group, p < 0.0001). RT was interrupted more frequently in the CMF/RT group respective to the RT group (8.5% vs. 4.1%; p = 0.006). There was no difference in late toxicity between the two groups. All patients in the concurrent group successfully received the planned dose of RT and CT. Local recurrence rate was 7.6% in CT/RT group and 9.8% in RT group; this difference was not statistically significant at univariate analysis (log-rank test p = 0.98). However, at multivariate analysis adjusted also for pathological tumor, pathological nodes, and age, the CT/RT group showed a statistically lower rate of local recurrence (p = 0.04). Conclusions: Whole-breast RT and concurrent CMF are a safe adjuvant treatment in terms of toxicity.

Livi, Lorenzo [Department of Radiotherapy, University of Florence, Florence (Italy)], E-mail: l.livi@dfc.unifi.it; Saieva, Calogero [Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Centre (CSPO), Scientific Institute of Tuscany, Florence (Italy); Borghesi, Simona; Paoletti, Lisa; Meattini, Icro; Rampini, Andrea; Petrucci, Alessia; Scoccianti, Silvia; Paiar, Fabiola [Department of Radiotherapy, University of Florence, Florence (Italy); Cataliotti, Luigi [Department of Surgery, University of Florence, Florence (Italy); Leonulli, Barbara Grilli [Department of Radiotherapy, University of Florence, Florence (Italy); Bianchi, Simonetta [Department of Pathology, University of Florence, Florence (Italy); Biti, Gian Paolo [Department of Radiotherapy, University of Florence, Florence (Italy)

2008-07-01

21

Successful low-dose concurrent chemotherapy and radiation for locally advanced or inoperable non-small cell lung carcinoma: a report of six cases.  

PubMed Central

Many studies now demonstrate high overall response rates with concurrent chemotherapy and radiation (CCR) for locoregionally advanced or inoperable non-small cell lung carcinoma (NSCLC) but often with severe toxicity and only modest improvement in survival beyond 3 years. We report a simple CCR protocol for NSCLC that has resulted in long-term disease-free survival with low toxicity. In this retrospective review, 84 patients with NSCLC were seen between 1985 and 1991. Of these, 10 patients had stage IIIa or IIIb NSCLC without effusion or inoperable NSCLC, with no failed prior treatment at the time of referral for oncology evaluation. Six of these were treated with CCR consisting of three cycles of cisplatin and 5-fluorouracil administered concurrently with radiation treatment followed by maintenance chemotherapy for at least five additional cycles. All six patients treated with this protocol had complete response with minimal side effects. Survival times ranged from 4.5 to more than 10 years. Three patients survived in complete remission; three others were in complete remission at the time of death due to unrelated causes. Stage III NSCLC without effusion and inoperable NSCLC can be treated effectively with concurrent local and systemic treatment without significant toxicity. In patients with complete response, maintenance chemotherapy may overcome residual microscopic systemic disease, leading to long-term survival and possible cure. The CCR strategy that resulted in this favorable outcome is noteworthy and should be pursued in larger numbers of patients. Images Figure 1 Figure 2 Figure 3 Figure 4

Anku, V.

2000-01-01

22

Preclinical Evaluation of Concurrent Medicinal Mushroom-Based Immune-Enhancement Supplementation in Dogs Undergoing Chemotherapy for Various Cancers  

Microsoft Academic Search

Chemotherapy is one of the most common treatments for canine cancer, although it is frequently quite toxic and can result in disruptions of the dog's normal biochemical and physiological cycles. Chemotherapy is known to often drive the dog's white blood cell count down (neutropenia), causing the immune system to weaken and raising susceptibility to opportunistic infections. This often causes chemotherapy

John C. Holliday; Britt M. Gianotti; Matt P. Cleaver; Marie N. Mullins; Sharon Y. West

2009-01-01

23

Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer  

PubMed Central

Objectives To evaluate the efficacy and treatment-related toxicity of accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer (LRIRC). Methods 72 patients with LRIRC who underwent the treatment were studied. Three-dimensional conformal accelerated hyperfractionation radiotherapy (3D-CAHRT) was performed and the dose was delivered with a schedule of 1.2 Gy twice daily, with an interval of at least 6 h between fractions, 5 days a week. Concurrent capecitabine chemotherapy was administered twice daily. After 36 Gy in 30 fractions over 3 weeks, patients were evaluated to define the resectability of the disease. If resection was not feasible irradiation was resumed until the total dose administered to the tumour reached 51.6–56.4 Gy. Results Two patients temporarily interrupted concurrent chemoradiation because of Grade IV diarrhoea. The remaining 70 patients completed the planned concurrent chemoradiation. In all patients, the complete response rate was 8.3% and the partial response rate was 51.4%. The overall response rate was 59.7% and clinical benefit rate was 93.1%. Symptomatic responses proved to be obvious and tumour resection was performed in 18 patients. The overall median survival time and median progression-free survival time were 32 and 17 months, respectively. 3 year overall survival and progression-free survival were 45.12% and 31.19%, respectively. Severely acute toxicities included Grade III–IV diarrhoea and granulocytopenia with 9.7% and 8.3% incidence respectively. Small bowel obstruction was severely late toxicity, and the incidence was 1.4%. Conclusion Three-dimensional conformal accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy might be an effective and well-tolerated regimen for patients with LRIRC.

Sun, D-S; Zhang, J-D; Li, L; Dai, Y; Yu, J-M; Shao, Z-Y

2012-01-01

24

Concurrent Radiotherapy and Gemcitabine for Unresectable Pancreatic Adenocarcinoma: Impact of Adjuvant Chemotherapy on Survival  

SciTech Connect

Purpose: To retrospectively analyze results of concurrent chemoradiotherapy (CCRT) using gemcitabine (GEM) for unresectable pancreatic adenocarcinoma. Methods and Materials: Records of 108 patients treated with concurrent external beam radiotherapy (EBRT) and GEM were reviewed. The median dose of EBRT in all 108 patients was 50.4 Gy (range, 3.6-60.8 Gy), usually administered in conventional fractionations (1.8-2 Gy/day). During radiotherapy, most patients received GEM at a dosage of 250 to 350 mg/m{sup 2} intravenously weekly for approximately 6 weeks. After CCRT, 59 patients (54.6%) were treated with adjuvant chemotherapy (AC), mainly with GEM. The median follow-up for all 108 patients was 11.0 months (range, 0.4-37.9 months). Results: Initial responses after CCRT for 85 patients were partial response: 26 patients, no change: 51 patients and progressive disease: 8 patients. Local progression was observed in 35 patients (32.4%), and the 2-year local control (LC) rate in all patients was 41.9%. Patients treated with total doses of 50 Gy or more had significantly more favorable LC rates (2-year LC rate, 42.9%) than patients treated with total doses of less than 50 Gy (2-year LC rate, 29.6%). Regional lymph node recurrence was found in only 1 patient, and none of the 57 patients with clinical N0 disease had regional lymph node recurrence. The 2-year overall survival (OS) rate and the median survival time in all patients were 23.5% and 11.6 months, respectively. Patients treated with AC had significantly more favorable OS rates (2-year OS, 31.8%) than those treated without AC (2-year OS, 12.4%; p < 0.0001). On multivariate analysis, AC use and clinical T stage were significant prognostic factors for OS. Conclusions: CCRT using GEM yields a relatively favorable LC rate for unresectable pancreatic adenocarcinoma, and CCRT with AC conferred a survival benefit compared to CCRT without AC.

Ogawa, Kazuhiko, E-mail: kogawa@med.u-ryukyu.ac.jp [Department of Radiology, University of the Ryukyus, Okinawa (Japan); Ito, Yoshinori [Department of Radiation Oncology, National Cancer Center, Tokyo (Japan); Hirokawa, Naoki [Department of Radiology, Sapporo Medical University, Sapporo (Japan); Shibuya, Keiko [Department of Radiation Oncology and Image-Applied Therapy, Kyoto University, Kyoto (Japan); Kokubo, Masaki [Department of Radiation Oncology, Institute of Biomedical Research and Innovation Hospital, Kobe (Japan); Ogo, Etsuyo [Department of Radiation Oncology, Kurume University, Kurume (Japan); Shibuya, Hitoshi [Department of Radiology, Tokyo Medical and Dental University, Tokyo (Japan); Saito, Tsutomu [Department of Radiation Oncology, Nihon University Itabashi Hospital, Tokyo (Japan); Onishi, Hiroshi [Department of Radiology, Yamanashi University, Yamanashi (Japan); Karasawa, Katsuyuki [Department of Radiation Oncology, Tokyo Metropolitan Komagome Hospital, Tokyo (Japan); Nemoto, Kenji [Department of Radiation Oncology, Yamagata University, Yamagata (Japan); Nishimura, Yasumasa [Department of Radiation Oncology, Kinki University School of Medicine, Osaka (Japan)

2012-06-01

25

Salivary Gland Tumors Treated With Adjuvant Intensity-Modulated Radiotherapy With or Without Concurrent Chemotherapy  

SciTech Connect

Purpose: To analyze the recent single-institution experience of patients with salivary gland tumors who had undergone adjuvant intensity-modulated radiotherapy (IMRT), with or without concurrent chemotherapy. Patients and Methods: We performed a retrospective analysis of 35 salivary gland carcinoma patients treated primarily at the Dana-Farber Cancer Institute between 2005 and 2010 with surgery and adjuvant IMRT. The primary endpoints were local control, progression-free survival, and overall survival. The secondary endpoints were acute and chronic toxicity. The median follow-up was 2.3 years (interquartile range, 1.2-2.8) among the surviving patients. Results: The histologic types included adenoid cystic carcinoma in 15 (43%), mucoepidermoid carcinoma in 6 (17%), adenocarcinoma in 3 (9%), acinic cell carcinoma in 3 (9%), and other in 8 (23%). The primary sites were the parotid gland in 17 (49%), submandibular glands in 6 (17%), tongue in 4 (11%), palate in 4 (11%), and other in 4 (11%). The median radiation dose was 66 Gy, and 22 patients (63%) received CRT. The most common chemotherapy regimen was carboplatin and paclitaxel (n = 14, 64%). A trend was seen for patients undergoing CRT to have more adverse prognostic factors, including Stage T3-T4 disease (CRT, n = 12, 55% vs. n = 4, 31%, p = .29), nodal positivity (CRT, n = 8, 36% vs. n = 1, 8%, p = .10), and positive margins (n = 13, 59% vs. n = 5, 38%, p = .30). One patient who had undergone CRT developed an in-field recurrence, resulting in an overall actuarial 3-year local control rate of 92%. Five patients (14%) developed distant metastases (1 who had undergone IMRT only and 4 who had undergone CRT). Acute Grade 3 mucositis, esophagitis, and dermatitis occurred in 8%, 8%, and 8% (1 each) of IMRT patients and in 18%, 5%, and 14% (4, 1, and 3 patients) of the CRT group, respectively. No acute Grade 4 toxicity occurred. The most common late toxicity was Grade 1 xerostomia (n = 8, 23%). Conclusions: Treatment of salivary gland malignancies with postoperative IMRT was well tolerated with a high rate of local control. Chemoradiotherapy resulted in excellent local control in a subgroup of patients with adverse prognostic factors and might be warranted in select patients.

Schoenfeld, Jonathan D., E-mail: jdschoenfeld@partners.org [Department of Radiation Oncology, Harvard Radiation Oncology Program, Boston, MA (United States); Sher, David J. [Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (United States); Norris, Charles M. [Department of Surgery, Division of Otolaryngology, Brigham and Women's Hospital, Boston, MA (United States); Haddad, Robert I.; Posner, Marshall R. [Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (United States); Department of Medicine, Brigham and Women's Hospital, Boston, MA (United States); Balboni, Tracy A.; Tishler, Roy B. [Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (United States)

2012-01-01

26

Realising massively concurrent systems on the SPACE machine  

Microsoft Academic Search

Highly concurrent systems occur frequently in the physical world. This paper focuses on a class of systems characterised as being highly concurrent and which are composed out of many simple parts which interact with other parts in their locality. It discusses how to describe these systems and introduces a cellular automata type of architecture which is used to simulate these

George Milne; Paul Cockshott; George McCaskill; Peter Barrie

1993-01-01

27

Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial  

PubMed Central

Background The most appropriate timing of chemotherapy and hormone therapy administration is a critical issue in early breast cancer patients. The purpose of our study was to compare the efficacy of concurrent vs sequential administration of adjuvant chemotherapy and tamoxifen. Methods Women with node-positive primary breast cancer were randomly assigned to receive tamoxifen (20 mg/d for 5 years) during (concurrent arm) or after (sequential arm) adjuvant chemotherapy. Chemotherapy consisted of alternating regimens of cyclophosphamide, epidoxorubicin, and 5-fluorouracil and cyclophosphamide, methotrexate, and 5-fluorouracil every 21 days for a total of 12 cycles. The primary endpoint was overall survival (OS), and secondary endpoints were toxic effects and disease-free survival (DFS). No provision for interim analyses was made in the original study protocol. Survival curves were estimated by the Kaplan–Meier method. Multivariable Cox regression models, adjusted for age, menopausal status, tumor stage, and lymph node and hormone receptor status, were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. Results From 1985 to 1992, 431 patients were randomly assigned and studied according to the intention-to-treat principle. After a maximum of 15.4 years of follow-up (median 12.3 years), the estimated actuarial 10-year OS was equivalent for the two study arms (concurrent arm: 111 patients, 66%, 95% CI = 59% to 72%; sequential arm: 114 patients, 65%, 95% CI = 59% to 72%, P = .86). No differences in DFS and toxic effects were evident. Four interim analyses were performed, but no alpha error adjustment was necessary because of the largely negative results of this final analysis (sequential vs concurrent arm: HR of death = 1.06, 95% CI = 0.78 to 1.44, P = .76; HR of relapse = 1.16, 95% CI = 0.88 to 1.52, P = .36). Conclusions No statistically significant differences in OS, DFS, and toxic effects between concurrent and sequential adjuvant chemo- and hormone therapies were observed. Our study does not support the superiority of one schedule of chemo- and hormone-therapy administration over the other. However, because of the limited statistical power of the study, these results must be considered with caution.

Sertoli, Mario Roberto; Pronzato, Paolo; Del Mastro, Lucia; Venturini, Marco; Taveggia, Paola; Zanardi, Elisa; Siffredi, Guido; Pastorino, Simona; Queirolo, Paola; Gardin, Giovanni; Wang, Ena; Monzeglio, Clara; Boccardo, Francesco; Bruzzi, Paolo

2011-01-01

28

Actors: A Model of Concurrent Computation in Distributed Systems.  

National Technical Information Service (NTIS)

A foundational model of concurrency is developed in this thesis. It examines issues in the design of parallel systems and show why the actor model is suitable for exploiting large-scale parallelism. Concurrency in actors is constrained only by the availab...

G. A. Agha

1985-01-01

29

A Matched-Case Comparison to Explore the Role of Consolidation Chemotherapy After Concurrent Chemoradiation in Cervical Cancer  

SciTech Connect

Purpose: The aim of this study was to compare the efficacy and toxicity of consolidation chemotherapy after concurrent chemoradiation (CCRT) and CCRT alone in patients with locally advanced cervical carcinoma. Methods and Materials: Using medical records from January 2001 to December 2007, 39 patients treated with consolidation chemotherapy after CCRT (Group 1) were matched to 39 patients treated with CCRT alone (Group 2). Consolidation chemotherapy consisted of three additional cycles of chemotherapy with cisplatin 60 mg/m{sup 2} (Day 1) and 5-fluorouracil 1,000 mg/m{sup 2} per day (Days 1-5) given every 3 weeks. The primary endpoint was overall survival. Results: During a median follow-up period of 35 months (range, 8-96 months), 10 (25.6%) and 16 (41.0%) patients showed disease progression in Groups 1 and 2, respectively. Distant recurrence with or without locoregional/lymphogenous recurrence occurred more frequently in Group 2 than in Group 1 (23.1% vs. 7.7%, p = 0.06). By contreast, there was no difference in locoregional or lymphogenous recurrence between the two groups. The rate of overall survival was higher in Group 1 than in Group 2 (92.7% vs. 69.9%, p = 0.042), whereas the difference in progression-free survival between the groups was not statistically significant (70.1% vs. 55.1%, p = 0.079). Although the difference was not statistically significant, neutropenia was more common in Group 1 than in Group 2 (10.9% vs. 4.7%, p = 0.07). Conclusions: Consolidation chemotherapy after CCRT may improve survival and reduce distant recurrence without additional toxicity compared to CCRT alone in patients with locally advanced cervical carcinoma.

Choi, Chel Hun; Lee, Yoo-Young; Kim, Min Kyu; Kim, Tae-Joong; Lee, Jeong-Won [Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Nam, Hee Rim; Huh, Seung Jae [Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Lee, Je-Ho; Bae, Duk-Soo [Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Kim, Byoung-Gie, E-mail: bksong.kim@samsung.com [Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of)

2011-12-01

30

Database Concurrency Control in Multilevel Secure Database Management Systems  

Microsoft Academic Search

Concurrent execution of transactions in database management systems (DBMSs) may lead to contention for access to data, which in a multilevel secure DBMS (MLS\\/DBMS) may lead to insecurity. Security issues involved in database concurrency control for MLS\\/DBMSs are examined, and it is shown how a scheduler can affect security. Data conflict security, (DC-security), a property that implies a system is

Thomas F. Keefe; Wei-tek Tsai; Jaideep Srivastava

1993-01-01

31

Secure Communications System Through Concurrent AJ and LPD Evaluation  

Microsoft Academic Search

In this paper, a systematic approach and their corresponding metrics for concurrent anti-jamming (AJ) and low probability\\u000a of detection (LPD) performance evaluations of a secure communications system are investigated. In general, it is necessary\\u000a to deal simultaneously with adversary threats of both active jamming and passive detection for a secure communications system\\u000a concern. For independent or concurrent AJ and LPD

Chien-Hsing Liao; Mu-King Tsay; Ze-Shin Lee

2009-01-01

32

Preliminary Results of a Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy With Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma in Endemic Regions of China  

SciTech Connect

Purpose: A prospective randomized trial was performed to evaluate the efficacy of concurrent chemotherapy and adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) in endemic regions of China. Methods and Materials: Between July 2002 and September 2005, 316 eligible patients were randomly assigned to receive either radiotherapy alone (RT) or chemoradiotherapy concurrent with adjuvant chemotherapy (CRT). All patients received 70 Gy in 7 weeks using standard RT portals and techniques. The CRT patients were given concurrent cisplatin (40 mg/m{sup 2} on Day 1) weekly during RT, followed by cisplatin (80 mg/m{sup 2} on Day 1) and fluorouracil (800 mg/m{sup 2} on Days 1-5) every 4 weeks (Weeks 5, 9, and 13) for three cycles after completion of RT. All patients were analyzed by intent-to-treat analysis. Results: The two groups were well-balanced in all prognostic factors and RT parameters. The CRT group experienced significantly more acute toxicity (62.6% vs. 32%, p = 0.000). A total of 107 patients (68%) and 97 patients (61%) completed all cycles of concurrent chemotherapy and adjuvant chemotherapy, with a median follow-up time of 29 months. The 2-year overall survival rate, failure-free survival rate, distant failure-free survival rate, and locoregional failure-free survival rate for the CRT and RT groups were 89.8% vs. 79.7% (p = 0.003), 84.6% vs. 72.5% (p = 0.001), 86.5% vs. 78.7% (p = 0.024), and 98.0% vs. 91.9% (p = 0.007), respectively. Conclusions: This trial demonstrated the significant survival benefits of concurrent chemotherapy plus adjuvant chemotherapy in patients with locoregionally advanced NPC in endemic regions of China.

Chen Yong; Liu Mengzhong; Liang Shaobo [State Key Laboratory of Oncology in Southern China, Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou (China); Zong Jingfeng [Department of Radiation Oncology, Fujian Provincial Tumor Hospital, Fuzhou (China); Mao Yanping; Tang Linglong [State Key Laboratory of Oncology in Southern China, Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou (China); Guo Ying [State Key Laboratory of Oncology in Southern China, Department of National Clinical Study Center for Anticancer Drugs, Cancer Center, Sun Yat-sen University, Guangzhou (China); Lin Aihua [Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou (China); Zeng Xiangfa [State Key Laboratory of Oncology in Southern China, Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou (China); Ma Jun [State Key Laboratory of Oncology in Southern China, Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou (China)], E-mail: majun2@mail.sysu.edu.cn

2008-08-01

33

Feasibility Study of Moderately Accelerated Intensity-Modulated Radiotherapy Plus Concurrent Weekly Cisplatin After Induction Chemotherapy in Locally Advanced Head-and Neck Cancer  

Microsoft Academic Search

Purpose: To evaluate the feasibility and efficacy of moderately accelerated intensity-modulated radiation therapy (IMRT) along with weekly cisplatin, after induction chemotherapy, in patients with locally advanced unresectable head and neck cancer (HNC). Methods and Materials: Patients with Stage III or IV locally advanced HNC, without progressive disease after three courses of induction chemotherapy, received concurrent chemo-IMRT (weekly cisplatin 30 mg\\/m²

Alessio G. Morganti; Samantha Mignogna; Francesco Deodato; Mariangela Massaccesi; Savino Cilla; Franco Calista; Giovanni Serafini; Cinzia Digesú; Gabriella Macchia; Vincenzo Picardi; Luciana Caravatta; Liberato Di Lullo; Gianfranco Giglio; Giuseppina Sallustio; Angelo Piermattei; Numa Cellini; Vincenzo Valentini

2011-01-01

34

Risk factors for acute esophagitis in non–small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy  

Microsoft Academic Search

Purpose: To determine the risk factors for acute esophagitis (AE) in non-small-cell lung cancer (NSCLC) patients treated with concurrent chemotherapy (CCT) and three-dimensional conformal radiotherapy (3D-CRT). Methods and Materials: Clinical data were retrospectively analyzed for 215 NSCLC patients treated with CCT and 3D-CRT during 2000-2003, 127 of whom also had induction chemotherapy (ICT). Carboplatin and paclitaxel were the most commonly

Xiong Wei; H. Helen. Liu; Susan L. Tucker; Zhongxing Liao; Chaosu Hu; Radhe Mohan; James D. Cox; Ritsuko Komaki

2006-01-01

35

Multiversion Concurrency Control for Multilevel Secure Database Systems  

Microsoft Academic Search

Consideration is given to the application of multiversion schedulers in multilevel secure database management systems (MLS\\/DBMSs). Transactions are vital for MLS\\/DBMSs because they provide transparency to concurrency and failure. Concurrent execution of transactions may lead to contention among subjects for access to data, which in MLS\\/DBMSs may lead to security problems. Multiversion schedulers reduce the contention for access to data

Thomas F. Keefe; Wei-tek Tsai

1990-01-01

36

Radiotherapy With or Without Concurrent Chemotherapy for Lymph Node Recurrence After Radical Surgery of Thoracic Esophageal Squamous Cell Carcinoma  

SciTech Connect

Purpose: To retrospectively compare the outcomes of patients with lymph node recurrence after radical surgery of esophageal cancer, when given radiotherapy with or without concurrent chemotherapy. Methods and Materials: Between January 1996 and December 2005, the data from 73 patients with lymph node recurrence after radical surgery of thoracic esophageal squamous cell carcinoma were retrospectively reviewed. The patients were separated into two groups: radiochemotherapy (RC, 31 patients) and radiotherapy alone (RA, 42 patients). Patients in the RC group received at least two cycles of 5-fluorouracil/cisplatin chemotherapy concurrently with radiotherapy. Results: The median duration of follow-up was 11 months (range, 2-48). The overall survival rate for all patients was 46.7% and 4.7% at 1 and 3 years, respectively. The median overall survival time was 9 months (95% confidence interval, 6.96-11.04) and 17 months (95% confidence interval, 13.61-20.39) for RA and RC groups, respectively. The survival rate at 1 and 3 years was 62.5% and 10.5% in the RC group and 33.8% and 0% in the RA group (p = .0049, log-rank test; hazard ratio for death, 0.52; 95% confidence interval, 0.30-0.92). Acute toxicities were more frequent in the RC group than in the RA group. No significant differences were found in the late toxicity profiles between the two groups. Conclusion: The results of the present retrospective analysis suggest that RC should be considered an effective and well-tolerated treatment of patients with thoracic esophageal squamous cell carcinoma and postoperative lymph node recurrence.

Lu Jincheng, E-mail: lujincheng@msn.co [Department of Radiotherapy, Jiangsu Cancer Hospital, Nanjing (China); Kong Cheng; Tao Hua [Department of Radiotherapy, Jiangsu Cancer Hospital, Nanjing (China)

2010-11-01

37

Clinical-dosimetric analysis of measures of dysphagia including gastrostomy-tube dependence among head and neck cancer patients treated definitively by intensity-modulated radiotherapy with concurrent chemotherapy  

Microsoft Academic Search

PURPOSE: To investigate the association between dose to various anatomical structures and dysphagia among patients with head and neck cancer treated by definitive intensity-modulated radiotherapy (IMRT) and concurrent chemotherapy. METHODS AND MATERIALS: Thirty-nine patients with squamous cancer of the head and neck were treated by definitive concurrent chemotherapy and IMRT to a median dose of 70 Gy (range, 68 to

Baoqing Li; Dan Li; Derick H Lau; D Gregory Farwell; Quang Luu; David M Rocke; Kathleen Newman; Jean Courquin; James A Purdy; Allen M Chen

2009-01-01

38

The engineering of concurrent simulations of complex systems  

Microsoft Academic Search

Concurrent process-oriented programming is a natural medium for simulating complex systems, particularly systems where many simple components interact in an environ- ment (which may itself be complex). There is little guidance for engineering complex systems simulation. In the context of simulation work to support immunological research, we explore relevant approaches to modelling, and draw on concepts from dependable and high-integrity

Fiona A. C. Polack; Paul S. Andrews; Adam T. Sampson

2009-01-01

39

EcliPSe: A System for High Performance Concurrent Simulation  

Microsoft Academic Search

SUMMARY A description of a system which provides for the concurrent execution of stochastic simulation applications is presented. The EcliPSe system provides high-level simulation primitives that enable common simulation tasks. An application programmer describes the simulation process in terms of these primitives using a sequential computation model. The system transparently replicates appropriate sections of the simulation when the program is

Vernon Rego

1991-01-01

40

Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers  

Microsoft Academic Search

Background. Reirradiation of locoregionally recurrent, previously irradiated head\\/neck cancer may be con- sidered in situations of unresectability, medical inoperability, or adverse pathologic features found at salvage resection. Methods. Retrospective cohort analysis of toxicity and sur- vival outcomes in locoregionally recurrent, previously irradiated patients with head\\/neck cancer treated with hyperfractionated split-course radiotherapy and concurrent chemotherapy.

John M. Watkins; Keisuke S. Shirai; Amy E. Wahlquist; Robert K. Stuart; Uzair B. Chaudhary; Elizabeth Garrett-Mayer; Terry A. Day; M. Boyd Gillespie; Anand K. Sharma

2009-01-01

41

IMRT With Simultaneous Integrated Boost and Concurrent Chemotherapy for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck  

SciTech Connect

Purpose: To evaluate the efficacy and toxicity of accelerated radiotherapy with concurrent chemotherapy in advanced head-and-neck squamous cell carcinoma. Methods and Materials: Between April 2003 and May 2008, 43 consecutive patients with advanced head-and-neck squamous cell carcinoma received accelerated chemoradiation with concurrent cisplatin or cetuximab. The doses for intensity-modulated radiotherapy with simultaneous integrated boost were 67.5, 60.0, and 54 Gy in 30 daily fractions of 2.25, 2.0, and 1.8 Gy to the planning target volumes for gross disease, high-risk nodes, and low-risk nodes, respectively. Results: Of the patients, 90.7% completed chemoradiotherapy as prescribed. The median treatment duration was 43 days (range, 38-55 days). The complete response rate was 74.4%. With median follow-up of 36.7 months (range, 16.8-78.1 months) in living patients, the estimated 1-, 2-, and 5-year locoregional control, overall survival, and disease-free survival rates were 82%, 82%, and 82%; 73%, 65%, and 61%; and 73%, 73%, and 70%, respectively. One treatment-related death occurred from renal failure. Grade 3 mucositis and dermatitis occurred in 13 patients (30.2%) and 3 patients (6.9%), respectively. Grade 2 xerostomia occurred in 12 patients (27.9%). In patients with adequate follow-up, 82% were feeding tube free by 6 months after therapy; 13% remained feeding tube dependent at 1 year. Grade 3 soft-tissue fibrosis, esophageal stricture, osteoradionecrosis, and trismus occurred in 3 patients (6.9%), 5 patients (11.6%), 1 patient (2.3%), and 3 patients (6.9%), respectively. Conclusions: Our results show that intensity-modulated radiotherapy with simultaneous integrated boost with concurrent chemotherapy improved local and regional control. Acute and late toxicities were tolerable and acceptable. A prospective trial of this fractionation regimen is necessary for further assessment of its efficacy and toxicity compared with other approaches.

Montejo, Michael E.; Shrieve, Dennis C. [Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah (United States); Bentz, Brandon G.; Hunt, Jason P.; Buchman, Luke O. [Division of Otolaryngology-Head Neck Surgery, Department of Surgery, Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah (United States); Agarwal, Neeraj [Department of Internal Medicine, Oncology Division, Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah (United States); Hitchcock, Ying J., E-mail: ying.hitchcock@hci.utah.edu [Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah (United States)

2011-12-01

42

Radiobiological compensation: A case study of uterine cervix cancer with concurrent chemotherapy  

SciTech Connect

The case of a patient diagnosed with uterine cervix cancer is presented as an example of the clinical application of the radiobiological compensation method implemented at Centro Estatal de Cancerologia de Durango. Radiotherapy treatment was initially modified to compensate for the chemotherapy component and, as medical complications arose during treatment delivery resulting in an 18 days gap, new compensation followed. All physical and radiobiological assumptions to calculate the Biologically Effective Dose in the external beam and brachytherapy parts of the treatment are presented. Good local control of the tumor was achieved, the theoretical tolerance limits for the organs at risk were not surpassed and the patient manifested no extensive morbidity.

Herrera, Higmar; Yanez, Elvia; Lopez, Jesus [Centro Estatal de Cancerologia de Durango, Victoria de Durango, Durango (Mexico); ISSSTE General Hospital Dr. Santiago Ramon y Cajal, Victoria de Durango, Durango (Mexico)

2012-10-23

43

Radiobiological compensation: A case study of uterine cervix cancer with concurrent chemotherapy  

NASA Astrophysics Data System (ADS)

The case of a patient diagnosed with uterine cervix cancer is presented as an example of the clinical application of the radiobiological compensation method implemented at Centro Estatal de Cancerología de Durango. Radiotherapy treatment was initially modified to compensate for the chemotherapy component and, as medical complications arose during treatment delivery resulting in an 18 days gap, new compensation followed. All physical and radiobiological assumptions to calculate the Biologically Effective Dose in the external beam and brachytherapy parts of the treatment are presented. Good local control of the tumor was achieved, the theoretical tolerance limits for the organs at risk were not surpassed and the patient manifested no extensive morbidity.

Herrera, Higmar; Yañez, Elvia; López, Jesús

2012-10-01

44

A Phase II Study of Radiotherapy and Concurrent Paclitaxel Chemotherapy in Breast-Conserving Treatment for Node-Positive Breast Cancer  

SciTech Connect

Purpose: Administering adjuvant chemotherapy before breast radiotherapy decreases the risk of systemic recurrence, but delays in radiotherapy could yield higher local failure. We assessed the feasibility and efficacy of placing radiotherapy earlier in the breast-conserving treatment course for lymph node-positive breast cancer. Methods and Materials: Between June 2000 and December 2004, 44 women with node-positive Stage II and III breast cancer were entered into this trial. Breast-conserving surgery and 4 cycles of doxorubicin (60 mg/m{sup 2})/cyclophosphamide (600 mg/m{sup 2}) were followed by 4 cycles of paclitaxel (175 mg/m{sup 2}) delivered every 3 weeks. Radiotherapy was concurrent with the first 2 cycles of paclitaxel. The breast received 39.6 Gy in 22 fractions with a tumor bed boost of 14 Gy in 7 fractions. Regional lymphatics were included when indicated. Functional lung volume was assessed by use of the diffusing capacity for carbon monoxide as a proxy. Breast cosmesis was evaluated with the Harvard criteria. Results: The 5-year actuarial rate of disease-free survival is 88%, and overall survival is 93%. There have been no local failures. Median follow-up is 75 months. No cases of radiation pneumonitis developed. There was no significant change in the diffusing capacity for carbon monoxide either immediately after radiotherapy (p = 0.51) or with extended follow-up (p = 0.63). Volume of irradiated breast tissue correlated with acute cosmesis, and acute Grade 3 skin toxicity developed in 2 patients. Late cosmesis was not adversely affected. Conclusions: Concurrent paclitaxel chemotherapy and radiotherapy after breast-conserving surgery shortened total treatment time, provided excellent local control, and was well tolerated.

Chen, William C. [Department of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH (United States); Kim, Janice [Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA (United States); Kim, Edward [Department of Radiation Oncology, Ohio State University Medical Center, Columbus, OH (United States); Silverman, Paula [Department of Medicine, University Hospitals Case Medical Center, Cleveland, OH (United States); Overmoyer, Beth [Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (United States); Cooper, Brenda W. [Department of Medicine, University Hospitals Case Medical Center, Cleveland, OH (United States); Anthony, Sue [Department of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH (United States); Shenk, Robert; Leeming, Rosemary [Department of Surgery, University Hospitals Case Medical Center, Cleveland, OH (United States); Hanks, Shelli H. [Arizona Institute of Urology, Tucson, AZ (United States); Lyons, Janice A., E-mail: janice.lyons@uhhospitals.org [Department of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH (United States)

2012-01-01

45

Chemotherapy  

MedlinePLUS

The term chemotherapy is used to describe cancer-killing drugs. Chemotherapy may be used to: Cure the cancer Prevent the cancer ... HOW CHEMOTHERAPY IS GIVEN Depending on the type of cancer and where it is found, chemotherapy may be given ...

46

System architecture for the concurrent evaluation of applicative program expressions  

SciTech Connect

The paper outlines the principles for the concurrent evaluation of applicative programs based on Berklings reduction language. The recursive style of program design supported by this language lends itself to a recursive partitioning scheme which, for suitable program expressions, generates dynamically a hierarchy of processes for the concurrent evaluation of subexpressions. This hierarchy can elegantly be mapped on to a system of cooperating reduction machines featuring a stack architecture. A special ticket mechanism enforces an upper limit on the number of processes that, at any time, may exist within the system, which does not significantly exceed the number of the available machines. 16 references.

Schmittgen, C.; Kluge, W.

1983-01-01

47

Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: Long-term results of the ARCOSEIN multicenter randomized study  

SciTech Connect

Purpose: In 1996, a multicenter randomized study was initiated that compared sequential vs. concurrent adjuvant chemotherapy (CT) with radiation therapy (RT) after breast-conserving surgery (ARCOSEIN study). After a median follow-up of 6.7 years (range, 4.3-9 years), we decided to prospectively evaluate the late effects of these 2 strategies. Methods and Materials: A total of 297 patients from the 5 larger participating institutions were asked to report for a follow-up examination. Seventy-two percent (214 patients) were eligible for evaluation of late toxicity. After breast-conserving surgery, patients were treated either with sequential treatment with CT first followed by RT (Arm A) or CT administered concurrently with RT (Arm B). In all patients, CT regimen consisted of mitoxantrone (12 mg/m{sup 2}), 5-FU (500 mg/m{sup 2}), and cyclophosphamide (500 mg/m{sup 2}), 6 cycles (Day 1 to Day 21). Conventional RT was delivered to the whole breast by administration of a 2 Gy per fraction protocol to a total dose of 50 Gy ({+-} boost to the primary tumor bed). The assessment of toxicity was blinded to treatment and was graded by the radiation oncologist, according to the LENT/SOMA scale. Skin pigmentation was also evaluated according to a personal 5-points scoring system (excellent, good, moderate, poor, very poor). Results: Among the 214 evaluable patients, 107 were treated in each arm. The 2 populations were homogeneous for patient, tumor, and treatment characteristics. Subcutaneous fibrosis (SF), telangectasia (T), skin pigmentation (SP), and breast atrophy (BA) were significantly increased in Arm B. No statistical difference was observed between the 2 arms of the study concerning Grade 2 or higher pain, breast edema, or lymphedema. No deaths were caused by late toxicity. Conclusion: After breast-conserving surgery, the concurrent use of CT with RT is significantly associated with an increase incidence of Grade 2 or greater late side effects.

Toledano, Alain [Department of Radiotherapy, Hospital Tenon AP-HP, Paris (France)]. E-mail: alain.toledano@gmail.com; Garaud, Pascal [Department of Radiotherapy Henry Kaplan, Hospital Bretonneau, Tours (France); Serin, Daniel [Department of Radiotherapy, Institut Sainte-Catherine, Avignon (France); Fourquet, Alain [Department of Radiotherapy, Institut Curie, Paris (France); Bosset, Jean-Francois [Department of Radiotherapy, Hospital Minjoz, Besancon (France); Breteau, Noel [Department of Radiotherapy, Hospital La Source, Orleans (France); Body, Gilles [Department of Gynecology, Hospital Bretonneau, Tours (France); Azria, David [Department of Radiotherapy, CRLCC Val d'Aurelle, Montpellier (France); Le Floch, Olivier [Department of Radiotherapy Henry Kaplan, Hospital Bretonneau, Tours (France); Calais, Gilles [Department of Radiotherapy Henry Kaplan, Hospital Bretonneau, Tours (France)

2006-06-01

48

Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer  

SciTech Connect

Purpose: To evaluate the safety and feasibility of concurrent radiation therapy and paclitaxel-based adjuvant chemotherapy, given either weekly or every 3 weeks, after adjuvant doxorubicin and cyclophosphamide (AC). Methods and Materials: After definitive breast surgery and AC chemotherapy, 40 patients with operable Stage II or III breast cancer received protocol-based treatment with concurrent paclitaxel and radiation therapy. Paclitaxel was evaluated on 2 schedules, with treatment given either weekly x 12 weeks (60 mg/m{sup 2}), or every 3 weeks x 4 cycles (135-175 mg/m{sup 2}). Radiation fields and schedules were determined by the patient's surgery and pathology. The tolerability of concurrent therapy was evaluated in cohorts of 8 patients as a phase I study. Results: Weekly paclitaxel treatment at 60 mg/m{sup 2} per week with concurrent radiation led to dose-limiting toxicity in 4 of 16 patients (25%), including 3 who developed pneumonitis (either Grade 2 [1 patient] or Grade 3 [2 patients]) requiring steroids. Efforts to eliminate this toxicity in combination with weekly paclitaxel through treatment scheduling and CT-based radiotherapy simulation were not successful. By contrast, dose-limiting toxicity was not encountered among patients receiving concurrent radiation with paclitaxel given every 3 weeks at 135-175 mg/m{sup 2}. However, Grade 2 radiation pneumonitis not requiring steroid therapy was seen in 2 of 24 patients (8%) treated in such a fashion. Excessive radiation dermatitis was not observed with either paclitaxel schedule. Conclusions: Concurrent treatment with weekly paclitaxel and radiation therapy is not feasible after adjuvant AC chemotherapy for early-stage breast cancer. Concurrent treatment using a less frequent paclitaxel dosing schedule may be possible, but caution is warranted in light of the apparent possibility of pulmonary injury.

Burstein, Harold J. [Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (United States)]. E-mail: hburstein@partners.org; Bellon, Jennifer R. [Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (United States); Galper, Sharon [Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (United States); Lu, H.-M. [Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (United States); Kuter, Irene [Department of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (United States); Taghian, Alphonse G. [Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (United States); Wong, Julia [Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (United States); Gelman, Rebecca [Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (United States); Department of Biostatistics, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (United States); Bunnell, Craig A. [Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (United States); Parker, Leroy M.; Garber, Judy E. [Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (United States); Winer, Eric P.; Harris, Jay R. [Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (United States); Powell, Simon N. [Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (United States)

2006-02-01

49

Predictors of Acute Esophagitis in Lung Cancer Patients Treated With Concurrent Three-Dimensional Conformal Radiotherapy and Chemotherapy  

SciTech Connect

Purpose: To evaluate the risk factors for acute esophagitis (AET) in lung cancer patients treated with concurrent 3D-CRT and chemotherapy. Methods and Materials: Data from 100 patients treated with concurrent chemoradiotherapy with a mean dose of 62.05 {+-} 4.64 Gy were prospectively evaluated. Esophageal toxicity was graded according to criteria of the Radiation Therapy Oncology Group. The following dosimetric parameters were analyzed: length and volume of esophagus in treatment field, percentage of esophagus volume treated to {>=}10, {>=}20, {>=}30, {>=}35, {>=}40, {>=}45, {>=}50, {>=}55, and {>=}60 Gy, and the maximum (D{sub max}) and mean doses (D{sub mean}) delivered to the esophagus. Also, we developed an esophagitis index (EI) to account the esophagitis grades over treatment time. Results: A total of 59 patients developed AET (Grade 1, 26 patients; Grade 2, 29 patients; and Grade 3, 4 patients). V50 was associated with AET duration (p = 0.017), AET Grade 1 duration (p = 0.016), maximum analgesia (p = 0.019), esophagitis index score (p = 0.024), and AET Grade {>=}1 (p = 0.058). If V50 is <30% there is a 47.3% risk of AET Grade {>=}1, which increases to 73.3% if V50 is {>=}30% (p = 0.008). The predictive abilities of models (sensitivity and specificity) were calculated by receiver operating characteristic curves. Conclusions: According to the receiver operating characteristic curve analysis, the 30% of esophageal volume receiving {>=}50 Gy was the most statistically significant factor associated with AET Grade {>=}1 and maximum analgesia (A{sub max}). There was an association with AET Grade {>=}2 but it did not achieve statistical significance (p = 0.076)

Rodriguez, Nuria [Department of Radiation Oncology, Hospital de la Esperanza, IMAS, Barcelona (Spain); Department of Medicine, Universitat Autonoma de Barcelona, Barcelona (Spain)], E-mail: nrodriguez@imas.imim.es; Algara, Manuel [Department of Radiation Oncology, Hospital de la Esperanza, IMAS, Barcelona (Spain); Universitat Pompeu Fabra, Barcelona (Spain); Foro, Palmira [Department of Radiation Oncology, Hospital de la Esperanza, IMAS, Barcelona (Spain); Lacruz, Marti [Department of Radiation Oncology, Hospital de la Esperanza, IMAS, Barcelona (Spain); Universitat Pompeu Fabra, Barcelona (Spain); Reig, Anna; Membrive, Ismael; Lozano, Joan; Lopez, Jose Luis [Department of Radiation Oncology, Hospital de la Esperanza, IMAS, Barcelona (Spain); Quera, Jaime [Department of Radiation Oncology, Hospital de la Esperanza, IMAS, Barcelona (Spain); Universitat Pompeu Fabra, Barcelona (Spain); Fernandez-Velilla, Enric; Sanz, Xavier [Department of Radiation Oncology, Hospital de la Esperanza, IMAS, Barcelona (Spain)

2009-03-01

50

Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer - a retrospective single center analysis  

PubMed Central

Background We report our experience in 49 consecutive patients with nasopharyngeal carcinoma who were treated by Intensity-modulated radiation therapy (IMRT) combined with simultaneous but not adjuvant chemotherapy (CHT). Methods The medical records of 49 patients with histologically proven primary nasopharygeal carcinoma treated with IMRT and concurrent platin-based CHT (predominantly cisplatin weekly) were retrospectively reviewed. The majority of patients showed advanced clinical stages (stage III/IV:72%) with undifferentiated histology (82%). IMRT was performed in step-and-shoot technique using an integrated boost concept in 84%. In this concept, the boost volume covered the primary tumor and involved nodes with doses of 66–70.4 Gy (single dose 2.2 Gy). Uninvolved regional nodal areas were covered with doses of 54–59.4 Gy (median single dose 1.8 Gy). At least one parotid gland was spared. None of the patients received adjuvant CHT. Results The median follow-up for the entire cohort was 48 months. Radiation therapy was completed without interruption in all patients and 76% of the patients received at least 80% of the scheduled CHT. Four local recurrences have been observed, transferring into 1-, 3-, and 5-year Local Control (LC) rates of 98%, 90% and 90%. One patient developed an isolated regional nodal recurrence, resulting in 1-, 3-, and 5-year Regional Control (RC) rates of 98%. All locoregional failures were located inside the radiation fields. Distant metastases were found in six patients, transferring into 1-, 3, and 5-year Distant Control (DC) rates of 92%, 86% and 86%. Progression free survival (PFS) rates after 1, 3 and 5 years were 86%, 70% and 69% and 1-, 3- and 5-year Overall Survival (OS) rates were 96%, 82% and 79%. Acute toxicity???grade III mainly consisted of dysphagia (32%), leukopenia (24%), stomatitis (16%), infection (8%) and nausea (8%). Severe late toxicity (grade III) was documented in 18% of the patients, mainly as xerostomia (10%). Conclusion Concurrent chemoradiation without the addition of adjuvant chemotherapy cycles using IMRT with an integrated boost concept yielded good disease control and overall survival in patients suffering from primary nasopharyngeal cancer with acceptable acute side effects and limited rates of late toxicity.

2013-01-01

51

Chemotherapy  

MedlinePLUS

( Quimioterapia ) Chemotherapy (say: kee-moe- ther -ah-pee) is the use of medicines to treat cancer. Cancer is a ... throughout the body making the person very sick. Chemotherapy medicines stop the growth of cancer cells. As ...

52

Chemotherapy  

MedlinePLUS

Chemotherapy Basics In-Depth Multimedia Expert Answers Expert Blog Resources What's New Reprints A single copy of ... may be reprinted for personal, noncommercial use only. Chemotherapy By Mayo Clinic staff Original Article: http://www. ...

53

Chemotherapy  

MedlinePLUS

... up? Login here Please leave this field empty Chemotherapy SHARE Share on Facebook Preview your comments Share ... Close Finish Home > Care and Treatment > Treatments Listen Chemotherapy is the use of drugs to treat cancer. ...

54

Concurrent Common Knowledge: Defining Agreement for Asynchronous Systems  

Microsoft Academic Search

In this paper we present a new, knowledge-theoretic definition of agreement designedfor asynchronous systems. In analogy with common knowledge, it is calledconcurrent common knowledge. Unlike common knowledge, it is a form of agreementthat is attainable asynchronously. In defining concurrent common knowledge, we givea logic with new modal operators and a formal semantics, both of which are based oncausality and consequently

Prakash Panangaden; Kim Taylor

1992-01-01

55

Concurrent design versioning system, based on XML file  

Microsoft Academic Search

Electrical engineers are interested in sharing knowledge with other disciplines like mechanics, thermal, etc.. Indeed, to design an electromechanical product requires more and more skills leading naturally to the concurrent design. A collaborative work, based on several exchanges (like data, expert rules, negotiations), by mainly using Internet protocols, needs dedicated supports, lighter than technical data management system and more dynamic.

Benoit Delinchant; Laurent Gerbaud; Frbdbric Wurtz; Eric Atienza

2002-01-01

56

Mechanizing compositional reasoning for concurrent systems: some lessons  

Microsoft Academic Search

The paper reports on experiences of mechanizing various proposals for compositional reasoning in concurrent systems. The work uses the UNITY formalism and the Isabelle proof tool. The proposals investigated include existential\\/universal properties, guarantees properties and progress sets. The results also apply to related proposals such as traditional assumption-commitment guarantees and Misra's closure properties. Findings that have been published in detail

Sidi O. Ehmety; Lawrence C. Paulson

2005-01-01

57

ACTORS: A model of concurrent computation in distributed systems  

Microsoft Academic Search

The transition from sequential to parallel computation is an area of critical concern in today's computer technology, particularly in architecture, programming languages, systems, and artificial intelligence. This book addresses issues in concurrency, and by producing both a syntactic definition and a denotational model of Hewitt's actor paradigm - a model of computation specifically aimed at constructing and analyzing distributed large-scale

G. Agha

1986-01-01

58

Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma  

SciTech Connect

Purpose: To define favorable pretreatment characteristics for overall survival (OS), progression-free survival (PFS), locoregional control, and freedom from distant metastasis for patients with recurrent and second primary head-and-neck cancer treated with concomitant chemotherapy and reirradiation. Methods and Materials: Our study population comprised a subset of 115 previously irradiated patients without overt metastases from 304 poor-prognosis head-and-neck cancer patients treated in seven consecutive phase I-II protocols. Of the 115 patients, 49, who had undergone surgical resection, were treated with a median of four cycles of concurrent chemotherapy and reirradiation and 66, who had not undergone surgical resection, were treated with a median of five cycles. The following regimens were used: 5-fluorouracil and hydroxyurea concurrent with reirradiation (FHX) (n = 14), cisplatin plus FHX (n = 23), paclitaxel plus FHX (n = 42), gemcitabine plus paclitaxel and 5-fluorouracil concurrent with reirradiation (n = 26), and irinotecan plus FHX (n = 10). Results: The median lifetime radiation dose was 131 Gy. The median follow-up for surviving patients was 67.4 months (range, 18.5-158.7). The median OS and PFS was 11 and 7 months (range, 0.2-158.7), respectively. The 3-year OS, PFS, locoregional control, and freedom from distant metastasis rate was 22%, 33%, 51%, and 61%, respectively. Multivariate analysis identified reirradiation dose, triple agent (cisplatin-, paclitaxel-, or gemcitabine-containing chemotherapy), and surgery before protocol treatment as independently prognostic for OS, PFS, and locoregional control. Triple-agent chemotherapy was prognostic for freedom from distant metastasis. Nineteen patients died of treatment-related toxicity, five of these of carotid hemorrhage. Conclusion: For recurrent and second primary head-and-neck cancer, trimodality therapy with surgery, concurrent chemotherapy, and reirradiation for a full second dose offers potential for long-term survival. Owing to the substantial toxicity and lack of an optimal regimen, reirradiation of recurrent head-and-neck cancer should be limited to clinical trials.

Salama, Joseph K. [Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL (United States); Vokes, Everett E. [Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL (United States); Section of Hematology/Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL (United States); Cancer Research Center, University of Chicago Pritzker School of Medicine, Chicago, IL (United States); Chmura, Steven J. [Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL (United States); Milano, Michael T. [Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL (United States); Kao, Johnny [Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL (United States); Stenson, Kirsten M. [Cancer Research Center, University of Chicago Pritzker School of Medicine, Chicago, IL (United States); Section of Otolaryngology/Head and Neck Surgery, University of Chicago Pritzker School of Medicine, Chicago, IL (United States); Witt, Mary Ellyn R.N. [Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL (United States); Haraf, Daniel J. [Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL (United States) and Cancer Research Center, University of Chicago Pritzker School of Medicine, Chicago, IL (United States)]. E-mail: dharaf@radonc.uchicago.edu

2006-02-01

59

Chemotherapy  

MedlinePLUS

What Is Chemotherapy? Chemotherapy (pronounced: kee-mo- thair -uh-pee), often just called chemo, is the use of medications to treat cancer . Cancer ... uncontrolled way. Cancer cells tend to divide rapidly; chemotherapy works by interfering with this, thereby preventing the ...

60

Concurrent Systems: Formal Development in CSP  

Microsoft Academic Search

This text serves as both a practical reference manual and an introduction for students using the formal specification language CSP and implementing it in the specification and verification of complex, real time and distributed systems. The book contains a tutorial introduction suitable for beginners and uses many examples as well as a realistic case study. The implementation of this case

Michael G. Hinchey; Stephen A. Jarvis

1995-01-01

61

Treatment of Stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: Impact of chemotherapy schemes  

SciTech Connect

Purpose: The aim of this study was to evaluate the impact of different chemotherapy regimens in patients with advanced nasopharyngeal carcinoma (NPC) treated by induction-concurrent chemoradiotherapy. Methods and Materials: Between 1998 and 2003, 75 Stage IV(A-B) NPC patients were treated with 3 cycles of induction chemotherapy with cisplatin plus 5-fluorouracil (PF) (n = 41) or cisplatin plus gemcitabine (PG) (n = 34), followed by accelerated radiotherapy in concurrence with 2 cycles of cisplatin. In 18 (24%) patients, cisplatin was completely replaced by carboplatin in both concurrent cycles, mainly because of borderline renal functions. Results: The median follow-up was 3.6 years. The 3-year locoregional failure-free survival, progression-free survival, and overall survival of the whole group were 80%, 68%, and 80% respectively. No significant difference was found between patients treated with either induction regimens. However, patients with only carboplatin in the 2 concurrent cycles had significantly inferior 3-year locoregional failure-free survival (56% vs. 86%, p = 0.014), progression-free survival (39% vs. 72%, p = 0.001), and overall survival (61% vs. 87%, p = 0.046) when compared with the rest of the group. In multivariate analysis, the complete replacement of cisplatin by carboplatin during concurrent chemoradiotherapy was still an independent adverse factor in locoregional failure-free survival (hazard ratio, 3.662; 95% CI, 1.145-11.765; p = 0.029) and progression-free survival (hazard ratio, 3.390; 95% CI, 1.443-7.937; p = 0.005). Conclusions: The more convenient PG regimen is as effective as the PF regimen as induction chemotherapy for patients with advanced NPC. Replacing cisplatin with carboplatin in the concurrent phase carries a poor prognosis.

Yau, T.K. [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China)]. E-mail: tkokyau@gmail.com; Lee, Anne [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China); Wong, Dominique [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China); Pang, Ellie S.Y. [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China); Ng, W.T. [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China); Yeung, Rebecca [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China); Soong, Inda S. [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China)

2006-11-15

62

Effect of Concurrent High-Dose Cisplatin Chemotherapy and Conformal Radiotherapy on Cervical Esophageal Cancer Survival  

SciTech Connect

Purpose: To determine whether a change in treatment policy to conformal, elective nodal radiotherapy and concurrent high-dose cisplatin improved survival for cervical esophageal cancer patients. Methods and Materials: All cervical esophageal cancer patients treated between 1997 and 2005 were restaged (1983 American Joint Committee on Cancer criteria). Patients treated before 2001 (previous cohort [PC]) were compared with those treated from 2001 onward (recent cohort [RC]). The PC institutional chemoradiotherapy protocol was 54 Gy in 20 fractions within 4 weeks, with 5-fluorouracil (1,000 mg/m{sup 2}) on Days 1-4 and either mitomycin C (10 mg/m{sup 2}) or cisplatin (75 mg/m{sup 2}) on Day 1. The RC institutional chemoradiotherapy protocol was conformal radiotherapy, 70 Gy in 35 fractions within 7 weeks, to the primary tumor and elective nodes, with high-dose cisplatin (100 mg/m{sup 2}) on Days 1, 22, and 43. Results: The median follow-up was 3.1 years (PC, 8.1 and RC, 2.3). Of 71 patients (25 women and 46 men), 21 of 29 in the PC and 29 of 42 in the RC were treated curatively (curative subgroup, n = 50). Between the two groups, no differences in overall survival or locoregional relapse-free survival were seen. The overall survival rate at 2 and 5 years was 35% (range, 24-47%) and 21% (range, 12-32%) in the whole group and 46% (range 32-60%) and 28% (range, 15-42%) in the curative group, respectively. In the curative group, no statistically significant prognostic factors were found. Trends toward better locoregional relapse-free survival were seen in women (2-year rate, 73% vs. for men, 36%; p = 0.08) and in patients aged >64 years (2-year rate, 68% vs. age {<=}64 years, 34%; p = 0.10). Conclusion: No survival improvement could be demonstrated after changing the treatment policy to high-dose cisplatin-based, conventionally fractionated conformal chemoradiotherapy. Female gender and older age might predict for better outcomes.

Huang Shaohui [Radiation Medicine Program, Princess Margaret Hospital, Toronto, ON (Canada); Lockwood, Gina [Department of Biostatistics, Princess Margaret Hospital, Toronto, ON (Canada); Brierley, James; Cummings, Bernard; Kim, John; Wong, Rebecca; Bayley, Andrew [Radiation Medicine Program, Princess Margaret Hospital, Toronto, ON (Canada); Department of Radiation Oncology, University of Toronto, Toronto, ON (Canada); Ringash, Jolie [Radiation Medicine Program, Princess Margaret Hospital, Toronto, ON (Canada); Department of Radiation Oncology, University of Toronto, Toronto, ON (Canada)], E-mail: Jolie.Ringash@rmp.uhn.on.ca

2008-07-01

63

[Prehepatectomy chemotherapy using hepatic artery infusion plus systemic chemotherapy for liver metastases from colorectal cancer].  

PubMed

The purpose of this study was to determine the efficacy of hepatic artery infusion (HAI) plus systemic chemotherapy (SYS) as the prehepatectomy chemotherapy for liver metastases from colorectal cancer. Clinicopathologic data were available for 117 patients who were treated with chemotherapy before liver surgery. Response rate of chemotherapy and frequency of liver resection after chemotherapy of patients treated with HAI/SYS (n=26; 65% and 96%, respectively) were higher than those treated with HAI alone (n=63; 41% and 70%) or SYS alone (n=28; 25% and 42%). Histological examination of adjacent nonneoplastic liver confirmed that severe sinusoidal dilatation was less frequent in HAI/SYS group than in SYS group, and moderate to severe steatosis was also less frequent in HAI/SYS group as compared to HAI group. The combination of regional HAI and systemic chemotherapy is an effective prehepatectomy regimen for the treatment of patients with aggressive liver metastases from colorectal cancer. PMID:21224543

Tanaka, Kuniya; Kumamoto, Takafumi; Nojiri, Kazunori; Mori, Ryotaro; Matsuyama, Ryusei; Takeda, Kazuhisa; Ota, Mitsuyoshi; Akiyama, Hirotoshi; Ichikawa, Yasushi; Endo, Itaru

2010-11-01

64

The evolution of the PVM concurrent computing system  

SciTech Connect

Concurrent and distributed computing, using portable software systems or environments on general purpose networked computing platforms, has recently gained widespread attention. Many such systems have been developed, and several are in production use. This paper describes the evolution of the PVM system, a software infrastructure for concurrent computing in networked environments. PVM has evolved over the past years; it is currently in use at several hundred institutions worldwide for applications ranging from scientific supercomputing to high performance computations in medicine, discrete mathematics, and databases, and for learning parallel programming. We describe the historical evolution of the PVM system, outline the programming model and supported features, present results gained from its use, list representative applications from a variety of disciplines that PVM has been used for, and comment on future trends and ongoing research projects.

Giest, G.A. [Oak Ridge National Lab., TN (United States); Sunderam, V.S. [Emory Univ., Atlanta, GA (United States). Dept. of Mathematics and Computer Science

1993-07-01

65

Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non-Small-Cell Lung Cancer: Southwest Oncology Group Study S0342  

PubMed Central

Purpose Randomized clinical trials failed to show a survival benefit for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors plus concurrent chemotherapy in patients with metastatic non–small-cell lung cancer (NSCLC), with preclinical data suggesting potential negative interactions. In contrast, pilot trials of the EGFR-targeted antibody, cetuximab, plus chemotherapy suggested enhanced antitumor activity. This randomized phase II trial was designed to select a cetuximab plus chemotherapy regimen for phase III evaluation. Patients and Methods Treatment-naive patients with advanced-stage NSCLC were randomly assigned to receive paclitaxel (225 mg/m2) and carboplatin (area under the curve, 6) every 3 weeks plus concurrent cetuximab (400 mg/m2 loading dose followed by 250 mg/m2 weekly) for four cycles followed by maintenance cetuximab or sequential paclitaxel-carboplatin for four cycles followed by cetuximab. Results Of 242 patients enrolled, 224 were eligible and assessable for response (106 and 118 patients in the concurrent and sequential arms, respectively). With a median follow-up time of 32 months, the median overall survival was 10.9 months (95% CI, 9.2 to 13.0 months) for patients receiving concurrent therapy and 10.7 months (95% CI, 8.5 to 12.8 months) for patients receiving sequential therapy (P = .57); 1-year survival rates were 45% (95% CI, 36% to 54%) and 44% (95% CI, 35% to 53%), respectively. Response rates and progression-free survival times were similar in both arms, as was grade 3 rash, whereas sensory neuropathy was higher in the concurrent arm (15% v 5% in the sequential arm; P = .036). Conclusion Although both regimens met the efficacy criterion for continued evaluation, the concurrent regimen of paclitaxel/carboplatin plus cetuximab was chosen.

Herbst, Roy S.; Kelly, Karen; Chansky, Kari; Mack, Philip C.; Franklin, Wilbur A.; Hirsch, Fred R.; Atkins, James N.; Dakhil, Shaker R.; Albain, Kathy S.; Kim, Edward S.; Redman, Mary; Crowley, John J.; Gandara, David R.

2010-01-01

66

Concurrent processes of CDP in object-based file system  

NASA Astrophysics Data System (ADS)

An object-based storage system - integrating advantages of both NAS and SAN - can be applied in large-capacity, lowcost and large-scale storage systems built from commodity disk devices. The continuous data protection or CDP is a well-known technique that continuously captures or tracks data modifications and stores changes independent of primary data, enabling data recovery - from any point in the past. An efficient file system optimized for CDP plays an important role in object-based storage systems. In this paper, concurrent processes during data backup and data recovery operations are discussed in details. To fully take the advantage of distributed system architectures, we make the concurrent data operations as far as possible during read, write, and recovery processes. A new backup data object placement strategy is present to work in coordination with a replica strategy in object-based distributed file systems. Backup data object can be placed in other object storage servers (or OSS for short) instead of the OSS where the original data is residing, when the backup data object matches certain conditions. For data recovery, we make the related OSSes to concurrently perform data object movement. All these strategies can efficiently reduce system response times.

Yao, Jie; Cao, Qiang; Huang, Jianzhong

2009-08-01

67

A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis.  

PubMed Central

We have evaluated the feasibility, toxicity, and tumour response of concurrent whole-brain radiotherapy (WBRT) and chemotherapy with cisplatin, vindesine and mitomycin in the treatment of 33 patients with brain metastasis from non-small-cell lung cancer (NSCLC). The imaging response demonstrated that 25 patients (75.8%) responded to brain lesions, including five complete responders, and the response rate to primary lesion was 18%. The treatment improved at least one grade of performance status in 30% and of neurological functions in 55% of the patients. The major toxicity was leucopenia (> or = grade 3, 84.4%). Median survival was 9.7 months and the 1-year survival rate was 40%. Concurrent WBRT and chemotherapy can be safely administered to patients with brain metastasis from NSCLC, with a remarkable response rate, improvement of neurological functions and encouraging survival duration.

Furuse, K.; Kamimori, T.; Kawahara, M.; Kodama, N.; Ogawara, M.; Atagi, S.; Naka, N.; Akira, M.; Kubota, K.

1997-01-01

68

Radiation Therapy in the Management of Head-and-Neck Cancer of Unknown Primary Origin: How Does the Addition of Concurrent Chemotherapy Affect the Therapeutic Ratio?  

SciTech Connect

Purpose: To determine how the addition of cisplatin-based concurrent chemotherapy to radiation therapy influences outcomes among a cohort of patients treated for head-and-neck cancer of unknown primary origin. Methods and Materials: The medical records of 60 consecutive patients treated by radiation therapy for squamous cell carcinoma of the head and neck presenting as cervical lymph node metastasis of occult primary origin were reviewed. Thirty-two patients (53%) were treated by concurrent chemoradiation, and 28 patients (47%) were treated by radiation therapy alone. Forty-five patients (75%) received radiation therapy after surgical resection, and 15 patients (25%) received primary radiation therapy. Thirty-five patients (58%) were treated by intensity-modulated radiotherapy. Results: The 2-year estimates of overall survival, local-regional control, and progression-free survival were 89%, 89%, and 79%, respectively, among patients treated by chemoradiation, compared to 90%, 92%, and 83%, respectively, among patients treated by radiation therapy alone (p > 0.05, for all). Exploratory analysis failed to identify any subset of patients who benefited from the addition of concurrent chemotherapy to radiation therapy. The use of concurrent chemotherapy was associated with a significantly increased incidence of Grade 3+ acute and late toxicity (p < 0.001, for both). Conclusions: Concurrent chemoradiation is associated with significant toxicity without a clear advantage to overall survival, local-regional control, and progression-free survival in the treatment of head-and-neck cancer of unknown primary origin. Although selection bias cannot be ignored, prospective data are needed to further address this question.

Chen, Allen M., E-mail: allen.chen@ucdmc.ucdavis.edu [Department of Radiation Oncology, University of California Davis School of Medicine, Sacramento, CA (United States); Farwell, D. Gregory [Department of Otolaryngology-Head and Neck Surgery, University of California Davis School of Medicine, Sacramento, CA (United States); Lau, Derick H. [Department of Medical Oncology, University of California Davis School of Medicine, Sacramento, CA (United States); Li Baoqing [Department of Radiation Oncology, University of California Davis School of Medicine, Sacramento, CA (United States); Luu, Quang; Donald, Paul J. [Department of Otolaryngology-Head and Neck Surgery, University of California Davis School of Medicine, Sacramento, CA (United States)

2011-10-01

69

Systems Concurrent Engineering for the Conception of a Hybrid Vehicle  

Microsoft Academic Search

\\u000a This paper presents a systems concurrent engineering approach for the conception of a hybrid vehicle. Traditional approaches\\u000a focuses on the product, development organization and the product concepts of operation (CONOPS). In those approaches the overall\\u000a view of the inherent complexity in the development of a product, its life cycle processes and their performing organizations\\u000a are not taken into consideration. The

Geilson Loureiro; Jonas Bianchini Fulindi; Letícia Azevedo Oliveira Fideles; Daniella Fernandes; Rosely Semabukuro; Carlos Oliveira Lino

70

Modeling Biological Systems in Stochastic Concurrent Constraint Programming  

Microsoft Academic Search

Abstract We present an application of stochastic Concurrent Constraint Programming (sCCP) for modeling biological systems. We provide a library of sCCP processes that can be used to describe straightforwardly biological networks. In the mean- while, we show that sCCP proves to be a general and extensible framework, allowing to describe a wide class of dynamical behaviours and kinetic laws.

Luca Bortolussi; Alberto Policriti

2008-01-01

71

Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer  

PubMed Central

Both induction chemotherapy and concurrent low-dose cisplatin have been shown to improve results of thoracic irradiation in the treatment of locally advanced non-small-cell lung cancer (NSCLC). This phase II study was designed to investigate activity and feasibility of a novel chemoradiation regimen consisting of induction chemotherapy followed by standard radiotherapy and concurrent daily low-dose cisplatin. Previously untreated patients with histologically/cytologically proven unresectable stage IIIA/B NSCLC were eligible. Induction chemotherapy consisted of vinblastine 5 mg m?2 intravenously (i.v.) on days 1, 8, 15, 22 and 29, and cisplatin 100 mg m?2 i.v. on days 1 and 22 followed by continuous radiotherapy (60 Gy in 30 fractions) given concurrently with daily cisplatin at a dose of 5 mg m?2 i.v. Thirty-two patients were enrolled. Major toxicity during induction chemotherapy was haematological: grade III–IV leukopenia was observed in 31% and grade II anaemia in 16% of the patients. The most common severe toxicity during concurrent chemoradiation consisted of grade III leukopenia (21% of the patients); grade III oesophagitis occurred in only two patients and pulmonary toxicity in one patient who died of this complication. Eighteen of 32 patients (56%, 95% CI 38–73%) had a major response (11 partial response, seven complete response). With a median follow-up of 38.4 months, the median survival was 12.5 months and the actuarial survival rates at 1, 2 and 3 years were 52%, 26% and 19% respectively. The median event-free survival was 8.3 months with a probability of 40%, 23% and 20% at 1, 2 and 3 years respectively. Induction chemotherapy followed by concurrent daily low-dose cisplatin and thoracic irradiation, in patients with locally advanced NSCLC, is active and feasible with minimal non-haematological toxicity. Long-term survival results are promising and appear to be similar to those of more toxic chemoradiation regimens, warranting further testing of this novel chemoradiation strategy. © 1999 Cancer Research Campaign

Ardizzoni, A; Grossi, F; Scolaro, T; Giudici, S; Foppiano, F; Boni, L; Tixi, L; Cosso, M; Mereu, C; Ratto, G Battista; Vitale, V; Rosso, R

1999-01-01

72

Chemotherapy  

MedlinePLUS Videos and Cool Tools

... burning during urination • severe diarrhea (more than 3 liquid stools) This document is for informational purposes and ... to take these meds after chemo. Drinking clear liquids before chemotherapy helps some patients decrease nausea. Appetite ...

73

Concurrent Chemoradiotherapy With Paclitaxel and Nedaplatin Followed by Consolidation Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Uterine Cervix: Preliminary Results of a Phase II Study  

SciTech Connect

Purpose: To evaluate the efficacy and toxicities of concurrent chemoradiotherapy (CCRT) and consolidation chemotherapy in patients with locally advanced squamous cell cervical carcinoma. Methods and Materials: Patients with LASCC (FIGO Stage IIB-IIIB) were treated with pelvic external beam radiotherapy (45 Gy for Stage IIB and 50 Gy for Stage III) and high-dose-rate intracavitary brachytherapy (50 Gy for Stage IIB and 35 Gy for Stage III). The cumulative dose at point A was 50 Gy for Stage IIB and 65 Gy for Stage III. Concurrent chemotherapy with paclitaxel (35 mg/m{sup 2}) and nedaplatin (20 mg/m{sup 2}) was given every week for 6 weeks. Consolidation chemotherapy with paclitaxel (135 mg/m{sup 2}) and nedaplatin (60 mg/m{sup 2}) was administered every 3 weeks for 4 cycles. Results: All patients completed CCRT, and 28 of 34 patients completed consolidation chemotherapy. The complete response rate was 88% (95% CI, 73-96%). The most common Grade 3 or higher toxicities were leukopenia/neutropenia (10.9% of the cycles). During a median follow up of 23 months (range, 14-30 months), 5 patients had locoregional failure and 1 patient had distant metastasis. The estimated 2-year progression-free survival and overall survival were 82% (95% CI, 68-95%) and 93% (95% CI, 83-100%), respectively. Grade 3 late complications occurred in 3 patients (9%). Conclusions: CCRT with paclitaxel and nedaplatin followed by consolidation chemotherapy is well tolerated and effective in patients with locally advanced squamous cell cervical carcinoma. Further randomized trials of comparing this regimen with the standard treatment are worth while.

Zhang Meiqin, E-mail: pianozmq@hotmail.co [Department of Gynecologic Oncology, Cancer Hospital, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai (China); Liu Suping; Wang, Xiang-E. [Department of Gynecologic Oncology, Cancer Hospital, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai (China)

2010-11-01

74

Concurrent design of an RTP chamber and advanced control system  

SciTech Connect

A concurrent-engineering approach is applied to the development of an axisymmetric rapid-thermal-processing (RTP) reactor and its associated temperature controller. Using a detailed finite-element thermal model as a surrogate for actual hardware, the authors have developed and tested a multi-input multi-output (MIMO) controller. Closed-loop simulations are performed by linking the control algorithm with the finite-element code. Simulations show that good temperature uniformity is maintained on the wafer during both steady and transient conditions. A numerical study shows the effect of ramp rate, feedback gain, sensor placement, and wafer-emissivity patterns on system performance.

Spence, P. [Sandia National Labs., Livermore, CA (United States); Schaper, C. [Microelectronics Control and Sensing, Inc., Mountain View, CA (United States); Kermani, A. [CVC Products, Inc., Fremont, CA (United States)

1995-12-31

75

Hematopoietic toxicity of regional radiation therapy. Correlations for combined modality therapy with systemic chemotherapy  

SciTech Connect

Using circulating granulocyte-monocyte precursor colony-forming units in culture (CFUc) numbers as a probe along with standard blood count (CBC), the authors have quantitatively examined the hematopoietic toxicity of conventionally fractionated radiation therapy (RT) when combined with concurrent systemic chemotherapy or when used alone. Among 20 patients with limited stage small cell lung cancer receiving systemic chemotherapy with cyclophosphamide, CCNU, and methotrexate, the addition of involved field chest RT resulted in increased hematopoietic toxicity as judged by increased need for platelet transfusion (P less than 0.05) and decreased frequency of measurable CFUc (P less than 0.04). Among 22 patients receiving regional radiotherapy alone consistent hematopoietic toxicity was also observed. This toxicity, although generally of only mild to moderate clinical significance, was detected earlier and to a greater degree in patients who required radiation to larger treatment volumes, who had significant amounts of bone marrow in the port, and who had a high percentage of cardiac output flowing through the port. These data suggest that the hematopoietic toxicity of regional radiotherapy may be additive to that of concurrent systemic chemotherapy and may occur more promptly and to a greater degree when treatment volumes are larger or incorporate increased amounts of marrow volume or cardiac output.

Abrams, R.A.; Lichter, A.S.; Bromer, R.H.; Minna, J.D.; Cohen, M.H.; Deisseroth, A.B.

1985-04-01

76

Radiation therapy for T2N0 laryngeal cancer: A retrospective analysis for the impact of concurrent chemotherapy on local control  

SciTech Connect

Purpose: The impact of concurrent chemotherapy on the local control in patients with T2N0 laryngeal cancer who receive radiation therapy (RT) was evaluated. Methods and Materials: Sixty-three patients with T2N0 laryngeal cancer who were treated by definitive RT were analyzed. The primary site of the cancer was the glottis in 50 patients, the supraglottis in 9 patients, and the subglottis in 4 patients. Thirty-six patients were treated by RT alone and the remaining 27 patients received concurrent chemoradiotherapy (CRT). Results: Complete response (CR) was obtained in 92% of the patients who received RT alone and 100% of the patients who received CRT. Voice preservation in the group who received CRT (89%) was significantly higher than that in the group treated by RT alone (61%). The 5-year disease-free survival rates in those who received concurrent CRT was significantly superior to that in the patients who received RT alone, although no significant difference was seen in the cause-specific survival rate between the 2 groups. The multivariate analysis revealed that the treatment method (RT alone vs. CRT) was the most significant risk factor that predicted recurrence after RT. Conclusion: Concurrent CRT had a positive impact on the local control of T2N0 laryngeal cancer.

Akimoto, Tetsuo [Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Gunma (Japan)]. E-mail: takimoto@showa.gunma-u.ac.jp; Nonaka, Tetsuo [Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Gunma (Japan); Kitamoto, Yoshizumi [Department of Radiology, Gunma Prefectural Gunma Cancer Center, Gunma (Japan); Ishikawa, Hitoshi [Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Gunma (Japan); Ninomiya, Hiroshi [Department of Otolaryngology, Gunma University Graduate School of Medicine, Maebashi, Gunma (Japan); Chikamatsu, Kazuaki [Department of Otolaryngology, Gunma University Graduate School of Medicine, Maebashi, Gunma (Japan); Furuya, Nobuhiko [Department of Otolaryngology, Gunma University Graduate School of Medicine, Maebashi, Gunma (Japan); Hayakawa, Kazushige [Department of Radiology, Kitasato University, Kitasato (Japan); Mitsuhashi, Norio [Department of Radiology, Tokyo Women's Medical University, Tokyo (Japan); Nakano, Takashi [Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Gunma (Japan)

2006-03-15

77

Involved-field radiotherapy versus elective nodal irradiation in combination with concurrent chemotherapy for locally advanced non-small cell lung cancer: a prospective randomized study.  

PubMed

This prospective randomized study is to evaluate the locoregional failure and its impact on survival by comparing involved field radiotherapy (IFRT) with elective nodal irradiation (ENI) in combination with concurrent chemotherapy for locally advanced non-small cell lung cancer. It appears that higher dose could be delivered in IFRT arm than that in ENI arm, and IFRT did not increase the risk of initially uninvolved or isolated nodal failures. Both a tendency of improved locoregional progression-free survival and a significant increased overall survival rate are in favor of IFRT arm in this study. PMID:23762840

Chen, Ming; Bao, Yong; Ma, Hong-Lian; Hu, Xiao; Wang, Jin; Wang, Yan; Peng, Fang; Zhou, Qi-Chao; Xie, Cong-Hua

2013-05-13

78

Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer  

SciTech Connect

Purpose: Pretreatment anemia is an adverse prognostic variable in squamous cell head-and-neck cancer (HNC) patients treated with radiotherapy (RT) alone. Tumor hypoxia is an adverse parameter for treatment with RT alone or with RT and concurrent chemotherapy (CCT). Tumor hypoxia is more prevalent in patients who present with pretreatment hemoglobin (Hgb) concentrations less than 13 g/dL. RT/CCT improves survival over RT alone in advanced HNC, and its use is becoming more widespread. This study was performed to evaluate whether pretreatment Hgb less than 13 g/dL was correlated with treatment outcome in patients with advanced HNC treated with a uniform regimen of RT/CCT. Methods and materials: The study population consisted of patients with AJCC Stage III or IV, M0 HNC who were treated with 70 to 72.5 Gy accelerated hyperfractionated RT (1.25 Gy b.i.d.) and CCT consisting of 2 cycles of CDDP (12-20 mg/m{sup 2}/d x 5 days) and continuous infusion 5-FU (600 mg/m{sup 2}/d x 5 days) during Week 1 and Week 6. A planned break in RT occurred during Week 4. These patients were enrolled on the experimental arm of a prospective randomized trial that compared this regimen to hyperfractionated irradiation alone from 1990 to 1996. RT/CCT was delivered as standard therapy from 1996 to 2000. The primary endpoint was failure-free survival (FFS). Secondary endpoints included local-regional control and overall survival. Results: One hundred and fifty-nine patients were treated from 1990 to 2000. The median (25-75%) pretreatment Hgb was 13.6 (12.2-13.5) g/dL. Hgb was 13 g/dL or higher in 105 patients and less than 13 g/dL in 54 patients. Primary tumor sites included oropharynx (43%), hypopharynx/larynx (36%), oral cavity (9%), and nasopharynx (6%). Seventy-eight percent of the patients with Hgb 13 g/dL or higher and 92% of the patients with Hgb less than 13 g/dL had a primary tumor stage of T3 or T4 (p = 0.01). Node-positive disease was present in 74 of 105 (70%) of patients with Hgb 13 g/dL or higher patients and in 36/54 (67%) of patients with Hgb less than 13 g/dL patients. Median follow-up of surviving patients was 42 months (range, 4-128 months). Five-year FFS was 75% for patients with Hgb 13 g/dL or higher vs. 50% for patients with Hgb less than 13 g/dL had a (p < 0.01). A total of 49 failures occurred in both patient cohorts. The median (25-75%) decrease in Hgb during RT/CCT was 2.2 (1.3-3.1) g/dL, both in patients who failed and in those who remained disease-free. Conclusion: Pretreatment Hgb less than 13 g/dL is correlated with adverse outcomes in advanced HNC patients treated with RT/CCT. Whether anemia actually causes poor outcomes remains unknown. The therapeutic effect of anemia correction is being evaluated in prospective trials.

Prosnitz, Robert G. [Department of Radiation Oncology, Duke University Medical Center, Durham, NC (United States)]. E-mail: robert.prosnitz@duke.edu; Yao, Bin M.S. [Amgen, Inc. Thousand Oaks, CA (United States); Farrell, Catherine L. [Amgen, Inc. Thousand Oaks, CA (United States); Clough, Robert [Department of Radiation Oncology, Duke University Medical Center, Durham, NC (United States); Brizel, David M. [Department of Radiation Oncology, Duke University Medical Center, Durham, NC (United States)

2005-03-15

79

Concurrent Hyperfractionated Radiation Therapy and Chemotherapy in Locally Advanced (Stage III) Non-Small-Cell Lung Cancer: Single Institution Experience With 600 Patients  

SciTech Connect

Purpose: Our institutional experience with the use of hyperfractionated radiation therapy (RT) alone or concurrently with chemotherapy (RT-CHT) in Stage III non-small-cell lung cancer was reviewed. Methods and Materials: Three phase III and two phase II studies included a total of 600 patients. Hyperfractionated RT alone was given to 127 patients, and hyperfractionated RT-CHT was given to 473 patients. RT doses were 64.8 Gy and 69.6 Gy (using 1.2 Gy twice daily) and 67.6 Gy (using 1.3 Gy twice daily). CHT consisted of concurrent administration of carboplatin and etoposide to 409 patients and concurrent administration of carboplatin and paclitaxel to 64 patients. Results: The median survival times were 19 months, 21 months, and 12 months for all, RT-CHT, and RT-only patients, respectively. The survival difference between the RT-CHT and RT group was significant (p < 0.0001). Four-year rates of local progression-free survival (LPFS) and distant metastasis-free survival (DMFS) were 29% and 35%, respectively, for the entire group. The RT-CHT group had significantly better LPFS rates than the RT group (31% for the RT-CHT group vs. 16% for the RT group; p = 0.0015) but not DMFS rates (36% for the RT-CHT group vs. 36% for the RT group, p = 0.0571). Acute high-grade esophagitis, pneumonitis, and hematological toxicities were seen most frequently and in 11%, 9%, and 12% of patients, respectively. Late high-grade esophageal and bronchopulmonary toxicity were each seen in 6% of patients. Conclusions: Compared to the majority of existing phase II and III studies, this study reconfirmed the excellent results achieved with concurrent RT-CHT, including low toxicity. Concurrent RT-CHT results in survival benefit primarily by increasing LPFS, not DMFS.

Jeremic, Branislav, E-mail: nebareje@gmail.com [Department of Oncology, University Hospital, Kragujevac (Serbia); Milicic, Biljana; Milisavljevic, Slobodan [Department of Oncology, University Hospital, Kragujevac (Serbia)

2012-03-01

80

MACHINE PROTECTION SYSTEM FOR CONCURRENT OPERATION OF RHIC AND BLIP.  

SciTech Connect

The Brookhaven 200MeV linac is a multipurpose machine used to inject low intensity polarized protons for RHIC (Relativistic Heavy Ion Collider), as well as to inject high intensity protons to BLIP (Brookhaven Linac Isotope Producer), a medical isotope production facility. If high intensity protons were injected to RHIC by mistake, administrative radiation limits could be exceeded or sensitive electronics could be damaged. In the past, the changeover from polarized proton to high intensity proton operation has been a lengthy process, thereby never allowing the two programs to run simultaneously. To remedy this situation and allow concurrent operation of RHIC and BLIP, an active interlock system has been designed to monitor current levels in the AGS using two current transformers with fail safe circuitry and associated electronics to inhibit beam to RHIC if high intensity currents are detected.

WILINSKI, M.; BELLAVIA, S.; GLENN, J.W.; MAUSNER, L.F.; UNGER, K.L.

2005-05-16

81

A State Transformation Equivalence for Concurrent Systems: Exhibited Functionality-equivalence  

Microsoft Academic Search

Most of the equivalence notions for concurrent systems proposed in recent years are defined in terms of sequences (posets) of observable actions, and therefore they are not suitable for comparing two systems whose actions are defined at different levels of detail. In this paper a new equivalence notion for concurrent systems (more precisely for contact-free S-labelled EN systems) is introduced:

Fiorella De Cindio; Giorgio De Michelis; Lucia Pomello; Carla Simone

1988-01-01

82

Feasibility Study of Moderately Accelerated Intensity-Modulated Radiotherapy Plus Concurrent Weekly Cisplatin After Induction Chemotherapy in Locally Advanced Head-and Neck Cancer  

SciTech Connect

Purpose: To evaluate the feasibility and efficacy of moderately accelerated intensity-modulated radiation therapy (IMRT) along with weekly cisplatin, after induction chemotherapy, in patients with locally advanced unresectable head and neck cancer (HNC). Methods and Materials: Patients with Stage III or IV locally advanced HNC, without progressive disease after three courses of induction chemotherapy, received concurrent chemo-IMRT (weekly cisplatin 30 mg/m{sup 2} plus simultaneous integrated boost IMRT). A total of 67.5 Gy in 30 fractions were delivered to primary tumor and involved nodes, 60 Gy in 30 fractions to high-risk nodal areas, and 55.5 Gy in 30 fractions to low-risk nodal areas. Results: In all, 36 patients (median age, 56 years) with International Union Against Cancer (UICC) Stage III (n = 5) and IV (n = 31) were included. Of the 36 patients, 17 had received CF (cisplatin and 5-fluorouracil (CF) and 19 had received docetaxel cisplatin and 5-fluorouracil (DCF). During concurrent chemoradiation, 11 of 36 patients (30.5%) experienced Grade III mucositis (CF, 47%; DCF, 15%; p < 0.04). Grade III pharyngeal-esophageal toxicity was observed in 5 of 19 patients (26.3%; CF, 0.0%; DCF, 26.3%; p = 0.02). Two patients died of complications (5.5%). After chemoradiation, the complete response rate was 63.8%. Two-year local control was 88.7%. Two-year progression free survival and overall survival were 74.5% and 60.9%, respectively. Conclusions: In our experience, a moderately accelerated chemo-IMRT was feasible after induction chemotherapy. However, a noteworthy early death rate of 5.5% was observed. Intensive supportive care strategies should be defined to better manage radiation-induced toxic effects. Longer follow-up is required to determine the incidence of late radiation toxicities and tumor control rates.

Morganti, Alessio G. [Department of Radiotherapy, 'John Paul II' Center for High Technology Research and Education in Biomedical Sciences, Campobasso (Italy); Mignogna, Samantha [Department of Palliative Therapies, 'John Paul II' Center for High Technology Research and Education in Biomedical Sciences, Campobasso (Italy); Deodato, Francesco; Massaccesi, Mariangela [Department of Radiotherapy, 'John Paul II' Center for High Technology Research and Education in Biomedical Sciences, Campobasso (Italy); Cilla, Savino [Department of Medical Physics, 'John Paul II' Center for High Technology Research and Education in Biomedical Sciences, Campobasso (Italy); Calista, Franco [Department of Palliative Therapies, 'John Paul II' Center for High Technology Research and Education in Biomedical Sciences, Campobasso (Italy); Serafini, Giovanni [Department of Head and Neck Surgery, General Hospital, Termoli (Italy); Digesu, Cinzia [Department of Radiotherapy, 'John Paul II' Center for High Technology Research and Education in Biomedical Sciences, Campobasso (Italy); Macchia, Gabriella, E-mail: gmacchia@rm.unicatt.i [Department of Radiotherapy, 'John Paul II' Center for High Technology Research and Education in Biomedical Sciences, Campobasso (Italy); Picardi, Vincenzo; Caravatta, Luciana [Department of Radiotherapy, 'John Paul II' Center for High Technology Research and Education in Biomedical Sciences, Campobasso (Italy); Di Lullo, Liberato [Department of Oncology, General Hospital, Isernia (Italy); Giglio, Gianfranco [Department of Oncology, General Hospital, Campobasso (Italy); Sallustio, Giuseppina [Department of Radiology, 'John Paul II' Center for High Technology Research and Education in Biomedical Sciences, Campobasso (Italy); Piermattei, Angelo [Department of Medical Physics, 'John Paul II' Center for High Technology Research and Education in Biomedical Sciences, Campobasso (Italy)

2011-03-15

83

Heuristic networks for concurrent pursuit-evasion systems  

Microsoft Academic Search

We consider briefly the linguistic geometry tools and their application to solving 2D optimization problem for autonomous robotic vehicles participating in the aerospace pursuit-evasion game. In this problem we allow the agents to move simultaneously if necessary. A comparison of the searches for aerial and concurrent cases shows that search reduction achieved in the concurrent case is even more dramatic

Boris Stilman

1995-01-01

84

Hypofractionated Accelerated Radiotherapy With Concurrent Chemotherapy For Locally Advanced Squamous Cell Carcinoma of the Head and Neck  

SciTech Connect

Purpose: To investigate the tumor control rates in locally advanced head-and-neck cancer using accelerated hypofractionated radiotherapy with chemotherapy. Methods and Materials: The data from patients with squamous cell cancer of the larynx, oropharynx, oral cavity, and hypopharynx (International Union Against Cancer Stage II-IV), who received accelerated hypofractionated radiotherapy with chemotherapy between January 1, 1998, and April 1, 2005, were retrospectively analyzed. Two different chemotherapy schedules were used, carboplatin and methotrexate, both single agents administered on an outpatient basis. The endpoints were overall survival, local control, and disease-free survival. Results: A total of 81 patients were analyzed. The 2-year overall survival rate was 71.6% (95% confidence interval [CI], 61.5-81.8%). The 2-year disease-free survival rate was 68.6% (95% CI, 58.4-78.8%). The 2-year local control rate was 75.4% (95% CI, 65.6-85.1%). When excluding patients with Stage II oral cavity, larynx, and hypopharynx tumors, 68 patients remained. For these patients, the 2-year overall survival, local control, and disease-free survival rate was 67.6% (95% CI, 56.0-79.2%), 72.0% (95% CI, 61.0-83.0%), and 64.1% (95% CI, 52.6-75.7%), respectively. Conclusion: Accelerated hypofractionated radiotherapy and synchronous chemotherapy can achieve high tumor control rates while being resource sparing and should be the subject of prospective evaluation.

Sanghera, Paul [Cancer Centre, Queen Elizabeth Hospital, Birmingham (United Kingdom); McConkey, Chris [Clinical Trials Unit, University of Warwick, Coventry (United Kingdom); Ho, Kean-Fatt [Cancer Centre, Queen Elizabeth Hospital, Birmingham (United Kingdom); Glaholm, John [Cancer Centre, Queen Elizabeth Hospital, Birmingham (United Kingdom); Hartley, Andrew [Cancer Centre, Queen Elizabeth Hospital, Birmingham (United Kingdom)]. E-mail: andrew.hartley@uhb.nhs.uk

2007-04-01

85

A neural-based concurrency control algorithm for database systems  

Microsoft Academic Search

Concurrency control (CC) algorithms guarantee the correctness and consistency criteria for concurrent execution of a set of\\u000a transactions in a database. A precondition that is seen in many CC algorithms is that the writeset (WS) and readset (RS) of\\u000a transactions should be known before the transaction execution. However, in real operational environments, we know the WS and\\u000a RS only for

Mansour Sheikhan; Mohsen Rohani; Saeed Ahmadluei

86

Research on group decision support system for concurrent product development process  

Microsoft Academic Search

There are many complex evaluation and decision-making problems in concurrent product development process. In order to improve the efficiency of multi-discipline work team for concurrent product development. The evaluation and decision tools should be provided. In the paper, the characteristics of group decision during concurrent product development process are analyzed and a group decision support system (GDSS) with multi-agent structure

Haiyan Zhao; Youliang Zhang; Ziliang Wang; Sik-fun Lee; Wing-chcong Kwong

2003-01-01

87

Automatic verification of finite state concurrent system using temporal logic specifications: a practical approach  

Microsoft Academic Search

We give an efficient procedure for verifying that a finite state concurrent system meets a specification expressed in a (propositional) branching-time temporal logic. Our algorithm has complexity linear in both the size of the specification and the size of the global transition graph for the concurrent system. We also show how the logic and our algorithm can be modified to

Edmund M. Clarke; E. Allen Emerson; A. Prasad Sistla

1983-01-01

88

Integrated Information Systems for Electronic Chemotherapy Medication Administration  

PubMed Central

Introduction: Chemotherapy administration is a highly complex and distributed task in both the inpatient and outpatient infusion center settings. The American Society of Clinical Oncology and the Oncology Nursing Society (ASCO/ONS) have developed standards that specify procedures and documentation requirements for safe chemotherapy administration. Yet paper-based approaches to medication administration have several disadvantages and do not provide any decision support for patient safety checks. Electronic medication administration that includes bar coding technology may provide additional safety checks, enable consistent documentation structure, and have additional downstream benefits. Methods: We describe the specialized configuration of clinical informatics systems for electronic chemotherapy medication administration. The system integrates the patient registration system, the inpatient order entry system, the pharmacy information system, the nursing documentation system, and the electronic health record. Results: We describe the process of deploying this infrastructure in the adult and pediatric inpatient oncology, hematology, and bone marrow transplant wards at Vanderbilt University Medical Center. We have successfully adapted the system for the oncology-specific documentation requirements detailed in the ASCO/ONS guidelines for chemotherapy administration. However, several limitations remain with regard to recording the day of treatment and dose number. Conclusion: Overall, the configured systems facilitate compliance with the ASCO/ONS guidelines and improve the consistency of documentation and multidisciplinary team communication. Our success has prompted us to deploy this infrastructure in our outpatient chemotherapy infusion centers, a process that is currently underway and that will require a few unique considerations.

Levy, Mia A.; Giuse, Dario A.; Eck, Carol; Holder, Gwen; Lippard, Giles; Cartwright, Julia; Rudge, Nancy K.

2011-01-01

89

High-dose Extended-Field Irradiation and High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Cervical Cancer With Positive Para-Aortic Lymph Nodes  

SciTech Connect

Purpose: To determine the efficacy and toxicity of extended-field radiotherapy (RT) with concurrent platinum-based chemotherapy in patients with uterine cervical carcinoma and positive para-aortic nodes. Methods and Materials: We retrospectively reviewed the results for 33 women with Stage IB-IVB cervical cancer. Each patient had received 59.4 Gy, including a three-dimensional conformal boost to the para-aortic lymph nodes and 41.4-50.4 Gy of external beam radiotherapy to the pelvis. Each patient also underwent six or seven applications of high-dose-rate brachytherapy (median, 5 Gy to point A at each session). Results: The median follow-up period of surviving patients was 39 months. The most common acute toxicity was hematologic, observed in 23 women. Severe acute and late gastrointestinal toxicity was observed in 3 and 4 patients, respectively. More than three-quarters of patients showed a complete response, encompassing the primary mass, metastatic pelvic, and para-aortic lymph nodes. Of the 33 women, 15 had no evidence of disease, 6 had persistent disease, 4 developed in-field failures, and 6 developed distant failures. The 5-year overall and disease-free survival rate was 47% and 42%, respectively. Conclusion: Concurrent chemoradiotherapy with extended-field radiotherapy is feasible in women with uterine cervical carcinoma and positive para-aortic lymph nodes, with acceptable late morbidity and a high survival rate, although it was accompanied by substantial acute toxicity.

Kim, Young Seok; Kim, Jong Hoon; Ahn, Seung Do; Lee, Sang-wook; Shin, Seong Soo [Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of); Nam, Joo-Hyun; Kim, Young-Tak; Kim, Yong-Man; Kim, Jong-Hyeok [Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of); Choi, Eun Kyung [Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of)], E-mail: ekchoi@amc.seoul.kr

2009-08-01

90

Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma  

SciTech Connect

Purpose: To compare the benefit achieved by concurrent chemoradiotherapy (CRT) and/or accelerated fractionation (AF) vs. radiotherapy (RT) alone with conventional fractionation (CF) for patients with T3-4N0-1M0 nasopharyngeal carcinoma (NPC). Methods and Materials: All patients were irradiated with the same RT technique to {>=}66 Gy at 2 Gy per fraction, conventional five fractions/week in the CF and CF+C (chemotherapy) arms, and accelerated six fractions/week in the AF and AF+C arms. The CF+C and AF+C patients were given the Intergroup 0099 regimen (concurrent cisplatin plus adjuvant cisplatin and 5-fluorouracil). Results: Between 1999 and April 2004, 189 patients were randomly assigned; the trial was terminated early because of slow accrual. The median follow-up was 2.9 years. When compared with the CF arm, significant improvement in failure-free survival (FFS) was achieved by the AF+C arm (94% vs. 70% at 3 years, p = 0.008), but both the AF arm and the CF+C arm were insignificant (p {>=} 0.38). Multivariate analyses showed that CRT was a significant factor: hazard ratio (HR) = 0.52 (0.28-0.97), AF per se was insignificant: HR = 0.68 (0.37-1.25); the interaction of CRT by AF was strongly significant (p = 0.006). Both CRT arms had significant increase in acute toxicities (p < 0.005), and the AF+C arm also incurred borderline increase in late toxicities (34% vs. 14% at 3 years, p = 0.05). Conclusions: Preliminary results suggest that concurrent chemoradiotherapy with accelerated fractionation could significantly improve tumor control when compared with conventional RT alone; further confirmation of therapeutic ratio is warranted.

Lee, Anne W.M. [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China)]. E-mail: awmlee@ha.org.hk; Tung, Stewart Y. [Tuen Mun Hospital, Hong Kong (China); Chan, Anthony T.C. [Prince of Wales Hospital, Hong Kong (China); Chappell, Rick [Department of Biostatistics, University of Wisconsin Medical School, Madison, WI (United States); Fu, Y.-T. [Queen Elizabeth Hospital, Hong Kong (China); Lu, Tai-Xiang [Cancer Center, Sun Yat Sen University, Guangzhou (China); Tan, Terence [National Cancer Center, Singapore (Japan); Chua, Daniel T.T. [Queen Mary Hospital, Hong Kong (China); O'Sullivan, Brian [Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario (Canada); Xu, Shirley L. [Center for Clinical Trials, Chinese University of Hong Kong, Hong Kong (China); Pang, Ellie S.Y. [Center for Epidemiology and Biostatistics, Chinese University of Hong Kong, Hong Kong (China); Sze, W.-M. [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China); Leung, T.-W. [Tuen Mun Hospital, Hong Kong (China); Kwan, W.-H. [Prince of Wales Hospital, Hong Kong (China); Chan, Paddy [Queen Elizabeth Hospital, Hong Kong (China); Liu, X.-F. [Cancer Center, Sun Yat Sen University, Guangzhou (China); Tan, E.-H. [National Cancer Center, Singapore (Japan); Sham, Jonathan [Queen Mary Hospital, Hong Kong (China); Siu, Lillian [Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario (Canada); Lau, W.-H. [Queen Elizabeth Hospital, Hong Kong (China)

2006-09-01

91

Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: Which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study  

Microsoft Academic Search

BACKGROUND: There is currently no standard adjuvant therapy for patients with curatively resected extrahepatic biliary tract cancer (EHBTC). The aim of this study was to analyze the clinical features and outcomes between patients undergoing adjuvant concurrent chemoradiation therapy (CCRT) alone and those undergoing CCRT followed by adjuvant chemotherapy after curative resection. METHODS: We included 120 patients with EHBTC who underwent

Kyu-Hyoung Lim; Do-Youn Oh; Eui Kyu Chie; Jin-Young Jang; Seock-Ah Im; Tae-You Kim; Sun-Whe Kim; Sung Whan Ha; Yung-Jue Bang

2009-01-01

92

Concurrent common knowledge: a new definition of agreement for asynchronous systems  

Microsoft Academic Search

In this paper we discuss a new knowledgetheoretic definition of agreement appropriate to asynchronous systems. This definition has two important features; first, it uses causality rather than time in its definition and, second, this form of agreement is attainable. In analogy with common knowledge, it is called concurrent common knowledge. Concurrent common knowledge has several applications and we give analyses

Praskash Panangaden; Kim Taylor

1988-01-01

93

Deadlock avoidance in flexible manufacturing systems with concurrently competing process flows  

Microsoft Academic Search

The concurrent flow of multiple jobs through a FMS can lead to deadlock conditions due to competition for limited resources in the system. The authors develop a Petri net (PN) model of concurrent job flow and dynamic resource allocation in an FMS and define deadlock in terms of transition enabling in the PN model. The problem of deadlock avoidance is

Z. A. Banaszak; B. H. Krogh

1990-01-01

94

A Multiple Views Management System for Concurrent Engineering and PLM  

Microsoft Academic Search

Product Lifecycle Management (PLM) is an approach for controlling and exploiting product-related information throughout its lifecycle as needed by various business functions. Concurrent engineering (CE) integrates several disciplines contributing to product design. Both PLM and CE involve information sharing amongst disciplines having a specific point of view regarding the product. While each discipline exerts its own expertise and methods on

Nadjib Bouikni; Louis Rivest; Alain Desrochers

2008-01-01

95

Report on the feasibility of hypercube concurrent processing systems in computational fluid dynamics  

NASA Astrophysics Data System (ADS)

The feasibility of using hypercube-connected concurrent processor systems for problems in computational fluid dynamics is studied. Both explicit and implicit numerical methods are considered and several alternative implementations of these methods are evaluated on concurrent processor systems. A Lax-Wendroff explicit method was designed and implemented for the Navier-Stokes equations. The code runs on the Intel iPSC concurrent processor system. Tests of this code show that it is reasonably efficient. The Beam and Warming implicit factored method was designed and implemented for Berger's equation. Preliminary tests show that the efficiency of code is poor.

Bruno, J.

1986-03-01

96

Primary central nervous system lymphoma: Treatment with chemotherapy and radiotherapy  

Microsoft Academic Search

Between 1989 and 1993, 22 HIV negative patients with primary central nervous system lymphoma (PCNLS) were treated with three different regimens. In group A, 13 patients received preradiotherapy systemic and intrathecal methotrexate (MTX), radiotherapy (RT) and three courses of post-RT chemotherapy (CT) with thiotepa and procarbazine. In group B, 4 patients received a similar CT only after RT and without

M. Sarazin; A. Ameri; A. Monjour; A. Nibio; M. Poisson; J. Y. Delattre

1995-01-01

97

Severe Rhabdomyolysis Associated With Concurrent Use of Simvastatin and Sirolimus After Cisplatin-Based Chemotherapy in a Kidney Transplant Recipient.  

PubMed

Objectives: Cardiovascular disease is the most common cause of sickness and death for long-term kidney transplant recipients, and dyslipidemia is an important risk factor for developing cardiovascular disease. Lipid-lowering strategies, with the use of statins, have been shown to reduce the cardiovascular risks related to dyslipidemia, but concomitant use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and immunosuppressive agents may increase the risk of rhabdomyolysis owing to a drug-drug interaction. We report a case of simvastatin-induced rhabdomyolysis and acute kidney injury triggered by addition of sirolimus and cisplatin-based chemotherapy to a kidney transplant recipient who had previously tolerated chronic statin therapy. PMID:23734754

Hong, Yu Ah; Kim, Hyung Duk; Jo, Kwanhoon; Park, Yun Kyung; Lee, Jonghoon; Sun, In O; Chung, Byung Ha; Park, Cheol Whee; Yang, Chul Woo; Choi, Bum Soon

2013-05-29

98

A concurrent distributed system for aircraft tactical decision generation  

Microsoft Academic Search

A research program investigating the use of artificial intelligence (AI) techniques to aid in the development of a tactical decision generator (TDG) for within visual range (WVR) air combat engagements is discussed. The application of AI programming and problem-solving methods in the development and implementation of a concurrent version of the computerized logic for air-to-air warfare simulations (CLAWS) program, a

John W. McManus

1990-01-01

99

Elective lymph node irradiation late course accelerated hyper-fractionated radiotherapy plus concurrent cisplatin-based chemotherapy for esophageal squamous cell carcinoma: a phase II study  

PubMed Central

Background In this phase II study, we evaluated the efficacy, toxicity, and patterns of failure of elective lymph node irradiation (ENI) late course accelerated hyper-fractionated radiotherapy (LCAHRT) concurrently with cisplatin-based chemotherapy (CHT) for esophageal squamous cell carcinoma (ESCC). Methods Patients with clinical stage II-IVa (T1-4N0-1M0 or M1a) ESCC were enrolled between 2004 and 2011. Radiation therapy (RT) comprised two courses: The first course of radiation covered the primary and metastatic regional tumors and high risk lymph nodal regions, given at 2 Gy per fraction for a dose of 40 Gy. In the second course, LCAHRT was delivered to the boost volume twice a day for an additional 19.6 Gy in 7 treatment days, using 1.4 Gy per fraction. Two cycles of CHT were given at the beginning of RT. Results The median age and Karnofsky performance status were 63 years and 80, respectively. The American Joint Committee on Cancer stage was II in 14 (20.6%) patients, III in 32 (47.1%), and IVa in 22 (32.3%). With a median follow-up of 18.5 months, the overall survival at 1-, 3-, 5-year were 75.5%, 46.5%, 22.7% for whole group patients, versus 78.6%, 49.4%, 39.9% for patients with stage II–III. The patterns of first failure from local recurrence, regional failure, and distant metastasis were seen in 20.6%, 17.6%, and 19.1%, respectively. The most frequent acute high-grade (? 3) toxicities were esophagitis and leucopenia, occurred in 26.4% and 32.4%. Conclusions ENI LCAHRT concurrently with CHT was appeared to be an effective regimen for ESCC patient with a favorable and tolerated profile. Further observation with longer time and randomized phase III trial is currently underway. Trial registration ChiCTR-TRC-09000568

2013-01-01

100

The optimistic locking concurrency controlling algorithm based on relative position and its application in real-time collaborative editing system  

Microsoft Academic Search

Locking mechanism is a popular concurrency control mechanism in distributed computing and database system used to ensure data integrity by prohibiting concurrent conflicting updates on shared data objects. The response of traditional locking is slow, so it can't be used as concurrency controlling strategy for real-time distributed collaborative systems. In this paper, we proposed a responsive fine-grain optimistic locking concurrency

Qirong Mao; Jinfeng Wang; Yongzhao Zhan

2004-01-01

101

The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck  

Microsoft Academic Search

Purpose  Several studies have shown that the concurrent administration of chemotherapy (CHT) and radiotherapy (RT) is superior to RT\\u000a alone in patients with inoperable non-metastatic squamous cell carcinoma of the head and neck (InSCCHN). We compared the efficacy\\u000a and safety profile of RT and concurrent cisplatin CHT given in two different schedules to patients with previously untreated\\u000a InSCCHN.\\u000a \\u000a \\u000a \\u000a Methods  Fifty patients with

Kazim Uygun; Ahmet Bilici; Hakan Karagol; Murat Caloglu; Irfan Cicin; Gorkem Aksu; Merdan Fayda; Sernaz Uzunoglu

2009-01-01

102

Synthesis of concurrent system interface modules with automatic protocol conversion generation  

Microsoft Academic Search

We describe a new high-level compiler called Integral for designing system interface modules. The input is a high-level concurrent algorithmic specification that can model complex concurrent control flow, logical and arithmetic computations, abstract communication, and low-level behavior. For abstract communication between two communicating modules that obey different I\\/O protocols, the necessary protocol conversion behaviors are automatically synthesized using a Petri

Bill Lin; Steven Vercauteren

1994-01-01

103

Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia—a randomized, placebo-controlled, double-blind safety and efficacy study  

Microsoft Academic Search

Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) administered after acute myeloid leukemia (AML) chemotherapy (CT) failed to shorten the time of transfusion-dependent thrombocytopenia in a previous study. In this multicenter, randomized, placebo-controlled, double-blind study we determined the effect of administration of PEG-rHuMGDF prior to CT and of administration prior, concurrent, and 1 day post CT on platelet recovery and

K. Geissler; J. A. Liu Yin; A. Ganser; M. A. Sanz; J. Szer; A. Raghavachar; D. Hoelzer; C. Martinez; K. Taylor; L. Kanz; L. B. To; E. Archimbaud

2003-01-01

104

NETWORK LANGUAGES FOR CONCURRENT MULTIAGENT SYSTEMS D R A F T  

Microsoft Academic Search

This paper** reports new results in the development of Linguistic Geometry towards concurrent multiagent aerospace systems. This formal theory is intended to discover the inner properties of human expert heuristics, which have been successful in a certain class of complex control systems, and apply them to different systems. The Linguistic Geometry relies on the formalization of search heuristics of the

Boris Stilman

105

Dynamic priority ceilings: A concurrency control protocol for real-time systems  

Microsoft Academic Search

Real-time systems have stringent deadline requirements for their tasks. To meet the requirements, a real-time system must use scheduling algorithms that ensure a predictable response even in the face of mutually exclusive accesses to critical sections. We present a concurrency control protocol for systems using the earliest deadline first scheduling algorithm. The protocol specifies a dynamic priority ceiling for each

Min-Ih Chen; Kwei-Jay Lin

1990-01-01

106

Chemotherapy for metastatic tumors to the central nervous system  

Microsoft Academic Search

Management of patients with central nervous system metastases poses numerous challenges. This review focuses on the use of\\u000a chemotherapy in these patients, addressing treatment difficulties such as drug resistance and possible solutions. The impact\\u000a of the blood-brain barrier is considered less of a limitation than once thought. The advent of targeted signal transduction\\u000a inhibitors is noted in this context. The

Charles A. Conrad

2001-01-01

107

Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer  

Microsoft Academic Search

We review the current literature on systemic therapy for patients with metastatic renal cell carcinoma. Metastatic renal\\u000a cell carcinoma remains highly resistant to chemotherapy and hormonal agents not justifying its use as a single agent. Interleukin-2\\u000a immunotherapy is the most effective treatment for metastatic renal cell carcinoma available today. There is evidence that\\u000a interleukin-2 improves survival and yields long-lasting remissions

Hans Heinzer; Edith Huland; Hartwig Huland

2001-01-01

108

The database design for a decision support system for breast cancer chemotherapy  

Microsoft Academic Search

Post operative adjuvant chemotherapy of operable breast cancer has rapidly expanded in the past quarter of century. At present adjuvant chemotherapy administration is widely used in clinical practice even by physicians who are not involved full-time in cancer patient care. A decision support system is presented for post operative adjuvant chemotherapy for breast cancer. The system has been implemented in

C. Ruggieroa; M. Giacominia; G. Bondadonna; P. Valagussa; R. Demicheli

1998-01-01

109

Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer  

SciTech Connect

Purpose: For locoregionally advanced inoperable non-small-cell lung cancer (NSCLC), concurrent chemoradiotherapy has become a standard therapy. We conducted a Phase II trial to examine the efficacy and toxicity of adding gemcitabine and vinorelbine induction chemotherapy to concurrent chemoradiotherapy with oral etoposide and cisplatin. Methods and Materials: Eligibility included inoperable clinical Stage III NSCLC without pleural effusion, ECOG performance status 0-1, and weight loss {<=}5%. Induction chemotherapy consisted of three cycles of gemcitabine 1,000 mg/m{sup 2} and vinorelbine 30 mg/m{sup 2}, each given i.v. on Days 1 and 8, every 3 weeks. During once-daily thoracic radiotherapy (1.8 Gy/day, total 63 Gy), two cycles of oral etoposide (100 mg on Days 1-5 and 8-12) plus cisplatin (50 mg/m{sup 2} on Days 1 and 8) were given concurrently 4 weeks apart. Results: Between April 2002 and November 2003, 42 patients were enrolled and 40 were included in response and toxicity evaluation. The median age was 59 years and 13 patients had IIIA and 27 had IIIB; 24 had squamous ca, 12 had adenocarcinoma, and 4 had others. Objective tumor responses were obtained in 29 patients (72.5%), including 18 (45.0%) after induction chemotherapy. After a median follow-up of 23.8 months, the median survival time and progression-free survival was 23.2 months and 10.9 months, respectively, with 2-year survival rate of 43.9%. For the patients with supraclavicular nodal involvement, the median survival time was 11.8 months with 2-year survival rate of 16.7%, whereas the corresponding figures were 27.8 months and 52.0%, respectively, for those without supraclavicular nodal involvement. Toxicity of induction chemotherapy was mild and well tolerated. However, concurrent chemoradiotherapy was associated with G3/4 hematologic toxicity in 75.7%, G3 esophagitis in 24.2%, and two treatment-related deaths. There were nonlife-threatening late toxicities in additional 6 patients. Conclusions: Induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with etoposide and cisplatin showed very promising survival in patients with Stage III NSCLC, especially in those without supraclavicular nodal involvement, which warrants further evaluation.

Lee, Dae Ho [Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi (Korea, Republic of); Han, Ji-Youn [Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi (Korea, Republic of); Cho, Kwan Ho [Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi (Korea, Republic of); Pyo, Hong Ryull [Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi (Korea, Republic of); Kim, Hyae Young [Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi (Korea, Republic of); Yoon, Sung Jin B.S. [Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi (Korea, Republic of); Lee, Jin Soo [Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi (Korea, Republic of)]. E-mail: jslee@ncc.re.kr

2005-11-15

110

High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study  

PubMed Central

Background Increasing the radiotherapy dose can result in improved local control for non-small-cell lung cancer (NSCLC) and can thereby improve survival. Accelerated hypofractionated radiotherapy can expose tumors to a high dose of radiation in a short period of time, but the optimal treatment regimen remains unclear. The purpose of this study was to evaluate the feasibility of utilizing high-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for the treatment of local advanced NSCLC. Methods Untreated patients with unresectable stage IIIA/IIIB NSCLC or patients with a recurrence of NSCLC received accelerated hypofractionated three-dimensional conformal radiotherapy. The total dose was greater than or equal to 60 Gy. The accelerated hypofractionated radiotherapy was conducted once daily at 3 Gy/fraction with 5 fractions per week, and the radiotherapy was completed in 5 weeks. In addition to radiotherapy, the patients also received at least 1 cycle of a concurrent two-drug chemotherapy regimen of NVB and CBP. Results A total of 26 patients (19 previously untreated cases and 7 cases of recurrent disease) received 60Gy-75Gy radiotherapy with concurrent chemotherapy. All of the patients underwent evaluations for toxicity and preliminary therapeutic efficacy. There were no treatment-related deaths within the entire patient group. The major acute adverse reactions were radiation esophagitis (88.5%) and radiation pneumonitis (42.3%). The percentages of grade III acute radiation esophagitis and grade III radiation pneumonitis were 15.4% and 7.7%, respectively. Hematological toxicities were common and did not significantly affect the implementation of chemoradiotherapy after supportive treatment. Two patients received high dose of 75 Gy had grade III late esophageal toxicity, and none had grade IV and above. Grade III and above late lung toxicity did not occur. Conclusion High-dose accelerated hypofractionated three-dimensional conformal radiotherapy with a dose of 60 Gy or greater with concurrent NVB and CBP chemotherapy might be feasible. However esophagus toxicity needs special attention. A phase I trial is recommended to obtain the maximum tolerated radiation dose of accelerated hypofractionated radiotherapy with concurrent chemotherapy.

2013-01-01

111

A concurrent facility design procedure for flexible manufacturing systems  

Microsoft Academic Search

This paper describes a facility design procedure for minimizing work-in-process (WIP) storage requirements in a flexible manufacturing system (FMS). An FMS is defined as a set of workcenters in a line layout that are linked by a materials handling system consisting of an automated guided vehicle system (AGVS) supplemented by a secondary handling system. The secondary handling system is used

Charles J. Malmborg

1994-01-01

112

ICOS: an intelligent concurrent object-oriented synthesis methodology for multiprocessor systems  

Microsoft Academic Search

The design of multiprocessor architectures differs from uniprocessor systems in that the number of processors and their interconnection must be considered. This leads to an enormous increase in the design-space exploration time, which is exponential in the total number of system components. The methodology proposed here, called Intelligent Concurrent Object-Oriented Synthesis (ICOS) methodology, makes feasible the synthesis of complex multiprocessor

Pao-Ann Hsiung; Chung-Hwang Chen; Trong-Yen Lee; Sao-Jie Chen

1998-01-01

113

Refinement and Verification of Concurrent Systems Specified in Object-Z and CSP  

Microsoft Academic Search

The formal development of large or complex systems can often be facilitated by the use ofmore then one formal specification language. Such a combination of languages is particularlysuited to the specification of concurrent or distributed systems, where both the modellingof processes and state is necessary. This paper presents an approach to refinement andverification of specifications written using a combination of

Graeme Smith

1997-01-01

114

Property Preserving Abstractions for the Verification of Concurrent Systems  

Microsoft Academic Search

We study property preserving transformations for reactive systems. The main idea isthe use of simulations parameterizedby Galois connections (ff; fl), relating the lattices of propertiesof two systems. We propose and study a notion of preservation of properties expressed by formulasof a logic, by a function ff mapping sets of states of a system S into sets of states of a

Claire Loiseaux; Susanne Graf; Joseph Sifakis; Ahmed Bouajjani; Saddek Bensalem; David Probst

1995-01-01

115

Concurrent testing of droplet-based microfluidic systems for multiplexed biomedical assays  

Microsoft Academic Search

We present a concurrent testing methodology for detecting catastrophic faults in droplet-based microfluidic systems and investigate the related problems of test planning and resource optimization. We apply this methodology to a droplet-based microfluidic array that was fabricated and used to perform multiplexed glucose and lactate assays. The test approach interleaves test application with the biomedical assays and prevents resource conflicts.

Fei Su; Sule Ozev; Krishnendu Chakrabarty

2004-01-01

116

Scheduling Support for Concurrency and Parallelism in the Mach Operating System  

Microsoft Academic Search

Changes in the use of multiprocessors are placing new demands on operating system schedulers. This article describes some of the new challenges posed by parallel and concurrent applications, and introduces techniques developed by the Mach project to meet these challenges. An overview of the techniques of timesharing scheduling and a description of the Mach scheduler are also included. This article

David L. Black

1990-01-01

117

A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma  

SciTech Connect

Purpose: The aim of this study was to compare toxicity/efficacy of conventional radiotherapy using delayed accelerated concomitant boost radiotherapy (CBRT) vs. intensity-modulated radiotherapy (IMRT) in the setting of concurrent chemotherapy (CT) for locally advanced oropharyngeal carcinoma. Methods and Materials: Between September 1998 and June 2004, a total of 293 consecutive patients were treated at our institution for cancer of the oropharynx. Of these, 112 had Stage III/IV disease and squamous cell histology. In all, 41 were treated with IMRT/CT and 71 were treated with CBRT/CT, both to a median dose of 70 Gy. Most common CT was a planned two cycles given every 3 to 4 weeks of cisplatin, 100 mg/m{sup 2} i.v., but an additional cycle was given to IMRT patients when possible. Both groups were well-matched for all prognostic factors. Results: Median follow-up was 46 months (range, 3-93 months) for the CBRT patients and 31 months (range, 20-64 months) for the IMRT group. Three-year actuarial local-progression-free, regional-progression-free, locoregional progression-free, distant-metastases-free, disease-free, and overall survival rates were 85% vs. 95% (p = 0.17), 95% vs. 94% (p = 0.90), 82% vs. 92% (p = 0.18), 85% vs. 86% (p = 0.78), 76% vs. 82% (p = 0.57), and 81% vs. 91% (p = 0.10) for CBRT and IMRT patients, respectively. Three patients died of treatment-related toxicity in the CBRT group vs. none undergoing IMRT. At 2 years, 4% IMRT patients vs. 21% CBRT patients were dependent on percutaneous endoscopic gastrostomy (p = 0.02). Among those who had {>=}20 months follow-up, there was a significant difference in Grade {>=}2 xerostomia as defined by the criteria of Radiation Therapy and Oncology Group, 67% vs. 12% (p = 0.02), in the CBRT vs. IMRT arm. Conclusion: In the setting of CT for locally advanced oropharyngeal carcinoma, IMRT results in lower toxicity and similar treatment outcomes when compared with CBRT.

Lee, Nancy Y. [Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)]. E-mail: leen2@mskcc.org; Arruda, Fernando F. de [Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Puri, Dev R. [Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Wolden, Suzanne L. [Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Narayana, Ashwatha [Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Mechalakos, James [Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Venkatraman, Ennapadam S. [Department of Biostatics, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Kraus, Dennis [Department of Surgery, Division of Head and Neck Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Shaha, Ashok [Department of Surgery, Division of Head and Neck Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Shah, Jatin P. [Department of Surgery, Division of Head and Neck Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Pfister, David G. [Department of Medicine, Division of Head and Neck Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Zelefsky, Michael J. [Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)

2006-11-15

118

Monitoring Dosimetric Impact of Weight Loss With Kilovoltage (KV) Cone Beam CT (CBCT) During Parotid-Sparing IMRT and Concurrent Chemotherapy  

SciTech Connect

Purpose: Parotid-sparing head-and-neck intensity-modulated radiotherapy (IMRT) can reduce long-term xerostomia. However, patients frequently experience weight loss and tumor shrinkage during treatment. We evaluate the use of kilovoltage (kV) cone beam computed tomography (CBCT) for dose monitoring and examine if the dosimetric impact of such changes on the parotid and critical neural structures warrants replanning during treatment. Methods and materials: Ten patients with locally advanced oropharyngeal cancer were treated with contralateral parotid-sparing IMRT concurrently with platinum-based chemotherapy. Mean doses of 65 Gy and 54 Gy were delivered to clinical target volume (CTV)1 and CTV2, respectively, in 30 daily fractions. CBCT was prospectively acquired weekly. Each CBCT was coregistered with the planned isocenter. The spinal cord, brainstem, parotids, larynx, and oral cavity were outlined on each CBCT. Dose distributions were recalculated on the CBCT after correcting the gray scale to provide accurate Hounsfield calibration, using the original IMRT plan configuration. Results: Planned contralateral parotid mean doses were not significantly different to those delivered during treatment (p > 0.1). Ipsilateral and contralateral parotids showed a mean reduction in volume of 29.7% and 28.4%, respectively. There was no significant difference between planned and delivered maximum dose to the brainstem (p = 0.6) or spinal cord (p = 0.2), mean dose to larynx (p = 0.5) and oral cavity (p = 0.8). End-of-treatment mean weight loss was 7.5 kg (8.8% of baseline weight). Despite a {>=}10% weight loss in 5 patients, there was no significant dosimetric change affecting the contralateral parotid and neural structures. Conclusions: Although patient weight loss and parotid volume shrinkage was observed, overall, there was no significant excess dose to the organs at risk. No replanning was felt necessary for this patient cohort, but a larger patient sample will be investigated to further confirm these results. Nevertheless, kilovoltage CBCT is a valuable tool for patient setup verification and monitoring of dosimetric variation during radiotherapy.

Ho, Kean Fatt, E-mail: hokeanfatt@hotmail.com [Academic Radiation Oncology, The Christie NHS Foundation Trust, Manchester (United Kingdom); Marchant, Tom; Moore, Chris; Webster, Gareth; Rowbottom, Carl [North Western Medical Physics, The Christie NHS Foundation Trust, Manchester (United Kingdom); Penington, Hazel [Wade Radiotherapy Research Centre, The Christie NHS Foundation Trust, Manchester (United Kingdom); Lee, Lip; Yap, Beng; Sykes, Andrew; Slevin, Nick [Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester (United Kingdom)

2012-03-01

119

Mobile UNITY: A Language and Logic for Concurrent Mobile Systems  

Microsoft Academic Search

Traditionally, a distributed system has been viewed as a collection of fixed computational elements connected by a static network. Prompted by recent advances in wireless communications technology, the emerging field of mobile computing is challenging these assumptions by providing mobile hosts with connectivity that may change over time, raising the possibility that hosts may be called upon to operate while

Peter J. McCann; Gruia-Catalin Roman

1996-01-01

120

Concurrency control strategy in real-time collaborative editing system  

Microsoft Academic Search

The common synchronous problems in a real-time collaborative editing system are analysed and classified in this paper. The limitations of existing methods which solved the synchronous problems are discussed. In order to solve these problems, the operation conversion algorithm and document marking algorithm are studied. An operation conversion method based on conceal\\/resume mechanism is proposed to solve the synchronous problems

Junlan Liu; Yan Shao; Guifa Teng; Wei Yao; Sufen Dong

2010-01-01

121

Concurrent synaptic and systems memory consolidation during sleep.  

PubMed

Memories are consolidated during sleep by two apparently antagonistic processes: (1) reinforcement of memory-specific cortical interactions and (2) homeostatic reduction in synaptic efficiency. Using fMRI, we assessed whether episodic memories are processed during sleep by either or both mechanisms, by comparing recollection before and after sleep. We probed whether LTP influences these processes by contrasting two groups of individuals prospectively recruited based on BDNF rs6265 (Val66Met) polymorphism. Between immediate retrieval and delayed testing scheduled after sleep, responses to recollection increased significantly more in Val/Val individuals than in Met carriers in parietal and occipital areas not previously engaged in retrieval, consistent with "systems-level consolidation." Responses also increased differentially between allelic groups in regions already activated before sleep but only in proportion to slow oscillation power, in keeping with "synaptic downscaling." Episodic memories seem processed at both synaptic and systemic levels during sleep by mechanisms involving LTP. PMID:23761912

Mascetti, Laura; Foret, Ariane; Schrouff, Jessica; Muto, Vincenzo; Dideberg, Vinciane; Balteau, Evelyne; Degueldre, Christian; Phillips, Christophe; Luxen, André; Collette, Fabienne; Bours, Vincent; Maquet, Pierre

2013-06-12

122

Usefulness of Interim FDG-PET After Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Sequential Induction Chemotherapy Followed by Concurrent Chemoradiotherapy  

SciTech Connect

Purpose: Induction chemotherapy (ICT) has been used to select patients for organ preservation and determine subsequent treatments in patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN). Still, the clinical outcomes of LASCCHN patients who showed response to ICT are heterogeneous. We evaluated the efficacy of interim 18-fluoro-2-deoxy-glucose positron emission tomography (FDG-PET) after ICT in this specific subgroup of LASCCHN patients who achieved partial response (PR) after ICT to predict clinical outcomes after concurrent chemoradiotherapy (CCRT). Methods and Materials: Twenty-one patients with LASCCHN who showed PR to ICT by Response Evaluation Criteria In Solid Tumors before definitive CCRT were chosen in this retrospective analysis. FDG-PET was performed before and 2-4 weeks after ICT to assess the extent of disease at baseline and the metabolic response to ICT, respectively. We examined the correlation of the metabolic response by the percentage decrease of maximum standardized uptake value (SUVmax) on the primary tumor or lymph node after ICT or a specific threshold of SUVmax on interim FDG-PET with clinical outcomes including complete response (CR) rate to CCRT, progression-free survival (PFS), and overall survival (OS). Results: A SUVmax of 4.8 on interim FDG-PET could predict clinical CR after CCRT (100% vs. 20%, p = 0.001), PFS (median, not reached vs. 8.5 mo, p < 0.001), and OS (median, not reached vs. 12.0 months, p = 0.001) with a median follow-up of 20.3 months in surviving patients. A 65% decrease in SUVmax after ICT from baseline also could predict clinical CR after CCRT (100% vs. 33.3%, p = 0.003), PFS (median, not reached vs. 8.9 months, p < 0.001) and OS (median, not reached vs. 24.4 months, p = 0.001) of the patients. Conclusion: These data suggest that interim FDG-PET after ICT might be a useful determinant to predict clinical outcomes in patients with LASCCHN receiving sequential ICT followed by CCRT.

Yoon, Dok Hyun; Cho, Yoojin [Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of); Kim, Sang Yoon; Nam, Soon Yuhl; Choi, Seung-Ho; Roh, Jong-Lyel [Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of); Lee, Sang-wook; Song, Si Yeol [Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of); Lee, Jeong Hyun [Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of); Kim, Jae Seung [Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of); Cho, Kyung-Ja [Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of); Kim, Sung-Bae, E-mail: sbkim3@amc.seoul.kr [Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of)

2011-09-01

123

Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer  

PubMed Central

The optimal adjuvant treatment modality for gastric cancer has not been well defined. The aim of this study was to evaluate the efficacy and feasibility of adjuvant combined systemic and intraperitoneal chemotherapy (ACSIP) in high-risk patients with locally advanced gastric cancer. Between June 2003 and December 2008, 62 eligible patients with serosa-infiltrating and/or node-positive gastric cancer following curative gastrectomy with D2 lymphadenectomy received ACSIP, consisting of intravenous oxaliplatin 85 mg/m2 on day 1 followed by leucovorin (LV) 200 mg/m2 and 5-fluorouracil (5-FU) 450 mg/m2 on days 1–3, intraperitoneal 5-FU 600 mg/m2 on days 4–5 and cisplatin (CDDP) 40 mg/m2 on day 5. Survival rates, the sites of first treatment failure and safety were analyzed. At a median follow-up of 45 months (range 7–101), the 3-year disease-free survival (DFS) and overall survival (OS) rates were 66.1 and 74.2%, respectively. Initial peritoneal and hepatic failures were found in 6 (24.0%) and 3 (12.0%) of the 25 patients with recurrence, respectively. Neutropenia, gastrointestinal side effects and peripheral neuropathy were the most common grade 3–4 toxicities; however, they were all infrequent and manageable. No serious surgical complications or treatment-related mortality was observed. The results of this study indicate that ACSIP is effective and feasible for locally advanced gastric cancer with encouraging survival rates and possibly decreased peritoneal and hepatic recurrences. The benefits of this promising combined adjuvant treatment modality warrant further studies.

XUE, SHENG-LIU; SU, HUA-FANG; HU, XIAO-QU; DENG, XIA; HU, MEI-LONG; XIE, CONG-YING

2012-01-01

124

Pulmonary toxicity in stage III non-small cell lung cancer patients treated with high dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: A secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105  

PubMed Central

Purpose CALGB 30105 tested two different concurrent chemoradiotherapy platforms with high dose (74 Gy) 3-D conformal radiotherapy (3DCRT) following two cycles of induction chemotherapy for stage IIIA/IIIB NSCLC patients to determine if either could achieve a primary endpoint of > 18 month median survival. Final results of 30105 demonstrated that induction carboplatin and gemcitabine and concurrent gemcitabine 3DCRT was not feasible due to treatment related toxicity. However, induction and concurrent carboplatin/paclitaxel with 74 Gy 3DCRT had a median survival of 24 months, and is the basis for the experimental arm in CALGB 30610/RTOG 0617/N0628. We conducted a secondary analysis of all patients to determine predictors of treatment related pulmonary toxicity. Methods and Materials Patient, tumor, and treatment related variables were analyzed to determine their relation with treatment related pulmonary toxicity. Results Older age, higher N stage, larger PTV1, smaller TLV/PTV1 ratio, larger V20, and larger mean lung dose were associated with increasing pulmonary toxicity on univariate analysis. Multivariate analysis confirmed that V20 and nodal stage as well as treatment with concurrent gemcitabine were associated with treatment related toxicity. A high risk group comprising patients with N3 disease and V20>38% was associated with 80% of grade 3–5 pulmonary toxicity cases. Conclusions Elevated V20 and N3 disease status are important predictors of treatment related pulmonary toxicity in patients treated with high dose 3DCRT with concurrent chemotherapy. Further studies may use these metrics in considering patients for these treatments.

Salama, Joseph K.; Stinchcombe, Thomas E.; Gu, Lin; Wang, Xiaofei; Morano, Karen; Bogart, Jeffrey A.; Crawford, Jeffrey C.; Socinski, Mark A.; Blackstock, A. William; Vokes, Everett E.

2011-01-01

125

Pulmonary Toxicity in Stage III Non-Small Cell Lung Cancer Patients Treated With High-Dose (74 Gy) 3-Dimensional Conformal Thoracic Radiotherapy and Concurrent Chemotherapy Following Induction Chemotherapy: A Secondary Analysis of Cancer and Leukemia Group B (CALGB) Trial 30105  

SciTech Connect

Purpose: Cancer and Leukemia Group B (CALGB) 30105 tested two different concurrent chemoradiotherapy platforms with high-dose (74 Gy) three-dimensional conformal radiotherapy (3D-CRT) after two cycles of induction chemotherapy for Stage IIIA/IIIB non-small cell lung cancer (NSCLC) patients to determine if either could achieve a primary endpoint of >18-month median survival. Final results of 30105 demonstrated that induction carboplatin and gemcitabine and concurrent gemcitabine 3D-CRT was not feasible because of treatment-related toxicity. However, induction and concurrent carboplatin/paclitaxel with 74 Gy 3D-CRT had a median survival of 24 months, and is the basis for the experimental arm in CALGB 30610/RTOG 0617/N0628. We conducted a secondary analysis of all patients to determine predictors of treatment-related pulmonary toxicity. Methods and Materials: Patient, tumor, and treatment-related variables were analyzed to determine their relation with treatment-related pulmonary toxicity. Results: Older age, higher N stage, larger planning target volume (PTV)1, smaller total lung volume/PTV1 ratio, larger V20, and larger mean lung dose were associated with increasing pulmonary toxicity on univariate analysis. Multivariate analysis confirmed that V20 and nodal stage as well as treatment with concurrent gemcitabine were associated with treatment-related toxicity. A high-risk group comprising patients with N3 disease and V20 >38% was associated with 80% of Grades 3-5 pulmonary toxicity cases. Conclusions: Elevated V20 and N3 disease status are important predictors of treatment related pulmonary toxicity in patients treated with high-dose 3D-CRT and concurrent chemotherapy. Further studies may use these metrics in considering patients for these treatments.

Salama, Joseph K., E-mail: joseph.salama@duke.edu [Duke University Medical Center, Durham, NC (United States); Stinchcombe, Thomas E. [University of North Carolina at Chapel Hill, Chapel Hill, NC (United States); Gu Lin; Wang Xiaofei [CALGB Statistical Center, Duke University Medical Center, Durham, NC (United States); Morano, Karen [Quality Assurance Review Center, Lincoln, RI (United States); Bogart, Jeffrey A. [State University of New York Upstate Medical University, Syracuse, NY (United States); Crawford, Jeffrey C. [Duke University Medical Center, Durham, NC (United States); Socinski, Mark A. [University of North Carolina at Chapel Hill, Chapel Hill, NC (United States); Blackstock, A. William [Wake Forest University School of Medicine, Winston-Salem, NC (United States); Vokes, Everett E. [University of Chicago, Chicago, IL (United States)

2011-11-15

126

Association of Clinical and Dosimetric Factors with Postoperative Pulmonary Complications in Esophageal Cancer Patients Receiving Intensity-Modulated Radiation Therapy and Concurrent Chemotherapy Followed by Thoracic Esophagectomy  

Microsoft Academic Search

Background  To investigate the association between clinical\\/dosimetric factors and postoperative pulmonary complications (PPC) in esophageal\\u000a cancer patients undergoing neoadjuvant chemotherapy and intensity-modulated radiation therapy (IMRT) followed by thoracic\\u000a esophagectomy.\\u000a \\u000a \\u000a \\u000a Methods  The data from 52 patients receiving combined modality treatment were analyzed. Chemotherapy was taxane-based in 43 and 5-fluorouracil-based\\u000a in 9 patients. IMRT (40–45 Gy, median 40 Gy, at 1.8–2 Gy per fraction) was given using

Feng-Ming Hsu; Yung-Chie Lee; Jang-Ming Lee; Chih-Hung Hsu; Chia-Chi Lin; Yu-Chieh Tsai; Jian-Kuen Wu; Jason Chia-Hsien Cheng

2009-01-01

127

Transdermal evaporation delivery system of praziquantel for schistosomiasis japonicum chemotherapy.  

PubMed

A transdermal evaporation delivery system (TEDS) of praziquantel (PZQ) was developed by selecting ethylene glycol monophenyl ether as a nonvolatile component solvent and ethanol as a volatile component solvent to control efficiently the transmission and morbidity of the global schistosomiasis, providing a convenient administration system of PZQ for both humans and domestic animals. The solubility of PZQ in TEDS was more than 400 mg/mL when the ethanol concentration was 50% (w/w) in the solvent mixture at 32 °C, enabling to adapt requirements for the treatment of schistosomiasis. The highest serum drug concentration reached 35.93 µg/mL after transdermal administration of TEDS of PZQ in rabbits, being 6.3-fold higher than that after oral administration at the same dose. The TEDS of PZQ achieved treatment efficacy with the worm reduction of 100% when it was applied in the experimental treatment of Schistosoma japonicum in rabbits. The TEDS of PZQ that provides passive and nonocclusive delivery, having the inexpensive cost, low skin irritation rates, and precise dose of administration, should find application in the transmission control and chemotherapy of global schistosomiasis. PMID:21319162

Wang, Lei; Zheng, Xinsheng; Fang, Yan; Wang, Yi; Duan, Cunzheng; Yao, Baoan

2011-02-11

128

Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial  

PubMed Central

Background Accelerated hypofractionated radiotherapy can shorten total treatment time and overcome the accelerated repopulation of tumour cells during radiotherapy. This therapeutic approach has demonstrated good efficacy in the treatment of locally advanced non-small-cell lung cancer (NSCLC). However, the optimal fractionation scheme remains uncertain. The purpose of this phase I trial was to explore the maximum tolerated dose (MTD) of accelerated hypofractionated three-dimensional conformal radiotherapy (3-DCRT) (at 3 Gy/fraction) administered in combination with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for unresectable stage III NSCLC. Methods Previously untreated cases of unresectable stage III NSCLC received accelerated hypofractionated 3-DCRT, delivered at 3 Gy per fraction, once daily, with five fractions per week. The starting dose was 66 Gy and an increment of 3 Gy was utilized. Higher doses continued to be tested in patient groups until the emergence of dose-limiting toxicity (DLT). The MTD was regarded as the dose that was one step below the dose at which DLT occurred. Patients received at least one cycle of a concurrent two-drug chemotherapy regimen of NVB and CBP. Results A total of 13 patients were enrolled and progressed through three dose escalation groups: 66 Gy, 69 Gy, and 72 Gy. No treatment-related deaths occurred. The major adverse events included radiation oesophagitis, radiation pneumonitis, and neutropenia. Nausea, fatigue, and anorexia were commonly observed, although the magnitude of these events was typically relatively minor. Among the entire group, four instances of DLT were observed, including two cases of grade 3 radiation oesophagitis, one case of grade 3 radiation pneumonitis, and one case of grade 4 neutropenia. All of these cases of DLT occurred in the 72 Gy group. Therefore, 72 Gy was designated as the DLT dose level, and the lower dose of 69 Gy was regarded as the MTD. Conclusions For unresectable stage III NSCLC 69 Gy (at 3 Gy/fraction) was the MTD of accelerated hypofractionated 3-DCRT administered in combination with concurrent NVB and CBP chemotherapy. The toxicity of this chemoradiotherapy regimen could be tolerated. A phase II trial is recommended to further evaluate the efficacy and safety of this regimen.

2013-01-01

129

Concurrent Programming Made Easy  

Microsoft Academic Search

The task of programming concurrent systems is substan- tially more difficult than the task of programming sequen- tial systems with respect to both correctness and efficiency. In this paper we describe a constraint-based methodology for writing concurrent applications. A system is modeled as: (a) a set of processes containing a sequence of \\

Rafael Ramirez; Andrew E. Santosa; Roland H. C. Yap

2000-01-01

130

A Phase I/II trial of radiotherapy concurrent with TS-1 plus cisplatin in patients with clinically resectable type 4 or large type 3 gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1205.  

PubMed

A Phase I/II trial of radiotherapy administered concurrently with TS-1 plus cisplatin has been initiated in Japanese patients with clinical resectable type 4 or large type 3 gastric cancer. The aim of this trial is to determine the recommended dose of TS-1 and cisplatin combined with radiotherapy at a fixed dose in the Phase I study, and to evaluate the efficacy and safety in the Phase II study. The primary endpoint for Phase II is the pathological complete response rate, assessed using surgically resected specimens. Secondary endpoints are the response rate, progression-free survival, overall survival, operation transitional rate, R0 resection rate, rate of treatment completion, rate of down-staging and rates of postoperative complications and adverse events. In Phase II, a total of 30 patients will be enrolled in the Osaka Gastrointestinal Cancer Chemotherapy Study Group trial over a period of 6 years. PMID:23447812

Imano, Motohiro; Furukawa, Hiroshi; Yokokawa, Masaki; Nishimura, Yasumasa; Kurokawa, Yukinori; Satoh, Taroh; Sakai, Daisuke; Yasuda, Takushi; Imamoto, Haruhiko; Tujinaka, Toshimasa; Shimokawa, Toshio; Shiozaki, Hitoshi

2013-02-26

131

Concurrent Chemoradiotherapy Followed by Consolidation Chemotherapy With Bi-Weekly Docetaxel and Carboplatin for Stage III Unresectable, Non-Small-Cell Lung Cancer: Clinical Application of a Protocol Used in a Previous Phase II Study  

SciTech Connect

Purpose: To assess the clinical applicability of a protocol evaluated in a previously reported phase II study of concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin in patients with stage III, unresectable, non-small-cell lung cancer (NSCLC). Methods and Materials: Between January 2000 and March 2006, 116 previously untreated patients with histologically proven, stage III NSCLC were treated with concurrent chemoradiotherapy. Radiation therapy was administered in 2-Gy daily fractions to a total dose of 60 Gy in combination with docetaxel, 30 mg/m{sup 2}, and carboplatin at an area under the curve value of 3 every 2 weeks during and after radiation therapy. Results: The median survival time for the entire group was 25.5 months. The actuarial 2-year and 5-year overall survival rates were 53% and 31%, respectively. The 3-year cause-specific survival rate was 60% in patients with stage IIIA disease, whereas it was 35% in patients with stage IIIB disease (p = 0.007). The actuarial 2-year and 5-year local control rates were 62% and 55%, respectively. Acute hematologic toxicities of Grade {>=}3 severity were observed in 20.7% of patients, while radiation pneumonitis and esophagitis of Grade {>=}3 severity were observed in 2.6% and 1.7% of patients, respectively. Conclusions: The feasibility of the protocol used in the previous phase II study was reconfirmed in this series, and excellent treatment results were achieved.

Saitoh, Jun-Ichi, E-mail: junsaito@sannet.ne.jp [Division of Radiation Oncology, Saitama Cancer Center, Saitama (Japan); Saito, Yoshihiro; Kazumoto, Tomoko; Kudo, Shigehiro; Yoshida, Daisaku; Ichikawa, Akihiro [Division of Radiation Oncology, Saitama Cancer Center, Saitama (Japan); Sakai, Hiroshi; Kurimoto, Futoshi [Division of Respiratory Disease, Saitama Cancer Center, Saitama (Japan); Kato, Shingo [Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba (Japan); Shibuya, Kei [Department of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma (Japan)

2012-04-01

132

Systemic Chemotherapy for Metastatic Tumors of the Central Nervous System  

Microsoft Academic Search

The incidence of brain metastases exceeds 100,000 per year in the United States (21), thus making tumor metastasis to the central nervous system (CNS) a significant challenge in the management of patients\\u000a with solid tumors. To put this into perspective, brain metastases occur at almost one order of magnitude greater than primary\\u000a malignant brain tumors. Metastatic tumors to the brain

Charles A. Conrad; W. K. Alfred Yung

133

Feasibility and Efficacy of Induction Docetaxel, Cisplatin, and 5-Fluorouracil Chemotherapy Combined With Cisplatin Concurrent Chemoradiotherapy for Nonmetastatic Stage IV Head-and-Neck Squamous Cell Carcinomas  

SciTech Connect

Purpose: To report the experience of treating selected fit patients with locally advanced head-and-neck squamous cell carcinoma with three cycles of induction TPF (docetaxel 75 mg/m{sup 2}, cisplatin 75 mg/m{sup 2}, 5-fluorouracil 750 mg/m{sup 2}, Days 2-5) followed by concurrent three-weekly bolus cisplatin 100 mg/m{sup 2} chemoradiotherapy. Methods and Materials: Between March 2006 and February 2010, 66 patients with nonmetastatic Stage IV head-and-neck squamous cell carcinoma were treated in a single institution with three cycles of induction TPF, followed by radical radiotherapy with concurrent cisplatin 100 mg/m{sup 2}. Results: Median age was 54 years (range, 33-69 years). Median follow-up was 21 months (range, 4-55 months). During TPF, Grade 3 toxicity occurred in 18 patients (27%), dose modifications in 10 (15%), delays in 3 (5%), and unplanned admissions in 6 (9%); a clinical tumor response was documented in 60 patients (91%). Median time from the final cycle of TPF to commencing radiotherapy was 22 days. Sixty-two patients (94%) received radical radiotherapy, and all completed treatment with no delays {>=}3 days. One, two, and three cycles of concurrent cisplatin were delivered to 18 patients (29%), 38 patients (61%), and 3 patients (5%), respectively. Ninety-two percent of patients received enteral feeding; median weight loss during treatment was 7%. Forty-two patients (68%) had unplanned admissions with no on-treatment deaths. Three unrelated deaths occurred after treatment. At 1 year after treatment, 21% of patients without disease progression remained gastrostomy dependent. Of 58 assessable patients, 50 (86%) achieved a complete response after treatment. One- and 2-year progression-free survival, cause-specific survival, and overall survival were 88%, 92%, and 86% and 80%, 85%, and 80%, respectively. Conclusion: The combination of induction TPF with concurrent cisplatin chemoradiotherapy in patients with locally advanced head and neck squamous cell carcinoma is tolerable, with encouraging efficacy.

Prestwich, Robin J., E-mail: Robin.Prestwich@leedsth.nhs.uk [Department of Clinical Oncology, St. James's Institute of Oncology, Leeds (United Kingdom); Oeksuez, Didem Colpan; Dyker, Karen; Coyle, Catherine; Sen, Mehmet [Department of Clinical Oncology, St. James's Institute of Oncology, Leeds (United Kingdom)

2011-11-15

134

Systemic Taxotere Chemotherapy for Metastatic Tumor Pleurisy in Cats with Spontaneous Breast Cancer  

Microsoft Academic Search

Systemic and intrapleural chemotherapy for metastatic tumor pleurisy was carried out in cats with breast carcinoma. The animals\\u000a (n=18) were divided into 2 groups. Cats of the systemic chemotherapy group received 3–6 courses of taxotere (30 mg\\/m2; n=7) or 3 courses of taxotere (20 mg\\/m2) in combination with doxorubicin (20 mg\\/m2 at 21-day intervals (n=5) during the adjuvant period of

M. N. Yakunina; E. M. Treshalina

2011-01-01

135

Prevention of chemotherapy-induced alopecia using an effective scalp cooling system  

Microsoft Academic Search

Alopecia is a distressing side-effect of cancer treatment. Taxanes (TX), anthracyclines (ANR) and etoposide (ET) have been consistently associated with significant alopecia. We studied an effective scalp cooling system, the Penguin Cold Cap system™, for the prevention of chemotherapy-induced alopecia in 70 patients receiving chemotherapy, including one of the following major alopecia-causing agents: Group A, TX-based regimes (without ANR); Group

P Katsimbri; A Bamias; N Pavlidis

2000-01-01

136

Concurrence of rheumatoid arthritis and systemic lupus erythematosus: report of 11 cases.  

PubMed Central

The concurrence of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) has been reported infrequently. Eleven patients are described here with both RA and SLE, in whom the diagnoses were separated by one to 24 years. Because of the difficulty in diagnosing RA occurring subsequent to SLE, only patients with classical RA as their initial diagnosis were included. Further difficulties arise because arthritis is common to both diseases and may be deforming in SLE, antinuclear antibodies (ANA) are not uncommon in RA, and rheumatoid factor (RF) may be seen in SLE. Nonetheless, judicious application of the American Rheumatism Association (ARA) criteria allows both diagnoses to be made in the individual patient. In our patients there was erosive arthritis in nine, rheumatoid nodules in five, and urinary abnormalities in 10. Serological evidence of RA and SLE with positive RF and ANA and raised DNA antibodies was universal, all patients had haematological evidence of SLE, and all but one decreased serum complement levels. These cases suggest that the concurrence of RA and SLE is not as rare as previously considered and may occur more often than expected by chance alone. Images

Cohen, M G; Webb, J

1987-01-01

137

Penn researchers repair immune system in leukemia patients following chemotherapy:  

Cancer.gov

A new treatment using leukemia patients’ own infection-fighting cells appears to protect them from infections and cancer recurrence following treatment with fludarabine-based chemotherapy, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

138

Correctness of Concurrent Executions of Closed Nested Transactions in Transactional Memory Systems  

NASA Astrophysics Data System (ADS)

A generally agreed upon requirement for correctness of concurrent executions in Transactional Memory systems is that all transactions including the aborted ones read consistent values. Opacity is a recently proposed correctness criterion that satisfies the above requirement. Our first contribution in this paper is extending the opacity definition for closed nested transactions. Secondly, we define conflicts appropriate for optimistic executions which are commonly used in Software Transactional Memory systems. Using these conflicts, we define a restricted, conflict-preserving, class of opacity for closed nested transactions the membership of which can be tested in polynomial time. As our third contribution, we propose a correctness criterion that defines a class of schedules where aborted transactions do not affect consistency of the other transactions. We define a conflict-preserving subclass of this class as well. Both the class definitions and the conflict definition are new for nested transactions.

Peri, Sathya; Vidyasankar, Krishnamurthy

139

Curative-intent stereotactic body radiation therapy for residual breast cancer liver metastasis after systemic chemotherapy  

Microsoft Academic Search

Liver metastases from breast cancer are generally treated with systemic therapy such as chemotherapy or hormonotherapy. However,\\u000a local treatment options such as resection, radiofrequency ablation (RFA), and radiotherapy can also be considered to treat\\u000a oligometastases. We report the case of a 45-year-old female treated with stereotactic body radiotherapy (SBRT) after chemotherapy\\u000a against a solitary liver metastasis from primary breast cancer.

Naofumi KagaraYoshiaki; Yoshiaki Nakano; Ami Watanabe; Junichi Inatome; Hidetoshi Nakamura; Chiwan Kim; Katsuki Danno; Hirokazu Taniguchi; Toshiyuki Kanoh; Yutaka Kimura; Tadashi Ohnishi; Takeshi Tono; Takushi Monden; Shingi Imaoka; Kazufumi Kagawa

140

Concurrent programming  

SciTech Connect

This book presents an overview of concurrent programming, including some of the basic concurrency problems. Low level mutual exclusion algorithms are discussed. Other topics covered include: Synchronization in the Unix kernel; Semaphore; Buffering techniques; Mascot real-time design; and Parallel processing of sets of data.

Axford, T.

1989-01-01

141

Optimal treatment with systemic chemotherapy, complete surgical excision and hyperthermic intraperitoneal chemotherapy for a desmoplastic small round cell tumor in an adult male patient.  

PubMed

Desmoplastic small round cell tumor (DSRCT) is a very rare but aggressive malignancy. It is usually observed in males during adolescent and early adulthood. The tumor primarily affects the intra-abdominal serosal and is characterized by distinctive histological and immunophenotypic features and by the specific reciprocal translocation EWS-WT1. Prognosis is mainly poor with a mean survival approximately of 2.5 years. However, long-term survivals have been reported using aggressive multimodal therapy based on complete surgical excision, systemic chemotherapy and radiotherapy. The addition of hyperthermic intraperitoneal chemotherapy in the multimodal approach has been reported in very few cases but no effect on survival has been clearly demonstrated. We report a case of a 51-year old adult patient presenting with a DSRCT treated with aggressive therapy based on systemic chemotherapy, complete cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy, resulting in a long term survival of 4 years. PMID:20537477

Lauridant-Philippin, G; Ledem, N; Lemoine, F; Gouerant, S; Guillemet, C; Michel, P; Scotte, M; Di Fiore, F

2010-06-02

142

The Application of Concurrent Engineering in the Installation of Foam Fire Extinguishing Piping System  

Microsoft Academic Search

Although the concept of concurrent engineering has been widely applied in the manufacturing industry, there is growing awareness and interest in the adoption of Concurrent Engineering (CE) in the Construction Industry because CE has the potential to make construction projects less fragmented, reduce project duration, improve project quality, reduce total project cost and increase project competitiveness. The integration of a

T. P. Tsai; H. C. Yang; P. H. Liao

2011-01-01

143

On Distributed Multi-Point Concurrent Test System and Its Implementation  

NASA Astrophysics Data System (ADS)

As the rapid expansion of the Internet, novel network applications are constantly emerging accompanied by the increasingly growing of the complexity for network protocols. As a result, IP routers are becoming more and more important in today’s Internet. However, test methodology and test systems for IP routers often fall behind the state of the art. Based on the deficiency of current stand-alone test systems, this paper analyzes the necessity for distributed test architecture and introduces a new test system called Distributed Multi-point Concurrent Test System (DMC-TS) which can mirror real-world networks in the test experiments and conduct conformance testing, performance testing and interoperability testing for the routers under test. Key issues for the implementation of DMC-TS are discussed, especially on test synchronization problem. Consequently, two types of test synchronization problem are pointed out with the corresponding solutions. Some experiments are carried out to illustrate the feasibility and practicability of DMC-TS.

Luo, Hao; Zeng, Huaxin

144

Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.  

PubMed

PURPOSE We started a phase II trial of induction chemotherapy and concurrent hyperfractionated chemoradiotherapy followed by either surgery or boost chemoradiotherapy in patients with advanced, stage III disease. The purpose is to achieve better survival in the surgery group with minimum morbidity and mortality. PATIENTS AND METHODS Patients treated from 1998 to 2002 with neoadjuvant chemoradiotherapy and surgical resection for stage III NSCLC were analyzed. The treatment consisted of four cycles of induction chemotherapy with carboplatin/paclitaxel followed by chemoradiotherapy with a reduced dose of carboplatin/paclitaxel and accelerated hyperfractionated radiotherapy with 1.5 Gy twice daily up to 45 Gy. After restaging, operable patients underwent thoracotomy. Inoperable patients received chemoradiotherapy up to 63 Gy. Study end points included resectability, pathologic response, and survival. Results One hundred twenty patients were enrolled; 25% patients had stage IIIA, 73% had stage IIIB, and 2% stage IV. After treatment, 47.5% had downstaging, 29.2% had stable disease, and 23.3% had progressive disease. Thirty patients (25%) were not eligible for operation because of progressive disease, stable disease, and/or functional deterioration with one treatment-related death. The 30-day mortality was 5% in patients who underwent operation. The 5-year survival rate for 120 patients was 21.7%, and it was 43.1% in patients with complete resection. In postoperative patients with stage N0 disease, 5-year survival was 53.3%; if stage N2 or N3 disease was still present, 5-year survival was 33.3%. CONCLUSION Staging and treatment with chemoradiotherapy and complete resection performed in experienced centers achieve acceptable morbidity and mortality. PMID:20100967

Friedel, Godehard; Budach, Wilfried; Dippon, Juergen; Spengler, Werner; Eschmann, Susanne Martina; Pfannenberg, Christina; Al-Kamash, Fawaz; Walles, Thorsten; Aebert, Hermann; Kyriss, Thomas; Veit, Stefanie; Kimmich, Martin; Bamberg, Michael; Kohlhaeufl, Martin; Steger, Volker; Hehr, Thomas

2010-01-25

145

Preoperative Concurrent Radiation Therapy and Chemotherapy for Bulky Stage IB2, IIA, and IIB Carcinoma of the Uterine Cervix With Proximal Parametrial Invasion  

SciTech Connect

Purpose: To evaluate toxicity, local tumor control, and survival after preoperative chemoradiation for operable bulky cervical carcinoma. Methods and Materials: Between December 1991 and July 2006, 92 patients with operable bulky stage IB2, IIA, and IIB cervical carcinoma without pelvic or para-aortic nodes on pretreatment imaging were treated. Treatment consisted of preoperative external beam pelvic radiation therapy (EBRT) and concomitant chemotherapy (CT) during the first and fourth weeks of radiation combining 5-fluorouracil and cisplatin. The pelvic radiation dose was 40.5 Gy over 4.5 weeks. EBRT was followed by low-dose rate uterovaginal brachytherapy with a total dose of 20 Gy in 62 patients. After a median rest period of 44 days, all patients underwent Class II modified radical hysterectomy with bilateral pelvic lymphadenectomy. Thirty patients who had not received preoperative uterovaginal brachytherapy underwent postoperative low-dose-rate vaginal brachytherapy at a dose of 20 Gy. The mean follow-up was 46 months. Results: Pathologic residual tumor was observed in 43 patients. After multivariate analysis, additional preoperative uterovaginal brachytherapy was the single significant predictive factor for pathologic complete response rate (p = 0.019). The 2- and 5-year disease-free survival (DFS) rates were 80.4% and 72.2%, respectively. Pathologic residual cervical tumor was the single independent factor decreasing the probability of DFS (p = 0.020). Acute toxicities were moderate. Two severe ureteral complications requiring surgical intervention were observed. Conclusions: Concomitant chemoradiation followed by surgery for operable bulky stage I-II cervical carcinoma without clinical lymph node involvement can be used with acceptable toxicity. Pathologic complete response increases the probability of DFS.

Huguet, Florence; Cojocariu, Oana-Maria [Department of Radiation Oncology, Tenon Hospital A.P.-H.P., Cancerest, GHU Est, Paris VI University, Paris (France); Levy, Pierre [Department of Public Health, Tenon Hospital A.P.-H.P., Cancerest, GHU Est, Paris VI University, Paris (France); Lefranc, Jean-Pierre [Department of Gynecologic Surgery, Pitie-Salpetriere Hospital A.P.-H.P., Paris (France); Darai, Emile [Department of Gynecology and Obstetrics, Tenon Hospital A.P.-H.P., Cancerest, GHU Est, Paris VI University, Paris (France); Jannet, Denis; Ansquer, Yan [Department of Gynecology and Obstetrics, Saint-Antoine Hospital A.P.-H.P., Paris (France); Lhuillier, Pierre-Eugene [Department of Gynecology and Obstetrics, Fontainebleau Hospital, Fontainebleau (France); Benifla, Jean-Louis [Department of Gynecology and Obstetrics, Rothschild Hospital A.P.-H.P., Paris (France); Seince, Nathalie [Department of Gynecology and Obstetrics, Jean Verdier Hospital, Bondy (France); Touboul, Emmanuel [Department of Radiation Oncology, Tenon Hospital A.P.-H.P., Cancerest, GHU Est, Paris VI University, Paris (France)], E-mail: emmanuel.touboul@tnn.aphp.fr

2008-12-01

146

Phase I Trial Using Patupilone (Epothilone B) and Concurrent Radiotherapy for Central Nervous System Malignancies  

SciTech Connect

Purpose: Based on preclinical data indicating the radiosensitizing potential of epothilone B, the present study was designed to evaluate the toxicity and response rate of patupilone, an epothilone B, with concurrent radiotherapy (RT) for the treatment of central nervous system malignancies. Methods and Materials: The present Phase I study evaluated the toxicities associated with patupilone combined with RT to establish the maximal tolerated dose. Eligible patients had recurrent gliomas (n = 10) primary (n = 5) or metastatic (n = 17) brain tumors. Dose escalation occurred if no dose-limiting toxicities, defined as any Grade 4-5 toxicity or Grade 3 toxicity requiring hospitalization, occurred during treatment. Results: Of 14 patients, 5 were treated with weekly patupilone at 1.5 mg/m{sup 2}, 4 at 2.0 mg/m{sup 2}, 4 at 2.5 mg/m{sup 2}, and 1 at 4 mg/m{sup 2}. Of 18 patients, 7 were treated in the 6-mg/m{sup 2} group, 6 in the 8-mg/m{sup 2} group, and 5 in the 10-mg/m{sup 2} group. Primary central nervous system malignancies received RT to a median dose of 60 Gy. Central nervous system metastases received whole brain RT to a median dose of 37.4 Gy, and patients with recurrent gliomas underwent stereotactic RT to a median dose of 37.5 Gy. One dose-limiting toxicity (pneumonia) was observed in group receiving 8-mg/m{sup 2} every 3 weeks. At the subsequent dose level (10 mg/m{sup 2}), two Grade 4 dose-limiting toxicities occurred (renal failure and pulmonary hemorrhage); thus, 8 mg/m{sup 2} every 3 weeks was the maximal tolerated dose and the recommended Phase II dose. Conclusion: Combined with a variety of radiation doses and fractionation schedules, concurrent patupilone was well tolerated and safe, with a maximal tolerated dose of 8 mg/m{sup 2} every 3 weeks.

Fogh, Shannon; Machtay, Mitchell; Werner-Wasik, Maria; Curran, Walter J.; Bonanni, Roseann [Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA (United States); Axelrod, Rita [Department of Medical Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA (United States); Andrews, David [Department of Neurosurgery, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA (United States); Dicker, Adam P., E-mail: adam.dicker@jeffersonhospital.or [Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA (United States)

2010-07-15

147

Prognostic Value of Pretreatment Carcinoembryonic Antigen After Definitive Radiotherapy With or Without Concurrent Chemotherapy for Squamous Cell Carcinoma of the Uterine Cervix  

SciTech Connect

Purpose: To evaluate whether pretreatment carcinoembryonic antigen (CEA) levels have a prognostic role in patients after definitive radiotherapy for squamous cell carcinoma (SCC) of the uterine cervix. Methods and Materials: A retrospective study of 550 patients was performed. The SCC antigen (SCC-Ag) and CEA levels were regarded as elevated when they were {>=}2 and {>=}5 ng/mL, respectively. A total of 208 patients underwent concurrent chemoradiotherapy (CCRT). The Kaplan-Meier method was used to calculate the distant metastasis (DM), local failure (LF), disease-free survival (DFS), and overall survival (OS) rates. Multivariate analysis was performed using the Cox proportional hazards model. The hazard ratio (HR) with 95% confidence interval (CI) was evaluated for the risk of a poor prognosis. Results: Compared with the patients with normal CEA/SCC-Ag levels, CEA levels {>=}10 ng/mL but without elevated SCC-Ag levels was an independent factor for LF (HR, 51.81; 95% CI, 11.51-233.23; p < .001), DM (HR, 6.04; 95% CI, 1.58-23.01; p = .008), DFS (HR, 10.17; 95% CI, 3.18-32.56; p < .001), and OS (HR, 5.75; 95% CI, 1.82-18.18; p = .003) after RT alone. However, no significant role for CEA was noted in patients with SCC-Ag levels {>=}2 ng/mL. In patients undergoing CCRT, a CEA level {>=}10 ng/mL was an independent factor for LF (HR, 2.50; 95% CI, 1.01-6.21; p = .047), DM (HR, 3.41; 95% CI, 1.56-7.46; p = .002), DFS (HR, 2.73; 95% CI, 1.39-5.36; p = .003), and OS (HR, 3.93; 95% CI 1.99-7.75; p < .001). A SCC-Ag level of {>=}40 ng/mL was another prognostic factor for DM, DFS, and OS in patients undergoing not only CCRT, but also RT alone. The 5-year OS rate for CCRT patients with CEA <10 ng/mL and {>=}10 ng/mL was 75.3% and 35.8%, respectively (p < .001). CCRT was an independent factor for better OS (HR, 0.69; 95% CI, 0.50-0.97; p = .034). Conclusion: Pretreatment CEA levels in patients with SCC of the uterine cervix provide complementary information for predicting LF, DM, DFS, and OS, except for in patients with abnormal SCC-Ag levels before RT alone. More aggressive therapy might be advisable for patients with CEA levels of {>=}10 ng/mL.

Huang, Eng-Yen [Department of Radiation Oncology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Taiwan (China); School of Traditional Chinese Medicine, Chang Gung University College of Medicine, Taiwan (China); Hsu, Hsuan-Chih [Department of Radiation Oncology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Taiwan (China); School of Medicine, Chang Gung University College of Medicine, Taiwan (China); Sun, Li-Min [Department of Radiation Oncology, Zuoying Armed Forces General Hospital, Kaohsiung City, Taiwan (China); Chanchien, Chan-Chao [School of Medicine, Chang Gung University College of Medicine, Taiwan (China); Department of Gynecologic Oncology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Taiwan (China); Lin, Hao [Department of Gynecologic Oncology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Taiwan (China); Chen, Hui-Chun [Department of Radiation Oncology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Taiwan (China); Tseng, Chih-Wen; Ou, Yu-Che; Chang, Hung-Yao [Department of Gynecologic Oncology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Taiwan (China); Fang, Fu-Min [Department of Radiation Oncology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Taiwan (China); School of Traditional Chinese Medicine, Chang Gung University College of Medicine, Taiwan (China); Huang, Yu-Jie; Wang, Chang-Yu [Department of Radiation Oncology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Taiwan (China); Lu, Hsien-Ming; Tsai, Ching-Chou [Department of Gynecologic Oncology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Taiwan (China); and others

2011-11-15

148

Computerized decision support for concurrent utilization review using the HELP system.  

PubMed Central

OBJECTIVE: Development and evaluation of computerized concurrent utilization review (UR) support taking advantage of a clinically rich computerized patient database. DESIGN: The Automated Support System for Utilization Review (ASSURE) applies the Appropriateness Evaluation Protocol (AEP) Day of Care criteria to computerized patient data in the HELP hospital information system. This paper reports the development, verification, and validation of ASSURE. MEASUREMENTS: Implementation correctness was verified by measuring agreement with a nurse reviewer, using separate sample sets for all 20 criteria for a total of 560 current inpatients. Usefulness in detecting inappropriate days of care was validated by two nurse reviewers who were crossed with manual and computer-assisted review methods in a blocked design for 168 current inpatients. Agreement with reviewers, sensitivity, specificity, positive predictive value, and negative predictive value were measured. RESULTS: Agreement was very good for satisfaction of criteria, and good for appropriateness of day of care. A patient day identified by ASSURE as potentially inappropriate would be twice as likely to be judged inappropriate by a reviewer as a randomly selected patient day. Review of the 10% of patient days identified as potentially inappropriate by ASSURE would identify approximately 21% of the inappropriate days of care. CONCLUSION: ASSURE is a clinically useful tool for screening adult acute care patients for inappropriate days of care, and promises to make a major contribution to reducing health care costs. The prognosis for successful routine clinical use is good.

Nelson, B D; Gardner, R M; Hedrick, G; Gould, P

1994-01-01

149

Inclusion of Thermal Protection Systems in Spacecraft Thermal-Stress Analysis using Concurrent Engineering Techniques  

NASA Astrophysics Data System (ADS)

Creating compatible thermal and structural mathematical models is complicated by the different meshing requirements of the thermal and structural disciplines. Often times, the structural model is of significantly higher fidelity requiring the thermal model to grow to an intractable size if full compatibility is to be assured. Given that the structural finite element mesh can be transformed into a thermal model, the network description remains incomplete until the appropriate thermal protection system (TPS) features are added. For entry heating studies, a high fidelity TPS mesh is required to accurately predict structural temperatures. Additionally, local pressure, temperature and heating variations further complicate the analysis. A technique for the efficient extraction of thermal protection system thickness data from CAD geometry is presented. The technique allows for application of complicated TPS cross-sections consisting of different materials and permits local pressure and heating rate variations. The resulting process has been successfully demonstrated on the X-38 crew return vehicle configuration and serves as a prototype for concurrent engineering techniques using a combination of custom and commercial software tools.

Rickman, Steven L.

2002-07-01

150

Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: Effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival  

SciTech Connect

Purpose: Three Phase II studies of preoperative radiotherapy and concurrent 5FU chemotherapy were undertaken. The primary endpoints were acute toxicity and pathologic complete response rate (pCR). Secondary endpoints were local recurrence-free survival (LRFS), disease-free survival (DFS), and overall survival (OS). Methods and Materials: A total of 134 patients with adenocarcinoma of the rectum (clinical T3/T4 or N1/N2) were treated. The initial cohort received 40 Gy in 20 fractions, the second 46 Gy in 23 fractions, and the third 50 Gy in 25 fractions. 5FU (225 mg/m{sup 2}/day) was given continuously throughout radiotherapy. A total of 121 patients underwent surgical resection. Results: Treatment was well tolerated. Grade 3/4 acute toxicity was observed in 13%, 4%, and 14% of patients in the 40 Gy, 46 Gy, and 50 Gy cohorts, respectively (p = 0.20). pCR was documented in 15%, 23%, and 33% of patients, respectively (p = 0.07). The 2-year actuarial LRFS was 72%, 90%, and 89% (p = 0.02); DFS was 62%, 84%, and 78% (p = 0.02); and OS was 72%, 94%, and 92%, respectively (p = 0.03). Conclusions: All treatment schedules were well tolerated. There was a trend toward increased pCR with higher doses. A statistically significant increase in LRFS, DFS, and OS was seen with radiation doses of 46 Gy and greater, but there was no difference between 46 Gy and 50 Gy.

Wiltshire, Kirsty L. [Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario (Canada)]. E-mail: kirsty.wiltshire@lycos.com; Ward, Iain G. [Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario (Canada); Swallow, Carol [Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario (Canada); Oza, Amit M. [Department of Medical Oncology and Haematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario (Canada); Cummings, Bernard [Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario (Canada); Pond, Gregory R. [Department of Biostatistics, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario (Canada); Catton, Pamela [Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario (Canada); Kim, John [Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario (Canada); Ringash, Jolie [Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario (Canada); Wong, Chong S. [Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario (Canada); Wong, Rebecca; Siu, Lillian L.; Moore, Malcolm [Department of Medical Oncology and Haematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario (Canada); Brierley, James [Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario (Canada)

2006-03-01

151

Phase II Study of Accelerated High-Dose Radiotherapy With Concurrent Chemotherapy for Patients With Limited Small-Cell Lung Cancer: Radiation Therapy Oncology Group Protocol 0239  

SciTech Connect

Purpose: To investigate whether high-dose thoracic radiation given twice daily during cisplatin-etoposide chemotherapy for limited small-cell lung cancer (LSCLC) improves survival, acute esophagitis, and local control rates relative to findings from Intergroup trial 0096 (47%, 27%, and 64%). Patients and Methods: Patients were accrued over a 3-year period from 22 US and Canadian institutions. Patients with LSCLC and good performance status were given thoracic radiation to 61.2 Gy over 5 weeks (daily 1.8-Gy fractions on days 1-22, then twice-daily 1.8-Gy fractions on days 23-33). Cisplatin (60 mg/m{sup 2} IV) was given on day 1 and etoposide (120 mg/m{sup 2} IV) on days 1-3 and days 22-24, followed by 2 cycles of cisplatin plus etoposide alone. Patients who achieved complete response were offered prophylactic cranial irradiation. Endpoints included overall and progression-free survival; severe esophagitis (Common Toxicity Criteria v 2.0) and treatment-related fatalities; response (Response Evaluation Criteria in Solid Tumors); and local control. Results: Seventy-two patients were accrued from June 2003 through May 2006; 71 were evaluable (median age 63 years; 52% female; 58% Zubrod 0). Median survival time was 19 months; at 2 years, the overall survival rate was 36.6% (95% confidence interval [CI] 25.6%-47.7%), and progression-free survival 19.7% (95% CI 11.4%-29.6%). Thirteen patients (18%) experienced severe acute esophagitis, and 2 (3%) died of treatment-related causes; 41% achieved complete response, 39% partial response, 10% stable disease, and 6% progressive disease. The local control rate was 73%. Forty-three patients (61%) received prophylactic cranial irradiation. Conclusions: The overall survival rate did not reach the projected goal; however, rates of esophagitis were lower, and local control higher, than projected. This treatment strategy is now one of three arms of a prospective trial of chemoradiation for LSCLC (Radiation Therapy Oncology Group 0538/Cancer and Leukemia Group B 30610).

Komaki, Ritsuko, E-mail: rkomaki@mdanderson.org [Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Paulus, Rebecca [Radiation Therapy Oncology Group Statistical Center, Philadelphia, Pennsylvania (United States); Ettinger, David S. [Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland (United States); Videtic, Gregory M.M. [Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio (United States); Bradley, Jeffrey D. [Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri (United States); Glisson, Bonnie S. [Department of Thoracic/Head and Neck Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Langer, Corey J. [Thoracic Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania (United States); Sause, William T. [Radiation Center, LDS Hospital, Salt Lake City, Utah (United States); Curran, Walter J. [Department of Radiation Oncology, Jefferson Medical College, Philadelphia, Pennsylvania (United States); Choy, Hak [Department of Radiation Oncology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas (United States)

2012-07-15

152

Concurrent validity of a trunk tri-axial accelerometer system for gait analysis in older adults.  

PubMed

The aim of this study was (1) to determine the concurrent validity of a trunk tri-axial accelerometer system (DynaPort) with the GAITRite system for spatio-temporal gait parameters at preferred, slow and fast self-selected walking speed that were recorded for averaged and individual step data in an older adult population and (2) to compare the levels of agreement for averaged step data from different walking distances and individual step data. The levels of agreement between the two systems for averaged step data was excellent for walking speed, cadence, step duration and step length (intraclass correlation coefficients (ICCs) between 0.99 and 1.00, ratios limits of agreement (RLOA) between 0.7% and 3.3%), moderate for variability of step duration (ICCs between 0.88 and 0.98 and RLOAs between 19% and 34%) and low for variability of step length (ICCs between 0.24 and 0.33 and RLOAs between 73% and 87%). The levels of agreement for individual step duration and step length were moderate with ICCs between 0.81 and 0.89 and with RLOAs between 9% and 13%. Comparing RLOAs from averaged step data across the different walking distances and individual step data, the RLOAs decreased with increased number of steps. The results of this study demonstrate that the DynaPort system, which allows measurements in real life conditions, is a highly valid tool for assessment of spatio-temporal gait parameters for averaged step data across a walkway length of approximately 20m in independent living elderly. Gait variability measures and individual step data need to be viewed with caution because of the moderate to low levels of agreement between the two systems. PMID:19070494

Hartmann, Antonia; Luzi, Susanna; Murer, Kurt; de Bie, Rob A; de Bruin, Eling D

2008-12-12

153

Effects of Neoadjuvant Intraperitoneal/Systemic Chemotherapy (Bidirectional Chemotherapy) for the Treatment of Patients with Peritoneal Metastasis from Gastric Cancer  

PubMed Central

Novel multidisciplinary treatment combined with neoadjuvant intraperitoneal-systemic chemotherapy protocol (NIPS) and peritonectomy was developed. Ninety-six patients were enrolled. Peritoneal wash cytology was performed before and after NIPS through a port system. Patients were treated with 60?mg/m2 of oral S-1 for 21 days, followed by a 1-week rest. On days 1, 8, and 15, 30?mg/m2 of Taxotere and 30?mg/m2 of cisplatin with 500?mL of saline were introduced through the port. NIPS is done 2 cycles before surgery. Three weeks after NIPS, 82 patients were eligible to intend cytoreductive surgery (CRS) by gastrectomy + D2 dissection + periotnectomy to achieve complete cytoreduction. Sixty-eight patients showed positice cytology before NIPS, and the positive cytology results became negative in 47 (69%) patients after NIPS. Complete pathologic response on PC after NIPS was experienced in 30 (36.8%) patients. Stage migration was experienced in 12 patients (14.6%). Complete cytoreduction was achieved in 58 patients (70.7%). By the multivariate analysis, complete cytoreduction and pathologic response became a significantly good survival. However the high morbidity and mortality, stringent patient selection is important. The best indications of the therapy are patients with good pathologic response and PCI ? 6, which are supposed to be removed completely by peritonectomy.

Yonemura, Yutaka; Elnemr, Ayman; Endou, Yoshio; Ishibashi, Haruaki; Mizumoto, Akiyoshi; Miura, Masahiro; Li, Yan

2012-01-01

154

Advanced real-time bus system for concurrent data paths used in high-performance image processing  

NASA Astrophysics Data System (ADS)

In this paper we present a new bus protocol satisfying extreme real time demands. It has been applied to a high performance quality inspection system which can involve up to eight sensors of various types. Thanks to the modular configuration this multi-sensor inspection system acts on the outside as a single sensor image processing system. In general, image processing systems comprise three basic functions (i) image acquisition, (ii) image processing and (iii) output of processed data. The data transfers for these three fundamental functions can be accomplished either by individual bus systems or by a single bus. In case of using a single bus the system complexity of the implementation, i.e. Development of protocols, hardware employment and EMC technical considerations, is far smaller. An important goal of the new protocol design is to support extremely fast communication between individual processing modules. For example, the input data (image acquisition) is transferred in real time to individual processing modules. Concurrent to this communication the processed data are being transferred to the output module. Therefore, the key function of this protocol is to realize concurrent data paths (data rates over 1.2 Gbit/s) by using principles of pipeline architectures and methods of time division multiplex. Moreover, the new bus protocol enables concurrent data transfers via a single bus system. In this paper the function of the new bus protocol including hardware layout and innovative bus arbiter are described in details.

Brodersen, Jorg; Palkovich, Roland; Landl, Dieter; Furtler, Johannes; Dulovits, Martin

2004-05-01

155

Multiple Cancers in a Patient with Systemic Sclerosis and Aggravated Interstitial Lung Disease by Chemotherapy  

PubMed Central

Although the relationship between malignancy risk with systemic sclerosis (SSc) has been inconclusive, there are some previous studies for a positive correlation. Most patients with SSc have some degree of lung parenchymal involvement in the form of interstitial thickening and fibrosis. Interstitial lung disease is the most common pulmonary manifestation of SSc. Interstitial lung disease following chemotherapy (5-fluorouracil, leucovorin, and oxaliplatin [FOLFOX]) is an uncommon life-threatening complication and it is induced by oxaliplatin. We report a case of multiple cancers in a patient with SSc and aggravated interstitial lung disease by chemotherapy.

Lee, Seok Jong; Cho, Hyung Jun; Lee, Kyeong Soo; Kim, Sung Jun; Cho, Gu Min; Lee, Ha Ni

2013-01-01

156

Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system  

Microsoft Academic Search

Arterial infusion chemotherapy has become one of the major treatments for malignant tumors. Since 1988, we have attempted repeated arterial infusion of anticancer drugs using an implantable drug delivery system in 68 patients who had inoperable hepatocellular carcinoma (HCC). Most of our patients could not undergo transcatheter arterial embolization (TAE) because of extreme tumor extension and\\/or accompanying advanced liver cirrhosis.

Takashi Iwamiya; Satoshi Sawada; Yoshio Ohta

1994-01-01

157

Complementary therapies for side effects of chemotherapy and radiotherapy in the upper gastrointestinal system  

Microsoft Academic Search

IntroductionChemotherapy and radiotherapy remain the mainstay of treatment for patients with advanced malignant disease that is incurable by local surgery. However, effective use of these therapies is limited by toxic effects. Serious side effects in the upper GI system include mucositis, xerostomia, nausea and vomiting. Standard care for these side effects is suboptimal. Recent studies suggest complementary and alternative medicine

Elad Schiff; Eran Ben-Arye

2011-01-01

158

Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy.  

PubMed

Conventional cytotoxic chemotherapy has not provided clinical benefit or prolonged survival for patients with advanced HCC. This review summarizes the results of prospective clinical trials of several categories of systemic therapy, with emphasis on the more promising results from recent trials of biologically targeted therapeutic agents in HCC. PMID:18236117

Thomas, Melanie B; O'Beirne, James P; Furuse, Junji; Chan, Anthony T C; Abou-Alfa, Ghassan; Johnson, Philip

2008-01-31

159

Partial response after transcatheter arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable colon cancer and hepatic metastasis: (case report).  

PubMed

We report here a case of partial response to hepatic arterial infusion chemotherapy in a patient who developed serious hepatic failure due to unresectable colorectal cancer and hepatic metastasis and showed resistance to systemic chemotherapy with molecular targeted drugs, mFOLFOX6, and FOLFIRI. The patient was a 60-year-old woman who underwent sigmoidectomy for sigmoid colon cancer, lateral posterior hepatic segmentectomy for metastatic liver cancer, and postoperative radiation therapy for metastatic lung cancer. As first-line systemic chemotherapy, mFOLFOX6 (oxaliplatin, 5-fluorouracil, and leucovorin), bevacizumab?+?FOLFIRI (irinotecan, 5-fluorouracil, leucovorin), and anti-epidermal growth factor receptor antibody ?+ irinotecan were administered, in that order. However, recurrent hepatic metastasis was exacerbated, which induced serious hepatic failure manifested by general malaise, jaundice, abnormal hepatic function, difficulty in walking due to bilateral lower extremity edema, and decreased appetite. The patient was admitted in a serious condition. After hospitalization, the patient received hepatic arterial infusion chemotherapy with 5-fluorouracil and l-leucovorin. After two complete courses, the symptoms improved. The patient's performance status also improved, and she was discharged from the hospital. Four months after discharge, the patient had continued outpatient chemotherapy and maintained excellent performance status. Although HAIC is not presently considered an alternative to systemic chemotherapy, it is sometimes effective in patients who show resistance to molecular targeted drug therapy, FOLFOX, and FOLFIRI, and in whom hepatic metastasis is a key factor in determining prognosis and serious hepatic failure. Further studies should be performed in the future to verify these findings. PMID:23957924

Sawai, Katsuji; Goi, Takanori; Koneri, Kenji; Katayama, Kanji; Yamaguchi, Akio

2013-08-17

160

Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.  

PubMed

Oral paclitaxel is not inherently bioavailable because of the overexpression of P-glycoprotein by intestinal cells and the significant first-pass extraction by cytochrome P450-dependent processes. This study sought to simulate the toxicological and pharmacological profile of a clinically relevant schedule of paclitaxel administered on clinically relevant i.v. dosing schedules in patients with advanced solid malignancies using oral paclitaxel administered with cyclosporin A, an inhibitor of both P-glycoprotein and P450 CYP3A. Nine patients were treated with a single course of oral paclitaxel in its parenteral formulation at a paclitaxel dose level of 180, 360, or 540 mg. Cyclosporin A was administered at a dose of 5 mg/kg p.o. 1 h before and concurrently with oral paclitaxel. Blood sampling was performed to evaluate the pharmacokinetics of paclitaxel, 6-alpha-hydroxypaclitaxel, 3-p-hydroxypaclitaxel, and cyclosporin A. The pharmacokinetic behavior of paclitaxel was characterized using both compartmental and noncompartmental methods. Model-estimated parameters were used to simulate paclitaxel concentrations after once daily and twice daily oral administration of paclitaxel and cyclosporin A. Aside from an unpleasant taste, the oral regimen was well tolerated, and there were no grade 3 or 4 drug-related toxicities. The systemic exposure to paclitaxel, as assessed by maximum plasma concentration (Cmax) and area under the plasma concentration versus time curve (AUC) values, did not increase as the dose of paclitaxel was increased from 180 to 540 mg, and there was substantial interindividual variability (4-6-fold) at each dose level. Mean paclitaxel Cmax values approached plasma concentrations achieved with clinically relevant parenteral dose schedules, averaging 268+/-164 ng/ml. AUC values averaged 3306+/-1977 ng x h/ ml, which was significantly lower than AUC values achieved with clinically relevant i.v. paclitaxel dose schedules. However, computer simulations using pharmacokinetic parameters derived from the present study demonstrated that pharmacodynamically relevant steady-state plasma paclitaxel concentrations of at least 0.06 microM would be achieved after protracted once daily and twice daily dosing with oral paclitaxel and cyclosporin A. Paclitaxel metabolites were detectable in three patients, and the 6-alpha-hydroxypaclitaxel: paclitaxel and 3-p-hydroxypaclitaxel:paclitaxel AUC ratios averaged 0.63 and 0.86, respectively; these values were substantially higher than values reported in patients treated with i.v. paclitaxel. Oral paclitaxel was bioavailable in humans when administered in combination with oral cyclosporin A 5 mg/kg 1 h before and concurrently with paclitaxel treatment, and plasma paclitaxel concentrations achieved with this schedule were biologically relevant and approached concentrations attained with clinically relevant parenteral dose schedules. However, treatment of patients with oral paclitaxel using a single oral dose administration schedule failed to achieve sufficiently high systemic drug exposure and pharmacodynamic effects. In contrast, computer simulations demonstrated that clinically relevant pharmacodynamic effects are likely to be achieved with multiple once daily and twice daily oral paclitaxel-cyclosporin A dosing schedules. PMID:10999729

Britten, C D; Baker, S D; Denis, L J; Johnson, T; Drengler, R; Siu, L L; Duchin, K; Kuhn, J; Rowinsky, E K

2000-09-01

161

The TRIDEC System-of-Systems; Choreography of large-scale concurrent tasks in Natural Crisis Management  

NASA Astrophysics Data System (ADS)

The project Collaborative, Complex, and Critical Decision-Support in Evolving Crises (TRIDEC), co-funded by the European Commission in its Seventh Framework Programme aims at establishing a network of dedicated, autonomous legacy systems for large-scale concurrent management of natural crises utilising heterogeneous information resources. TRIDEC's architecture reflects the System-of- Systems (SoS) approach which is based on task-oriented systems, cooperatively interacting as a collective in a common environment. The design of the TRIDEC-SoS follows the principles of service-oriented and event-driven architectures (SOA & EDA) exceedingly focusing on a loose coupling of the systems. The SoS approach in combination with SOA and EDA has the distinction of being able to provide novel and coherent behaviours and features resulting from a process of dynamic self-organisation. Self-organisation is a process without the need for a central or external coordinator controlling it through orchestration. It is the result of enacted concurrent tasks in a collaborative environment of geographically distributed systems. Although the individual systems act completely autonomously, their interactions expose emergent structures of evolving nature. Particularly, the fact is important that SoS are inherently able to evolve on all facets of intelligent information management. This includes adaptive properties, e.g. seamless integration of new resource types or the adoption of new fields in natural crisis management. In the case of TRIDEC with various heterogeneous participants involved, concurrent information processing is of fundamental importance because of the achievable improvements regarding cooperative decision making. Collaboration within TRIDEC will be implemented with choreographies and conversations. Choreographies specify the expected behaviour between two or more participants; conversations describe the message exchange between all participants emphasising their logical relation. The TRIDEC choreography will be based on the definition of Behavioural Interfaces and Service Level Agreements, which describe the interactions of all participants involved in the collaborative process by binding the tasks of dedicated systems to high-level business processes. All methods of a Behavioural Interfaces can be assigned dynamically to the activities of a business process. This allows it to utilise a system during the run-time of a business process and thus, for example enabling task balancing or the delegation of responsibilities. Since the individual parts of a SoS are normally managed independently and operate autonomously because of their geographical distribution it is of vital importance to ensure the reliability (robustness and correctness) of their interactions which will be achieved by applying the Design by Contract (DbC) approach to the TRIDEC architecture. Key challenge for TRIDEC is establishing a reliable adaptive system which exposes an emergent behaviour, for example intelligent monitoring strategies or dynamic system adaptions even in case of partly system failures. It is essential for TRIDEC that for example redundant parts of the system can take over tasks from defect components in a process of re-organising its network.

Häner, R.; Wächter, J.

2012-04-01

162

Phase I Study of Concurrent High-Dose Three-Dimensional Conformal Radiotherapy With Chemotherapy Using Cisplatin and Vinorelbine for Unresectable Stage III Non-Small-Cell Lung Cancer  

SciTech Connect

Purpose: To determine the maximum tolerated dose in concurrent three-dimensional conformal radiotherapy (3D-CRT) with chemotherapy for unresectable Stage III non-small-cell lung cancer (NSCLC). Patients and Methods: Eligible patients with unresectable Stage III NSCLC, age {>=}20 years, performance status 0-1, percent of volume of normal lung receiving 20 GY or more (V{sub 20}) {<=}30% received three to four cycles of cisplatin (80 mg/m{sup 2} Day 1) and vinorelbine (20 mg/m{sup 2} Days 1 and 8) repeated every 4 weeks. The doses of 3D-CRT were 66 Gy, 72 Gy, and 78 Gy at dose levels 1 to 3, respectively. Results: Of the 17, 16, and 24 patients assessed for eligibility, 13 (76%), 12 (75%), and 6 (25%) were enrolled at dose levels 1 to 3, respectively. The main reasons for exclusion were V{sub 20} >30% (n = 10) and overdose to the esophagus (n = 8) and brachial plexus (n = 2). There were 26 men and 5 women, with a median age of 60 years (range, 41-75). The full planned dose of radiotherapy could be administered to all the patients. Grade 3-4 neutropenia and febrile neutropenia were noted in 24 (77%) and 5 (16%) of the 31 patients, respectively. Grade 4 infection, Grade 3 esophagitis, and Grade 3 pulmonary toxicity were noted in 1 patient, 2 patients, and 1 patient, respectively. The dose-limiting toxicity was noted in 17% of the patients at each dose level. The median survival and 3-year and 4-year survival rates were 41.9 months, 72.3%, and 49.2%, respectively. Conclusions: 72 Gy was the maximum dose that could be achieved in most patients, given the predetermined normal tissue constraints.

Sekine, Ikuo, E-mail: isekine@ncc.go.jp [Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo (Japan); Sumi, Minako; Ito, Yoshinori [Division of Radiation Oncology, National Cancer Center Hospital, Tokyo (Japan); Horinouchi, Hidehito; Nokihara, Hiroshi; Yamamoto, Noboru; Kunitoh, Hideo; Ohe, Yuichiro; Kubota, Kaoru; Tamura, Tomohide [Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo (Japan)

2012-02-01

163

A web-based advisory system for process and material selection in concurrent product design for a manufacturing environment  

Microsoft Academic Search

This paper reports the work of selecting suitable manufacturing processes and materials in concurrent design for manufacturing environment. In the paper, a fuzzy knowledge-based decision support method is proposed for multi-criteria decision-making in evaluating and selecting possible manufacturing process\\/material combinations in terms of the total production cost. Based on the proposed method, a prototype Web-based knowledge-intensive manufacturing consulting service system

Xuan F. Zha

2005-01-01

164

Feasibility of Concurrent Treatment with the Scanning Ultrasound Reflector Linear Array System (SURLAS) and the Helical Tomotherapy System  

PubMed Central

Purpose To evaluate the feasibility of concurrent treatment with the Scanning Ultrasound Reflector Linear Array System (SURLAS) and helical tomotherapy (HT) intensity modulated radiation therapy (IMRT). Methods The SURLAS was placed on a RANDO phantom simulating a patient with superficial or deep recurrent breast cancer. A Megavoltage CT (MVCT) of the phantom with and without the SURLAS was obtained in the HT system. MVCT images with the SURLAS were obtained for two configurations: i) with the SURLAS' long axis parallel and ii) perpendicular to the longitudinal axis of the phantom. The MVCT simulation data set was then transferred to a radiation therapy planning station. Organs at risk (OAR) were contoured including the lungs, heart, abdomen and spinal cord. The metallic parts of the SURLAS were contoured as well and constraints were assigned to completely or directionally block radiation through them. The MVCT-simulation data set and regions of interest (ROI) files were subsequently transferred to the HT planning station. Several HT plans were obtained with optimization parameters that are usually used in the clinic. For comparison purposes, planning was also performed without the SURLAS on the phantom. Results All plans with the SURLAS on the phantom showed adequate dose covering 95% of the planning target volume (PTV D95%), average dose and coefficient of variation of the planning target volume (PTV) dose distribution regardless of the SURLAS' orientation with respect to the RANDO phantom. Likewise, all OAR showed clinically acceptable dose values. Spatial dose distributions and dose-volume histogram (DVH) evaluation showed negligible plan degradation due to the presence of the SURLAS. Beam-on time varied depending on the selected optimization parameters. Conclusion From the perspective of the radiation dosage, concurrent treatment with the SURLAS and HT IMRT is feasible as demonstrated by the obtained clinically acceptable treatment plans. In addition, proper orientation of the SURLAS may be of benefit in reducing dose to organs at risk in some cases.

Penagaricano, Jose A.; Moros, Eduardo; Novak, Petr; Yan, Yulong; Corry, Peter

2010-01-01

165

Cervical mobilisation: concurrent effects on pain, sympathetic nervous system activity and motor activity  

Microsoft Academic Search

Recent findings that spinal manual therapy (SMT) produces concurrent hypoalgesic and sympathoexcitatory effects have led to the proposal that SMT may exert its initial effects by activating descending inhibitory pathways from the dorsal periaqueductal gray area of the midbrain (dPAG). In addition to hypoalgesic and sympathoexcitatory effects, stimulation of the dPAG in animals has been shown to have a facilitatory

M. Sterling; G. Jull; A. Wright

2001-01-01

166

Proving Ptolemy Right: The Environment Abstraction Framework for Model Checking Concurrent Systems  

Microsoft Academic Search

The parameterized verification of concurrent algorithms an d protocols has been addressed by a variety of recent methods. Experience shows that there is a trade-off between techniques which are widely applicable but depend on non- trivial human guidance, and fully automated approaches which are tailored for narrow classes of applications. In this spectrum, we propose a new framework based on

Edmund M. Clarke; Muralidhar Talupur; Helmut Veith

2008-01-01

167

Phase II Trial of Combined Modality Therapy With Concurrent Topotecan Plus Radiotherapy Followed by Consolidation Chemotherapy for Unresectable Stage III and Selected Stage IV Non-Small-Lung Cancer  

SciTech Connect

Purpose: The optimal combination of chemotherapy and radiotherapy (RT) and the role of consolidation chemotherapy in patients with locally advanced non-small-cell lung cancer (NSCLC) are unknown. Topotecan is active against NSCLC, can safely be combined with RT at effective systemic doses, and can be given by continuous infusion, making it an attractive study agent against locally advanced NSCLC. Methods and Materials: In this pilot study, 20 patients were treated with infusion topotecan 0.4 mg/m{sup 2}/d with three-dimensional conformal RT to 63 Gy both delivered Monday through Friday for 7 weeks. Patients without progression underwent consolidation chemotherapy with etoposide and a platinum agent for one cycle followed by two cycles of docetaxel. The study endpoints were treatment response, time to progression, survival, and toxicity. Results: Of the 20 patients, 19 completed induction chemoradiotherapy and 13 completed consolidation. Of the 20 patients, 18 had a partial response and 1 had stable disease after induction chemoradiotherapy. The 3-year overall survival rate was 32% (median, 18 months). The local and distant progression-free survival rate was 30% (median, 21 months) and 58% (median, not reached), respectively. Three patients developed central nervous system metastases, 1 within 228 days, 1 within 252 days, and 1 within 588 days. Three patients had pulmonary emboli. Therapy was well tolerated with 1 of 20 developing Grade 4 lymphopenia. Grade 3 hematologic toxicity was seen in 17 of 20 patients but was not clinically significant. Other Grade 3 toxicities included esophagitis in 3, esophageal stricture in 2, fatigue in 8, and weight loss in 1. Grade 3 pneumonitis occurred in 6 of 20 patients. Conclusion: Continuous infusion topotecan with RT was well tolerated and active in the treatment of poor-risk patients with unresectable Stage III NSCLC.

Seung, Steven K. [Oregon Clinic, Portland, OR (United States); Department of Radiation Oncology, Earle A. Chiles Research Institute, Portland, OR (United States)], E-mail: steven.seung@providence.org; Ross, Helen J. [Mayo Clinic, Scottsdale, AZ (United States)

2009-03-01

168

Brief chemotherapy, involved field radiation therapy, and central nervous system prophylaxis for paranasal sinus lymphoma.  

PubMed

Lymphoma of the paranasal sinus is a rare tumor characterized by bulky local disease, early systemic dissemination, and a propensity for central nervous system (CNS) spread. Treatment with radiation alone generally has been disappointing. Based on previous encouraging reports of initial brief chemotherapy followed by involved field radiation therapy (IFRT) for localized large cell lymphoma, four consecutive patients with paranasal sinus lymphoma were treated with 6 weeks of chemotherapy followed by IFRT and CNS prophylaxis. All patients had bulky localized disease and diffuse large cell lymphoma. Complete response was seen in all patients, and none have had a relapse (minimum follow-up, 25 months; range, 25 to 32 months). Chemotherapy and radiation therapy were well tolerated. One patient developed an osteogenic sarcoma in the radiation field 32 months after completion of therapy. Administration of early frequent chemotherapy followed by IFRT and CNS prophylaxis appears to be an effective treatment strategy for patients with localized large cell lymphoma of the paranasal sinuses. PMID:1375527

Cooper, D L; Ginsberg, S S

1992-06-15

169

Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer  

Microsoft Academic Search

BACKGROUND: Drug resistance in breast cancer is a major obstacle to successful chemotherapy. In this study we used cDNA microarray technology to examine gene expression profiles obtained from fine needle aspiration (FNA) of primary breast tumors before and after systemic chemotherapy. Our goal was to determine the feasibility of obtaining representative expression array profiles from limited amounts of tissue and

Christos Sotiriou; Trevor J Powles; Mitch Dowsett; Amir A Jazaeri; Andrew L Feldman; Laura Assersohn; Chandramouli Gadisetti; Steven K Libutti; Edison T Liu

2002-01-01

170

Synthesis of concurrent systems for an atomic read\\/atomic write model of computation  

Microsoft Academic Search

Paul C. ATTIEySchool of Computer ScienceFlorida International Universityattie@fiu.eduE. Allen EMERSONzDepartment of Computer SciencesThe University of Texas at Austinemerson@cs.utexas.eduAbstractMethods for mechanically synthesizing concurrent programs from temporal logic specifications have been proposed(cf. [EC82, MW84, PR89, PR89b, AM94]). An important advantage of these synthesis methods is that they obviatethe need to manually construct a program and compose a proof ...

Paul C. Attie; E. Allen Emerson

1996-01-01

171

Concurrent performance of two memory tasks: Evidence for domain-specific working memory systems  

Microsoft Academic Search

Previous studies of dual-task coordination in working memory have shown a lack of dual-task interference when a verbal memory\\u000a task is combined with concurrent perceptuomotor tracking. Two experiments are reported in which participants were required\\u000a to perform pairwise combinations of (1) a verbal memory task, a visual memory task, and perceptuomotor tracking (Experiment\\u000a 1), and (2) pairwise combinations of the

Gianna Cocchini; Robert H. Logie; Sergio Della Sala; Sarah E. MacPherson; Alan D. Baddeley

2002-01-01

172

Concurrency by Inheritance in C  

Microsoft Academic Search

Many attempts have been made to add concurrency to C++, but much ofthe work has not exploited the power of C++, and often extensive compilerextensions are made. This paper shows how the object-oriented facilities of C++are powerful enough to encapsulate concurrency creation and control. We havedeveloped a concurrent C++-based system which we call ABC++. We show howwe can provide, with

Eshrat Arjomandi; William O'farrell; Ivan Kalas; Gita Koblents; Frank Ch. Eigler; Guang G. Gao

1995-01-01

173

Ada concurrent programming  

SciTech Connect

In this book, Narain Gehani explains the concurrent programming facilities in Ada and shows how to use them effectively in writing concurrent programs. He also surveys concurrent programming facilities in other languages, discusses issues specific to concurrent programming, and examines the limitations of the concurrent programming facilities in Ada. Topics considered include an introduction to concurrent programming, the concurrent programming model in Ada, and a survey of other concurrent programming models; tasking, i.e., concurrent programming facilities in Ada; task types; exceptions and tasking; device drivers; real-time programming; topics related to concurrent programming; more examples of concurrent programming; and synopsis of sequential programming in Ada.

Gehani, N.

1984-01-01

174

The PVM (Parallel Virtual Machine) system: Supercomputer level concurrent computation on a network of IBM RS/6000 power stations  

SciTech Connect

The PVM (Parallel Virtual Machine) system enables supercomputer level concurrent computations to be performed on interconnected networks of heterogeneous computer systems. Specifically, a network of 13 IBM RS/6000 powerstations has been successfully used to execute production quality runs of superconductor modeling codes at more than 250 Mflops. This work demonstrates the effectiveness of cooperative concurrent processing for high performance applications, and shows that supercomputer level computations may be attained at a fraction of the cost on distributed computing platforms. This paper describes the PVM programming environment and user facilities, as they apply to hardware platforms comprising a network of IBM RS/6000 powerstations. The salient design features of PVM will be discussed; including heterogeneity, scalability, multilanguage support, provisions for fault tolerance, the use of multiprocessors and scalar machines, an interactive graphical front end, and support for profiling, tracing, and visual analysis. The PVM system has been used extensively, and a range of production quality concurrent applications have been successfully executed using PVM on a variety of networked platforms. The paper will mention representative examples, and discuss two in detail. The first is a material sciences problem that was originally developed on a Cray 2. This application code calculates the electronic structure of metallic alloys from first principles and is based on the KKR-CPA algorithm. The second is a molecular dynamics simulation for calculating materials properties. Performance results for both applicants on networks of RS/6000 powerstations will be presented, and accompanied by discussions of the other advantages of PVM and its potential as a complement or alternative to conventional supercomputers.

Sunderam, V.S. (Emory Univ., Atlanta, GA (USA). Dept. of Mathematics and Computer Science); Geist, G.A. (Oak Ridge National Lab., TN (USA))

1991-01-01

175

Highly concurrent scalar processing  

Microsoft Academic Search

High speed scalar processing is an essential characteristic of high performance general purpose computer systems. Highly concurrent execution of scalar code is difficult due to data dependencies and conditional branches. This paper proposes an architectural concept called guarded instructions to reduce the penalty of conditional branches in deeply pipelined processors. A code generation heuristic, the decision tree scheduling technique, reorders

Peter Y.-T. Hsu; Edward S. Davidson

1986-01-01

176

Sketching concurrent data structures  

Microsoft Academic Search

We describe PSKETCH, a program synthesizer that helps program- mers implement concurrent data structures. The system is based on the concept of sketching, a form of synthesis that allows pro- grammers to express their insight about an implementation as a partial program: a sketch. The synthesizer automatically completes the sketch to produce an implementation that matches a given cor- rectness

Armando Solar-lezama; Christopher Grant Jones; Rastislav Bodík

2008-01-01

177

Concurrent programming without locks  

Microsoft Academic Search

Mutual exclusion locks remain the de facto mechanism for concurrency control on shared-memory data structures. However, their apparent simplicity is deceptive: It is hard to design scalable locking strategies because locks can harbor problems such as priority inversion, deadlock, and convoying. Furthermore, scalable lock-based systems are not readily composable when building compound operations. In looking for solutions to these problems,

Keir Fraser; Tim Harris

2007-01-01

178

The Concurrency Column  

Microsoft Academic Search

Process calculi like ACP, CCS, CSP and various flavours of the ?-calculus are popular specification formalisms for concurrent, distribu ted and possibly mo- bile systems. The semantic theory of process calculi has been the subject of extensive investigation for about twenty five years now, and several robust, general principles and results applying to a variety of different formalisms have been

Luca Aceto

179

Concurrent engineering and product specification  

Microsoft Academic Search

The paper examines the process by which product specifications are developed and used within a concurrent engineering environment. Models of the product development process are analysed and evaluated for their potential use within concurrent engineering. A model is proposed for the product development process and the requirements for a computer aided system are considered.

A. R. Young; N. Allen

1996-01-01

180

New Approaches to Understand Cognitive Changes Associated With Chemotherapy for Non-Central Nervous System Tumors.  

PubMed

CONTEXT: Researchers have described a constellation of cognitive deficits (e.g., impairments in executive functions, working memory, attention, and information-processing speed) associated with cancer treatment, and specifically chemotherapy, for non-central nervous system tumors. However, findings have been inconsistent, largely because of measurement and study design issues. OBJECTIVES: To propose ways for researchers to more clearly delineate and characterize the mild cognitive deficits and related outcomes that appear to affect a subset of cancer patients and suggest methods to make more effective use of the existing data to understand risk factors for impaired neuropsychological functioning. METHODS: We examined the literature on the relationship between chemotherapy and cognitive impairment, as well as related literature on neuropsychological measurement, structural and functional neuroimaging, alternative measures of health outcomes, and integrative data analysis. RESULTS: A more comprehensive picture of cognitive functioning might be obtained by incorporating nontraditional ecological measures, self-reports, computational modeling, new neuroimaging methods, and markers of occupational functioning. Case-control and integrative data analytic techniques potentially could leverage existing data to identify risk factors for cognitive dysfunction and test hypotheses about the etiology of these effects. CONCLUSIONS: There is a need to apply new research approaches to understand the real-world functional implications of the cognitive side effects of chemotherapy to develop and implement strategies to minimize and remediate these effects before, during, and after cancer treatment. PMID:23522517

Nelson, Wendy L; Suls, Jerry

2013-03-21

181

Chemotherapy Effects  

MedlinePLUS

... saved articles window. My Saved Articles » My ACS » Chemotherapy Effects Chemotherapy drugs are powerful medicines that can cause side ... on the side effects most commonly caused by chemotherapy, this is a good place to start. Managing ...

182

On Optimistic Methods for Concurrency Control  

Microsoft Academic Search

Most current approaches to concurrency control in database systems rely on locking of data objects as a control mechanism. In this paper, two families of nonlocking concurrency controls are presented. The methods used are \\

H. T. Kung; John T. Robinson

1979-01-01

183

Concurrent manipulation of binary search trees  

Microsoft Academic Search

The concurrent manipulation of a binary search tree is considered in this paper. The systems presented can support any number of concurrent processes which perform searching, insertion, deletion, and rotation (reorganization) on the tree, but allow any process to lock only a constant number of nodes at any time. Also, in the systems, searches are essentially never blocked. The concurrency

H. T. Kung; Philip L. Lehman

1980-01-01

184

Palliative Chemotherapy  

MedlinePLUS

... and Families Take the Quiz What Is Palliative Chemotherapy? March, 2009 Author: David Weissman, MD Cancer specialists (oncologists) recommend chemotherapy in one of two situations. For some cancers, ...

185

Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non–small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT)  

Microsoft Academic Search

Purpose: To investigate factors associated with treatment-related pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy. Patients and Methods: We retrospectively analyzed data from 223 patients treated with definitive concurrent chemoradiotherapy. Treatment-related pneumonitis was graded according to Common Terminology Criteria for Adverse Events version 3.0. Univariate and multivariate analyses were performed to identify predictive factors. Results: Median follow-up was

Shulian Wang; Zhongxing Liao; Xiong Wei; Helen H. Liu; Susan L. Tucker; Chao-su Hu; Rodhe Mohan; James D. Cox; Ritsuko Komaki

2006-01-01

186

Concurrent tool and production system design for a surface broach cutting tool: a knowledge-based systems approach  

Microsoft Academic Search

This paper presents the economics of broaching operations, as analysed within the framework of concurrent design of the broach tool and its operating conditions. The tool is specified by its cutting teeth—tooth structure, tooth pitch and the number of such teeth—which in turn determine the length of the tool. Its operation is specified by the depth of cut per tooth

W. ROBERT TERRY; REUVEN KARNI; YANG-JENQ HUANG

1992-01-01

187

Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy.  

PubMed Central

Between 1984 and 1990, 94 women presenting to the Edinburgh Breast Unit with operable breast cancer of 4 cm or greater in diameter (T2, T3, N0, N1, M0) were given preoperative systemic therapy. Initially, all women received hormone therapy, with CHOP (cyclophosphamide 1 g m(-2), doxorubicin 50 mg m(-2), vincristine 1.4 mg m(-2) to a maximum of 2 mg and prednisolone 40 mg per day orally for 5 days) chemotherapy being administered to those who failed to respond by 3 months. After April 1987, first-line hormone therapy was only offered to women with oestrogen receptor (ER)-moderate/-rich (> 20 fmol mg(-1) protein) tumours, and CHOP was reserved for those women whose tumours failed to respond to hormone therapy and for those with ER-negative/-poor tumours. Response data have been published previously (Anderson et al, 1991). After a median follow-up of 7.5 years, there is no difference in survival between those women given initial hormone therapy and those given chemotherapy, with neither group having yet reached its median survival. The two key factors that predicted for a poor survival were the number of involved axillary nodes after preoperative systemic therapy (P < 0.00001) and a lack of response to preoperative therapy (P < 0.05). These data suggest that many women with ER-moderate/-rich tumours will have a good prognosis after preoperative hormone therapy alone. However, it is possible to identify, by their post-systemic therapy axillary node status, a group of women who still have an appalling prognosis after preoperative chemotherapy or hormone therapy.

Cameron, D. A.; Anderson, E. D.; Levack, P.; Hawkins, R. A.; Anderson, T. J.; Leonard, R. C.; Forrest, A. P.; Chetty, U.

1997-01-01

188

Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy.  

PubMed

Between 1984 and 1990, 94 women presenting to the Edinburgh Breast Unit with operable breast cancer of 4 cm or greater in diameter (T2, T3, N0, N1, M0) were given preoperative systemic therapy. Initially, all women received hormone therapy, with CHOP (cyclophosphamide 1 g m(-2), doxorubicin 50 mg m(-2), vincristine 1.4 mg m(-2) to a maximum of 2 mg and prednisolone 40 mg per day orally for 5 days) chemotherapy being administered to those who failed to respond by 3 months. After April 1987, first-line hormone therapy was only offered to women with oestrogen receptor (ER)-moderate/-rich (> 20 fmol mg(-1) protein) tumours, and CHOP was reserved for those women whose tumours failed to respond to hormone therapy and for those with ER-negative/-poor tumours. Response data have been published previously (Anderson et al, 1991). After a median follow-up of 7.5 years, there is no difference in survival between those women given initial hormone therapy and those given chemotherapy, with neither group having yet reached its median survival. The two key factors that predicted for a poor survival were the number of involved axillary nodes after preoperative systemic therapy (P < 0.00001) and a lack of response to preoperative therapy (P < 0.05). These data suggest that many women with ER-moderate/-rich tumours will have a good prognosis after preoperative hormone therapy alone. However, it is possible to identify, by their post-systemic therapy axillary node status, a group of women who still have an appalling prognosis after preoperative chemotherapy or hormone therapy. PMID:9376273

Cameron, D A; Anderson, E D; Levack, P; Hawkins, R A; Anderson, T J; Leonard, R C; Forrest, A P; Chetty, U

1997-01-01

189

Phase I Trial Using Proteasome Inhibitor Bortezomib and Concurrent Temozolomide and Radiotherapy for Central Nervous System Malignancies  

SciTech Connect

Purpose: To evaluate the toxicity and response rate of bortezomib with concurrent radiotherapy and temozolomide in the treatment of patients with central nervous system malignancies. Patients and Methods: This open-label, dose-escalation, Phase I clinical study evaluated the safety of three dose levels of intravenously administered bortezomib (0.7, 1.0, and 1.3 mg/m{sup 2}/dose) on Days 1, 4, 8, and 11 of a 21-day cycle, in addition to concurrent radiotherapy and temozolomide at a daily dose of 75 mg/m{sup 2} starting on Day 1. The primary endpoint was dose-limiting toxicity, defined as any Grade 4-5 toxicity or Grade 3 toxicity directly attributable to protocol treatment, requiring hospitalization and/or radiotherapy interruption. The secondary endpoints included feasibility, non-dose-limiting toxicity, and treatment response. Results: A total of 27 patients were enrolled, 23 of whom had high-grade glioma (10 recurrent and 13 newly diagnosed). No dose-limiting toxicities were noted in any dose group, including the highest (1.3 mg/m{sup 2}/dose). The most frequent toxicities were Grade 1 and 2 stomatitis, erythema, and alopecia. All 27 patients were evaluable for response. At a median follow-up of 15.0 months, 9 patients were still alive, with a median survival of 17.4 months for all patients and 15.0 months for patients with high-grade glioma. Conclusion: Bortezomib administered at its typical 'systemic' dose (1.3 mg/m{sup 2}) is well tolerated and safe combined with temozolomide and radiotherapy when used in the treatment of central nervous system malignancies. A Phase II study to characterize efficacy is warranted.

Kubicek, Gregory J.; Werner-Wasik, Maria; Machtay, Mitchell; Mallon, Gayle [Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA (United States); Myers, Thomas [Genzyme Inc., Cambridge, MA (United States); Ramirez, Michael [Department of Medical Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA (United States); Andrews, David [Department of Neurosurgery, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA (United States); Curran, Walter J. [Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA (United States); Dicker, Adam P. [Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA (United States)], E-mail: Adam.dicker@jeffersonhospital.org

2009-06-01

190

ABC++: Concurrency by Inheritance in C  

Microsoft Academic Search

Many aftempts have been made to add con-currency to C+ +, often by extensive compiler extensions, but much of the work has not exploited the power of C+ +. This pa er shows how the object-oriented facilities of [+ + are powerful enough to encapsulate concurrency creation and control. We have developed a concurrent C+ +-based prototype system (ABC+ +)

Eshrat Arjomandi; William G. O'farrell; Ivan Kalas; Gita Koblents; Frank Ch. Eigler; Guang R. Gao

1995-01-01

191

Conversion to Resectability Using Hepatic Artery Infusion Plus Systemic Chemotherapy for the Treatment of Unresectable Liver Metastases From Colorectal Carcinoma  

PubMed Central

Purpose To determine the conversion to resectability in patients with unresectable liver metastases from colorectal cancer treated with hepatic arterial infusion (HAI) plus systemic oxaliplatin and irinotecan (CPT-11). Patients and Methods Forty-nine patients with unresectable liver metastases (53% previously treated with chemotherapy) were enrolled onto a phase I protocol with HAI floxuridine and dexamethasone plus systemic chemotherapy with oxaliplatin and irinotecan. Results Ninety-two percent of the 49 patients had complete (8%) or partial (84%) response, and 23 (47%) of the 49 patients were able to undergo resection in a group of patients with extensive disease (73% with > five liver lesions, 98% with bilobar disease, 86% with ? six segments involved). For chemotherapy-naïve and previously treated patients, the median survival from the start of HAI therapy was 50.8 and 35 months, respectively. The only baseline variable significantly associated with a higher resection rate was female sex. Variables reflecting extensive anatomic disease, such as number of lesions or number of vessels involved, were not significantly associated with the probability of resection. Conclusion The combination of regional HAI floxuridine/dexamethasone and systemic oxaliplatin and irinotecan is an effective regimen for the treatment of patients with unresectable liver metastases from colorectal cancer, demonstrating a 47% conversion to resection (57% in chemotherapy-naïve patients). Future randomized trials should compare HAI plus systemic chemotherapy with systemic therapy alone to assess the additional value of HAI therapy in converting patients with hepatic metastases to resectability.

Kemeny, Nancy E.; Melendez, Fidel D. Huitzil; Capanu, Marinela; Paty, Philip B.; Fong, Yuman; Schwartz, Lawrence H.; Jarnagin, William R.; Patel, Dina; D'Angelica, Michael

2009-01-01

192

Concurrent Abstract Predicates  

Microsoft Academic Search

\\u000a Abstraction is key to understanding and reasoning about large computer systems. Abstraction is simple to achieve if the relevant\\u000a data structures are disjoint, but rather difficult when they are partially shared, as is often the case for concurrent modules.\\u000a We present a program logic for reasoning abstractly about data structures that provides a fiction of disjointness and permits\\u000a compositional reasoning.

Thomas Dinsdale-Young; Mike Dodds; Philippa Gardner; Matthew J. Parkinson; Viktor Vafeiadis

2010-01-01

193

Multivariate analysis of brain metabolism reveals chemotherapy effects on prefrontal cerebellar system when related to dorsal attention network  

PubMed Central

Background Functional brain changes induced by chemotherapy are still not well characterized. We used a novel approach with a multivariate technique to analyze brain resting state [18?F]FDG-PET in patients with lymphoma, to explore differences on cerebral metabolic glucose rate between chemotherapy-treated and non-treated patients. Methods PET/CT scan was performed on 28 patients, with 14 treated with systemic chemotherapy. We used a support vector machine (SVM) classification, extracting the mean metabolism from the metabolic patterns, or networks, that discriminate the two groups. We calculated the correct classifications of the two groups using the mean metabolic values extracted by the networks. Results The SVM classification analysis gave clear-cut patterns that discriminate the two groups. The first, hypometabolic network in chemotherapy patients, included mostly prefrontal cortex and cerebellar areas (central executive network, CEN, and salience network, SN); the second, which is equal between groups, included mostly parietal areas and the frontal eye field (dorsal attention network, DAN). The correct classification membership to chemotherapy or not chemotherapy-treated patients, using only one network, was of 50% to 68%; however, when all the networks were used together, it reached 80%. Conclusions The evidenced networks were related to attention and executive functions, with CEN and SN more specialized in shifting, inhibition and monitoring, DAN in orienting attention. Only using DAN as a reference point, indicating the global frontal functioning before chemotherapy, we could better classify the subjects. The emerging concept consists in the importance of the investigation of brain intrinsic networks and their relations in chemotherapy cognitive induced changes.

2013-01-01

194

Simulating Truly Concurrent CSP  

NASA Astrophysics Data System (ADS)

Process algebras like CSP provide a convenient intermediate-level formalism for the design of concurrent systems by allowing processes to be combined in parallel in such a way that the designer abstracts synchronization mechanisms and simultaneity of events. However some purposes require potential simultaneity to be made explicit. One approach is to produce new semantics models encapsulating that information. The approach taken here is to use the standard models and the CSP tool, FDR, to simulate a process in such a way to reveal potentially-simultaneous events. The simulation is achieved by a construction that splits events into start and end events and monitors the result in a manner faithful to the original process. The method is applied to determine pairs of possibly concurrent events and to compute maximal simultaneity in a CSP design.

Kleine, Moritz; Sanders, J. W.

195

Coordinated Spiral: Concurrent Modeling and Simulation Development with C4ISR Systems.  

National Technical Information Service (NTIS)

Currently Modeling and Simulation (M&S) requirements in support of Command, Control, Communications, Computer, Intelligence, Surveillance and Reconnaissance (C4ISR) systems tend to be developed following the effected C4ISR system fielding. The resultant d...

S. C. Johnston

2002-01-01

196

A tandem architecture for cooperating knowledge-based concurrent engineering systems  

Microsoft Academic Search

This paper proposes a tandem architecture for cooperating heterogeneous expert systems. Two levels of meta and working expert systems are involved. The working-level expert systems (W-ES), which may be implemented in their own computational environments and in private proof languages, are mainly for application computations. The meta-level expert systems (M-ES), using a common argument language, are mainly responsible for cooperation.

Guo Q. Huang; Derek Sheldon

1994-01-01

197

Heuristic Networks for Aerospace Systems Control: Totally Concurrent Motions D R A F T  

Microsoft Academic Search

This paper* reports new results in the development of Linguistic Geometry for multiagent systems. The Linguistic Geometry allows for the decomposition of a complex system into a dynamic hierarchy of subsystems, solving intractable search problems by reducing the search dramatically. In this paper we consider briefly the Linguistic Geometry tools and their application to the new multiagent system represented 2D

Boris Stilman

198

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial  

Microsoft Academic Search

Summary Background Results from phase II studies in patients with stage IIIA non-small-cell lung cancer with ipsilateral mediastinal nodal metastases (N2) have shown the feasibility of resection after concurrent chemotherapy and radiotherapy with promising rates of survival. We therefore did this phase III trial to compare concurrent chemotherapy and radiotherapy followed by resection with standard concurrent chemotherapy and defi nitive

Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi III; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox

2009-01-01

199

Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation.  

PubMed

PTLD of the CNS is a rare complication of solid organ transplantation, and there are only case reports/series available in the literature. Current literature suggests that CNS PTLD carries a worse prognosis than PTLD outside the CNS, and most are of B-cell lineage, predominantly monomorphic, and are associated with EBV infection. Because this disorder is so rare, there is no standard chemotherapy for pediatric patients with CNS PTLD and reported therapies for EBV-associated CNS PTLD are heterogeneous with mixed results. Since outcomes of CNS PTLD are historically poor, we attempted to develop a novel therapeutic treatment regimen. Based on a review of the literature and with the help of a multidisciplinary team, we created a regimen of chemotherapy that included dexamethasone and high-dose methotrexate in addition to intravenous and intraventricular Rituximab in two pediatric patients. The intraventricular chemotherapy succeeded in shrinking the tumor in both of our patients; however, as shown in the second case, the clinical outcome depends on the location of the tumor. Systemic and intraventricular therapies hold promise in the management of EBV-associated CNS PTLD; however the rarity of this entity prevents the development of well-designed studies necessary for the establishment of an evidence-based treatment standard. PMID:22646132

Twombley, Katherine; Pokala, Hanumantha; Ardura, Monica I; Harker-Murray, Paul; Johnson-Welch, Sarah F; Weinberg, Arthur; Seikaly, Mouin

2012-05-30

200

[Combination therapy for inoperable cholangiocellular carcinoma-systemic chemotherapy and hepatic arterial injection].  

PubMed

We report the case of a 52-year-old woman with cholangiocellular carcinoma (CCC) involving the lymph node and lung metastases who was admitted to our hospital because of right abdominal pain and anorexia. We started systemic chemotherapy(SCT) comprising 5-fluorouracil(5-FU; 1 g) and gemcitabine(GEM; 1 g) biweekly. After 1 course of SCT, we treated her with high-dose hepatic arterial injection (6 g 5-FU/1 week). This chemotherapy regimen improved her symptoms. After placing an arterial port into the right femoral artery, we continued SCT comprising GEM biweekly and hepatic arterial injection(HAI) of 5-FU weekly. Finally, we opted for weekly HAI and simultaneous SCT of 5-FU and GEM biweekly. The SCT dose of 5-FU was 1,000 mg and the dose of GEM ranged from 800 to 1,000 mg. For HAI, the dose of 5-FU was changed to between 250 and 750 mg. Lymph node metastases disappeared and lung metastases were reduced by this treatment. Because the lung metastases had progressed after 10 months, we increased the SCT dose of 5-FU to 1,500 mg and the dose of GEM to 1,200 mg. We also added systemic mitomycin C and prolonged the injection time of systemic 5-FU from 3 hours to 3 days. The lung metastases were reduced by this treatment. Our patient is still alive and has worked for more than 1 year. We recommend combination therapy of SCT and HAI for CCC with metastases. PMID:23267917

Hasuike, Yasunori; Iwagami, Yoshifumi; Kira, Toshihiko; Hirao, Satoshi

2012-11-01

201

Understanding Chemotherapy  

MedlinePLUS

... with your doctor or nurse. I am getting chemo to: _____________________ _____________________ _____________________ _____________________ _____________________ _____________________ _____________________ _____________________ Check with your doctor or nurse before ... or nurse. This is how I will get chemo: _____________________ _____________________ _____________________ _____________________ _____________________ _____________________ _____________________ _____________________ Understanding Chemotherapy When will I get chemotherapy? You ...

202

Chemotherapy-induced mucositis: The role of mucin secretion and regulation, and the enteric nervous system.  

PubMed

Alimentary mucositis is a severe, dose-limiting, toxic side effect of cytotoxic chemotherapy and radiotherapy. Patients with mucositis often have reductions or breaks imposed on cytotoxic therapy, which may lead to reduced survival. Furthermore, there is an increased risk of infection and hospitalization, compounding the cost of treatment. There are currently limited therapeutic options for mucositis, and no effective prevention available. Mucin expression and secretion have been shown to be associated with mucositis. Furthermore, mucins exhibit protective effects on the alimentary tract through reducing mechanical and chemical stress, preventing bacterial overgrowth and penetration, and digestion of the mucosa. Additionally, a number of studies have implicated some key neurotransmitters in both mucositis and mucin secretion, suggesting that the enteric nervous system may also play a key role in the development of mucositis. PMID:23827812

Thorpe, Daniel; Stringer, Andrea; Butler, Ross

2013-07-01

203

Concurrent Computing  

NSDL National Science Digital Library

* a preliminary introduction to essential networking concepts, * parallel computing and types of parallel computers, * basics of message-passing parallel computing,* embarrassingly parallel computations,* partitioning and divide-and-conquer strategies,* pipelined computations, * synchronous computations,* programming with shared memory, pthreads,* parallel sorting algorithms,* numerical algorithms,* searching and optimization,* distributed computing using grids,* networks for high-performance cluster computing, and * parallel I/O and parallel file systems.

Apon, Amy

204

A laser/EMAT (electromagnetic-acoustic transducer) concurrent weld inspection system  

SciTech Connect

A noncontacting ultrasonic sensor system is being developed for on-line inspection of thick section welds made by a robotic gas metal arc welding (GMAW) system. The sensor system consists of a pulsed laser for generating the ultrasound and an electromagnetic-acoustic transducer (EMAT) for receiving it. The sensor will follow closely behind the weld head and inspect the solidified weld bead for flaws. The main advantage of this technique is that flaws can be found and repaired before they are covered by subsequent welding passes. This is expected to be much simpler and less likely to induce further flaws than current practice since a large amount of otherwise good weld metal need not be removed to reach and repair a flaw. The system also monitors the welding process, i.e., detection of a large number of flaws indicates that the process is no longer operating as planned. In this paper, the technique for detecting incomplete sidewall penetration is demonstrated and methods for improving the system are discussed. 12 refs., 3 figs., 1 tab.

Johnson, J.A.; Carlson, N.M.

1990-01-01

205

Modeling behavioral design patterns of concurrent objects  

Microsoft Academic Search

Object-oriented software development practices are being rapidly adopted within increasingly complex systems, including reactive, real-time and concurrent system applications. While data modeling is performed very well under current object-oriented development practices, behavioral modeling necessary to capture critical information in real-time, reactive, and concurrent systems is often lacking. Addressing this deficiency, we offer an approach for modeling and analyzing concurrent object-oriented

Robert G. Pettit IV; Hassan Gomaa

2006-01-01

206

Concurrent systemic AA amyloidosis can discriminate primary sclerosing cholangitis from IgG4-associated cholangitis  

PubMed Central

Chronic hepatobiliary inflammatory diseases are not widely acknowledged as underlying disorders of systemic AA amyloidosis, except epidemic schistosomiasis. Among them, primary sclerosing cholangitis (PSC) might initiate amyloid A protein deposition in diverse tissues, giving rise to systemic amyloidosis, due to a progressive and unresolved inflammatory process, and its possible association with inflammatory bowel diseases. Nevertheless, only one such case has been reported in the literature to date. We report a 69-year-old Japanese woman with cirrhosis who was diagnosed with PSC complicated with systemic AA amyloidosis, without any evidence of other inflammatory disorders. As a result of cholestasis in conjunction with biliary strictures and increased serum IgG4, the presence of IgG4+ plasma cells was examined systemically, resulting in unexpected documentation of Congo-red-positive amyloid deposits, but not IgG4+ plasma cells, in the liver, stomach and salivary glands. Elevated serum IgG4 is the hallmark of IgG4-related disease, including IgG4-associated cholangitis, but it has also been demonstrated in certain patients with PSC. Amyloid A deposits in multiple organs associated with an indolent clinical course that progresses over many years might have a diagnostic value in discriminating PSC from IgG4-associated cholangitis.

Kato, Takehiro; Komori, Atsumasa; Bae, Sung-Kwan; Migita, Kiyoshi; Ito, Masahiro; Motoyoshi, Yasuhide; Abiru, Seigo; Ishibashi, Hiromi

2012-01-01

207

Living donor liver transplantation for children with liver failure and concurrent multiple organ system failure  

Microsoft Academic Search

Liver transplantation for pediatric patients in liver failure and multiple organ system failure (MOSF) often results in poor patient survival. Progression of organ failure occurs while awaiting a cadaveric allograft. Therefore, we considered living donor liver transplantation (LDLT) in this critically ill group of children and report our initial results with comparison to a similar group who received cadaveric donation

Cara L. Mack; Mario Ferrario; Michael Abecassis; Peter F. Whitington; Riccardo A. Superina; Estella M. Alonso

2001-01-01

208

A collection of software tools for analyzing designs of concurrent software systems  

Microsoft Academic Search

We present results from a research project to investigate the feasibility of software tools for analyzing designs of software systems. Such analysis would help the software developer to assess the acceptability of designs before the development of the software moves from the design phase into the implementation phase. If this could be done, futile implementation efforts based on faulty designs

Allan M. Stavely; David C. Becker; Susan P. Orr; Gregory B. Titus

1985-01-01

209

Exploiting transition locality in automatic verification of finite-state concurrent systems  

Microsoft Academic Search

In this paper we show that statistical properties of the transition graph of a system to be verified can be exploited to improve memory or time performances of verification algorithms. We show experimentally that protocols exhibit transition locality. That is, with respect to levels of a breadth-first state space exploration, state transitions tend to be between states belonging to close

Giuseppe Della Penna; Benedetto Intrigila; Igor Melatti; Enrico Tronci; Marisa Venturini Zilli

2004-01-01

210

Page-based optimistic concurrency control for memory-mapped persistent object systems  

Microsoft Academic Search

New app1ication.a th.at support cooperative work of users on. distributed computers often share perai9ten.t data atru.cturea that con,tain poinders. For th.eae ap- p1ication.a. th,e un.derlyin,g system, often wea th,e \\

Shigekazu Inohara; Yoji Shigehata; Keitaro Uehara; Hajime Miyazawa; Kouhei Yamamoto; Takashi Masuda

1995-01-01

211

Concurrent Validity of the "Working with Others Scale" of the ICIS Employment Interview System  

ERIC Educational Resources Information Center

|The purpose of this study was to determine if the Working with Others Scale from the American Association of School Personnel Administrators (AASPA) Interactive Computer Interview System (ICIS) was a valid predictor of practicing teachers' interpersonal skills and abilities to work well with colleagues. Participants in the study were all employed…

Cassidy, Martha W.

2011-01-01

212

A CONCURRENT NEURAL NETWORK - GENETIC PROGRAMMING MODEL FOR DECISION SUPPORT SYSTEMS  

Microsoft Academic Search

This paper suggests a decision support system for tactical air combat environment using a combination of unsuper- vised learning for clustering the data and three well known genetic programming techniques to classify the different decision re- gions accurately. The genetic programming techniques used are: Linear Genetic programming (LGP), Multi Expression Pro- gramming (MEP) and Gene Expression Programming (GEP). The clustered

AJITH ABRAHAM; CRINA GROSAN; CONG TRAN; LAKHMI JAIN

213

A Semantic Integration of Object-Z and CSP for the Specification of Concurrent Systems  

Microsoft Academic Search

. This paper presents a method of formally specifying concurrentsystems which uses the object-oriented state-based specificationlanguage Object-Z together with the process algebra CSP. Object-Z providesa convenient way of modelling complex data structures needed todefine the component processes of such systems, and CSP enables theconcise specification of process interactions. The basis of the integrationis a semantics of Object-Z classes identical to

Graeme Smith

1997-01-01

214

First principles of concurrent engineering: A competitive strategy for electronic product development. CALS/concurrent engineering task group-electronic systems  

NASA Astrophysics Data System (ADS)

The U.S. electronics industry is in trouble. Progressively more electronic components and critical technologies are available only from foreign sources. The problems of maintaining a sufficient level of military readiness and a competitive commercial electronics industry to support a healthy economy are directly linked. The majority of problems are directly related to inherent insufficiencies in the way the products are engineered and the processes that manufacture, test, and support them. Outlined here are the principles of current engineering for electronics development. The competitive strategy is part of the Computer-aided Acquisition and Logistic Support (CALS) system.

Linton, L.; Hall, D.; Hutchison, K.; Hoffman, D.; Evanczuk, S.

1991-09-01

215

Complications Encountered with a Transfemorally Placed Port-Catheter System for Hepatic Artery Chemotherapy Infusion  

SciTech Connect

A port-catheter system was implanted via femoral artery access for hepatic artery chemotherapy infusion. Implantation was attempted in 90 patients and was successful in 88. Blood flow redistribution was performed using embolization coils. In the first ten patients a soft heparin-coated infusion catheter was used. For the following 78 patients we used a stiffer catheter coated with fluorine-acryl-styrene-urethane-silicone (FASUS) copolymer. The catheter was connected to a port implanted subcutaneously below the level of the inguinal ligament. Complications during the procedure and after placement were observed in 7 of 90 patients and 24 of 88 patients, respectively. These included catheter obstruction (11%), dislocation of the catheter tip (10%), drug toxicity (5.7%), and catheter infection (3.4%). In 6 of 10 patients with catheter obstruction, recanalization of the port system was achieved. In 7 of 9 patients with dislocation of the indwelling catheter tip, replacement of the port system was successful. Our complications appear to be comparable with those encountered with the subclavian/brachial approach when the new catheter coating is used. Notable is the avoidance of cerebral infarcts.

Kuroiwa, Toshiro; Honda, Hiroshi; Yoshimitsu, Kengo; Irie, Hiroyuki; Aibe, Hitoshi; Tajima, Tsuyoshi; Shinozaki, Kenji; Masuda, Kouji [Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582 (Japan)

2001-03-15

216

Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation.  

PubMed

High-dose chemotherapy followed by autologous stem cell transplantation has been shown to be feasible and highly effective in newly diagnosed primary central nervous system lymphoma. In this retrospective multicenter study, we investigated prognosis and baseline risk factors in patients with primary central nervous system lymphoma who underwent this treatment approach. We retrospectively analyzed 105 immunocompetent patients with primary central nervous system lymphoma who underwent high-dose chemotherapy followed by autologous stem cell transplantation with or without whole brain radiotherapy as first-line consolidation treated at 12 German centers between 1997 and 2011. We estimated survival rates and investigated the impact of age, performance status, serum lactate dehydrogenase level, and deep brain involvement on overall and progression-free survival. Patients were additionally categorized into three prognostic groups according to the Memorial Sloan Kettering Cancer Center prognostic model. After a median follow up of 47 months, median progression-free survival and overall survival was reached after 85 and 121 months; 2- and 5-year survival rates were 82% and 79%, respectively. The Memorial Sloan Kettering Cancer Center prognostic model did not predict survival. Only age revealed some evidence of prognostic relevance. Overall response rate was 95%; of those patients with progressive disease before high-dose chemotherapy, 7 of 20 achieved ongoing complete remission after therapy without whole brain radiation therapy. Transplantation-associated mortality was 2.8%. High-dose chemotherapy followed by autologous stem cell transplantation is a highly effective and safe treatment modality for selected primary central nervous system lymphoma patients. Superiority compared to standard chemotherapy still warrants further investigation. PMID:23300179

Schorb, Elisabeth; Kasenda, Benjamin; Atta, Johannes; Kaun, Stephan; Morgner, Anke; Hess, Georg; Elter, Thomas; von Bubnoff, Nikolas; Dreyling, Martin; Ringhoffer, Mark; Krause, Stefan W; Derigs, Günter; Klimm, Beate; Niemann, D; Fritsch, Kristina; Finke, Jürgen; Illerhaus, Gerald

2013-01-08

217

Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer.  

PubMed

Venous thromboembolism (VTE) following breast cancer chemotherapy is common. Chemotherapy-induced alterations in markers of haemostasis occur during chemotherapy. It is unclear how rapidly this occurs, whether this is upregulated in patients developing VTE and whether changes predict for VTE. Markers of haemostasis, functional clotting assays and vascular endothelial growth factor were measured before chemotherapy and at 24 h, 4 days, 8 days and 3 months following commencement of chemotherapy in early and advanced breast cancer patients and in age- and sex-matched controls. Duplex ultrasound imaging was performed after 1 month or if symptomatic. Of 123 patients, 9.8% developed VTE within 3 months. Activated partial thromboplastin time (APTT), prothrombin time (PT), D-dimer, fibrinogen, platelet count, VEGF and fibrinogen were increased in cancer. Fibrinogen, D-dimer, VEGF and tissue factor were increased, at baseline, in patients subsequently developing VTE. D-dimer of less than 500 ng ml(-1) has a negative predictive value of 97%. Activated partial thromboplastin time, PT and thrombin-antithrombin showed significantly different trends, as early as within 24 h, in response to chemotherapy in patients subsequently developing VTE. Markers of coagulation and procoagulants are increased, before chemotherapy, in patients who subsequently develop VTE. A group of patients at minimal risk of VTE can be identified, allowing targeted thrombopropylaxis to the higher risk group. PMID:18766191

Kirwan, C C; McDowell, G; McCollum, C N; Kumar, S; Byrne, G J

2008-09-02

218

Entropy exchange, coherent information, and concurrence  

SciTech Connect

For a simple model we derive analytic expressions of entropy exchange and coherent information, from which relations between them and the concurrence are drawn. We find that in the quantum evolution the entropy exchange exhibits behavior opposite to that of the concurrence, whereas the coherent information shows features very similar to those of the concurrence. The meaning of this result for general systems is discussed.

Xiang Yang; Xiong Shijie [National Laboratory of Solid State Microstructures and Department of Physics, Nanjing University, Nanjing 210093 (China)

2007-07-15

219

Debugging Concurrent Ada Programs by Deterministic Execution  

Microsoft Academic Search

A language-based approach to deterministic execution debugging of concurrent Ada programs is presented. The approach is to define synchronization (SYN)-sequences of a concurrent Ada program in terms of Ada language constructs and to replay such SYN-sequences without the need for system-dependent debugging tools. It is shown how to define a SYN-sequence of a concurrent Ada program in order to provide

Kuo-chung Tai; Richard H. Carver; Evelyn E. Obaid

1991-01-01

220

The effect of rice seeding rate and fish stocking on the floodwater ecology of the rice field in direct-seeded, concurrent rice-fish systems  

Microsoft Academic Search

Concurrent, rice-fish systems in the Mekong Delta, Vietnam, are characterized by a rice field surrounded by a trench. Rice is direct seeded and fish are reared in polyculture. The most common species for polyculture are silver barb Barbodes gonionotus (Bleeker), common carp Cyprinus carpio L. and Nile tilapia Oreochromis niloticus (L.). In a 1996–97 rice-fish experiment, the effects of (1)

Nico Vromant; Nguyen T. H. Chau; Frans Ollevier

2001-01-01

221

Concurrent Chemoradiotherapy in Resected Extrahepatic Cholangiocarcinoma  

SciTech Connect

Purpose: Extrahepatic cholangiocarcinoma is a rare malignancy. Despite radical resection, survival remains poor, with high rates of local and distant failure. To clarify the role of radiotherapy with chemotherapy, we performed a retrospective analysis of resected patients who had undergone chemoradiotherapy. Methods and Materials: A total of 45 patients (13 with proximal and 32 with distal disease) underwent resection plus radiotherapy (median dose, 50.4 Gy). All but 1 patient received concurrent fluoropyrimidine-based chemotherapy. The median follow-up was 30 months for all patients and 40 months for survivors. Results: Of the 45 patients, 33 underwent adjuvant radiotherapy, and 12 were treated neoadjuvantly. The 5-year actuarial overall survival, disease-free survival, metastasis-free survival, and locoregional control rates were 33%, 37%, 42%, and 78%, respectively. The median survival was 34 months. No patient died perioperatively. Patient age {<=}60 years and perineural involvement adversely affected survival on univariate analysis. Patients undergoing R0 resection had a significantly improved rate of local control but no survival advantage. Despite having more advanced disease at presentation, patients treated neoadjuvantly had a longer survival (5-year survival 53% vs. 23%, p = 0.16) and similar rates of Grade 2-3 surgical morbidity (16% vs. 33%, p = 0.24) compared with those treated in the postoperative setting. Conclusion: These study results suggest a possible local control benefit from chemoradiotherapy combined with surgery in patients with advanced, resected biliary cancer. Furthermore, our results suggest that a treatment strategy that includes preoperative chemoradiotherapy might result in improved tumor resectability with similar surgical morbidity compared with patients treated postoperatively, as well as potentially improved survival outcomes. Distant failure remains a significant failure pattern, suggesting the need for more effective systemic therapy.

Nelson, John W.; Ghafoori, A. Paiman; Willett, Christopher G. [Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC (United States); Tyler, Douglas S.; Pappas, Theodore N.; Clary, Bryan M. [Department of General Surgery, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC (United States); Hurwitz, Herbert I.; Bendell, Johanna C.; Morse, Michael A. [Department of Internal Medicine, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC (United States); Clough, Robert W. [Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC (United States); Czito, Brian G. [Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC (United States)], E-mail: Czito001@mc.duke.edu

2009-01-01

222

Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin  

PubMed Central

Background We evaluate the long-term survival of patients with peritoneal carcinomatosis (PC) treated with systemic chemotherapy regimens, and the impact of the of the retrospective peritoneal disease severity score (PSDSS) on outcomes. Methods One hundred sixty-seven consecutive patients treated with PC from colorectal cancer between years 1987-2006 were identified from a prospective institutional database. These patients either received no chemotherapy, 5-FU/Leucovorin or Oxaliplatin/Irinotecan-based chemotherapy. Stratification was made according to the retrospective PSDSS that classifies PC patients based on clinically relevant factors. Survival analysis was performed using the Kaplan-Meier method and comparison with the log-rank test. Results Median survival was 5 months (95% CI, 3-7 months) for patients who had no chemotherapy, 11 months (95% CI, 6-9 months) for patients treated with 5 FU/LV, and 12 months (95% CI, 4-20 months) for patients treated with Oxaliplatin/Irinotecan-based chemotherapy. Survival differed between patients treated with chemotherapy compared to those patients who did not receive chemotherapy (p = 0.026). PSDSS staging was identified as an independent predictor for survival on multivariate analysis [RR 2.8 (95%CI 1.5-5.4); p < 0.001]. Conclusion A trend towards improved outcomes is demonstrated from treatment of patients with PC from colorectal cancer using modern systemic chemotherapy. The PSDSS appears to be a useful tool in patient selection and prognostication in PC of colorectal origin.

2010-01-01

223

Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study.  

PubMed

Brain gray matter alterations have been reported in cross-sectional magnetic resonance imaging (MRI) studies of breast cancer patients after cancer treatment. Here we report the first prospective MRI study of women undergoing treatment for breast cancer, with or without chemotherapy, as well as healthy controls. We hypothesized that chemotherapy-associated changes in gray matter density would be detectable 1 month after treatment, with partial recovery 1 year later. Participants included breast cancer patients treated with (CTx+, N = 17) or without (CTx-, N = 12) chemotherapy and matched healthy controls (N = 18). MRI scans were acquired at baseline (after surgery but before radiation, chemotherapy, and/or anti-estrogen treatment), 1 month after completion of chemotherapy (M1), and 1 year later (Y1). Voxel-based morphometry (VBM) was used to evaluate gray matter density differences between groups and over time. There were no between-group gray matter differences at baseline. Group-by-time interactions showed declines from baseline to M1 in both cancer groups relative to controls. Within-group analyses indicated that at M1 relative to baseline the CTx+ group had decreased gray matter density in bilateral frontal, temporal, and cerebellar regions and right thalamus. Recovery was seen at Y1 in some regions, although persistent decreases were also apparent. No significant within-group changes were found in the CTx- or control groups. Findings were not attributable to recency of cancer surgery, disease stage, psychiatric symptoms, psychotropic medication use, or hormonal treatment status. This study is the first to use a prospective, longitudinal approach to document decreased brain gray matter density shortly after breast cancer chemotherapy and its course of recovery over time. These gray matter alterations appear primarily related to the effects of chemotherapy, rather than solely reflecting host factors, the cancer disease process, or effects of other cancer treatments. PMID:20690040

McDonald, Brenna C; Conroy, Susan K; Ahles, Tim A; West, John D; Saykin, Andrew J

2010-08-06

224

Chemotherapy: What Every Patient Should Know  

MedlinePLUS

SkinCancerNet Article Chemotherapy: What Every Patient Should Know Chemotherapy is the use of cancer-fighting medications to stop the growth of ... or systemic (taken by mouth or injected). Topical Chemotherapy Topical chemotherapy is used to treat non-melanoma ...

225

Concurrence of superpositions  

SciTech Connect

Bounds on the concurrence of the superposition state in terms of the concurrences of the states being superposed are found in this paper. The bounds on concurrence are quite different from those on the entanglement measured by von Neumann entropy [Linden et al., Phys. Rev. Lett. 97, 100502 (2006)]. In particular, a nonzero lower bound can be provided if the states being superposed are properly constrained.

Yu, Chang-shui; Yi, X. X.; Song, He-shan [Department of Physics, Dalian University of Technology, Dalian 116024 (China)

2007-02-15

226

The family of concurrent logic programming languages  

Microsoft Academic Search

Concurrent logic languages are high-level programming languages for parallel and distributed systems that offer a wide range of both known and novel concurrent programming techniques. Being logic programming languages, they preserve many advantages of the abstract logic programming model, including the logical reading of programs and computations, the convenience of representing data structures with logical terms and manipulating them using

Ehud Y. Shapiro

1989-01-01

227

Multiversion concurrency control—theory and algorithms  

Microsoft Academic Search

Concurrency control is the activity of synchronizing operations issued by concurrently executing programs on a shared database. The goal is to produce an execution that has the same effect as a serial (noninterleaved) one. In a multiversion database system, each write on a data item produces a new copy (or version) of that data item. This paper presents a theory

Philip A. Bernstein; Nathan Goodman

1983-01-01

228

Hierarchical Concurrent Finite State Machines in Ptolemy  

Microsoft Academic Search

We implement a finite state machine (FSM) domain for specifying and simulating control functionality of a system within the Ptolemy software environment. The FSM domain is successfully integrated with synchronous data- flow (SDF) and discrete-event (DE) concurrency domains in Ptolemy. In this heterogeneous combination, the seman- tics of FSM, concurrency and hierarchy are naturally sup- ported in a manner similar

Bilung Lee; Edward A. Lee

1998-01-01

229

Concurrent Engineering support in Software Engineering  

Microsoft Academic Search

The evolution of Software Engineering methodology, from waterfall to spiral, from spiral to agile, indicates that high concurrency, iterative development and short cycles are key factors for effective Software Engineering. It is widely accepted that supporting (i.e., formalizing controlling, automating and optimizing) concurrent engineering processes is needed to increase predictability of cost, quality and development time. Unfortunately, current systems (e.g.,

Jacky Estublier; Sergio Garcia

2006-01-01

230

Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified According to the Retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin.  

National Technical Information Service (NTIS)

Background: We evaluate the long-term survival of patients with peritoneal carcinomatosis (PC) treated with systemic chemotherapy regimens, and the impact of the of the retrospective peritoneal disease severity score (PSDSS) on outcomes. Methods: One hund...

A. Stojadinovic J. Doerfer J. Esquivel J. O. Pelz T. C. Chua

2010-01-01

231

Liposomal-lupane system as alternative chemotherapy against cutaneous leishmaniasis: Macrophage as target cell.  

PubMed

Leishmania amazonensis causes human diseases that range from self-healing to diffusion cutaneous lesions. The chemotherapy of leishmaniasis requires long-term treatment and has been based on the use of pentavalent antimonials. Liposomes have been used as antileishmanial drug carries and have adjuvant activity in vaccines against several microorganisms, representing an important option to the development of new therapeutics for the disease. In this study, we developed a liposomal formulation containing lupane [3?,6?,16?-trihydroxylup-20(29)-ene], isolated from fruits of Combretum leprosum with pharmacological properties as antinociceptive, anti-inflammatory, antiulcerogenic and antileishmanial activities. The aim of the present study was to evaluate the efficacy of liposomal-lupane in L. amazonensis-infection model. Liposomes were prepared by the extrusion method with DPPC, DPPS and cholesterol at 5:1:4 weight ratio. The lupane (2mg/mL) was added to the lipid mixture, solubilized in chloroform and dried under nitrogen flow. The activity of liposomal-lupane was conducted in vitro with mouse peritoneal infected macrophages. Furthermore, mice were infected in the right hind footpad with 10(5) stationary growth phase of L. amazonensis promastigotes. After 6weeks, animals were treated with liposomal-lupane for 15days by intraperitoneal injection. The evolution of disease was monitored weekly by measuring footpad thickness with a caliper. Threedays after the treatment, peritoneal macrophages were collected, plated and production of the cytokines IL-10 and IL-12 was evaluated in supernatants of the cultures after 24h. The results indicate that the liposomal system containing lupane achieved here is a promising tool to confer antileishmanial activity to infected macrophages. PMID:23933281

Barros, Neuza B; Migliaccio, Vanessa; Facundo, Valdir A; Ciancaglini, Pietro; Stábeli, Rodrigo G; Nicolete, Roberto; Silva-Jardim, Izaltina

2013-08-06

232

An Expert View of the System Dynamics Modeling Process: Concurrences and Divergences Searching for Best Practices in System Dynamics Modeling  

Microsoft Academic Search

We intended this research both to discover a set of core practices in the system-dynamics modeling process and to identify the best of them according to the knowledgeable opinion of a recognized group of experts in the field. The paper addresses two questions: (1) What aspects of the system dynamics modeling process are common to all model building regardless of

Ignacio J. Martínez-Moyano; George P. Richardson

233

Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: A pilot study of a new digitized scalp-cooling system used in 74 patients  

Microsoft Academic Search

Goals. The aim of this study was to examine the efficacy and safety of a new digitized, controlled, scalp-cooling system to prevent chemotherapy-induced alopecia.Method. Seventy-four female cancer patients who received 13 varying chemotherapy regimens were included in a nonrandomized pilot study. The Digni 2–3 with Dignicap system consists of a refrigerator unit and a control unit integrated into a mobile

Mona Ridderheim; Maria Bjurberg; Anita Gustavsson

2003-01-01

234

Anticancer Chemotherapy.  

National Technical Information Service (NTIS)

Despite troubled beginnings, anticancer chemotherapy has made significant contribution to the control of cancer in man, particularly within the last two decades. Early conceptual observations awakened the scientific community to the potentials of cancer c...

R. E. Weller

1988-01-01

235

Surviving Chemotherapy  

NSDL National Science Digital Library

Lecture outlinne, with embedded notes, to serve as a starting point for in-class discussion, student research and presentation. Lecture provides a review of cancer, chemotherapy, risk factors for cancer, and correlations between all and nutrition.

Dr. Margaret A McMichael (Baton Rouge Community College Biological Sciences)

2008-08-15

236

Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: Updated results of a randomized multicentric trial in advanced head-and-neck cancer  

SciTech Connect

Purpose: To prove an expected benefit of concurrent radiochemotherapy (RCT), a two-arm randomized multicentric study was performed. In a subgroup analysis the influence of pretherapeutical hemoglobin level (p-Hb) on survival under locoregional control (SLC) was tested. Patients and Methods: The study included primarily untreated Stage III/IV (International Union Against Cancer [UICC]) oropharyngeal and hypopharyngeal carcinomas. Patients were randomized to receive either hyperfractionated (hf) and accelerated (acc) RCT with two cycles 5-fluorouracil (600 mg/m{sup 2}/day) and carboplatin (70 mg/m{sup 2}/day) on Days 1-5 and 29-33 or hf-acc radiotherapy (RT) alone. Total RT dose in both arms was 69.9 Gy in 38 days in concomitant boost technique. Results: After a median follow-up time of 57 months, SLC is significantly better in RCT than in RT (p = 0.01), with median SLC of 17 months and 11 months, respectively. Also overall survival (OS) shows a benefit for RCT (p 0.016), with a median survival of 23 months for RCT and 16 months for RT. However, the benefit in SLC and OS is not seen in hypopharyngeal carcinomas. In a multivariate analysis of oropharyngeal cancer patients, p-Hb levels lower than 12.7 g/dL resulted in lower SLC compared with higher p-Hb levels up to 13.8 g/dL. P-Hb levels >13.8 g/dL did not further improve SLC. Conclusions: Hyperfractionated-accelerated RCT is superior to hf-acc RT in oropharyngeal carcinomas. P-Hb levels >13.8 g/dL do not further improve SLC.

Semrau, Robert [Department of Radiation Oncology, University of Cologne, Cologne (Germany)]. E-mail: Robert.Semrau@uk-koeln.de; Mueller, Rolf-Peter [Department of Radiation Oncology, University of Cologne, Cologne (Germany); Stuetzer, Hartmut [Department of Medical Statistics and Epidemiology, University of Cologne, Cologne (Germany); Staar, Susanne [Department of Radiation Oncology, Krankenhaus-St-Juergens, Bremen (Germany); Schroeder, Ursula [ENT Department, University of Cologne, Cologne (Germany); Guntinas-Lichius, Orlando [ENT Department, University of Cologne, Cologne (Germany); Kocher, Martin [Department of Radiation Oncology, University of Cologne, Cologne (Germany); Eich, Hans Theodor [Department of Radiation Oncology, University of Cologne, Cologne (Germany); Dietz, Andreas [ENT Department, University of Leipzig, Leipzig (Germany); Flentje, Michael [Department of Radiation Oncology, University of Wuerzburg, Wuerzburg (Germany); Rudat, Volker [Department of Radiation Oncology, University of Hamburg, Hamburg (Germany); Volling, Peter [ENT Department, Evangelisches Krankenhaus Oldenburg, Oldenburg (Germany); Schroeder, Michael [ENT Department, Klinikum Kassel, Kassel (Germany); Eckel, Hans Edmund [ENT Department, Landeskrankenhaus Klagenfurt, Klagenfurt (Austria)

2006-04-01

237

Specifying concurrent objects  

Microsoft Academic Search

The object-oriented style of programming (OOP) is gaining increasing importance as a practical technique for organizing large designs and programs. Another striking aspect of OOP is its potential for concurrent and distributed applications which is based on the fact that objects may coexist in time and concurrently may exchange information by message passing. Up to now, however, there is only

Bernd J. Krämer

1989-01-01

238

Concurrent Software Engineering Project  

ERIC Educational Resources Information Center

|Concurrent engineering or overlapping activities is a business strategy for schedule compression on large development projects. Design parameters and tasks from every aspect of a product's development process and their interdependencies are overlapped and worked on in parallel. Concurrent engineering suffers from negative effects such as…

Stankovic, Nenad; Tillo, Tammam

2009-01-01

239

Concurrent search structure algorithms  

Microsoft Academic Search

A dictionary is an abstract data type supporting the actions member, insert, and delete. A search structure is a data structure used to implement a dictionary. Examples include B trees, hash structures, and unordered lists. Concurrent algorithms on search structures can achieve more parallelism than standard concurrency control methods would suggest, by exploiting the fact that many different search structure

Dennis Shasha; Nathan Goodman

1988-01-01

240

DARPA Initiative in Concurrent Engineering (DICE). Phase 2.  

National Technical Information Service (NTIS)

The mission of the DICE program is to create a Concurrent Engineering environment that will result in reduced (DARPA Initiative in Concurrent Engineering) time to market, improved total quality and lower cost for products or systems developed and supporte...

K. J. Singh

1990-01-01

241

An Aspect-Oriented Framework for Concurrent Applications  

Microsoft Academic Search

In this paper we describe an aspect-oriented framework forwriting concurrent and distributed applications. A system is modeledas: (a) a set of (sequential) processes, and (b) a set of constraints whichcapture the concurrent behaviour of the system. The key advantages arethat (1) there is a clear separation of these two aspects of the systemi.e. concurrency and functionality, (2) processes are coordinated

Rafael Ramirez; Andrew E. Santosa

2003-01-01

242

French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC)  

SciTech Connect

Background: Unresectable carcinomas of the oropharynx and hypopharynx still have a poor long-term prognosis. Following a previous phase II study, this phase III multicenter trial was conducted between November 1997 and March 2002. Methods: Nontreated, strictly unresectable cases were eligible. Twice-daily radiation: two fractions of 1.2 Gy/day, 5 days per week, with no split (D1{sup {yields}}D46). Total tumor doses: 80.4 Gy/46 day (oropharynx), 75.6 Gy/44 day (hypopharynx). Chemotherapy (arm B): Cisplatin 100 mg/m{sup 2} (D1, D22, D43); 5FU, continuous infusion (D1{sup {yields}}D5), 750 mg/m{sup 2}/day cycle 1; 430 mg/m{sup 2}/day cycles 2 and 3. Results: A total of 163 evaluable patients. Grade 3-4 acute mucositis 82.6% arm B/69.5% arm A (NS); Grade 3-4 neutropenia 33.3% arm B/2.4% arm A (p < 0.05). Enteral nutrition through gastrostomy tube was more frequent in arm B before treatment and at 6 months (p < 0.01). At 24 months, overall survival (OS), disease-free survival (DFS), and specific survival (SS) were significantly better in arm B. OS: 37.8% arm B vs. 20.1% arm A (p = 0.038); DFS: 48.2% vs. 25.2% (p = 0.002); SS: 44.5% vs. 30.2% (p 0.021). No significant difference between the two arms in the amount of side effects at 1 and 2 years. Conclusion: For these unresectable cases, chemoradiation provides better outcome than radiation alone, even with an 'aggressive' dose-intensity radiotherapy schedule.

Bensadoun, Rene-Jean [Department of Radiation Oncology, Centre Antoine Lacassagne, Nice (France)]. E-mail: rene-jean.bensadoun@nice.fnclcc.fr; Benezery, Karen [Department of Radiation Oncology, Centre Antoine Lacassagne, Nice (France); Dassonville, Olivier [Department of Head and Neck Surgery, Centre Antoine Lacassagne, Nice (France); Magne, Nicolas [Department of Radiation Oncology, Centre Antoine Lacassagne, Nice (France); Poissonnet, Gilles [Department of Head and Neck Surgery, Centre Antoine Lacassagne, Nice (France); Ramaioli, Alain [Department of Statistics Unit, Centre Antoine Lacassagne, Nice (France); Lemanski, Claire [Centre Val d'Aurelle-Paul Lamarque, Montpellier (France); Bourdin, Sylvain [Centre Rene-Gauducheau, Nantes (France); Tortochaux, Jacques [Centre Jean-Perrin, Clermont-Ferrand (France); Peyrade, Frederic [Department of Medical Oncology, Centre Antoine Lacassagne, Nice (France); Marcy, Pierre-Yves [Department of Radiology, Centre Antoine Lacassagne, Nice (France); Chamorey, Emmanuel Phar [Department of Statistics Unit, Centre Antoine Lacassagne, Nice (France); Vallicioni, Jacques [Department of Head and Neck Surgery, Centre Antoine Lacassagne, Nice (France); Seng Hang [Centre Henri-Becquerel, Rouen (France); Alzieu, Claude [Institut Paoli-Calmettes, Marseille (France); Gery, Bernard [Centre Francois-Baclesse, Caen (France); Chauvel, Pierre [Department of Radiation Oncology, Centre Antoine Lacassagne, Nice (France); Schneider, Maurice [Department of Medical Oncology, Centre Antoine Lacassagne, Nice (France); Santini, Jose [Department of Otolaryngology, University Hospital, Nice (France); Demard, Francois [Department of Head and Neck Surgery, Centre Antoine Lacassagne, Nice (France); Calais, Gilles [Hopital Jean Bretonneau, Tours (France)

2006-03-15

243

Alterations in Procoagulant, Anticoagulant, and Fibrinolytic Systems Before and After Start of Induction Chemotherapy in Children With Acute Lymphoblastic Leukemia.  

PubMed

Induction chemotherapy is associated with increased thrombosis risk in children with acute lymphoblastic leukemia (ALL). In this prospective study, we explored the effects of ALL and induction chemotherapy on the procoagulant, anticoagulant, and fibrinolytic systems in 20 children with ALL. The levels of d-dimer, factor VIII, von Willebrand factor, protein C, antithrombin III, and thrombin-activated fibrinolysis inhibitor (TAFI) were elevated at diagnosis. These changes were not related with peripheral blast count. The levels of fibrinogen, d-dimer, coagulation inhibitors, and plasminogen decreased, whereas the levels of tissue factor pathway inhibitor and plasminogen activator inhibitor 1 increased progressively following prednisolone monotherapy, administration of vincristine plus daunorubicin, and l-asparaginase. The levels of factor VIII, d-dimer, and TAFI remained elevated during the study period. In conclusion, coagulation activation and impaired fibrinolysis already exist at diagnosis, whereas induction chemotherapy leads to reactivation of coagulation and progressive impairment in fibrinolytic and anticoagulant capacities in childhood ALL. PMID:22751908

Albayrak, Meryem; Gürsel, Turkiz; Kaya, Zuhre; Koçak, Ulker

2012-06-29

244

Influence of complementary Viscum album (Iscador) administration on microcirculation and immune system of ear, nose and throat carcinoma patients treated with radiation and chemotherapy.  

PubMed

With the techniques of vital microscopic and reflection spectrometric imaging, representative characteristics of microcirculation and immunology of white blood cells were evaluated before, during and after radiotherapy and chemotherapy of patients suffering from ear, nose and throat carcinomas. Adverse effects of radiotherapy and chemotherapy on the microcirculation and the immune system were decreased and reconstitution processes were accelerated by complementary administration of a standardized mistletoe extract (Iscador). PMID:15816634

Klopp, R; Schmidt, W; Werner, E; Werner, M; Niemer, W; Beuth, J

245

Intraocular non-Hodgkin's lymphoma treated with systemic and intrathecal chemotherapy and radiotherapy  

Microsoft Academic Search

A case of therapy-resistant bilateral intermediate uveitis is presented. Vitreous biopsy and lumbar puncture resulted in the diagnosis of high-grade malignant non-Hodgkin's lymphoma (NHL). Because chemotherapy and radiotherapy continue to yield better results in the treatment of NHL and a cure can be reached in a large group of patients with high-grade malignant NHL, early diagnosis is very important. We

A. J. P. Rouwen; P. W. Wijermans; T. N. Boen-Tan; J. S. Stilma

1989-01-01

246

A Coq Library for Verification of Concurrent Programs  

Microsoft Academic Search

Abstract Thanks to recent advances, modern proof assistants now enable verification of realistic sequential programs. However, regarding the concurrency paradigm, previous work essentially focused on formalization of abstract systems, such as pure concurrent calculi, which are too minimal to be realistic. In this paper, we propose a library that enables verification of realistic concurrent programs in the Coq proof assistant.

Reynald Affeldt; Naoki Kobayashi

2008-01-01

247

Initiative in Concurrent Engineering (DICE). Phase 1.  

National Technical Information Service (NTIS)

The mission of the DICE program is to create a Concurrent Engineering environment that will result in reduced time to market, improved total quality and lower cost for products or systems developed and supported by large organizations. This environment wi...

K. J. Singh

1990-01-01

248

Concurrence in collective models  

SciTech Connect

We review the entanglement properties in collective models and their relationship with quantum phase transitions. Focusing on the concurrence, which characterizes the two-spin entanglement, we show that for first-order transitions, this quantity is singular but continuous at the transition point, contrary to the common belief. We also propose a conjecture for the concurrence of arbitrary symmetric states which connects it with a recently proposed criterion for bipartite entanglement.

Vidal, Julien [Laboratoire de Physique Theorique de la Matiere Condensee, CNRS UMR 7600, Universite Pierre et Marie Curie, 4 Place Jussieu, 75252 Paris Cedex 05 (France)

2006-06-15

249

Cost-effectiveness of concurrent supercomputers  

Microsoft Academic Search

This article introduces a mathematical function that describes the latent concurrency inherent in an arbitrary program with given initial conditions. The concurrency function is used to derive asymptotic estimates for speedup, including Amdahl's Law. It provides a new method for analyzing cost-effectiveness of the processor-memory-communications constituents of a computing system for applications where system cost and execution time are mutually

H. L. Resnikoff

1987-01-01

250

HIV chemotherapy  

Microsoft Academic Search

The use of chemotherapy to suppress replication of the human immunodeficiency virus (HIV) has transformed the face of AIDS in the developed world. Pronounced reductions in illness and death have been achieved and healthcare utilization has diminished. HIV therapy has also provided many new insights into the pathogenesis and the viral and cellular dynamics of HIV infection. But challenges remain.

Douglas D. Richman

2001-01-01

251

Hepatic Arterial Infusion Chemotherapy Using Fluorouracil Followed by Systemic Therapy Using Oxaliplatin Plus Fluorouracil and Leucovorin for Patients with Unresectable Liver Metastases from Colorectal Cancer  

SciTech Connect

The purpose of this study was to assess retrospectively the sequential treatment of hepatic arterial infusion (HAI) chemotherapy followed by systemic therapy using oxaliplatin plus 5-flourouracil (5-FU) and leucovorin, namely, FOLFOX, for patients with liver metastases from colorectal cancer. We reviewed 20 patients with unresectable liver metastases from colorectal cancer. Patients were initially treated with HAI chemotherapy until disease progression (5-fluorouracil, 1000 mg/m{sup 2} intra-arterial infusion, weekly) and then with FOLFOX thereafter (FOLFOX4, n = 13; modified FOLFOX6, n = 7). Adverse events, tumor response, and time to progression for each therapy were evaluated retrospectively, and overall survival was estimated. Toxicity of HAI chemotherapy was generally mild. Of 20 patients, adverse events leading to treatment discontinuation occurred in only 1 patient (5%) during initial therapy using HAI chemotherapy, while 9 patients (45%) exhibited adverse events during subsequent FOLFOX therapy. For HAI chemotherapy and FOLFOX, objective response rates were 85.0% and 35.0%, respectively, and median time to progression was 11.6 and 5.1 months, respectively. Median overall survival was 30.1 months. In conclusion, the sequence of HAI chemotherapy followed by FOLFOX is a promising treatment strategy for the long-term use of active chemotherapeutic agents, leading to a superior tumor response and fewer toxic effects in patients with unresectable liver metastases from colorectal cancer.

Seki, Hiroshi, E-mail: hseki@niigata-cc.jp; Ozaki, Toshirou; Shiina, Makoto [Niigata Cancer Center Hospital, Department of Radiology (Japan)

2009-07-15

252

Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review  

PubMed Central

Until now only intravenous and oral formulations of 5HT3 receptor antagonists have been available. Recently a new formulation of a 5HT3 receptor antagonist, transdermal granisetron, has been developed, and approved by the FDA. Three phase I studies to evaluate its pharmacokinetic profile have shown that granisetron administered by a transdermal delivery system is absorbed by passive diffusion and maximal concentration is reached 48 hours after patch application. The patch of 52 cm2, which contains 34.3 mg of granisetron, releases 3.3 mg of the drug every day and maintains a stable average plasma concentration of 2.2 ng/mL over 6 days, similar to levels obtained with 2 mg of oral granisetron, administered every day during the same period of time. Two randomized as yet unpublished clinical trials (phase II/III) have been conducted to evaluate the antiemetic efficacy of transdermal granisetron in chemotherapy-induced nausea and vomiting, in patients receiving moderately and highly emetogenic chemotherapy, compared with 2 mg of oral granisetron. More than 800 cancer patients were included in the trials. The rate of complete control of acute emesis was 49% for the phase II trial and 60% for the phase III trial. Neither trial showed a statistically significant difference between transdermal and oral granisetron. The control of delayed emesis was observed in 46% of patients, and there were no statistically significant differences between transdermal and oral granisetron. The most common adverse effects in both trials were constipation (<7%) and headache (<1%); there were no statistically significant differences between transdermal and oral granisetron. These data show that transdermal granisetron is effective and safe in controlling acute emesis induced by chemotherapy with both moderate and high emetogenic potential. Efficacy and safety of transdermal granisetron are fully comparable with that of oral granisetron. More clinical trials using regimens of 2 or 3 drugs, including dexamethasone and/or aprepitant, are needed to confirm the place of transdermal granisetron in the control of chemotherapy-induced nausea and vomiting.

Tuca, Albert

2010-01-01

253

Hyperthermia as Adjunct to Intravesical Chemotherapy for Bladder Cancer  

PubMed Central

Nonmuscle invasive bladder cancer remains a very costly cancer to manage because of high recurrence rates requiring long-term surveillance and treatment. Emerging evidence suggests that adjunct and concurrent use of hyperthermia with intravesical chemotherapy after transurethral resection of bladder tumor further reduces recurrence risk and progression to advanced disease. Hyperthermia has both direct and immune-mediated cytotoxic effect on tumor cells including tumor growth arrest and activation of antitumor immune system cells and pathways. Concurrent heat application also acts as a sensitizer to intravesical chemotherapy agents. As such the ability to deliver hyperthermia to the focus of tumor while minimizing damage to surrounding benign tissue is of utmost importance to optimize the benefit of hyperthermia treatment. Existing chemohyperthermia devices that allow for more localized heat delivery continue to pave the way in this effort. Current investigational methods involving heat-activated drug delivery selectively to tumor cells using temperature-sensitive liposomes also offer promising ways to improve chemohyperthermia efficacy in bladder cancer while minimizing toxicity to benign tissue. This will hopefully allow more widespread use of chemohyperthermia to all bladder cancer patients, including metastatic bladder cancer.

Owusu, Richmond A.; Abern, Michael R.; Inman, Brant A.

2013-01-01

254

Systemic Chemotherapy prior to Cytoreductive Surgery and HIPEC for Carcinomatosis from Appendix Cancer: Impact on Perioperative Outcomes and Short-Term Survival  

PubMed Central

Background and Objectives. Systemic chemotherapy administered prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mucinous adenocarcinoma of appendiceal origin (PMCA) is associated with a significant rate of histological response. The impact of preoperative systemic chemotherapy (PSC) on intraperitoneal tumor burden, completeness of cytoreduction, and perioperative complications is unknown. Methods. We analyzed prospectively collected data from our HIPEC database. Thirty-four patients with PMCA were prospectively recruited and treated with PSC. Perioperative variables and survival in this group of patients were compared against 24 patients with PMCA who did not receive PSC. Results. Ten of 34 patients (29%) receiving PSC had a complete or near complete histological response. Patients receiving PSC had a lower peritoneal carcinomatosis index, required fewer peritonectomies and visceral resections, and achieved complete cytoreduction more frequently compared to patients with no preoperative chemotherapy. The incidence of perioperative complications and survival were not significantly different between the two groups. However, patients with complete histological response had better overall survival compared to patients without complete response. Conclusions. Preoperative systemic chemotherapy in appendix-originated PMCA is associated with a significant rate of histological response which may reduce the tumor burden, facilitate less aggressive and more complete CRS, and improve short-term survival in patients with a significant histological response.

Bijelic, Lana; Kumar, Anjali S.; Stuart, O. Anthony; Sugarbaker, Paul H.

2012-01-01

255

Chemotherapy in conjoint aging-tumor systems: some simple models for addressing coupled aging-cancer dynamics  

PubMed Central

Background In this paper we consider two approaches to examining the complex dynamics of conjoint aging-cancer cellular systems undergoing chemotherapeutic intervention. In particular, we focus on the effect of cells growing conjointly in a culture plate as a precursor to considering the larger multi-dimensional models of such systems. Tumor cell growth is considered from both the logistic and the Gompertzian case, while normal cell growth of fibroblasts (WI-38 human diploid fibroblasts) is considered as logistic only. Results We demonstrate, in a simple approach, how the interdependency of different cell types in a tumor, together with specifications of for treatment, can lead to different evolutionary patterns for normal and tumor cells during a course of therapy. Conclusions These results have significance for understanding appropriate pharmacotherapy for elderly patients who are also undergoing chemotherapy.

2010-01-01

256

The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer  

PubMed Central

There is increasing evidence that the presence of a systemic inflammatory response plays an important role in survival following curative resection for colorectal cancer. The present study evaluated the relationship between C-reactive protein concentrations and survival in a cohort of patients receiving adjuvant 5-fluorouracil (5-FU) chemotherapy following potentially curative resection for colorectal cancer. In all, 222 patients undergoing potentially curative resection for colorectal cancer were studied. Of these, 50 patients received adjuvant 5-FU-based chemotherapy. Circulating concentrations of C-reactive protein were measured prior to surgery. The minimum follow-up was 15 months; the median follow-up of the survivors was 38 months. During this period 61 patients died, 32 patients of their cancer and 29 of intercurrent disease. In those patients who did not receive adjuvant chemotherapy, age (P<0.001), Dukes stage (P<0.05) and an elevated C-reactive protein (P<0.01) were significantly associated with survival. In those patients who did receive adjuvant chemotherapy, an elevated C-reactive protein concentration (P<0.01) was significantly associated with survival. The presence of a systemic inflammatory response is an independent predictor of poor outcome in patients receiving adjuvant 5-FU-based chemotherapy following potentially curative resection for colorectal cancer.

Crozier, J E M; McKee, R F; McArdle, C S; Angerson, W J; Anderson, J H; Horgan, P G; McMillan, D C

2006-01-01

257

Modeling Behavioral Patterns of Concurrent Objects Using Petri Nets  

Microsoft Academic Search

Object-oriented software development practices are being rapidly adopted within increasingly complex systems, including reactive, real-time and concurrent system applications. While data modeling is performed very well under current object-oriented development practices, behavioral modeling necessary to capture critical information in real-time, reactive, and concurrent systems is often lacking. Addressing this deficiency, we offer an approach for modeling and analyzing concurrent object-oriented

Robert G. Pettit Iv; Hassan Gomaa

2006-01-01

258

Concurrent Subspaces Analysis  

Microsoft Academic Search

A representative subspace is significant for image analysis, while the corresponding techniques often suffer from the curse of dimensionality dilemma. In this paper, we pro- pose a new algorithm, called Concurrent Subspaces Analysis (CSA), to derive representative subspaces by encoding image objects as 2 nd or even higher order ten- sors. In CSA, an original higher dimensional tensor is transformed

Dong Xu; Shuicheng Yan; Lei Zhang; Hong-Jiang Zhang; Zhengkai Liu; Heung-yeung Shum

2005-01-01

259

HIV chemotherapy  

NASA Astrophysics Data System (ADS)

The use of chemotherapy to suppress replication of the human immunodeficiency virus (HIV) has transformed the face of AIDS in the developed world. Pronounced reductions in illness and death have been achieved and healthcare utilization has diminished. HIV therapy has also provided many new insights into the pathogenesis and the viral and cellular dynamics of HIV infection. But challenges remain. Treatment does not suppress HIV replication in all patients, and the emergence of drug-resistant virus hinders subsequent treatment. Chronic therapy can also result in toxicity. These challenges prompt the search for new drugs and new therapeutic strategies to control chronic viral replication.

Richman, Douglas D.

2001-04-01

260

Concurrent fractional and equilibrium crystallisation  

NASA Astrophysics Data System (ADS)

This paper proposes the concept of concurrent fractional and equilibrium crystallisation (CFEC) in a multi-phase magmatic system in light of experimental results on diffusivities of elements and other species in minerals and melts. A group of equations are presented to describe how the concentrations of an element or isotope change in fractionated solid, equilibrated solid, melt, liquid, and gas phases, as well as in magma, as a function of distribution coefficients and mass fractions during the CFEC process. CFEC model is a generalised and unified formulation that is valid, not only for pure fractional crystallisation (FC) and perfect equilibrium crystallisation (EC) singly, as two of its limiting end-member cases, but also for the geologically more important process of concurrent fractional and equilibrium crystallisation. The concept that both fractional and equilibrium crystallisation can operate concurrently in a magmatic system, for a given element, among different minerals, and even within different-sized crystal grains of the very same mineral phase, is of fundamental importance in deepening our current understanding of magmatic differentiation processes. CFEC probably occurs more frequently in the natural world than either pure fractional or perfect equilibrium crystallisation alone, as a result of the interplay of varying diffusivities of elements under diverse physicochemical conditions, different residence time and growth rates of mineral phases in magmas, and varying grain sizes within each phase and among different phases. The marked systematic variations in trace element concentrations in the melts of the Bishop Tuff have long been perplexing and difficult to reconcile with existing models of differentiation. CFEC, which is able to better explain the scatter trends in a systematic way than fractional crystallisation, is considered to be the cause.

Sha, Lian-Kun

2012-06-01

261

Spin squeezing and concurrence  

NASA Astrophysics Data System (ADS)

We study the relations between spin squeezing and concurrence, and find that they are qualitatively equivalent for an ensemble of spin-1/2 particles with exchange symmetry and parity, if we adopt the spin squeezing criterion given in the recent work by Tóth et al (2007 Phys. Rev. Lett. 99 250405). This suggests that the spin squeezing has more intimate relations with pairwise entanglement. We exemplify the result by considering a superposition of two Dicke states.

Yin, Xiaolei; Wang, Xiaoqian; Ma, Jian; Wang, Xiaoguang

2011-01-01

262

Concurrent Bisimulations in Petri Nets  

Microsoft Academic Search

Summary After various attempts, an equivalence relation is defined for labelled Petri nets, on the base of the concurrency semantics of net theory. This relation, called Fully Concurrent bisimulation and abbreviated FC-bisimulation, preserves the level of concurrency of visible operations and, under some conditions, allows to enforce injective labelling on them. Refinements of a visible operation are also defined and

Eike Best; Raymond R. Devillers; Astrid Kiehn; Lucia Pomello

1991-01-01

263

Chemotherapy for Bone Cancer  

MedlinePLUS

... cancer Next Topic Targeted therapy for bone cancer Chemotherapy for bone cancer Chemotherapy (chemo) is the use ... etoposide or ifosfamide and doxorubicin Side effects of chemotherapy Chemo kills cancer cells, but it will also ...

264

Chemotherapy and Pregnancy  

MedlinePLUS

... or visit us online at: www.OTISpregnancy.org . Chemotherapy and Pregnancy This sheet talks about the risks ... advice from your health care provider. What is chemotherapy? Chemotherapy is a term that describes the use ...

265

Chemotherapy for Kidney Cancer  

MedlinePLUS

... cancer Next Topic Targeted therapies for kidney cancer Chemotherapy for kidney cancer Chemotherapy (chemo) uses anti-cancer ... have already been tried. Possible side effects of chemotherapy Chemo drugs work by attacking cells that are ...

266

Chemotherapy for Gallbladder Cancer  

MedlinePLUS

... often 5-FU or capecitabine is used. Possible side effects Chemotherapy drugs work by attacking cells that are dividing ... chemotherapy, which can lead to side effects. The side effects of chemotherapy depend on the type and dose of drugs ...

267

The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer  

PubMed Central

Anaplastic thyroid cancer represents 1%–2% of thyroid cancers. For its aggressiveness, it is considered a systemic disease at the time of diagnosis. Surgery remains the cornerstone of therapy in resectable tumor. Traditional chemotherapy has little effect on metastatic disease. A multimodality approach, incorporating cytoreductive surgical resection, chemoradiation, either concurrently or sequentially, and new promising target therapies is advisable. Doxorubicin is the most commonly used agent, with a response rate of 22%. Recently, other chemotherapy agents have been used, such as paclitaxel and gemcitabine, with superimposable activity and response rates of 10%–20%. However, survival of patients with anaplastic thyroid cancer has changed little in the past 50 years, despite more aggressive systemic and radiotherapies. Several new agents are currently under investigation. Some of them, such as sorafenib, imatinib, and axitinib have been tested in small clinical trials, showing promising disease control rates ranging from 35%–75%. Referral of patients for participation in clinical trials is needed.

Denaro, Nerina; Nigro, Cristiana Lo; Russi, Elvio G; Merlano, Marco C

2013-01-01

268

Comparison of three systems for concurrent production of high quality mohair and meat from Angora male kids  

Microsoft Academic Search

Castrated Angora kids (n=210, initial BW=25.4±4.0kg) approximately 7 months of age were used in two consecutive years (2002 and 2003) to evaluate three production systems and coats in terms of animal performance, carcass traits, mohair production and quality, and production costs. In both years, half the animals were assigned to an innovative feeding system (RF) that consisted of an open-sided

C. J. Lupton; J. E. Huston; J. W. Hruska; B. F. Craddock; F. A. Pfeiffer; W. L. Polk

2008-01-01

269

Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?  

Technology Transfer Automated Retrieval System (TEKTRAN)

Despite nearly two decades of research investigating the use of dietary antioxidant supplementation during conventional chemotherapy and radiation therapy, controversy remains about the efficacy and safety of this complementary treatment. Several studies of concurrent antioxidant administration with...

270

Concurrent calorimetric and interferometric studies of steady-state natural convection from miniaturized horizontal single plate-fin systems and plate-fin arrays  

NASA Astrophysics Data System (ADS)

Concurrent calorimetric and interferometric studies have been conducted to investigate the effect that reduction of the base-plate dimensions has on the steady-state performance of the rate of natural convection heat transfer from miniaturized horizontal single plate-fin systems and plate-fin arrays. The effect was studied through comparison of the present results with those of earlier relevant calorimetric, interferometric, or numerical studies. Results shown that a reduction of the base-plate area by 74% increased natural convection coefficient by 1.5 times to 26.0 W m-2 K-1 for single fin systems and by 1.8 times to 18 W m-2 K-1 for fin arrays in the range of the base-plate temperature excess of 20-50°C. A simple correlation for the Nusselt number of miniaturized horizontal plate-fin arrays is proposed in the range of Rayleigh number divided by the number of fins to the 2.7 power from 2 × 10 to 5 × 105.

Harahap, Filino; Lesmana, Herry; Sambegoro, Poetro Lebdo

2010-10-01

271

Optimization of Concurrent Deployments of the Juvenile Salmon Acoustic Telemetry System and Other Hydroacoustic Equipment at John Day Dam  

Microsoft Academic Search

The purpose of this report is to document the results of the acoustic optimization study conducted at John Day Dam during January and February 2008. The goal of the study was to optimize performance of the Juvenile Salmon Acoustic Telemetry System (JSATS) by determining deployment and data acquisition methods to minimize electrical and acoustic interference from various other acoustic sampling

Gene R. Ploskey; James S. Hughes; Fenton Khan; Jina Kim; Brian L. Lamarche; Gary E. Johnson; Eric Y. Choi; Derrek M. Faber; Matthew C. Wilberding; Zhiqun Deng; Mark A. Weiland; Shon A. Zimmerman; Eric S. Fischer; Aaron W. Cushing

2008-01-01

272

TA4 -- Self-Instruction Materials for the Professional Standards Review Organizations (PSRO) Management Information System (PMIS) Federal Reports Manual -- Concurrent Review Reporting.  

National Technical Information Service (NTIS)

This document, one in a series dealing with professional standards review organizations (PSRO's), contains self-instruction materials designed to assist in accurately reporting concurrent review activities of PSRO's through the use of the PSRO Management ...

1976-01-01

273

Chemotherapy-induced peripheral neuropathy  

Microsoft Academic Search

Recent advances in the development and administration of chemotherapy for malignant diseases have led to prolonged survival\\u000a of patients and the promise of a return to normal lives. This progress comes with a price, however, and the nervous system\\u000a is frequently the target of therapy-induced toxicity. Unlike more immediate toxicities that affect the gastrointestinal tract\\u000a and bone marrow, chemotherapy-induced neurotoxicity

Bushra Malik; Mark Stillman

2008-01-01

274

A novel co-locational and concurrent fNIRS\\/EEG measurement system: Design and initial results  

Microsoft Academic Search

We describe here the design, set-up and first time classification results of a novel co-locational functional Near-Infrared Spectroscopy\\/Electroencephalography (fNIRS\\/EEG) recording device suitable for brain computer interfacing applications using neural-hemodynamic signals. Our dual-modality system recorded both hemodynamic and electrical activity at seven sites over the motor cortex during an overt finger-tapping task. Data was collected from two subjects and classified offline

Darren J. Leamy; Tomas E. Ward

2010-01-01

275

Tumor Specific Gene Expression and Tumor Specific Vector Replication for Systemic Chemotherapy Sensitization Treatment of Breast Cancer.  

National Technical Information Service (NTIS)

Once breast cancer recurs after initial surgery or radiation therapy and is found to be incompletely responsive to salvage chemotherapy, there is no established treatment that can prolong survival. To address this problem, the Deisseroth laboratory has de...

A. B. Deisseroth

2002-01-01

276

Multi-targeting cancer chemotherapy using temperature-responsive drug carrier systems  

Microsoft Academic Search

Recently, a growing number of nano-scale drug carrier systems (e.g., drug–polymer conjugates, liposomes, and polymeric micelles) attract great attention for targeting cancer therapy due to a passively selective accumulation at solid tumor tissues and a subsequent anti-cancer activity. However, for the present drug targeting carrier systems, the target-selective delivery and release of loaded drugs are incapable to control completely. To

Masamichi Nakayama; Teruo Okano

2011-01-01

277

Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma  

Microsoft Academic Search

The purpose of this study is to evaluate the efficacy and toxicity of radiation therapy (RT) with concurrent temozolomide\\u000a (TMZ) chemotherapy followed by adjuvant TMZ in children with diffuse intrinsic pontine glioma (DIPG). Newly diagnosed patients\\u000a younger than 18 years with histologically proven DIPG were treated with focal radiotherapy to a dose of 54 Gy in 30 fractions\\u000a along with concurrent daily

Andrea Chassot; Sandra Canale; Pascale Varlet; Stephanie Puget; Thomas Roujeau; Laura Negretti; Frederic Dhermain; Xavier Rialland; Marie Anne Raquin; Jacques Grill; Christelle Dufour

278

Exposure, infection, systemic cytokine levels and antibody responses in young children concurrently exposed to schistosomiasis and malaria.  

PubMed

Despite the overlapping distribution of Schistosoma haematobium and Plasmodium falciparum infections, few studies have investigated early immune responses to both parasites in young children resident in areas co-endemic for the parasites. This study measures infection levels of both parasites and relates them to exposure and immune responses in young children. Levels of IgM, IgE, IgG4 directed against schistosome cercariae, egg and adult worm and IgM, IgG directed against P. falciparum schizonts and the merozoite surface proteins 1 and 2 together with the cytokines IFN-?, IL-4, IL-5, IL-10 and TNF-? were measured by ELISA in 95 Zimbabwean children aged 1-5 years. Schistosome infection prevalence was 14·7% and that of Plasmodium infection was 0% in the children. 43. 4% of the children showed immunological evidence of exposure to schistosome parasites and 13% showed immunological evidence of exposure to Plasmodium parasites. Schistosome-specific responses, indicative of exposure to parasite antigens, were positively associated with cercariae-specific IgE responses, while Plasmodium-specific responses, indicative of exposure to parasite antigens, were negatively associated with responses associated with protective immunity against Plasmodium. There was no significant association between schistosome-specific and Plasmodium-specific responses. Systemic cytokine levels rose with age as well as with schistosome infection and exposure. Overall the results show that (1) significantly more children are exposed to schistosome and Plasmodium infection than those currently infected and; (2) the development of protective acquired immunity commences in early childhood, although its effects on infection levels and pathology may take many years to become apparent. PMID:21813042

Imai, Natsuko; Rujeni, Nadine; Nausch, Norman; Bourke, Claire D; Appleby, Laura J; Cowan, Graeme; Gwisai, Reggis; Midzi, Nicholas; Cavanagh, David; Mduluza, Takafira; Taylor, David; Mutapi, Francisca

2011-08-04

279

Exposure, infection, systemic cytokine levels and antibody responses in young children concurrently exposed to schistosomiasis and malaria  

PubMed Central

SUMMARY Despite the overlapping distribution of Schistosoma haematobium and Plasmodium falciparum infections, few studies have investigated early immune responses to both parasites in young children resident in areas co-endemic for the parasites. This study measures infection levels of both parasites and relates them to exposure and immune responses in young children. Levels of IgM, IgE, IgG4 directed against schistosome cercariae, egg and adult worm and IgM, IgG directed against P. falciparum schizonts and the merozoite surface proteins 1 and 2 together with the cytokines IFN-?, IL-4, IL-5, IL-10 and TNF-? were measured by ELISA in 95 Zimbabwean children aged 1–5 years. Schistosome infection prevalence was 14·7% and that of Plasmodium infection was 0% in the children. 43. 4% of the children showed immunological evidence of exposure to schistosome parasites and 13% showed immunological evidence of exposure to Plasmodium parasites. Schistosome–specific responses, indicative of exposure to parasite antigens, were positively associated with cercariae-specific IgE responses, while Plasmodium-specific responses, indicative of exposure to parasite antigens, were negatively associated with responses associated with protective immunity against Plasmodium. There was no significant association between schistosome-specific and Plasmodium-specific responses. Systemic cytokine levels rose with age as well as with schistosome infection and exposure. Overall the results show that (1) significantly more children are exposed to schistosome and Plasmodium infection than those currently infected and; (2) the development of protective acquired immunity commences in early childhood, although its effects on infection levels and pathology may take many years to become apparent.

IMAI, NATSUKO; RUJENI, NADINE; NAUSCH, NORMAN; BOURKE, CLAIRE D.; APPLEBY, LAURA J.; COWAN, GRAEME; GWISAI, REGGIS; MIDZI, NICHOLAS; CAVANAGH, DAVID; MDULUZA, TAKAFIRA; TAYLOR, DAVID; MUTAPI, FRANCISCA

2011-01-01

280

PMJ panel discussion overview on mask complexities, cost, and cycle time in 32-nm system LSI generation: conflict or concurrent?  

NASA Astrophysics Data System (ADS)

This is a report on a panel discussion organized in Photomask Japan 2008, where the challenges about "Mask Complexities, Cost, and Cycle Time in 32-nm System LSI Generation" were addressed to have a look over the possible solutions from the standpoints of chipmaker, commercial mask shop, DA tool vendor and equipments makers. The wrap-up is as follows: Mask complexities justify the mask cost, while the acceptable increase rate of 32nm-mask cost significantly differs between mask suppliers or users side. The efficiency progress by new tools or DFM has driven their cycle-time reductions. Mask complexities and cost will be crucial issues prior to cycle time, and there seems to be linear correlation between them. Controlling complexity and cycle time requires developing a mix of advanced technologies, and especially for cost reduction, shot prices in writers and processing rates in inspection tools have been improved remarkably by tool makers. In addition, activities of consortium in Japan (Mask D2I) are expected to enhance the total optimization of mask design, writing and inspection. The cycle-time reduction potentially drives the lowering of mask cost, and, on the other, the pattern complexities and tighter mask specifications get in the way to 32nm generation as well as the nano-economics and market challenges. There are still many difficult problems in mask manufacturing now, and we are sure to go ahead to overcome a 32nm hurdle with the advances of technologies and collaborations by not only technologies but also finance.

Hosono, Kunihiro; Kato, Kokoro

2008-10-01

281

Phase I Trial of Concurrent Administration of Topotecan and Docetaxel for Cancer Treatment  

Microsoft Academic Search

Docetaxel and topotecan have been used as individual chemotherapy agents in cancer treatment.However,the com- bined effect of these two drugs has not been thoroughly investigated.In a phase I clinical trial,patients previously treat- ed with chemotherapy were treated with concurrent administration of the two drugs;topotecan was administered as a 30-minute infusion,followed by a 30- minute docetaxel infusion.The treat- ment cycle was

D. Richard Ishmael; Hong Liu; John A. Nordquist; Robert E. Nordquist; Wei R. Chen

282

Single observable concurrence measurement without simultaneous copies  

SciTech Connect

We present a protocol that allows us to obtain the concurrence of any two-qubit pure state by performing a minimal and optimal tomography of one of the subsystems through measuring a single observable of an ancillary four-dimensional qudit. An implementation for a system of trapped ions is also proposed, which can be achieved with present-day experimental techniques.

Salles, A.; Melo, F. de; Matos Filho, R. L. de; Zagury, N. [Instituto de Fisica, Universidade Federal do Rio de Janeiro, Caixa Postal 68528, Rio de Janeiro, RJ 21941-972 (Brazil); Retamal, J. C. [Departamento de Fisica, Universidad de Santiago de Chile, Casilla 307, Correo 2, Santiago (Chile)

2006-12-15

283

Suspension analyses for concurrent logic programs  

Microsoft Academic Search

Concurrent logic languages specify reactive systems which consist of collections of communicating processes. The presence of unintended suspended computations is a common programming error which is difficult to detect using standard debugging and testing techniques. We develop a number of analyses, based on abstract interpretation, which succeed if a program is definitely suspension free. If an analysis fails, the program

Michael Codish; Moreno Falaschi; Kim Marriott

1994-01-01

284

From Recovery Blocks to Concurrent Atomic Actions  

Microsoft Academic Search

This paper reviews the development of error recovery structures that support general fault tolerance, and describes a new object-oriented scheme for error recovery in concurrent systems that generalizes existing schemes based on either conversations or transactions. This new scheme, which is based on what we term a Coordinated Atomic Action, is intended to facilitate the provision of means of tolerating

Brian Randell; Alexander Romanovsky; Cecilia M F Rubira; Robert J Stroud; Zhixue Wu; Jie Xu

285

Leibniz on monadic action & divine concurrence  

Microsoft Academic Search

Leibniz insists that his metaphysical system is consistent with the orthodox doctrine of divine concurrence, i.e., the view according to which, for any individual action in nature, both God and the created individual substance jointly contribute to the production of the act. Leibniz articulates the doctrine as follows: (DC) For any effect brought about by the act of a created

T. Allan Hillman

2008-01-01

286

CFMEA: Concurrent Failure Mode and Effect Analysis  

Microsoft Academic Search

In the paper, an attempt is made to develop Concurrent Failure Mode and Effect Analysis (CFMEA) of Component Based Software System (CBSS) using a graph theoretic approach. The proposed approach is an improvement over the present practiced procedures. Using the approach reliability evaluation of CBSS can be done effectively and extensively at the early design stage. The important feature of

Nitin Upadhyay; Bharat M. Deshpande; V. P. Agrawal

2010-01-01

287

Virchow lymph node metastatic recurrence of sigmoid colon cancer with severe lymph node metastases successfully treated using systemic chemotherapy combined with radiotherapy.  

PubMed

Metastatic recurrence of colon cancer in the left supraclavicular lymph node (Virchow lymph node) is rare, and to date there are no reports on radiotherapy as treatment. We report on a case of metastatic recurrence of sigmoid colon cancer in the Virchow lymph node with severe lymph node metastases successfully treated with a combined modality therapy of systemic chemotherapy and radiotherapy. The case is of a 58-year-old man, who underwent sigmoid excision and lymph node excision, and subsequently received systemic chemotherapy. After left supraclavicular lymph node recurrence appeared he later received radiotherapy. Complete response was achieved, and there has been no further recurrence, to date, 10 months after the radiotherapy. Radiotherapy was effective as a local treatment, and local control of distant metastasis of colonic cancer may lead to a good prognosis. PMID:23780983

Ohchi, Takafumi; Akagi, Yoshito; Kinugasa, Tetsushi; Ishibashi, Yoshiaki; Tanaka, Natsuki; Fujino, Shinya; Kibe, Shiro; Yuge, Kotaro; Sasatomi, Teruo; Mizobe, Tomoaki; Oka, Yosuke; Hong, Kawang Dae; Shirouzu, Kazuo

2013-07-01

288

Treatment of a primary intracranial germ cell tumor with systemic chemotherapy  

Microsoft Academic Search

Primary germ cell neoplasms of the central nervous system (CNS) are rare tumors which generally respond to radiotherapy. Experience is limited in managing the refractory patient. We report a patient whose suprasellar dysgerminoma responded completely to 5,000 rad. Seven years later, disease recurrence was refractory to an additional 4,000 rad. Theorizing that the ''blood-brain barrier'' was no longer intact after

Jeffrey J. Kirshner; Sandra J. Ginsberg; Alicia V. Fitzpatrick; Robert L. Comis

1981-01-01

289

Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy  

Microsoft Academic Search

Between 1984 and 1990, 94 women presenting to the Edinburgh Breast Unit with operable breast cancer of 4 cm or greater in diameter (T2, T3, N0, N1, M0) were given preoperative systemic therapy. Initially, all women received hormone therapy, with CHOP (cyclophosphamide 1 g m(-2), doxorubicin 50 mg m(-2), vincristine 1.4 mg m(-2) to a maximum of 2 mg and

DA Cameron; EDC Anderson; P Levack; RA Hawkins; TJ Anderson; RCF Leonard; APM Forrest; U Chetty

1997-01-01

290

Immunohistological profiling by B-cell differentiation status of primary central nervous system lymphoma treated by high-dose methotrexate chemotherapy  

Microsoft Academic Search

Primary central nervous system lymphoma (PCNSL) remains a devastating disease with poor prognosis, despite the improvement\\u000a offered by methotrexate (MTX)-based chemotherapy. Several studies have attempted to identify biomarkers predictive of prognosis,\\u000a which are expected to be both clinically useful and biologically important for understanding PCNSL. The present study attempts\\u000a to classify human immunodeficiency virus (HIV)-unrelated PCNSL patients treated with radiation

Manabu Kinoshita; Naoya Hashimoto; Shuichi Izumoto; Yoshiko Okita; Naoki Kagawa; Motohiko Maruno; Takanori Ohnishi; Norio Arita; Toshiki Yoshimine

2010-01-01

291

High Pathologic Complete Response in HER 2-positive Locally Advanced Breast Cancer after Primary Systemic Chemotherapy with Weekly Docetaxel and Epirubicin  

Microsoft Academic Search

Background: To evaluate pathological complete response rate and to identify the predictor of response after primary systemic chemotherapy (PST) with weekly docetaxel and epirubicin for locally advanced breast cancer. Methods: Sixty-three patients with locally advanced breast cancer received three cycles PST on day 1 and 8 of each 3-week cycle with epirubicin and docetaxel (epirubicin 45 mg\\/m2 intra- venous bolus,

Shin-Cheh Chen; Hsien-Kun Chang; Yung-Chang Lin; Swei Hsueh; Yun-Chung Cheung; Wai-Man Leung; Chien-Sheng Tsai; Yung-Feng Lo; Hsiu-Pei Tsai; Shih-Che Shen; Miin-Fu Chen

292

Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy  

Microsoft Academic Search

Summary In order to identify factors predictive of central nervous system (CNS) metastasis, we reviewed the histories of 579 patients treated with epirubicin-based chemotherapy for metastatic breast cancer. Statistical analysis included Kaplan–Meier survival plots, Cox’s regression analysis and competing risk analysis using the cumulative incidence. Median follow-up-time was 137 months (range 0–183+). In this period, one hundred and twenty-four patients (21.4%)

Marianne Ryberg; Dorte Nielsen; Kell Osterlind; Per Kragh Andersen; Torben Skovsgaard; Per Dombernowsky

2005-01-01

293

Concurrent Engineering Concepts Applied to Concurrent Education and Research  

Microsoft Academic Search

Concurrent Engineering (CE) has attracted more attention in recent years regarding its reducing the time to market, cutting down the total cost, and improving quality. As a new concept and methodology, CE has not been widely implemented in industry, research and engineering education yet. This paper describes a newly developed CE course which employs the method of concurrent education. Similar

Jack Zhou; Shlomo Carmi; Alan Lau; Spiros Koulas

294

Concurrent C++: Concurrent Programming with Class(es)  

Microsoft Academic Search

ion and Concurrent ProgrammingAll the advantages of using data abstraction facilities for sequential programming also apply to concurrentprogramming. Specifically, with regard to concurrent programming, data abstraction facilities can providea better, higher-level and more robust interface for the services provided by one or more processes. Classescan be used to ensure that the protocol for interacting with a process is properly observed

Narain H. Gehani; William D. Roome

1988-01-01

295

Computational model, method, and system for kinetically-tailoring multi-drug chemotherapy for individuals  

DOEpatents

A method and system for tailoring treatment regimens to individual patients with diseased cells exhibiting evolution of resistance to such treatments. A mathematical model is provided which models rates of population change of proliferating and quiescent diseased cells using cell kinetics and evolution of resistance of the diseased cells, and pharmacokinetic and pharmacodynamic models. Cell kinetic parameters are obtained from an individual patient and applied to the mathematical model to solve for a plurality of treatment regimens, each having a quantitative efficacy value associated therewith. A treatment regimen may then be selected from the plurlaity of treatment options based on the efficacy value.

Gardner, Shea Nicole (San Leandro, CA)

2007-10-23

296

Concurrent engineering: an application in the hospitality industry  

Microsoft Academic Search

Summary form only given. One of the trends in today's business environment is that of teams. One system for implementing teams is concurrent engineering. Several methodologies have been developed to utilize and manage concurrent engineering principles in the manufacturing industries. Process value estimation methodology (PVE) allows management to target processes that are ripe for reengineering and prevents cost reduction that

S. M. Siha; B. P. Lingaraj

1997-01-01

297

A concurrent reactive Esterel processor based on multi-threading  

Microsoft Academic Search

Esterel is a concurrent synchronous language for developing reactive systems. As an alternative to the classical software and hardware synthesis paths, the reactive processing ap- proach uses a specialized processor with an instruction set tailored to Esterel. A principal diculty when compiling onto a reactive processor is the faithful, ecient implemen- tation of concurrency. This paper presents a novel reactive

Xin Li; Reinhard Von Hanxleden

2006-01-01

298

A methodology for concurrent process-circuit optimization  

Microsoft Academic Search

In order to optimize integrated circuit designs, it is critical not only for circuit designers to adjust circuit geometries but also for process developers to adjust device characteristics for optimal overall system performance. This paper describes concurrent process-circuit optimization (CPCO), a methodology for concurrent integrated circuit optimization that spans the fabrication process design and circuit design disciplines. CPCO enables process

Arun N. Lokanathan; Jay B. Brockman

1999-01-01

299

Logic synthesis of multilevel circuits with concurrent error detection  

Microsoft Academic Search

This paper presents a procedure for synthesizing multilevel circuits with concurrent error detection. All errors caused by single stuck- at faults are detected using a parity-check code. The synthesis procedure (implemented in Stanford CRC's TOPS synthesis system) fully automates the design process, and reduces the cost of concurrent error detection compared with previous methods. An algorithm for selecting a good

Nur A. Touba; Edward J. Mccluskey

1997-01-01

300

Prognostic analysis of adjuvant chemotherapy in patients with nasopharyngeal carcinoma.  

PubMed

Background: Concurrent chemoradiation has become the standard of treatment in locally advanced nasopharyngeal carcinoma. However, the exact magnitude of the benefits of adjuvant chemotherapy is still unclear. Materials & methods: This is a retrospective assessment of 181 patients with newly diagnosed, locally advanced nasopharygeal carcinoma who received concurrent chemoradiation followed by adjuvant chemotherapy with cisplatin plus fluorouracil in one institution between 2004 and 2010. Results: The median follow-up period was 40 months (range: 2.1-96.6 months). The estimated 5-year survival rate of patients with and without adjuvant chemotherapy were 83.6 and 66.7%, respectively (p = 0.027). Patients receiving two to three cycles of adjuvant chemotherapy had improved outcomes compared with those without adjuvant chemotherapy or who had received one cycle. Multivariate analysis showed that both advanced stage and suboptimal treatment of adjuvant chemotherapy were adverse risk factors in terms of overall survival and disease-specific survival. Conclusion: Adjuvant chemotherapy with two to three cycles of cisplatin plus fluorouracil improved the survival of nasopharyngeal carcinoma patients. PMID:24106898

Lin, Ching-Chan; Chen, Tzu-Ting; Lin, Chen-Yuan; Hsieh, Ching-Yun; Lin, Po-Han; Chien, Chun-Ru; Chiu, Chang-Fang; Yeh, Su-Peng

2013-10-01

301

Management of chemotherapy-induced peripheral neuropathy  

Microsoft Academic Search

Recent advances in the development and administration of chemotherapy for malignant diseases have been rewarded with prolonged\\u000a survival rates. The cost of progress has come at a price and the nervous system is frequently the target of chemotherapy-induced\\u000a neurotoxicity. Unlike more immediate toxicities that effect the gastrointestinal tract and bone marrow, chemotherapy-induced\\u000a neurotoxicity is frequently delayed in onset and may

Mark Stillman; Juan P. Cata

2006-01-01

302

Estimating concurrence via entanglement witnesses  

SciTech Connect

We show that each entanglement witness detecting a given bipartite entangled state provides an estimation of its concurrence. We illustrate our result with several well-known examples of entanglement witnesses and compare the corresponding estimation of concurrence with other estimations provided by the trace norm of partial transposition and realignment.

Jurkowski, Jacek; Chruscinski, Dariusz [Institute of Physics, Nicolaus Copernicus University ul. GrudziaPdzka 5/7, PL-87-100 Torun (Poland)

2010-05-15

303

Chemotherapy-induced peripheral neuropathy.  

PubMed

Recent advances in the development and administration of chemotherapy for malignant diseases have led to prolonged survival of patients and the promise of a return to normal lives. The cost of progress comes with a price, however, and the nervous system is frequently the target of therapy-induced toxicity. Unlike more immediate toxicities that affect the gastrointestinal tract and bone marrow, chemotherapy-induced neurotoxicity is frequently delayed in onset and may progress over time. In the peripheral nervous system, the major brunt of the toxic attack is directed against the peripheral nerve, targeting the neuronal cell body, the axonal transport system, the myelin sheath, and glial support structures, resulting in chemotherapy-induced peripheral neuropathy. PMID:18367040

Malik, Bushra; Stillman, Mark

2008-01-01

304

Intraarterial Chemotherapy or Chemoembolization for Locally Advanced and/or Recurrent Hepatic Tumors: Evaluation of the Feeding Artery with an Interventional CT System  

SciTech Connect

Purpose: To evaluate the utility of an interventional CT system for intraarterial chemotherapy or chemoembolization for locally advanced and/or recurrent hepatic tumors.Methods: Thirty-eight patients with locally advanced or recurrent hepatic tumors underwent 73 intraarterial contrast-enhanced CT (IA-CECT) examinations immediately before chemotherapy or chemoembolization. The degree of tumor vascularity on angiography and enhancement on IA-CECT was classified into three grades: no, mild, or marked vascularity. The IA-CECT grades were compared with the angiographic grades.Results: Twenty-nine (69%) of 42 examinations that were interpreted as having no or mild vascularity on angiography were classified as marked enhancement on IA-CECT. Based on IA-CECT findings, the position of the catheter was changed in 14 (19%) of 73 CT examinations. The reasons for the reposition were as follows: weak or no enhancement of the tumor (n = 11) or strong enhancement of the gallbladder wall (n = 3). The treatment strategy was changed in three patients (8%). No major complications relating to the interventional procedures were observed.Conclusions: IA-CECT is a reliable method when evaluating the perfusion of the tumor and adjacent normal tissues. The interventional CT system is useful for performing safe and effective intraarterial chemotherapy or chemoembolization in patients with locally advanced and/or recurrent hepatic tumors.

Hirai, Toshinori [Department of Radiology, Amakusa Medical Center, 854-1 Kameba, Hondo, Kumamoto 863-0046 (Japan); Korogi, Yukunori [Department of Radiology, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto 860-8556 (Japan); Ono, Ken; Maruoka, Kousei [Department of Radiology, Amakusa Medical Center, 854-1 Kameba, Hondo, Kumamoto 863-0046 (Japan); Harada, Kazunori [Department of Surgery, Amakusa Medical Center, 854-1 Kameba, Hondo, Kumamoto 863-0046 (Japan); Aridomi, Satoshi [Department of Internal Medicine, Amakusa Medical Center, 854-1 Kameba, Hondo, Kumamoto 863-0046 (Japan); Takahashi, Mutsumasa [Department of Radiology, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto 860-8556 (Japan)

2001-05-15

305

Partnership concurrency and coital frequency.  

PubMed

National HIV prevalence estimates across sub-Saharan Africa range from less than 1 percent to over 25 percent. Recent research proposes several explanations for the observed variation, including prevalence of male circumcision, levels of condom use, presence of other sexually transmitted infections, and practice of multiple concurrent partnerships. However, the importance of partnership concurrency for HIV transmission may depend on how it affects coital frequency with each partner. The coital dilution hypothesis suggests that coital frequency within a partnership declines with the addition of concurrent partners. Using sexual behavior data from rural Malawi and urban Kenya, we investigate the relationship between partnership concurrency and coital frequency, and find partial support for the coital dilution hypothesis. We conclude the paper with a discussion of our findings in light of the current literature on concurrency. PMID:23695523

Gaydosh, Lauren; Reniers, Georges; Helleringer, Stéphane

2013-09-01

306

Long-Term Follow-Up of Dose-Adapted and Reduced-Field Radiotherapy With or Without Chemotherapy for Central Nervous System Germinoma  

SciTech Connect

Purpose: To update our institutional experience with neoadjuvant chemotherapy and minimized radiotherapy vs. radiation monotherapy for intracranial germinoma. Methods and Materials: We retrospectively reviewed records of 59 patients with diagnosis of primary intracranial germinoma between 1977 and 2007. Treatment was irradiation alone or neoadjuvant platinum-based chemotherapy and local irradiation (initial tumor plus margin) for patients with localized complete response and reduced-dose craniospinal irradiation for others. Results: For the chemoradiotherapy group (n = 28), median follow-up was 7 years. No patient died. The freedom from progression (FFP) rate was 88% at 5 years and 80% at 10 years. In 4 patients, disease recurred 1.1 to 6.8 years after diagnosis. All were young male patients who received 30.6 Gy to local fields after complete response to chemotherapy. The FFP rate was 88% for local irradiation vs. 100% for more extensive fields (p = .06). For the radiotherapy-alone group (n = 31), median follow-up was 15 years. Overall and disease-free survival rates were 93% and 93% at 5 years and 90% and 87% at 15 years. In 5 patients, disease recurred 1.1 to 4.9 years after diagnosis. Most patients in this group were young men 18 to 23 years of age with suprasellar primary disease treated with about 50 Gy to local fields. The FFP rate was 44% for local irradiation vs. 100% for more extensive fields (p < .01). Conclusions: The addition of neoadjuvant chemotherapy to local-field radiotherapy reduced central nervous system cancer recurrence when high-risk patients were excluded by thorough pretreatment staging. There was trend toward improved central nervous system tumor control when larger fields (whole brain, whole ventricle, or craniospinal axis) were used.

Jensen, Ashley W. [Department of Radiation Oncology, Mayo Clinic, Rochester, MN (United States); Issa Laack, Nadia N., E-mail: laack.nadia@mayo.ed [Department of Radiation Oncology, Mayo Clinic, Rochester, MN (United States); Buckner, Jan C. [Department of Oncology, Mayo Clinic, Rochester, MN (United States); Schomberg, Paula J. [Department of Radiation Oncology, Mayo Clinic, Rochester, MN (United States); Wetmore, Cynthia J. [Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN (United States); Brown, Paul D. [Department of Radiation Oncology, Mayo Clinic, Rochester, MN (United States)

2010-08-01

307

[Combination of chemotherapy and radiotherapy for locally advanced non-small cell lung cancer].  

PubMed

Despite the progress in therapeutic strategies, overall survival of stage III non small cell lung cancers (NSCLC) is poor. Currently, the standard treatment for unresectable locally advanced NSCLC is concurrent chemoradiotherapy. However, oesophagitis is a major toxicity and this schedule should be reserved for patients with good performance status. Several platinum-based chemotherapies have been evaluated concurrently with radiotherapy and cisplatin-etoposide regimen remains the standard because full dose chemotherapy can be administered. Cisplatin-vinorelbine offers a good efficacy/toxicity profile. The optimal sequencing of concurrent chemoradiotherapy and chemotherapy is not well defined. Consolidation chemotherapy with docetaxel failed to show a better outcome. The new technologies in radiotherapy and dose escalation will certainly improve the efficacy of chemoradiotherapy and reduce toxicity. The integration of targeted therapies in the management of stage III NSCLC is also under investigation. PMID:18235400

Fournel, P

2007-10-01

308

Chemotherapy for Prostate Cancer  

MedlinePLUS

... dolor sit amet, consectetur adipiscing elit. Prostate Cancer: Chemotherapy Prostate cancer is the third leading cause of ... the United States. Over the past 10 years chemotherapy treatments have been shown to improve pain control ...

309

After chemotherapy - discharge  

MedlinePLUS

You had chemotherapy treatment for your cancer. Your risk for infections, bleeding, and skin problems may be high. You may still ... National Cancer Institute. Chemotherapy and you: support for ... (PDQ). Accessed May 11, 2012. Perry MC. Approach to the patient ...

310

Side Effects of Chemotherapy  

MedlinePLUS

... Men Living with Prostate Cancer Side Effects of Chemotherapy Side Effects Urinary Dysfunction Bowel Dysfunction Erectile Dysfunction ... Side Effects of Hormone Therapy Side Effects of Chemotherapy Side Effects: When to Seek Help PSA Rising ...

311

JAMA Patient Page: Chemotherapy  

MedlinePLUS

... between treatment cycles allows the body to rest. Side Effects Chemotherapy drugs are strong medicines that work to kill ... purchase bulk reprints, call 312/464-0776. Common side effects of chemotherapy treatment Nausea and vomiting Hair Temporary loss of ...

312

Chemotherapy for Malignant Mesothelioma  

MedlinePLUS

... chemotherapy, which can lead to side effects. The side effects of chemotherapy depend on the type and dose of drugs ... in some people. Be sure to report any side effects or changes you notice while getting chemotherapy to your medical team so that you can ...

313

A Logic for True Concurrency  

NASA Astrophysics Data System (ADS)

We propose a logic for true concurrency whose formulae predicate about events in computations and their causal dependencies. The induced logical equivalence is hereditary history preserving bisimilarity, and fragments of the logic can be identified which correspond to other true concurrent behavioural equivalences in the literature: step, pomset and history preserving bisimilarity. Standard Hennessy-Milner logic, thus (interleaving) bisimilarity, is also recovered as a fragment. We believe that this contributes to a rational presentation of the true concurrent spectrum and to a deeper understanding of the relations between the involved behavioural equivalences.

Baldan, Paolo; Crafa, Silvia

314

Concurrent Reachability Games  

Microsoft Academic Search

An open system can be modeled as a two-player game be- tween the system and its environment. At each round of the game, player 1 (the system) and player 2 (the environment) independently and simultaneously choose moves, and the two choices determine the next state of the game. Proper- ties of open systems can be modeled as objectives of these

Luca De Alfaro; Thomas A. Henzinger; Orna Kupferman

1998-01-01

315

Regional chemotherapy of colorectal cancer  

Microsoft Academic Search

Hepatic metastases are a major cause of mortality in patients with colorectal carcinoma. The rationale for hepatic arterial chemotherapy has an anatomical and pharmacological basis as presented below. The randomised studies are reviewed and demonstrate a significantly higher response rate with hepatic arterial therapy versus systemic therapy. Survival information is difficult to evaluate because some of the studies are small,

N. E Kemeny

1995-01-01

316

Five Years' Experience Treating Locally Advanced Cervical Cancer With Concurrent Chemoradiotherapy and High-Dose-Rate Brachytherapy: Results From a Single Institution  

SciTech Connect

Purpose: To assess the clinical outcomes after concurrent cisplatin chemotherapy and radiotherapy (RT) followed by high-dose-rate brachytherapy for locally advanced carcinoma of the cervix and perform a multivariate analysis of the prognostic factors. Methods and Materials: The outcomes were analyzed for all women treated between 1999 and 2004 with concurrent cisplatin chemotherapy and RT followed by high-dose-rate brachytherapy. Kaplan-Meier analysis was used for overall survival (OS), local control (LC), and distant control (DC). The Cox proportional hazards model was used to perform multivariate analysis of the prognostic variables. Results: The standard regimen comprised whole pelvic external RT 45 Gy in 25 fractions with concurrent weekly cisplatin 40 mg/m{sup 2}, followed by four high-dose-rate brachytherapy insertions of 6 Gy. Patients with radiologically enlarged para-aortic lymph nodes underwent extended-field RT. Of 92 patients, the OS rate was 72% at 2 years and 55% at 5 years. The LC rate was 76% at 2 years and 67% at 5 years. The DC rate was 68% at 2 years and 48% at 5 years. The most important prognostic factor for OS, LC, and DC was the pretreatment hemoglobin. For OS, the tumor size and the presence of enlarged lymph nodes were also important. For LC, the number of brachytherapy insertions was important; and for DC, the number of chemotherapy treatments was important. Of the patients, 4% experienced late Grade 3 or 4 toxicity. Conclusion: The results of our study have shown that the regimen is effective, with acceptable long-term side effects. In this cohort, the most important prognostic factor was the pretreatment hemoglobin level, a disease-related factor. However, more effective systemic treatments are needed.

Parker, Kate; Gallop-Evans, Eve [Velindre Cancer Centre, Whitchurch, Cardiff (United Kingdom); Hanna, Louise [Velindre Cancer Centre, Whitchurch, Cardiff (United Kingdom)], E-mail: louise.hanna@velindre-tr.wales.nhs.uk; Adams, Malcolm [Velindre Cancer Centre, Whitchurch, Cardiff (United Kingdom)

2009-05-01

317

Lower bounds on concurrence and separability conditions  

NASA Astrophysics Data System (ADS)

We obtain analytical lower bounds on the concurrence of bipartite quantum systems in arbitrary dimensions related to the violation of separability conditions based on local uncertainty relations and on the Bloch representation of density matrices. We also illustrate how these results complement and improve those recently derived [Chen, Albeverio, and Fei, Phys. Rev. Lett. 95, 040504 (2005)] by considering the Peres-Horodecki and the computable cross-norm or realignment criteria.

de Vicente, Julio I.

2007-05-01

318

Hepatic Arterial Chemotherapy for Colorectal Cancer Metastatic to the Liver  

Microsoft Academic Search

In advanced colorectal cancer, liver metastases are a major problem. In patients with liver metastases as the major site of disease hepatic arterial chemotherapy is a valid alternative to systemic treatment. In this review about hepatic arterial chemotherapy we will discuss the theoretical and practical aspects, the results and complications, the selection of patients for hepatic arterial chemotherapy, and its

Johanna M. G. H. van Riel; Cees J. van Groeningen; Giuseppe Giaccone; Herbert M. Pinedo

2000-01-01

319

Concurrent Reachability Games.  

National Technical Information Service (NTIS)

An open system can be modeled as a two-player game between the system and its environment. At each round of the game, player 1 (the system) and player 2 (the environment) independently and simultaneously choose moves, and the two choices determine the nex...

L. Alfaro O. Kupferman T. A. Henzinger

1998-01-01

320

Comparison of Fusion Imaging Using a Combined SPECT/CT System and Intra-arterial CT: Assessment of Drug Distribution by an Implantable Port System in Patients Undergoing Hepatic Arterial Infusion Chemotherapy  

SciTech Connect

Hepatic arterial infusion (HAI) chemotherapy is effective for treating primary and metastatic carcinoma of the liver. We compared the perfusion patterns of HAI chemotherapy on intra-arterial port-catheter computed tomography (iapc-CT) and fused images obtained with a combined single-photon emission computed tomography/computed tomography (SPECT/CT) system. We studied 28 patients with primary or metastatic carcinoma of the liver who bore an implantable HAI port system. All underwent abdominal SPECT using Tc-99m-MAA (185 Mbq); the injection rate was 1 mL/min, identical to the chemotherapy infusion rate, and 0.5 mL/sec for iapc-CT. Delivery was through an implantable port. We compared the intrahepatic perfusion (IHP) and extrahepatic perfusion (EHP) patterns of HAI chemotherapy on iapc-CT images and fused images obtained with a combined SPECT/CT system. In 23 of 28 patients (82%), IHP patterns on iapc-CT images and fused images were identical. In 5 of the 28 patients (18%), IHP on fusion images was different from IHP on iapc-CT images. EHP was seen on fused images in 12 of the 28 patients (43%) and on iapc-CT images in 8 patients (29%). In 17 patients (61%), upper gastrointestinal endoscopy revealed gastroduodenal mucosal lesions. EHP was revealed on fused images in 10 of these patients; 9 of them manifested gastroduodenal toxicity at the time of subsequent HAI chemotherapy. Fusion imaging using the combined SPECT/CT system reflects the actual distribution of the infused anticancer agent. This information is valuable not only for monitoring adequate drug distribution but also for avoiding potential extrahepatic complications.

Ikeda, Osamu, E-mail: osamu-3643ik@do9.enjoy.ne.jp; Kusunoki, Shinichiroh; Nakaura, Takeshi; Shiraishi, Shinya; Kawanaka, Kouichi; Tomiguchi, Seiji; Yamashita, Yasuyuki [Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, Department of Diagnostic Radiology (Japan); Takamori, Hiroshi; Chikamoto, Akira; Kanemitsu, Keiichiro [Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, Gastroenterological Surgery (Japan)

2006-06-15

321

Learning from Mistakes --- A Comprehensive Study on Real World Concurrency Bug Characteristics. In the proceedings of the 13th International Conference on Architecture Support for Programming Languages and Operating Systems (ASPLOS'08), March 2008  

Microsoft Academic Search

The reality of multi-core hardware has made concurrent programs;\\u000apervasive. Unfortunately, writing correct concurrent programs is;\\u000adifcult. Addressing this challenge requires advances in multiple;\\u000adirections, including concurrency bug detection, concurrent program;\\u000atesting, concurrent programming model design, etc. Designing;\\u000aeffective techniques in all these directions will signicantly;\\u000abenet from a deep understanding of real world concurrency bug;\\u000acharacteristics.;\\u000aThis paper provides

Yuanyuan Zhou; Shan Lu; Soyeon Park

2008-01-01

322

Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'  

PubMed Central

SUMMARY The diminution in certain aspects of cognitive function that is reported to occur in some patients during or after adjuvant cancer chemotherapy is variously known as ‘chemo-fog’, ‘chemo-brain’ or other such term. In addition to reported deficits in attention, concentration and other functions, most, if not all, of the studies report deficits involving visual-spatial function or visual memory. Since the visual system is part of the nervous system, it seems reasonable to ask if it is susceptible to some of the deleterious effects produced by adjuvant chemotherapeutic drugs. We propose here the possibility that some portion of the vision-related aspects of the ‘chemo-fog’ spectrum of cognitive deficits results from a direct action of the adjuvant drugs on the visual system or from drug / drug or site / site interaction between effects on the visual system and other critical brain regions.

Raffa, R. B.; Tallarida, R. J.

2011-01-01

323

The performance of multiversion concurrency control algorithms  

Microsoft Academic Search

A number of multiversion concurrency control algorithms have been proposed in the past few years. These algorithms use previous versions of data items in order to improve the level of achievable concurrency. This paper describes a simulation study of the performance of several multiversion concurrency control algorithms, investigating the extent to which they provide increases in the level of concurrency

Michael J. Carey; Waleed A. Muhanna

1986-01-01

324

On the impact of concurrent downloads  

Microsoft Academic Search

Concurrent downloads accelerate information access speed for individual web users. The speed-up comes from multiple connections launched for one subject download, which leads to unfairness at user level. In this paper, we study the impact of concurrent downloads on the network. Particularly, we investigate the fairness between users who employ different downloading concurrency. We also discuss how concurrent downloads affect

Yong Liu; Weibo Gong; Prashant J. Shenoy

2001-01-01

325

Learning from Mistakes --- A Comprehensive Study on Real World Concurrency Bug Characteristics. In the proceedings of the 13th International Conference on Architecture Support for Programming Languages and Operating Systems (ASPLOS'08), March 2008  

SciTech Connect

The reality of multi-core hardware has made concurrent programs pervasive. Unfortunately, writing correct concurrent programs is dif#2;cult. Addressing this challenge requires advances in multiple directions, including concurrency bug detection, concurrent program testing, concurrent programming model design, etc. Designing effective techniques in all these directions will signi#2;cantly bene#2;t from a deep understanding of real world concurrency bug characteristics. This paper provides the #2;rst (to the best of our knowledge) comprehensive real world concurrency bug characteristic study. Specifically, we have carefully examined concurrency bug patterns, manifestation, and #2;x strategies of 105 randomly selected real world concurrency bugs from 4 representative server and client opensource applications (MySQL, Apache, Mozilla and OpenOf#2;ce). Our study reveals several interesting #2;ndings and provides useful guidance for concurrency bug detection, testing, and concurrent programming language design. Some of our #2;ndings are as follows: (1) Around one third of the examined non-deadlock concurrency bugs are caused by violation to programmers' order intentions, which may not be easily expressed via synchronization primitives like locks and transactional memories; (2) Around 34% of the examined non-deadlock concurrency bugs involve multiple variables, which are not well addressed by existing bug detection tools; (3) About 92% of the examined concurrency bugs can be reliably triggered by enforcing certain orders among no more than 4 memory accesses. This indicates that testing concurrent programs can target at exploring possible orders among every small groups of memory accesses, instead of among all memory accesses; (4) About 73% of the examined non-deadlock concurrency bugs were not #2;xed by simply adding or changing locks, and many of the #2;xes were not correct at the #2;rst try, indicating the dif#2;culty of reasoning concurrent execution by programmers.

Yuanyuan Zhou Shan Lu Soyeon Park

2008-03-01

326

Quality-of-Life-Adjusted Survival Analysis of Concurrent Chemo Radiotherapy for Locally Advanced (Nonmetastatic) Nasopharyngeal Cancer  

Microsoft Academic Search

Purpose: To assess whether the benefits of adding cisplatin (CDDP) concurrent with radiotherapy, followed by adjuvant CDDP and fluorouracil, justifies the toxicity cost for nasopharyngeal cancer (NPC) using the quality-adjusted time without symptoms or toxicity (Q-TWiST) approach. Methods and Materials: One hundred seven patients treated with radiotherapy (RT) and 111 with concurrent chemotherapy and radiotherapy (CRT) were analyzed. The overall

Fei Gao; Joseph Wee; Hwee Bee Wong; David Machin

2010-01-01

327

Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy.  

PubMed

Colorectal carcinoma is, through to its high rate of liver metastasis (mCRC), the second most cause of cancer death worldwide. Tumor resection represents the only potential cure. In cases of unresectable disease systemic chemotherapy (sCHT) remains the therapy of choice. Modern sCHT regimens including biological agents can induce tumor response that leads to curative surgery of initially unresectable mCRC. However, liver-directed therapy via hepatic arterial infusion (HAI) may produce higher response rates than sCHT. Herein we studied whether a HAI of cetuximab (CE) plus bevacizumab (BE) with or without oxaliplatin (OX) can inhibit tumor growth in a rat model. WAG/Rij rats underwent subcapsular hepatic tumor implantation. After 10 days animals received either HAI or sCHT of CE plus BE, OX or all three drugs. Saline-treated animals served as controls. Tumor growth was estimated at day 10 and 13. On day 13 liver and tumor tissue was studied histologically and immunohistochemically. In controls the tumors grew about 50 %. OX alone was not capable of inhibiting tumor growth. In contrast, CE plus BE given as HAI significantly reduced tumor growth compared to sCHT (p < 0.05). HAI of CE plus BE combined with OX yielded an even more pronounced inhibition of tumor growth. Immunohistochemistry revealed a decreased tumor cell proliferation and tumor vascularization. The present study demonstrates that HAI of CE plus BE is effective to inhibit tumor growth. This effect is even more pronounced in combination with OX. Systemic application of these agents cannot achieve comparable effects. PMID:23187934

Sperling, Jens; Brandhorst, David; Schäfer, Thilo; Ziemann, Christian; Benz-Weißer, Anna; Scheuer, Claudia; Kollmar, Otto; Schilling, Martin K; Menger, Michael D

2012-11-27

328

Chemotherapy-Induced Neurotoxicity  

Microsoft Academic Search

\\u000a Chemotherapy-induced neurotoxicity is a common and dose-limiting side effect of many cancer treatments. While other dose-limiting\\u000a toxicities such as myelosupression and hypersensitivity reactions are largely amenable to treatment, chemotherapy-induced\\u000a neurotoxicity remains a significant problem, with limited treatment options and no standardized diagnostic or management criteria.\\u000a Receiving a full course of chemotherapy on schedule is a critical factor that determines patient

Susanna B. Park; Matthew C. Kiernan

329

Chemotherapy-induced neuropathy  

Microsoft Academic Search

Peripheral neuropathy is a common dose-limiting toxicity of chemotherapy. Chemotherapy-induced peripheral neuropathy (CIPN)\\u000a causes numerous debilitating symptoms, impairs functional capacity, and results in dose reductions or possible cessation of\\u000a chemotherapy. Analgesic or neurotropic agents are only modestly effective in treating neuropathic symptoms. Animal and human\\u000a studies into the pathogenesis of CIPN have demonstrated heterogeneity in the mechanism(s) of nerve injury

Anjali Bhagra; Ravi D. Rao

2007-01-01

330

Anaerobic NADH-Fumarate Reductase System Is Predominant in the Respiratory Chain of Echinococcus multilocularis, Providing a Novel Target for the Chemotherapy of Alveolar Echinococcosis?  

PubMed Central

Alveolar echinococcosis, which is due to the massive growth of larval Echinococcus multilocularis, is a life-threatening parasitic zoonosis distributed widely across the northern hemisphere. Commercially available chemotherapeutic compounds have parasitostatic but not parasitocidal effects. Parasitic organisms use various energy metabolic pathways that differ greatly from those of their hosts and therefore could be promising targets for chemotherapy. The aim of this study was to characterize the mitochondrial respiratory chain of E. multilocularis, with the eventual goal of developing novel antiechinococcal compounds. Enzymatic analyses using enriched mitochondrial fractions from E. multilocularis protoscoleces revealed that the mitochondria exhibited NADH-fumarate reductase activity as the predominant enzyme activity, suggesting that the mitochondrial respiratory system of the parasite is highly adapted to anaerobic environments. High-performance liquid chromatography-mass spectrometry revealed that the primary quinone of the parasite mitochondria was rhodoquinone-10, which is commonly used as an electron mediator in anaerobic respiration by the NADH-fumarate reductase system of other eukaryotes. This also suggests that the mitochondria of E. multilocularis protoscoleces possess an anaerobic respiratory chain in which complex II of the parasite functions as a rhodoquinol-fumarate reductase. Furthermore, in vitro treatment assays using respiratory chain inhibitors against the NADH-quinone reductase activity of mitochondrial complex I demonstrated that they had a potent ability to kill protoscoleces. These results suggest that the mitochondrial respiratory chain of the parasite is a promising target for chemotherapy of alveolar echinococcosis.

Matsumoto, Jun; Sakamoto, Kimitoshi; Shinjyo, Noriko; Kido, Yasutoshi; Yamamoto, Nao; Yagi, Kinpei; Miyoshi, Hideto; Nonaka, Nariaki; Katakura, Ken; Kita, Kiyoshi; Oku, Yuzaburo

2008-01-01

331

Combined chemotherapy and intra-arterial chemotherapy of retinoblastoma  

PubMed Central

Purpose Retinoblastoma (RB) is the most common primary malignant intraocular tumor in children. Although systemic chemotherapy has been the primary treatment, intra-arterial chemotherapy (IAC) represents a new treatment option. Here, we performed alternate systemic chemotherapy and IAC and retrospectively reviewed the efficacy and safety of this approach. Methods Patients diagnosed with intraocular RB between January 2000 and December 2011 at Severance Children's Hospital, Yonsei University, were reviewed. Before February 2010, the primary treatment for RB was chemotherapy (non-IAC/CTX). Since February 2010, the primary treatment for RB has been IAC (IAC/CTX). External beam radiotherapy or high-dose chemotherapy were used as "last resort" treatments just prior to enucleation at the time of progression or recurrence during primary treatment. Enucleation-free survival (EFS) and progression-free survival were assessed. Results We examined 19 patients (median age, 11.9 months; range, 1.4 to 75.6 months) with a sum of 25 eyes, of which, 60.0% were at advanced Reese Ellsworth (RE) stages. The enucleation rate was 33.3% at early RE stages and 81.8% at advanced RE stages (P=0.028). At 36 months, EFS was significantly higher in the IAC/CTX group than in the non-IAC/CTX group (100% vs. 40.0%, P=0.016). All 5 patients treated with IAC achieved eye preservation, although most patients were at advanced RE stages (IV-V). Conclusion Despite the limitation of a small sample size, our work shows that an alternative combined approach using IAC and CTX may be safe and effective for eye preservation in advanced RB.

Choi, Saerom; Han, Jung Woo; Kim, Hyosun; Kim, Beom Sik; Kim, Dong Joon; Lee, Sung Chul

2013-01-01

332

Consolidation Radiotherapy in Primary Central Nervous System Lymphomas: Impact on Outcome of Different Fields and Doses in Patients in Complete Remission After Upfront Chemotherapy  

SciTech Connect

Purpose: Avoidance radiotherapy or reduction of irradiation doses in patients with primary central nervous system lymphoma (PCNSL) in complete remission (CR) after high-dose methotrexate (HD-MTX)-based chemotherapy has been proposed to minimize the neurotoxicity risk. Nevertheless, no study has focused on the survival impact of radiation parameters, as far as we know, and the optimal radiation schedule remains to be defined. Methods and Materials: The impact on outcome and neurologic performance of different radiation fields and doses was assessed in 33 patients with PCNSL who achieved CR after MTX-containing chemotherapy and were referred to consolidation whole-brain irradiation (WBRT). Patterns of relapse were analyzed on computed tomography-guided treatment planning, and neurologic impairment was assessed by the Mini Mental Status Examination. Results: At a median follow-up of 50 months, 21 patients are relapse-free (5-year failure-free survival [FFS], 51%). WBRT doses {>=}40 Gy were not associated with improved disease control in comparison with a WBRT dose of 30 to 36 Gy (relapse rate, 46% vs. 30%; 5-year FFS, 51% vs. 50%; p = 0.26). Disease control was not significantly different between patients irradiated to the tumor bed with 45 to 54 Gy or with 36 to 44 Gy, with a 5-year FFS of 35% and 44% (p = 0.43), respectively. Twenty patients are alive (5-year overall survival, 54%); WB and tumor bed doses did not have an impact on survival. Impairment as assessed by the Mini Mental Status Examination was significantly more common in patients treated with a WBRT dose {>=}40 Gy. Conclusion: Consolidation with WBRT 36 Gy is advisable in patients with PCNSL in CR after HD-MTX-based chemotherapy. Higher doses do not change the outcome and could increase the risk of neurotoxicity.

Ferreri, Andres Jose Maria, E-mail: andres.ferreri@hsr.i [Unit of Lymphoid Malignancies, Department of Oncology, San Raffaele Scientific Institute, Milan (Italy); Medical Oncology Unit, Department of Oncology, San Raffaele Scientific Institute, Milan (Italy); Verona, Chiara [Unit of Lymphoid Malignancies, Department of Oncology, San Raffaele Scientific Institute, Milan (Italy); Internal Medicine Unit, Department of Oncology, San Raffaele Scientific Institute, Milan (Italy); Politi, Letterio Salvatore [Neuroradiology Unit, Department of Oncology, San Raffaele Scientific Institute, Milan (Italy); Chiara, Anna [Unit of Radiotherapy and Tomotherapy, Department of Oncology, San Raffaele Scientific Institute, Milan (Italy); Perna, Lucia [Medical Physics Unit, Department of Oncology, San Raffaele Scientific Institute, Milan (Italy); Villa, Eugenio; Reni, Michele [Medical Oncology Unit, Department of Oncology, San Raffaele Scientific Institute, Milan (Italy)

2011-05-01

333

Chemotherapy-induced alopecia.  

PubMed

Chemotherapy-induced alopecia is a distressing side effect common to certain treatment regimens in oncology. Unfortunately, chemotherapy-induced alopecia is an often overlooked or minor factor among our current research priorities and thus advances in amelioration have been minimal. This review offers a comprehensive examination of the clinically relevant basic science, clinical research, and current management options for chemotherapy-induced alopecia. We emphasize that hair loss secondary to chemotherapy is not as random or nonspecific in patterns or extent of disease, as one would initially perceive. Patient support and education information and templates are provided to facilitate patient treatment. PMID:22178150

Chon, Susan Y; Champion, Rachel W; Geddes, Elizabeth R; Rashid, Rashid M

2011-12-16

334

Using Dataflow Information to Improve Inter-Workflow Instance Concurrency  

Microsoft Academic Search

The control-flow-based design of traditional batch scheduling systems (i.e., Job A must finish before Job B is started) can constrain the concurrency in schedulers for high-performance computing (HPC) workloads. There are two main problems. First, the control-flow graph, representing the workflow, may be inherently limited in its degree of concurrency. Second, if the naming strategy of the input and output

Yang Wang; Paul Lu

2005-01-01

335

Chemotherapy for Childhood Hepatoblastoma and Hepatocellular Carcinoma  

Microsoft Academic Search

\\u000a Systemic chemotherapy plays a fundamental role in the cure of children diagnosed with hepatoblastoma. In fact for them, the\\u000a best chance of cure can be achieved only with a multidiscplinary approach that includes surgery and systemic chemotherapy.\\u000a Cisplatin-based regimes have been repeatedly shown by the different study groups to be the most effective therapy. Currently,\\u000a the 5 year overall survival

Giorgio Perilongo; Bruce Morland; Marcio Malogolowkin

336

Tumor Progression While on Chemotherapy  

PubMed Central

Objective: To evaluate the influence of the response to preoperative chemotherapy, especially tumor progression, on the outcome following resection of multiple colorectal liver metastases (CRM). Summary Background Data: Hepatic resection is the only treatment that currently offers a chance of long-term survival, although it is associated with a poor outcome in patients with multinodular CRM. Because of its better efficacy, chemotherapy is increasingly proposed as neoadjuvant treatment in such patients to allow or to facilitate the radicality of resection. However, little is known of the efficacy of such a strategy and the influence of the response to chemotherapy on the outcome of hepatic resection. Methods: We retrospectively analyzed the course of 131 consecutive patients who underwent liver resection for multiple (?4) CRM after systemic chemotherapy between 1993 and 2000, representing 30% of all liver resections performed for CRM in our institution during that period. Chemotherapy included mainly 5-fluorouracil, leucovorin, and either oxaliplatin or irinotecan for a mean of 9.8 courses (median, 9 courses). Patients were divided into 3 groups according to the type of response obtained to preoperative chemotherapy. All liver resections were performed with curative intent. We analyzed patient outcome in relation to response to preoperative chemotherapy. Results: There were 58 patients (44%) who underwent hepatectomy after an objective tumor response (group 1), 39 (30%) after tumor stabilization (group 2), and 34 (26%) after tumor progression (group 3). At the time of diagnosis, mean tumor size and number of metastases were similar in the 3 groups. No differences were observed regarding patient demographics, characteristics of the primary tumor, type of liver resection, and postoperative course. First line treatments were different between groups with a higher proportion of oxaliplatin- and/or irinotecan-based treatments in group 1 (P < 0.01). A higher number of lines of chemotherapy were used in group 2 (P = 0.002). Overall survival was 86%, 41%, and 28% at 1, 3, and 5 years, respectively. Five-year survival was much lower in group 3 compared with groups 1 and 2 (8% vs. 37% and 30%, respectively at 5 years, P < 0.0001). Disease-free survival was 3% compared with 21% and 20%, respectively (P = 0.02). In a multivariate analysis, tumor progression on chemotherapy (P < 0.0001), elevated preoperative serum CA 19–9 (P < 0.0001), number of resected metastases (P < 0.001), and the number of lines of chemotherapy (P < 0.04), but not the type of first line treatment, were independently associated with decreased survival. Conclusions: Liver resection is able to offer long-term survival to patients with multiple colorectal metastases provided that the metastatic disease is controlled by chemotherapy prior to surgery. Tumor progression before surgery is associated with a poor outcome, even after potentially curative hepatectomy. Tumor control before surgery is crucial to offer a chance of prolonged remission in patients with multiple metastases.

Adam, Rene; Pascal, Gerard; Castaing, Denis; Azoulay, Daniel; Delvart, Valerie; Paule, Bernard; Levi, Francis; Bismuth, Henri

2004-01-01

337

Multitasking-Pascal extensions solve concurrency problems  

SciTech Connect

To avoid deadlock (one process waiting for a resource than another process can't release) and indefinite postponement (one process being continually denied a resource request) in a multitasking-system application, it is possible to use a high-level development language with built-in concurrency handlers. Parallel Pascal is one such language; it extends standard Pascal via special task synchronizers: a new data type called signal, new system procedures called wait and send and a Boolean function termed awaited. To understand the language's use the author examines the problems it helps solve.

Mackie, P.H.

1982-09-29

338

Concurrent Dynamic Epistemic Logic  

Microsoft Academic Search

\\u000a When giving an analysis of knowledge in multiagent systems, one needs a framework in which higher-order information and its\\u000a dynamics can both be represented. A recent tradition starting in original work by Plaza treats all of knowledge, higher-order\\u000a knowledge, and its dynamics on the same foot. Our work is in that tradition. It also fits in approaches that not only

H. p. Van Ditmarsch; W. Van Der Hoek; B. P. Kooi

339

[Chemotherapy for thymic carcinoma].  

PubMed

Thymic epithelial neoplasm is a quite rare malignancy arising from the thymic epithelium, and comprises thymoma, thymic carcinoma, and thymic neuroendocrine carcinoma. The incidence of thymic carcinoma and neuroendocrine carcinoma is much less than thymoma, accounting for 1-4%of anterior mediastinal tumors. These rare tumors are called"orphan tumors,"and standards of clinical management(including chemotherapeutic regimens)have not yet been determined for them yet because of their rarity. In the advanced setting, palliative-intent chemotherapy has been applied using cisplatin-based triplet or quartet chemotherapy with second-generation antitumor drugs, with reference to chemotherapeutic regimens for invasive thymoma such as ADOC, CAP, and VIP chemotherapy. However, biological plausibility is lacking for this approach, given that these tumors differ from thymoma in their expression of cellular surface proteins such as c-Kit and epidermal growth factor receptors. While limited to thymic carcinoma, platinum doublet chemotherapy with a third-generation antitumor drug as first-line chemotherapy is anticipated to offer the same clinical efficacy as multiple-agent combination chemotherapy, but with less toxicities. In second-line or later-lines of chemotherapy, single-agent chemotherapy may be optimal. Molecular biological approaches have been under investigation, but molecular targeted agents remain unavailable. PMID:22584319

Okuma, Yusuke

2012-05-01

340

What's New in Chemotherapy Research?  

MedlinePLUS

... about chemotherapy Next Topic To learn more What’s new in chemotherapy research? Over the years, many people ... control, and some will come back. Several exciting new uses of chemotherapy and other agents hold even ...

341

Intratumor chemotherapy in combination with a systemic antimetastatic drug in the treatment of Lewis-lung carcinoma.  

PubMed

The effect of an antimetastatic agent plus intratumor chemotherapy was evaluated in mice bearing Lewis-lung carcinoma by measuring survival time and by histological examination. Polymeric flavan-3,4-diol (APF) from avocado seeds, Persea gratissima, administered alone directly into the tumor did not change survival time, although it partially destroyed the primary tumor. However, the drug administered in combination with an antimetastatic, 1,2-bis(3,5-dioxopiperazin-1-yl)ethane (ICRF-154), resulted in an increase in survival time. When 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) was used in place of polymeric flavanadiol as an intralesional drug, a significant increase in survival was also achieved. The effect of each drug alone and of their combination was evaluated by "responder analyses". Animals "cured" by the combination and rechallenged with 2 X 10(6) tumor cells showed that immunization could occur. PMID:3835980

De-Oliveira, M M; Nakamura, I T; Joussef, A C; Giannotti Filho, O

1985-01-01

342

Concurrent Omega-Regular Games  

Microsoft Academic Search

We consider two-player games which are played on a fi- nite state space for an infinite number of rounds. The games are concurrent, that is, in each round, the two play- ers choose their moves independently and simultaneously; the current state and the two moves determine a successor state. We consider omega-regular winning conditions on the resulting infinite state sequence.

Luca De Alfaro; Thomas A. Henzinger

2000-01-01

343

Solving problems on concurrent processors  

Microsoft Academic Search

This book explains how many major scientific algorithms can be used on large parallel machines. Based on five years of research on hypercubes, the book concentrates on practically motivated model problems, that serve to illustrate generic algorithmic and decomposition techniques. The authors include results for hypercube-class concurrent computers with up to 128 nodes, and the principles behind the extrapolation to

G Fox

1988-01-01

344

Compositional Semantics for Concurrent Prolog.  

National Technical Information Service (NTIS)

It is shown that a model designed for imperative languages can be used to give a formal description of Concurrent Prolog. This model is compositional: for any two conjunctions C1, C2 the meaning of (C1 and C2) can be obtained by applying a function to the...

J. N. Kok

1988-01-01

345

Concurrent Resurgence and Behavioral History  

ERIC Educational Resources Information Center

|The contribution of past experiences to concurrent resurgence was investigated in three experiments. In Experiment 1, resurgence was related to the length of reinforcement history as well as the reinforcement schedule that previously maintained responding. Specifically, more resurgence occurred when key pecks had been reinforced on a…

da Silva, Stephanie P.; Maxwell, Megan E.; Lattal, Kennon A.

2008-01-01

346

Concurrence dans le transport routier  

Microsoft Academic Search

Le secteur du transport routier, un mode de transport essentiel dans les économies de l'OCDE se repartit entre deux secteurs qui se distinguent largement, le transport de marchandises et le transport de passagers. Les secteurs examinés – le camionnage, le transport par cars, et les taxis – ont des caractéristiques assez distinctes et laissent place à la concurrence d'une manière

2002-01-01

347

A Simulator for Concurrent Objects  

Microsoft Academic Search

This paper in particular describes an environment for testing implementations of concurrent objectsthrough simulation. Proving linearizability of a data object is a nontrivial task. In [15], the proof of a simpleconcurrent set consists of five propositions, one lemma and one theorem. The more definitive approach ofverification is the subject of other papers [6, 15] including Herlihy and Wing's original POPL

Jeannette M. Wing; Chun Gong

1990-01-01

348

Concurrent set manipulation without locking  

Microsoft Academic Search

Set manipulation consists of the actions insert, delete, and member on keys. We propose a concurrent set manipulation algorithm that uses no locking at all and requires no aborts, relying instead on atomic read-modify-write operations on single (data) locations. The algorithm satisfies order-preserving serializability through conditions that are strictly looser than existing algorithms

Vladimir Lanin; Dennis Shasha

1988-01-01

349

Synthesis of VHDL concurrent processes  

Microsoft Academic Search

This paper presents two methoals for synthesis of VHDL siecijications containing concurrent processes. Our main objective is to preserve simulation\\/synthesis correspondence during high-level synthesis and to produce hardware that operates with a high degree of parallelism. The first method supports an unrestricted use of signals and wait statements and synthesizes synchronous hardware with global control of process synchronization for signal

Petru Eles; Marius Minea; Krzysztof Kuchcinski; Zebo Peng

1994-01-01

350

Serum retinol, alpha-tocopherol and systemic inflammatory response in metastatic colorectal carcinoma patients treated with combination chemotherapy and cetuximab.  

PubMed

Cetuximab is a chimeric antibody registered for the therapy of advanced colorectal carcinoma. Cancer and anticancer therapy are associated with oxidative stress, and disorders of antioxidant balance may be involved in the toxicity associated with anticancer treatment. The aim of the present study was to investigate the changes of serum retinol, alpha-tocopherol and C-reactive protein during the first month of treatment with cetuximab and chemotherapy. Twenty-five consecutive patients with metastatic colorectal carcinoma treated with a combination of chemotherapy and cetuximab were included in the present study. Serum retinol and alpha-tocopherol were determined by high-performance liquid chromatography and serum C-reactive protein was determined using commercial kits. Significant correlation was observed between baseline concentrations of retinol and C-reactive protein (r(s)=-0.54, p<0.01). Median survival of patients who had baseline serum retinol below 1.25 µmol/L was 10 mo compared to 18 mo for patients who had serum retinol equal or above 1.25 µmol/L (p<0.05); median survival of patients who had serum C-reactive protein below 24 mg/L was significantly longer compared to patients with C-reactive protein levels equal or above 24 mg/L (18 vs. 7 mo, p<0.05), but no difference in survival was observed based on alpha-tocopherol levels. Twenty-two patients had evaluation of retinol, alpha-tocopherol and C-reactive protein at least once during the follow up. Serum concentration of alpha-tocopherol decreased significantly during the therapy, but retinol and C-reactive protein concentrations remained unchanged. In conclusion, a significant correlation was observed between serum retinol and C-reactive protein. Serum alpha-tocopherol decreased significantly during the first month of combination therapy with cetuximab. Low retinol and high C-reactive protein concentrations were predictive of poor prognosis in this patient population. PMID:20924143

Melichar, Bohuslav; Krcmová, Lenka; Kalábová, Hana; Holecková, Petra; Kasparová, Markéta; Plísek, Jirí; Hyspler, Radomír; Studentová, Hana; Solichová, Dagmar

2010-01-01

351

Chemotherapy in recurrent ependymoma.  

PubMed

Surgical resection with or without radiation therapy confers long-term remission in approximately half of the patients newly diagnosed with ependymoma. Chemotherapy has a limited role in the management of ependymoma. In newly diagnosed infants, chemotherapy is utilized as an attempt to defer radiation. The use of chemotherapy in older children has provided no conclusive benefit. The largest experience with chemotherapy in ependymoma has been in children with recurrent disease. In this section, we will analyze the principal institutional and cooperative group phase I, phase II, and phase III clinical trials utilizing single-agent and multiagent chemotherapy in patients with recurrent ependymoma. In addition, future directions relating to novel medical oncologic therapies will also be discussed. PMID:9782208

Siffert, J; Allen, J C

1998-06-01

352

Primary Vaginal Cancer Treated With Concurrent Chemoradiation Using Cis-Platinum  

SciTech Connect

Purpose: To evaluate the feasibility of concurrent weekly Cis-platinum chemoradiation (CRT) in the curative treatment of primary vaginal cancer. Methods: A retrospective review was performed of all primary vaginal cancer patients treated with curative intent at the Ottawa Hospital Regional Cancer Centre between 1999 and 2004 using concurrent Cis-platinum CRT. Results: Twelve patients were treated with concurrent weekly CRT. The median age at diagnosis was 56 years (range, 34-69 years), and the median follow-up was 50 months (range, 11-75 months). Ten patients (83%) were diagnosed with squamous cell carcinoma and 2 patients (17%) with adenocarcinoma. The distribution according to stage was as follows: 6 (50%) Stage II, 4 (33%) Stage III, and 2 (17%) Stage IVA. All patients received pelvic external beam radiotherapy (EBRT) concurrently with weekly intravenous Cis-platinum chemotherapy (40 mg/m{sup 2}) followed by brachytherapy (BT). The median dose of EBRT was 4500 cGy given in 25 fractions over 5 weeks. Ten patients received interstitial BT, and 2 patients received intracavitary BT, with the median dose being 3000 cGy. The 5-year overall survival, progression-free survival, and locoregional progression-free survival rates were 66%, 75%, and 92%, respectively. Late toxicity requiring surgery occurred in 2 patients (17%). Conclusions: For the treatment of primary vaginal cancer, it is feasible to deliver concurrent weekly Cis-platinum chemotherapy with high-dose radiation, leading to excellent local control and an acceptable toxicity profile.

Samant, Rajiv [Department of Radiation Oncology, Ottawa Hospital Regional Cancer Centre, Ottawa, ON (Canada); Faculty of Medicine, University of Ottawa Hospital, Ottawa, ON (Canada)], E-mail: rsamant@ottawahospital.on.ca; Lau, Bedy [Department of Otolaryngology, University of British Columbia, Vancouver, BC (Canada); E, Choan [Department of Radiation Oncology, Ottawa Hospital Regional Cancer Centre, Ottawa, ON (Canada); Faculty of Medicine, University of Ottawa Hospital, Ottawa, ON (Canada); Le, Tien [Faculty of Medicine, University of Ottawa Hospital, Ottawa, ON (Canada); Department of Gynecologic Oncology, Ottawa Hospital, Ottawa, ON (Canada); Tam, Tiffany [Department of Radiation Oncology, McMaster University, Hamilton, ON (Canada)

2007-11-01

353

A critical overview of concurrent chemoradiotherapy in cervical cancer.  

PubMed

In February 1999, the National Cancer Institute of the US National Institutes of Health issued a communication stating that concurrent chemoradiotherapy should be considered as standard treatment for cervical cancer. This statement was based on the publication of five randomized prospective trials. On the basis of a critical review of these papers and others that identified different results, questions, doubts, and concerns have arisen about this therapeutic method. We analyzed the quality of the control groups managed with the standard treatment, noting data that may have altered these results, as well as analyzing the quality of chemotherapy, radiotherapy, and treatment compliance. In light of this analysis, we believe that further trials should be carried out with fairly balanced prognostic factors to demonstrate beyond a doubt that concurrent chemoradiotherapy is superior to radiotherapy alone. In developing countries where resources are scarce, this type of tumor is found frequently. Concurrent chemoradiotherapy would involve increased costs and supportive care, taking away resources from other vital areas. PMID:15485616

Sardi, Juan E; Boixadera, María A; Sardi, Juan J

2004-11-01

354

Chemotherapy-induced peripheral neuropathy  

Microsoft Academic Search

Recent advances in the development and administration of chemotherapy for malignant diseases have led to prolonged survival\\u000a of patients and the promise of a return to normal lives. The cost of progress comes with a price, however, and the nervous\\u000a system is frequently the target of therapy-induced toxicity. Unlike more immediate toxicities that affect the gastrointestinal\\u000a tract and bone marrow,

Bushra Malik; Mark Stillman

2008-01-01

355

Intraperitoneal chemotherapy: implications beyond ovarian cancer.  

PubMed

The National Cancer Institute (NCI) announced in January 2006 the use of intraperitoneal (IP) combined with IV chemotherapy postoperatively as the preferred treatment method for advanced ovarian cancer. The announcement stimulated the need for oncology nurses to become familiar with IP chemotherapy administration and patient management guidelines. IP administration allows a high concentration of chemotherapy to come into direct contact with tumors and surrounding tissues and organs. IP chemotherapy also is administered in clinical trials and some clinical settings for other histologies, such as low-grade gastrointestinal carcinoma and appendiceal carcinoma, which tend to spread locally before invading the bloodstream. Local-regional chemotherapy potentially is an ideal treatment for local spread of those peritoneal carcinomas. Overall side effects from regional treatment are less severe than with systemic treatment. Oncology nurses can help minimize and alleviate discomfort associated with IP chemotherapy administration. This article focuses on nursing management strategies for patients receiving IP chemotherapy for ovarian cancer and other peritoneal carcinomatosis. PMID:18063547

Marin, Keith; Oleszewski, Karen; Muehlbauer, Paula

2007-12-01

356

Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors  

ClinicalTrials.gov

Childhood Central Nervous System Choriocarcinoma; Childhood Central Nervous System Embryonal Tumor; Childhood Central Nervous System Germ Cell Tumor; Childhood Central Nervous System Germinoma; Childhood Central Nervous System Mixed Germ Cell Tumor; Childhood Central Nervous System Teratoma; Childhood Central Nervous System Yolk Sac Tumor; Childhood Pineal Parenchymal Tumor

2013-06-10

357

Interpretive Model for a ''A Concurrency Method''.  

National Technical Information Service (NTIS)

''A Concurrency Method'' is a language embodying the data flow characteristics of data-drive and single-assignment. The interpreter for ''A Concurrency Method'' models a physical machine with an architecture directed toward this language. The interpreter ...

C. L. Carter

1986-01-01

358

[Outpatient chemotherapy for lung cancer].  

PubMed

In order to maintain the QOL in lung cancer patients and also save on medical costs, chemotherapy should be performed on an outpatient basis as much as possible. If the performance status is good and their residence is nearby, then not only in the case of small cell lung cancer or unresectable non-small cell lung cancer, but also including postoperative adjuvant chemotherapy for non-small cell lung cancer, in all such suitable cases, chemotherapy can be performed on an outpatient basis. For example, by performing outpatient chemotherapy in moderate amounts for older people, the survival can be improved while maintaining the QOL. However,a single dose of cisplatin 60 to 80 mg/m(2) requires a high volume iv infusion, and the first chemotherapy treatment needs to be carried out in the hospital for nausea and vomiting control. For a regimen of combined anticancer drugs other than cisplatin and including carboplatin, such as paclitaxel, docetaxel, irinotecan, gemcitabine or vinorelbine, the required iv time is short, side effects such as nausea or vomiting are less severe,and it is easily performed on an outpatient basis. An oral anticancer drug, gefitinib, or S-1 can also be an effective choice for non-small cell lung cancer. Since lung cancer patients tend to be susceptible to obstructive pneumonia or pneumonia from opportunistic infections, these need particular attention at the time of neutropenia. In addition, strict caution is required in order to prevent prescription or medication errors, or medical accidents such as leakage of the intravenous drip. If severe side effects occur, then a system must be prepared in which the patient can make contact promptly in emergency situations and thus can be hospitalized as necessary. Outpatient chemotherapy for lung cancers is increasing in Japan, however, there are many issues including insufficient staff, overworked staff, or situations where home nursing care places a heavy burden on the family. The assignment of sufficient medical treatment fees, the rationalization of work responsibilities or further development of home assistance systems are therefore eagerly anticipated. PMID:17431337

Yoneda, Shuichi

2007-04-01

359

Intra-Arterial Chemotherapy in Cancer Treatment.  

National Technical Information Service (NTIS)

Contents: General studies with intraarterial chemotherapy; Intraarterial chemotherapy of head and neck cancer; Intraarterial chemotherapy for hepatic cancers; Intraarterial chemotherapy of the gastrointestinal tract; Intraarterial chemotherapy of the extr...

1982-01-01

360

Concurrent task effects on memory retrieval  

Microsoft Academic Search

Previous studies combining continuous free recall with a concurrent task have generally shown that concurrent tasks impose fairly negligible effects on memory retrieval. By contrast, dual-task studies employing either cued recall or semantic retrieval reveal gross memory impairment and suggest that retrieval is delayed by the centrally demanding phase of the concurrent tasks (i.e., response selection). To explore this conflict,

DOUG ROHRER; HAROLD E. PASHLER

2003-01-01

361

Chemotherapy of Rodent Malaria.  

National Technical Information Service (NTIS)

This report summarises the activities of the chemotherapy group for 13 months (12 months initial contract plus one month's extension). The work reported on also includes results obtained from the completion of studies commenced in Liverpool under the cont...

W. Peters

1981-01-01

362

Chemotherapy for Colorectal Cancer  

Microsoft Academic Search

Colorectal cancer is the most commonly diagnosed cancer in the EU. Various randomised studies have shown a survival benefit with chemotherapy in the adjuvant setting. Adjuvant chemotherapy with 5-fluorouracil\\/folinic acid (5FU\\/FA) for 6 months after curatively resected node-positive colon cancer has become the standard practice. However, controversy still exists regarding the optimal regimen and whether to treat node-negative patients. The

Sandeep Goyle; Anthony Maraveyas

2005-01-01

363

Chemotherapy for Testicular Cancer  

Microsoft Academic Search

The last 30 years have seen extraordinary advances in the management of metastatic germ cell cancer of the testis. Prior to\\u000a the advent of cisplatin-containing chemotherapy in the mid-1970s, chemotherapy was highly toxic, and gave poor results, with\\u000a cure unusual in those with advanced disease. Following the introduction of cisplatin, and subsequently etoposide, progress\\u000a has been rapid, not least in

Thomas R. Geldart; Graham M. Mead

364

Primary Tumor Necrosis Predicts Distant Control in Locally Advanced Soft-Tissue Sarcomas After Preoperative Concurrent Chemoradiotherapy  

SciTech Connect

Purpose: Various neoadjuvant approaches have been evaluated for the treatment of locally advanced soft-tissue sarcomas. This retrospective study describes a uniquely modified version of the Eilber regimen developed at the University of Chicago. Methods and Materials: We treated 34 patients (28 Stage III and 6 Stage IV) with locally advanced soft-tissue sarcomas of an extremity between 1995 and 2008. All patients received preoperative therapy including ifosfamide (2.5 g/m2 per day for 5 days) with concurrent radiation (28 Gy in 3.5-Gy daily fractions), sandwiched between various chemotherapy regimens. Postoperatively, 47% received further adjuvant chemotherapy. Results: Most tumors (94%) were Grade 3, and all were T2b, with a median size of 10.3 cm. Wide excision was performed in 29 patients (85%), and 5 required amputation. Of the resected tumor specimens, 50% exhibited high (>=90%) treatment-induced necrosis and 11.8% had a complete pathologic response. Surgical margins were negative in all patients. The 5-year survival rate was 42.3% for all patients and 45.2% for Stage III patients. For limb-preservation patients, the 5-year local control rate was 89.0% and reoperation was required for wound complications in 17.2%. The 5-year freedom-from-distant metastasis rate was 53.4% (Stage IV patients excluded), and freedom from distant metastasis was superior if treatment-induced tumor necrosis was 90% or greater (84.6% vs. 19.9%, p = 0.02). Conclusions: This well-tolerated concurrent chemoradiotherapy approach yields excellent rates of limb preservation and local control. The resulting treatment-induced necrosis rates are predictive of subsequent metastatic risk, and this information may provide an opportunity to guide postoperative systemic therapies.

MacDermed, Dhara M. [Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL (United States); Miller, Luke L. [Pritzker School of Medicine, University of Chicago, Chicago, IL (United States); Peabody, Terrance D.; Simon, Michael A.; Luu, Hue H.; Haydon, Rex C. [Section of Orthopaedic Surgery and Rehabilitation, Department of Surgery, University of Chicago, Chicago, IL (United States); Montag, Anthony G. [Department of Pathology, University of Chicago, Chicago, IL (United States); Undevia, Samir D. [Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL (United States); Connell, Philip P., E-mail: pconnell@radonc.uchicago.ed [Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL (United States)

2010-03-15

365

Hyperthermic Intraoperative Thoracoabdominal Chemotherapy  

PubMed Central

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for selected patients with pseudomyxoma peritonei (PMP) and diffuse malignant peritoneal mesothelioma (DMPM). Tumor infiltration of the hemidiaphragm requiring partial resection occurs as a result of large volume and/or invasive disease at this anatomic site. Transmission of disease from abdomen to chest is a great danger in this group of patients. From a prospective database, patients who had diaphragm resection and then hyperthermic thoracoabdominal chemotherapy (HITAC) as a component of a cytoreductive surgical procedure were identified. Data from control patients receiving HIPEC or hyperthermic intrathoracic chemotherapy (HITOC) were analyzed for comparison. The morbidity, mortality, survival, and recurrence rate within the thoracic space were presented. Thirty patients had partial resection of a hemidiaphragm as part of a cytoreductive surgical procedure that utilized HITAC. The pharmacologic benefit of intracavitary chemotherapy administration was documented with an area under the curve ratio of intracavitary concentration times time to plasma concentration times time of 27 ± 10 for mitomycin C and 75 ± 26 for doxorubicin. Comparing percent chemotherapy absorbed for a ninety-minute treatment showed the largest for HIPEC, then for HITAC, and lowest for HITOC. The incidence of grade 3 and 4 adverse events was 43%. There was no mortality. Adjustments in the chemotherapy dose are not necessary with HITAC. The morbidity was high, the survival was acceptable, and intrathoracic recurrence was low.

Sugarbaker, Paul H.; Chang, David; Stuart, O. Anthony

2012-01-01

366

Recurrent and Concurrent Neural Networks for Objects Recognition  

Microsoft Academic Search

A system based on a neural network framework is consid- ered. We used two neural networks, an Elman network (1)(2) and a Kohonen (concurrent) network (3), for a cate- gorization task. The input of the system are objects derived from three general prototypes: circle, square, polygon. We varied the size and orientation of the objects in a continuou s way.

Federico Cecconi; Marco Campenní

2006-01-01

367

Concurrency in Biological Modeling: Behavior, Execution and Visualization  

Microsoft Academic Search

Abstract Modeling natural systems is a complicated task that involves the concurrent behavior of various processes, mechanisms and objects. Here, we describe an approach that we have been taking in our group for several years, whereby the complexity of the problem is reduced by decomposing a natural system into its basic elements, which are then reassembled and combined to form

David Harel; Yaki Setty; Sol Efroni; Naamah Swerdlin; Irun R. Cohen

2008-01-01

368

Intensity-Modulated Radiation Therapy with Concurrent Carboplatin and Paclitaxel for Locally Advanced Head and Neck Cancer: Toxicities and Efficacy  

PubMed Central

Background. Intensity-modulated radiation therapy (IMRT) and alternative chemotherapy regimens strive to maintain efficacy while minimizing toxicity in locally advanced head and neck cancer (LAHNC) treatment. Our experience with concurrent IMRT and taxane-based chemotherapy is presented. Methods. A retrospective review of 150 consecutive patients with LAHNC treated with IMRT and concurrent taxane-based chemotherapy with curative intent was performed. The IMRT fractionation regimen consisted of 69.3 Gy to gross disease (2.1 Gy/fraction) and 56.1 Gy to prophylactic nodal sites (1.7 Gy/fraction). Weekly paclitaxel (30 mg/m2) and carboplatin (area under the concentration–time curve [AUC], 1) were given concurrently to all patients, and 69% received weekly induction with paclitaxel (60 mg/m2) and carboplatin (AUC, 2). Results. Over 90% of patients received the prescribed radiation dose. Ninety-six percent completed five or more cycles of concurrent chemotherapy, with similar tolerability for induction chemotherapy. A percutaneous endoscopic gastrostomy (PEG) tube was required in 80 patients, with 10 maintaining PEG use >18 months. Acute grade 4 mucositis and dermatitis developed in 2.0% and 4.0% of patients, respectively. No patient experienced nadir sepsis, grade ?3 late xerostomia, or significant nephropathy or gastrointestinal toxicity. Median follow-up was 30 months. The 3-year locoregional control rate was 83.2% with disease-free survival and overall survival rates of 78.8% and 76.5%, respectively. Conclusion. Rates of acute and late toxicities were low, with excellent radiation dose delivery and impressive tumor control at 3 years, suggesting that concurrent carboplatin and paclitaxel with IMRT is a reasonable therapeutic option for the curative treatment of LAHNC.

Vlacich, Gregory; Diaz, Roberto; Thorpe, Steven W.; Murphy, Barbara A.; Kirby, Wyndee; Sinard, Robert J.; Shakhtour, Bashar; Shyr, Yu; Murphy, Patrick; Netterville, James L.; Yarbrough, Wendell G.

2012-01-01

369

Concurrent engineering teams. Volume 2: Annotated bibliography  

NASA Astrophysics Data System (ADS)

Specific concurrent engineering practices vary among organizations. There are, however, various management practices that appear to work well for most organizations. This paper presents the reader with specific, useful examples from several defense contractors illustrating how multifunctional concurrent engineering teams are being organized and managed and how concurrent engineering team meetings are conducted and supported. The types of computer support that could be used to enhance the efficiency and effectiveness of concurrent engineering team meetings are identified. The general findings are that there exists a direct relationship between total quality management (TQM) and concurrent engineering, and that many applications of computer-aided group problem solving are possible and practical today for the concurrent engineering team meetings. Areas identified for additional research are the documentation of the decision process and rationale during the product and process definition, the capturing of lessons learned during the implementation of concurrent engineering, and the performance evaluation and training of team members.

Richter, Karen J.; Dierolf, David A.

1990-11-01

370

Apportioning: A Technique for Efficient Reachability Analysis of Concurrent Object-Oriented Programs  

Microsoft Academic Search

The object-oriented paradigm has been found to be useful for the construction of large and complex concurrent systems. Reachability analysis is an important and well-known tool for static (pre-run-time) analysis of concurrent programs. However, direct application of traditional reachability analysis to concurrent object-oriented programs has many problems, such as incomplete analysis for reusable classes (not safe) and increased computational complexity

Sridhar Iyer; S. Ramesh

2001-01-01

371

A framework for the performance analysis of concurrent B-tree algorithms  

Microsoft Academic Search

Many concurrent B-tree algorithms have been proposed, but they have not yet been satisfactorily analyzed. When transaction processing systems require high levels of concurrency, a restrictive serialization technique on the B-tree index can cause a bottleneck. In this paper, we present a framework for constructing analytical performance models of concurrent B-tree algorithms. The models can predict the response time and

Theodore Johnson; Dennis Shasha

1990-01-01

372

Inhaled chemotherapy in lung cancer: future concept of nanomedicine  

PubMed Central

Regional chemotherapy was first used for lung cancer 30 years ago. Since then, new methods of drug delivery and pharmaceuticals have been investigated in vitro, and in animals and humans. An extensive review of drug delivery systems, pharmaceuticals, patient monitoring, methods of enhancing inhaled drug deposition, safety and efficacy, and also additional applications of inhaled chemotherapy and its advantages and disadvantages are presented. Regional chemotherapy to the lung parenchyma for lung cancer is feasible and efficient. Safety depends on the chemotherapy agent delivered to the lungs and is dose-dependent and time-dependent. Further evaluation is needed to provide data regarding early lung cancer stages, and whether regional chemotherapy can be used as neoadjuvant or adjuvant treatment. Finally, inhaled chemotherapy could one day be administered at home with fewer systemic adverse effects.

Zarogoulidis, Paul; Chatzaki, Ekaterini; Porpodis, Konstantinos; Domvri, Kalliopi; Hohenforst-Schmidt, Wolfgang; Goldberg, Eugene P; Karamanos, Nikos; Zarogoulidis, Konstantinos

2012-01-01

373

Infrastructure for the Synchronization and Coordination of Concurrent Java Component Programs  

Microsoft Academic Search

This paper presents the Development Environment for Coordinated Concurrent Activities (DECCA), a system incorporating a methodology and toolkit for developing concurrent, coordinating systems in a high-level, component-oriented, reusable manner. A unique feature of DECCA is that it provides a Java API that enables behavior descriptions to be made using Java's conventional and OOP features, thus facilitating great flexibility in the

Sandeep Mitra; Sudhir Aggarwal

2000-01-01

374

Manufacturing process and material selection in concurrent collaborative design of MEMS devices  

Microsoft Academic Search

In this paper we present knowledge of an intensive approach and system for selecting suitable manufacturing processes and materials for microelectromechanical systems (MEMS) devices in concurrent collaborative design environment. In the paper, fundamental issues on MEMS manufacturing process and material selection such as concurrent design framework, manufacturing process and material hierarchies, and selection strategy are first addressed. Then, a fuzzy

Xuan F. Zha; H. Du

2003-01-01

375

Dynamically Rotate And Free for Test: The Path for FPGA Concurrent Test  

Microsoft Academic Search

Dynamically reconfigurable systems have benefited from a new class of FPGAs, recently introduced into the market, that enables partial and dynamic reconfiguration. While enabling concurrent reconfiguration without disturbing system operation, this technology also raises a new test challenge: to assure a continuously fault free operation independently of the circuit present after the reconfiguration process. A new structural concurrent test method,

Manuel G. Gericota; Gustavo R. Alves; José M. Ferreira

376

Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis.  

PubMed Central

We analysed outcome in 206 consecutive male patients treated for metastatic non-seminomatous germ cell tumour (NSGCT) of testicular or extragonadal origin treated with the POMB/ACE (cisplatin, vincristine, methotrexate, bleomycin, actinomycin D, cyclophosphamide, etoposide) regimen after division into prognostic groups by commonly used clinical classification systems and definitions of adverse prognosis. The adverse prognostic groups of all classification systems and definitions examined showed similar, but only moderate, sensitivity (71-81%) and specificity (52-56%) in predicting death. A simple definition of poor prognosis based on raised initial levels of serum tumour markers alpha fetoprotein (aFP) and human chorionic gonadotrophin (hCG) proved at least as useful (sensitivity 80%, specificity 55%) as other more complicated systems in predicting failure to achieve long-term survival. Comparison of survival between ultra-high dose cisplatin-based combination chemotherapy and patients treated with POMB/ACE shows no advantage from this more toxic approach. This suggests that good results in adverse prognosis patients can be achieved using conventional dose regimens administered intensively.

Hitchins, R. N.; Newlands, E. S.; Smith, D. B.; Begent, R. H.; Rustin, G. J.; Bagshawe, K. D.

1989-01-01

377

Concurrent engineering for composites. Final report  

SciTech Connect

The Total Quality Design (TQD) approach serves as a facilitation tool for the coupled decision making that is necessary for composites. The approach serves as a means of enabling the concurrent engineering of composites through the use of a composites design methodology, as well as the Composites Manufacturing and Design Guide (CMDG). This serves as a decision support system, enabling the design team to not only obtain pertinent information in the shortest possible time, but also serves through its discrimination stacks as a means of rejecting concepts that are not feasible with the customers needs and wants. This serves to reduce conflict. Actual case studies are described, and the methodology is further coupled with the TAGUCHI method, to enable efficient quality control in the RTM process. The methodology is structured so as to enable the design team to conquer barriers of communication, and work in an efficient manner for the successful realization of the design cycle. The approach and tools present a concurrent engineering approach to the application of the latest decision making management techniques to the product realization process for composites.

Wilkins, D.J.; Karbhari, V.M.; Henshaw, J.M.

1991-10-01

378

Development of a New Subclavian Arterial Infusion Chemotherapy Method for Locally or Recurrent Advanced Breast Cancer Using an Implanted Catheter-Port System After Redistribution of Arterial Tumor Supply  

SciTech Connect

Locally or recurrent advanced breast cancers can receive arterial blood supply from various arteries, such as the internal thoracic artery (ITA), the lateral thoracic artery, and the other small arterial branches originating from the subclavian artery. Failure to catheterize and subsequent formation of collateral arterial blood supply from various arteries are some of the reasons why the response to conventional selective transarterial infusion chemotherapy is limited and variable. To overcome this problem, we developed a new subclavian arterial infusion chemotherapy method using an implanted catheter-port system after redistribution of arterial tumor blood supply by embolizing the ITA. We named this technique ('redistributed subclavian arterial infusion chemotherapy' (RESAIC)). Using RESAIC, patients can be treated on an outpatient basis for extended periods of time. Eleven patients underwent RESAIC, and the complete remission and partial response rate in 10 evaluable patients was 90%: complete remission [CR] n = 4, partial remission n = 4, stable disease n = 1, and not evaluable n = 1. Three of four patients with CR had no distant metastasis, and modified radical mastectomy was performed 1 month after conclusion of RESAIC. The resected specimens showed no residual cancer cells, and pathologically confirmed complete remission was diagnosed in each of these cases. Although temporary grade-3 myelosuppression was seen in three patients who were previously treated by systemic chemotherapy, there was no other drug-induced toxicity or procedure-related complications. RESAIC produced a better response and showed no major complications compared with other studies despite the advanced stage of the cancers.

Takizawa, Kenji, E-mail: taki-lrl@vy.catv.ne.jp; Shimamoto, Hiroshi, E-mail: hshima@k8.dion.ne.jp; Ogawa, Yukihisa, E-mail: yukky-p406c@nifty.com; Yoshimatsu, Misako, E-mail: misako_yosh@yahoo.co.jp; Yagihashi, Kunihiro, E-mail: yagiku@hotmail.com; Nakajima, Yasuo, E-mail: y3naka@marianna-u.ac.j [St. Marianna University School of Medicine, Department of Radiology (Japan); Kitanosono, Takashi, E-mail: tkita1@mac.co [University of Rochester Medical Center, Department of Vascular/Interventional Radiology (United States)

2009-09-15

379

Adjuvant Concurrent Chemoradiation for Adenocarcinoma of the Distal Common Bile Duct  

SciTech Connect

Purpose: To examine the effect of adjuvant chemoradiation for adenocarcinoma of the distal common bile duct (DCBD) after pancreaticoduodenectomy (PD) on local control and survival. Methods and Materials: A total of 34 cases of adenocarcinoma of the DCBD were treated with PD and adjuvant chemoradiation at Johns Hopkins Hospital between 1994 and 2003. Median radiation dose was 5,040 cGy (range, 4,000-5,400 cGy). Concurrent 5-fluorouracil-based chemotherapy was given with radiation therapy, followed by maintenance chemotherapy. Results: The median follow-up of patients alive at the time of analysis was 41 months. Death occurred in 21 of 34 patients (62%) during the follow-up period, all from progressive, distant metastatic disease. Median overall survival was 36.9 months, with a 5-year survival of 35%. On multivariate analysis, only nodal status significantly predicted survival (p < 0.02). For patients with negative and positive lymph nodes, 5-year survival was 100% and 24%, respectively. Actuarial 5-year local control was 70%. Compared with historical controls who underwent PD alone, patients who underwent surgery and adjuvant chemoradiation had significantly longer survival (36.9 months vs. 22 months; p < 0.05). Overall survival was significantly longer for both lymph node negative and lymph node positive patients (p < 0.05). Conclusions: Adjuvant chemoradiation after PD for adenocarcinoma of the DCBD may improve local control and overall survival. The predominant mode of failure is distant metastatic disease, highlighting the need for improved systemic therapy.

Hughes, Michael A. [Therapeutic Radiologists, Inc., Kansas City, MO (United States)]. E-mail: michaelaaronhughes@gmail.com; Frassica, Deborah A. [Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (United States); Yeo, Charles J. [Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD (United States); Riall, Taylor S. [Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD (United States); Lillemoe, Keith D. [Department of Surgery, Indiana School of Medicine, Indianapolis, IN (United States); Cameron, John L. [Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD (United States); Donehower, Ross C. [Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD (United States); Laheru, Daniel A. [Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD (United States); Hruban, Ralph H. [Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD (United States); Abrams, Ross A. [Department of Radiation Oncology, Rush University Medical Center, Chicago, IL (United States)

2007-05-01

380

A Classification of Concurrency Failures in Java Components  

Microsoft Academic Search

The Java programming language supports concurrency. Concurrent programs are hard to test due to their inher- ent non-determinism. This paper presents a classification of concurrency failures that is based on a model of Java concurrency. The model and failure classification is used to justify coverage of synchronization primitives of concurrent components. This is achieved by constructing concurrency flow graphs for

Brad Long; Paul A. Strooper

2003-01-01

381

Leptin, cortisol and distinct concurrent training sequences.  

PubMed

In order to investigate the effects of distinct concurrent training sequences on serum leptin and cortisol levels, 10 subjects (27.1±4.8 years, body mass index 25.38±0.09) were submitted to a control session, concurrent training 1 and concurrent training 2. Samples of leptin and cortisol were collected. Concurrent training 1 consisted of indoor cycling followed by strength training and concurrent training 2 of strength training followed by indoor cycling. No exercises were performed at the control session. Blood was collected once again to verify the same variables. Shapiro-Wilk, 2-way ANOVA and Tukey post-hoc tests were used. There was a reduction in leptin levels after concurrent training 1 (?%=?-?16.04; p=0.05) and concurrent training 2 (?%=?-?8.54; p=0.02). Cortisol decreased after concurrent training 1 (?%=?-?26.32; p=0.02) and concurrent training 2 (?%=?-?33.57; p=0.05). There was a high and significant correlation between blood variables only in CS (lep PRE X cort PRE and cort POST: r=?-?0.80 and r=?-?0.81; lep POST X cort PRE and cort POST: r=?-?0.62 and r=?-?0.62). Concurrent training promoted a reduction in leptin and cortisol levels irrespective of sequence. PMID:22261823

Rosa, G; Dantas, E; Biehl, C; de Castro e Silva, H; Montano, M A E; de Mello, D B

2012-01-19

382

Rapid and sustained response of an intra- and extracranial large cell lymphoma mass to liposomal intrathecal Ara-C and R-MegaCEOP systemic chemotherapy.  

PubMed

Prognosis of patients suffering from secondary central nervous system (CNS) lymphoma is dismal. Intracranial spread of a lymphoma arising in adjacent extranodal tissues is a rare event. A 32-year-old patient was diagnosed with progressive diffuse large B-cell lymphoma (DLBCL) with extra- and intracranial localization. He complained of headache, left diplopia, marked rigidity of the neck muscles, and difficulty in swallowing and articulating words, caused by bilateral palsy of the XII cranial nerve. Computed tomography (CT) and positron emission tomography (PET) scans showed disease localizations in the occipital-cervical soft tissue, and cerebellar parenchyma. Due to the severity of the clinical picture, high-dose dexamethasone was immediately administered. Mild improvement was observed during the first 2 days of treatment, but dramatic reduction of symptoms and nerve palsy was documented only in the 48 h after the first intrathecal administration of liposomal Ara-C. Systemic R-MegaCEOP chemotherapy was started 7 days later. Concomitant intrathecal liposomal Ara-C injections were continued for a total of nine administrations during the eight cycles of immunochemotherapy without any toxicity observed. Interim and post-therapy PET showed complete resolution of radionuclide accumulation in the involved sites. Consolidation radiotherapy (36 Gy) was administered in involved areas after the completion of the immunochemotherapy program. At the time of writing, no cumulative neurotoxicity is evident at follow-up of 17 months from diagnosis and 9 months after the overall therapeutic program has been accomplished. PMID:19696967

Falchi, Lorenzo; Gunnellini, Marco; Franco, Laura; Ferrazza, Patrizia; Ascani, Stefano; Liberati, Anna Marina

2009-08-21

383

Chemotherapy and signaling  

PubMed Central

In recent years, oncologists have begun to conclude that chemotherapy has reached a plateau of efficacy as a primary treatment modality, even if toxicity can be effectively controlled. Emerging specific inhibitors of signaling and metabolic pathways (i.e., targeted agents) contrast with traditional chemotherapy drugs in that the latter primarily interfere with the DNA biosynthesis and the cell replication machinery. In an attempt to improve on the efficacy, combination of targeted drugs with conventional chemotherapeutics has become a routine way of testing multiple new agents in early phase clinical trials. This review discusses the recent advances including integrative systematic biology and RNAi approaches to counteract the chemotherapy resistance and to buttress the selectivity, efficacy and personalization of anticancer drug therapy.

Bagnyukova, Tetyana; Serebriiskii, Ilya G; Zhou, Yan; Hopper-Borge, Elizabeth A; Golemis, Erica A

2010-01-01

384

Concurrent Chemoradiotherapy for Esophageal Cancer With Malignant Fistula  

SciTech Connect

Background: We reviewed clinical results of chemoradiotherapy (CRT) in the treatment of patients with advanced esophageal cancer with fistulae that developed before or during CRT. Methods and Materials: The study group included 16 patients with fistulous esophageal cancer treated by means of CRT between 1999 and 2006. Nine patients had fistulae before CRT, whereas 7 developed fistulae during CRT. The group included 12 men and four women with a median age of 55 years (range, 37-77 years). There were 9 patients with Stage III disease and 7 with Stage IV disease. All tumors were squamous cell carcinomas. Two courses of concurrent chemotherapy were combined with radiation therapy; 60 Gy/30 fractions/7 weeks (1-week split). For 15 patients, low-dose protracted chemotherapy with 5-fluorouracil (250-300 mg/m{sup 2} x 14 days) and cisplatin (7 mg/m{sup 2} x 10 days) was administered, whereas full-dose cisplatin and 5-fluorouracil were administered to the remaining patient. Results: The planned dose of 60 Gy was delivered to 11 patients (69%), whereas radiation therapy was terminated early in 5 patients (40-58 Gy) because of acute toxicities, including two treatment-related deaths. Disappearance of fistulae was noted during or after CRT in 7 patients (44%). All three esophagomediastinal fistulae were closed, but only four of 13 esophagorespiratory fistulae were closed by CRT. For patients with Stage III, 1- and 2-year survival rates were 33% and 22%, respectively. Median survival time was 8.5 months. Conclusion: Despite significant toxicity, concurrent CRT appears effective at closing esophageal malignant fistulae.

Koike, Ryuta [Department of Radiation Oncology, Kinki University School of Medicine, Osaka (Japan); Nishimura, Yasumasa [Department of Radiation Oncology, Kinki University School of Medicine, Osaka (Japan)], E-mail: ynishi@med.kindai.ac.jp; Nakamatsu, Kiyoshi; Kanamori, Shuichi; Shibata, Toru [Department of Radiation Oncology, Kinki University School of Medicine, Osaka (Japan)

2008-04-01

385

CCA/CCR (Cancer Chemotherapy Abstracts/Cancer Chemotherapy Reports).  

National Technical Information Service (NTIS)

The evaluation of two publications, the primary journal, Cancer Chemotherapy Reports and the secondary journal, Cancer Chemotherapy Abstracts, attempted to cover several factors. Among these are: the strength of the support for these publications; charact...

1974-01-01

386

Chemotherapy-induced hepatotoxicity.  

PubMed

Most hepatotoxicity secondary to chemotherapy is idiosyncratic and, therefore, neither dose dependent nor predictable. Some chemotherapy is cleared by the liver and requires dose adjustment in the face of significant liver dysfunction. In addition, preexisting abnormal liver function has been shown to increase the risk of hepatotoxicity. In addition to typical hepatocellular injury, other presentations, including cholestasis and hepatic sinusoidal obstruction syndrome, also commonly occur. The outcomes can range from asymptomatic liver function test abnormalities, which resolve spontaneously, to cirrhosis, which occurs despite discontinuation of the chemotherapeutic agent. PMID:24099024

Thatishetty, Ameet V; Agresti, Nicholas; O'Brien, Christopher B

2013-08-22

387

Concurrent algorithms for autonomous robot navigation in an unexplored terrain  

SciTech Connect

Navigation planning is one of the vital aspects of any autonomous mobile robot. In this paper, we present concurrent algorithms for an autonomous robot navigation system that does not require a pre-learned obstacle terrain model. The terrain model is gradually built by integrating the information from multiple journeys. The available information is used to the maximum extent in navigation planning, and global optimality is gradually achieved. It is shown that these concurrent algorithms are free from deadlocks and starvation. The performance of the concurrent algorithms is analyzed in terms of the planning time, travel time, scanning time, and update time. A modified adjacency list is proposed as the data structure for the spatial graph that represents an obstacle terrain. The time complexities of various algorithms that access, maintain, and update the spatial graph are estimated, and the effectiveness of the implementation is illustrated.

Rao, S.V.N.; Iyengar, S.S.; Jorgensen, C.C.; Weisbin, C.R.

1986-01-01

388

Concurrence of superpositions of many states  

SciTech Connect

In this paper, we use the concurrence vector as a measure of entanglement, and investigate lower and upper bounds on the concurrence of a superposition of bipartite states as a function of the concurrence of the superposed states. We show that the amount of entanglement quantified by the concurrence vector is exactly the same as that quantified by I concurrence, so that our results can be compared to those given in Phys. Rev. A 76, 042328 (2007). We obtain a tighter lower bound in the case in which the two superposed states are orthogonal. We also show that when the two superposed states are not necessarily orthogonal, both lower and upper bounds are, in general, tighter than the bounds given in terms of the I concurrence. An extension of the results to the case with more than two states in the superpositions is also given.

Akhtarshenas, Seyed Javad [Department of Physics, University of Isfahan, Isfahan, Iran and Quantum Optics Group, University of Isfahan, Isfahan (Iran, Islamic Republic of)

2011-04-15

389

Correct Refactoring of Concurrent Java Code  

Microsoft Academic Search

\\u000a Automated refactorings as implemented in modern IDEs for Java usually make no special provisions for concurrent code. Thus,\\u000a refactored programs may exhibit unexpected new concurrent behaviors. We analyze the types of such behavioral changes caused\\u000a by current refactoring engines and develop techniques to make them behavior-preserving, ranging from simple techniques to\\u000a deal with concurrency-related language constructs to a framework that

Max Schäfer; Julian Dolby; Manu Sridharan; Emina Torlak; Frank Tip

2010-01-01

390

Factorization law for two lower bounds of concurrence  

SciTech Connect

We study the dynamics of two lower bounds of concurrence in bipartite quantum systems when one party goes through an arbitrary channel. We show that these lower bounds obey the factorization law similar to that of [Konrad et al., Nat. Phys. 4, 99 (2008)]. We also discuss the application of this property in an example.

Mirafzali, Sayyed Yahya; Sargolzahi, Iman; Ahanj, Ali; Javidan, Kurosh; Sarbishaei, Mohsen [Department of Physics, Ferdowsi University of Mashhad, Mashhad (Iran, Islamic Republic of); Khayyam Institute of Higher Education, Mashhad, Iran and School of Physics, Institute for Research in Fundamental Science (IPM), P. O. Box 19395-5531, Tehran (Iran, Islamic Republic of); Department of Physics, Ferdowsi University of Mashhad, Mashhad (Iran, Islamic Republic of)

2010-09-15

391

Exploiting distributed version concurrency in a transactional memory cluster  

Microsoft Academic Search

We investigate a transactional memory runtime system providing scaling and strong consistency for generic C++ and SQL appli- cations on commodity clusters. We introduce a novel page-level distributed concurrency control algorithm, called Distributed Mul- tiversioning (DMV). DMV automatically detects and resolves con- flicts caused by data races for distributed transactions accessing shared in-memory data structures. DMV's key novelty is in

Kaloian Manassiev; Madalin Mihailescu; Cristiana Amza

2006-01-01

392

The role of product safety and liability in concurrent engineering  

Microsoft Academic Search

This paper explores the role of product safety and liability in the early stages of product design in a concurrent engineering environment. The paper presents an overview of literature pertaining to the significance of product liability for manufacturers. Further, the paper presents a system approach to product safety, a conceptual framework for design for safety and liability, and a product

S Dowlatshahi

2001-01-01

393

The Relative Importance of Concurrent Writers and Weak Consistency Models  

Microsoft Academic Search

This paper presents a detailed comparison of the rela- tive importance of allowing concurrent writers versus the choice of the underlying consistency model. Our compari- son is based on single- and multiple-writer versions of a laz y release consistent (LRC) protocol, and a single-writer se- quentially consistent protocol, all implemented in the CVM software distributed shared memory system. We find

Peter J. Keleher

1996-01-01

394

The Time Warp Mechanism for Database Concurrency Control  

Microsoft Academic Search

In this paper we introduce the Time Warp mechanism as a new method for concurrency control in distributed database systems. Its major distinguishing features are first, a unification of transactions and data as two forms of the more general notion of object, and second, the use of object rollback as the fundamental tool for synchronization instead of blocking or abortion.

David R. Jefferson; Amihai Motro

1986-01-01

395

Concurrent design and manufacturing process of automotive composite components  

Microsoft Academic Search

Purpose – To present the findings of the research on the use of concurrent engineering in the development of polymeric based composite automotive clutch pedal. It covers the use of various IT such as expert system, FEA, CAD, mould flow and rapid prototyping in order to carry out various activities such as material selection, total design, design analysis and mould

S. M. Sapuan

2005-01-01

396

Evaluable multipartite entanglement measures: Multipartite concurrences as entanglement monotones  

NASA Astrophysics Data System (ADS)

We discuss the monotonicity of systematically constructed quantities aiming at the quantification of the entanglement properties of multipartite quantum systems, under local operations and classical communication. We provide a necessary and sufficient condition for the monotonicity of generalized multipartite concurrences which qualifies them as legitimate entanglement measures.

Demkowicz-Dobrza?ski, Rafa?; Buchleitner, Andreas; Ku?, Marek; Mintert, Florian

2006-11-01

397

Managing Chemotherapy Side Effects: Pain  

MedlinePLUS

... anD human services national institutes of health Managing Chemotherapy Side Effects Pain Call the doctor or nurse ... and am able to enjoy life more!” Managing Chemotherapy Side Effects: Pain Keep track of the pain. ...

398

Codelivery of curcumin and doxorubicin by MPEG-PCL results in improved efficacy of systemically administered chemotherapy in mice with lung cancer  

PubMed Central

Systemic administration of chemotherapy for cancer often has toxic side effects, limiting the doses that can be used in its treatment. In this study, we developed methoxy poly(ethylene glycol)-poly(caprolactone) (MPEG-PCL) micelles loaded with curcumin and doxorubicin (Cur-Dox/MPEG-PCL) that were tolerated by recipient mice and had enhanced antitumor effects and fewer side effects. It was shown that these Cur-Dox/MPEG-PCL micelles could release curcumin and doxorubicin slowly in vitro. The long circulation time of MPEG-PCL micelles and the slow rate of release of curcumin and doxorubicin in vivo may help to maintain plasma concentrations of active drug. We also demonstrated that Cur-Dox/MPEG-PCL had improved antitumor effects both in vivo and in vitro. The mechanism by which Cur-Dox/MPEG-PCL micelles inhibit lung cancer might involve increased apoptosis of tumor cells and inhibition of tumor angiogenesis. We found advantages using Cur-Dox/MPEG-PCL micelles in the treatment of cancer, with Cur-Dox/MPEG-PCL achieving better inhibition of LL/2 lung cancer growth in vivo and in vitro. Our study indicates that Cur-Dox/MPEG-PCL micelles may be an effective treatment strategy for cancer in the future.

Wang, Bi-Lan; Shen, Yong-mei; Zhang, Qiong-wen; Li, Yu-li; Luo, Min; Liu, Ze; Li, Yan; Qian, Zhi-yong; Gao, Xiang; Shi, Hua-shan

2013-01-01

399

Automated plan-recognition of chemotherapy protocols  

PubMed Central

Cancer patients are often treated with multiple sequential chemotherapy protocols ranging in complexity from simple to highly complex patterns of multiple repeating drugs. Clinical documentation procedures that focus on details of single drug events, however, make it difficult for providers and systems to efficiently abstract the sequence and nature of treatment protocols. We have developed a data driven method for cancer treatment plan recognition that takes as input pharmacy chemotherapy dispensing records and produces the sequence of identified chemotherapy protocols. Compared to a manually annotated gold standard, our method was 75% accurate and 80% precise for a breast cancer testing set (110 patients, 2,029 drug events), and 54% accurate and 63% precise for a lung cancer testing set (53 patients, 670 drug events). This method for cancer treatment plan recognition may provide clinicians and systems an abstracted view of the patient’s treatment history.

Bhatia, Haresh; Levy, Mia

2011-01-01

400

IMAGE - POLAR Concurrent Plasmapause Observations  

NASA Astrophysics Data System (ADS)

Two critical issues that influence the quantitative scientific value of the IMAGE Ultraviolet Camera (EUV) are: (1) the accuracy with which EUV imaging can be used to determine the position/location of the plasmapause; and (2) the sensitivity threshold of the EUV instrument. Previous studies have addressed these issues via correlation of EUV-extracted plasmapause locations with steep density gradient plasmapause encounters detected by the IMAGE Radio Plasma Imager (PRI) pre-/post-EUV observation, employing the caveat of corotation. Here, these issues are addressed through analysis of concurrent remote observations of the plasmasphere/plasmapause made by IMAGE EUV with simultaneous in-situ observations acquired by the Polar/TIDE/EFI instruments. Preliminary results are presented with regards to the validity of the extraction of the plasmapause using EUV and initial in-flight, in-situ estimates of the EUV sensitivity threshold. Early estimates suggest a sensitivity threshold for EUV of 25 ± 15 cm$^{-3}.

Adrian, M. L.; Gallagher, D. L.; Craven, P. D.

2004-12-01

401

Concurrent macular corneal dystrophy and keratoconus.  

PubMed

A 21-year-old female presented with progressive bilateral visual loss for the past 8 years. The patient had no history of systemic disease, surgery or medications. Complete ophthalmologic examination and topography were performed. On ophthalmic examination, uncorrected visual acuity was counting fingers at 2.5 m (20/50 with pinhole) in the right and left eyes. Both corneas appeared hazy on gross examination. On slit-lamp biomicroscopy, focal grayish-white opacities with indistinct borders were noted in the superficial and deep corneal stroma of both eyes. Both corneas were thin and bulging. Corneal topography showed a pattern consistent with keratoconus. The patient underwent penetrating keratoplasty (PKP). Histopathologic studies after PKP confirmed the diagnosis of macular corneal dystrophy and keratoconus in the same eye. The patient was clinically diagnosed as a case of concurrent macular dystrophy and keratoconus, which is a very rare presentation. PMID:22623870

Mohammad-Rabei, Hossein; Shojaei, Ahmad; Aslani, Mehdi

402

Concurrent Macular Corneal Dystrophy and Keratoconus  

PubMed Central

A 21-year-old female presented with progressive bilateral visual loss for the past 8 years. The patient had no history of systemic disease, surgery or medications. Complete ophthalmologic examination and topography were performed. On ophthalmic examination, uncorrected visual acuity was counting fingers at 2.5 m (20/50 with pinhole) in the right and left eyes. Both corneas appeared hazy on gross examination. On slit-lamp biomicroscopy, focal grayish-white opacities with indistinct borders were noted in the superficial and deep corneal stroma of both eyes. Both corneas were thin and bulging. Corneal topography showed a pattern consistent with keratoconus. The patient underwent penetrating keratoplasty (PKP). Histopathologic studies after PKP confirmed the diagnosis of macular corneal dystrophy and keratoconus in the same eye. The patient was clinically diagnosed as a case of concurrent macular dystrophy and keratoconus, which is a very rare presentation.

Mohammad-Rabei, Hossein; Shojaei, Ahmad; Aslani, Mehdi

2012-01-01

403

Chemotherapy and Your Mouth  

MedlinePLUS

... can also cause other things to happen in your body called side effects. Some of these problems affect the mouth and ... Does Chemotherapy Cause? You may have certain side effects in your mouth from ... drugs and how your body reacts to them. You may have these problems ...

404

Review: Chemotherapy Induced Alopecia  

Microsoft Academic Search

Chemotherapy-induced alopecia (CIA) is a distressing side effect common to certain treatment regimens in oncology. Unfortunately, CIA is an often overlooked or minor factor amongst our current research priorities and thus advances in amelioration have been minimal. This review offers a comprehensive examination of the clinically relevant basic science, clinical research, and current management options for CIA. We emphasize that

Susan Y. Chon; Rachel W. Champion; Elizabeth R. Geddes; Rashid M. Rashid

405

[Cardiovascular complications of chemotherapy].  

PubMed

In the last decades, oncological therapy has changed the natural history of many types of cancer, which can now be considered curable or as chronic or slowly progressive diseases. It is well known that chemotherapy and radiotherapy may induce cardiotoxicity. Anthracyclines are among the most active antineoplastic agents, and their cardiac effects have been known for a long time. In addition, there is an emerging role for potential cardiovascular effects of other chemotherapy drugs such as taxanes, antimetabolites (capecitabine) as well as targeted agents (monoclonal antibody trastuzumab and bevacizumab and the tyrosin-kinase inhibitor sunitinib). Patient treated with chemotherapy are at higher risk of cardiovascular events than the general population, so that having undergone chemotherapy may be considered as a novel cardiovascular risk factor. This review briefly summarizes the most important cardiovascular toxicities caused by antineoplastic pharmacological treatment and how cardiologists, oncologists and general practitioners should approach cancer patients while on treatment or during follow-up to prevent or manage cardiovascular events. PMID:23096398

Tovena, Daniela Maria; Inzoli, Alessandro; Donato, Giorgio; Gazzaniga, Pietrocarlo; Bianchessi, Clara

2012-10-01

406

Chemotherapy (For Parents)  

MedlinePLUS

... used, the dosage, and a child's general health affect the risk of developing unpleasant side effects. The good news is that most side effects ... end, though it may be a slightly different color or texture than it was before. To protect the head from ... Side Effects of Chemotherapy (continued) Mouth, Gum, and Throat Sores ...

407

Pharmacogenetics and cancer chemotherapy  

Microsoft Academic Search

Cancer chemotherapy is limited by significant inter-individual variations in responses and toxicities. Such variations are often due to genetic alterations in drug metabolising enzymes (pharmacokinetic polymorphisms) or receptor expression (pharmacodynamic polymorphisms). Pharmacogenetic screening prior to anticancer drug administration may lead to identification of specific populations predisposed to drug toxicity or poor drug responses. The role of polymorphisms in specific enzymes,

L. Iyer; M. J. Ratain

1998-01-01

408

Concurrent chemoradiotherapy in adjuvant treatment of breast cancer  

PubMed Central

Background The optimal sequencing of chemotherapy and radiotherapy after breast surgery was largely studied but remains controversial. Concurrent chemo-radiotherapy is a valuable method for adjuvant treatment of breast cancer which is under ongoing research program in our hospital. We are evaluating the feasibility of the concomitant use of chemotherapy retrospectively. Methods Two hundred forty four women having breast cancer were investigated in a retrospective study. All patients were either treated by radical surgery or breast conservative surgery. The study compares two adjuvant treatments associating concomitant chemotherapy and radiotherapy. In the first group (group A) the patients were treated by chemotherapy and radiotherapy in concomitant way using anthracycline (n = 110). In the second group (group B) the patients were treated by chemotherapy and radiotherapy in concomitant way using CMF treatment (n = 134). Chemotherapy was administered in six cycles, one each 3 weeks. Radiotherapy delivered a radiation dose of 50 Gy on the whole breast (or on the external wall) and/or on the lymphatic region. The Kaplan-Meier method was used to estimate the rates of disease free survival, loco-regional recurrence-free survival and overall survival. The Pearson Khi2 test was used to analyse the homogeneity between the two groups. The log-rank test was used to evaluate the differences between the two groups A and B. Results After 76.4 months median follow-up (65.3 months mean follow up), only one patient relapsed to loco-regional breast cancer when the treatment was based on anthracycline. However, 8 patients relapsed to loco-regional breast cancer when the treatment was based on CMF. In the anthracycline group, the disease free survival after 5 years, was 80.4% compared to 76.4% in the CMF group (Log-rank test: p = 0.136). The overall survival after 5 years was 82.5% and 81.1% in the anthracycline and CMF groups respectively (Log-rank test: p = 0.428). The loco-regional free survival at 5 years was equal to 98.6% in group A and 94% in group B (Log-rank test: p = 0,033). The rate of grade II and grade III anaemia was 13.9% and 6.7% in anthracycline group and CMF group respectively (Khi2-test: p = 0.009). The rate of grade II and grade III skin dermatitis toxicity was 4.5% in the group A and 0% in the group B (Khi2-test: p = 0.013). Conclusion From the 5 years retrospective investigation we showed similar disease free survival and overall survival in the two concurrent chemo-radiotherapy treatments based on anthracycline and CMF. However in the loco-regional breast cancer the treatment based on anthracycline was significantly better than that of the treatment based on CMF. There was more haematological and skin dermatitis toxicity in the anthracycline group.

Ismaili, Nabil; Mellas, Nawfel; Masbah, Ouafae; Elmajjaoui, Sanaa; Arifi, Samia; Bekkouch, Imane; Ahid, Samir; Bazid, Zakaria; Tazi, Mohammed Adnane; Erraki, Abdelouahed; El Mesbahi, Omar; Benjaafar, Noureddine; El Gueddari, Brahim El Khalil; Ismaili, Mohammed; Afqir, Said; Errihani, Hassan

2009-01-01

409

An application of the Design Structure Matrix to Integrated Concurrent Engineering  

Microsoft Academic Search

This paper demonstrates an application of the Design Structure Matrix (DSM) to Integrated Concurrent Engineering (ICE), an approach to conceptual space systems design intended to increase the pace of work by bringing together all relevant personnel in the same room to conduct focused, collaborative one-week design studies. Although the DSM methodology explicitly incorporates the concurrent aspects of engineering design, it

Mark S. Avnet; Annalisa L. Weigel

2010-01-01

410

Knowledge based and adaptive computational techniques for concurrent design of powder metallurgy parts  

Microsoft Academic Search

The practice of concurrent engineering (CE) is adopted widely to facilitate integrated design and manufacture by industry in order to maintain competitiveness in the market place. Use of near net-shape processes like powder metallurgy (PM) within a CE environment can give added benefits in terms of material utilisation and environmental considerations. A system for concurrent design of PM parts is

R. P Cherian; P. S Midha; L. N Smith; A. G Pipe

2001-01-01

411

Chemotherapy for Metastatic Colorectal Cancer  

Microsoft Academic Search

Metastatic colorectal cancer (mCRC), with few exceptions, remains incurable. However, chemotherapy can improve quantity and quality of life. Current chemotherapy regimens for mCRC have a median survival of over 2 years. Targeted agents in combination with established regimens can also improve survival. These chemotherapy regimens, including their common side effects, will be covered in this review article.

Robert Zaiden; Dat Pham

412

Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases  

Microsoft Academic Search

Background: Preoperative systemic chemotherapy is increasingly used in patients who undergo hepatic resection for colorectal liver metastases (CLM). Although chemotherapy-related hepatic injury has been reported, the incidence and the effect of such injury on patient outcome remain ill defined. Methods: A systematic review of relevant studies published before May 2006 was performed. Studies that reported on liver injury associated with

D. Zorzi; A. Laurent; T. M. Pawlik; G. Y. Lauwers; J.-N. Vauthey; E. K. Abdalla

2007-01-01

413

Successful neoadjuvant treatment with radiochemotherapy and systemic chemotherapy for the locally advanced pancreatic head cancer: report of a case.  

PubMed

A 49-year-old man was admitted to the hospital for the upper abdominal pain and was diagnosed as unresectable pancreatic head cancer because of the invasion around the superior mesenteric artery. He was treated with radiochemotherapy, followed by systemic gemcitabine alone for 3 courses. He was further treated with systemic gemcitabine plus S?1 combination therapy for 5 courses. CT examination after these treatments showed a dramatic reduction of the tumor at the head of the pancreas and a pancreatoduodenectomy was performed. Pathologically, there was no residual malignant tumor. He has had no recurrent tumor up until now. Several studies of gemcitabine plus S-1 combination therapy show higher response rates for unresectable tumors. The current case indicates the effectiveness of the radiochemotherapy and gemcitabine plus S?1 combination therapy for locally advanced pancreatic head cancer as a neoadjuvant setting. We consider that multidisciplinary treatment including gemcitabine plus S?1 therapy may prolong the survival time by curative operation. PMID:22086705

Masui, Toshihiko; Doi, Ryuichiro; Ogawa, Kohei; Kami, Kazuhiro; Machimoto, Takafumi; Seo, Satoru; Kawaguchi, Yoshiya; Egawa, Hiroto; Matsugu, Yasuhiro; Uemoto, Shinji

414

The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses  

Microsoft Academic Search

Major mechanisms underlying poor im- mune responses to autologous tumor- associated antigens are overwhelming tu- mor kinetics and the absence of effective T-cell costimulation by antigen-present- ing cells. To address these issues, leuke- mia and lymphoma mice were treated with the combination of chemotherapy and systemic immunotherapy with recom- binant soluble murine B7-immunoglobu- lin G (IgG) molecules. In this report,

Kathlene Runyon; Kwang Lee; Krystyna Zuberek; Mary Collins; John P. Leonard; Kyriaki Dunussi-Joannopoulos

2001-01-01

415

Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer  

Microsoft Academic Search

Purpose: A controversy exists regarding whether it is safe to delay radiation therapy until the completion of chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. Within the context of two concurrent randomized clinical trials we had the opportunity to evaluate outcomes for patients who received breast irradiation after completing different durations of chemotherapy.Methods and Materials: From July 1986

Arne Wallgren; Jacques Bernier; Richard D Gelber; Aron Goldhirsch; Mario Roncadin; David Joseph; Monica Castiglione-Gertsch

1996-01-01

416

The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer.  

PubMed

The aim of this study was to interrogate whether blood-borne inflammatory and nutritional markers predict long-term survival and response to neoadjuvant chemotherapy in radically treated oesophagogastric cancer patients. This retrospective study included 246 patients who underwent oesophageal resection for high-grade dysplasia or carcinoma between 2005 and 2010. The predictive value of routine preoperative immunonutritional blood tests was assessed for their association with survival and response to chemotherapy. On multivariate analysis, higher neutrophil-lymphocyte ratio (NLR) (p < 0.0001), N stage (p < 0.0001) and perineural invasion (p < 0.0001) were associated with poor overall survival. Regarding disease-free survival, multivariate analysis showed reduced serum albumin (p = 0.034), N stage (p < 0.0001), M stage (p = 0.037), vascular invasion (p < 0.0001) and presence of R1 resection (p = 0.003) to correlate with earlier recurrence. In those who received neoadjuvant chemotherapy, analysis of prechemotherapy characteristics showed only serum albumin (p = 0.037) to predict pathological response to chemotherapy. Preoperative immunonutritional markers, NLR and albumin, were independent prognostic markers for overall survival and disease-free survival, respectively, after oesophageal cancer resection. Prospective studies evaluating the role of immunonutritional modulation to improve response to chemotherapy and long-term outcome are required. PMID:23690267

Noble, Fergus; Hopkins, James; Curtis, Nathan; Kelly, Jamie J; Bailey, Ian S; Byrne, James P; Bateman, Adrian C; Bateman, Andrew R; Underwood, Timothy J

2013-05-21

417

Concurrent partnerships and HIV: an inconvenient truth.  

PubMed

The strength of the evidence linking concurrency to HIV epidemic severity in southern and eastern Africa led the Joint United Nations Programme on HIV/AIDS and the Southern African Development Community in 2006 to conclude that high rates of concurrent sexual partnerships, combined with low rates of male circumcision and infrequent condom use, are major drivers of the AIDS epidemic in southern Africa. In a recent article in the Journal of the International AIDS Society, Larry Sawers and Eileen Stillwaggon attempt to challenge the evidence for the importance of concurrency and call for an end to research on the topic. However, their "systematic review of the evidence" is not an accurate summary of the research on concurrent partnerships and HIV, and it contains factual errors concerning the measurement and mathematical modelling of concurrency.Practical prevention-oriented research on concurrency is only just beginning. Most interventions to raise awareness about the risks of concurrency are less than two years old; few evaluations and no randomized-controlled trials of these programmes have been conducted. Determining whether these interventions can help people better assess their own risks and take steps to reduce them remains an important task for research. This kind of research is indeed the only way to obtain conclusive evidence on the role of concurrency, the programmes needed for effective prevention, the willingness of people to change behaviour, and the obstacles to change. PMID:21406080

Epstein, Helen; Morris, Martina

2011-03-15

418

A Concurrent Support Course for Intermediate Algebra  

ERIC Educational Resources Information Center

|This article summarizes the creation and implementation of a concurrent support class for TRS 92--Intermediate Algebra, a developmental mathematics course at Fort Lewis College in Durango, Colorado. The concurrent course outlined in this article demonstrates a statistically significant increase in student success rates since its inception.…

Cooper, Cameron I.

2011-01-01

419

Serialization graph algorithms for multiversion concurrency control  

Microsoft Academic Search

We propose a new algorithmic framework for database concurrency control using multiple versions of data items and a serialization graph of the transactions as a synchronization technique, which generalizes all concurrency control methods known so far. This class of algorithms, called MVSGA for Multi Version Serialization Graph set of Algorithms, works by monitoring the acyclicity of the serialization graph which

Thanasis Hadzilacos

1988-01-01

420

Localisation et concurrence dans la banque  

Microsoft Academic Search

[fre] Localisation et concurrence dans la banque. . Cet article a pour objet de recenser les apports récents de la théorie bancaire concernant les relations entre concurrence et localisation dans la banque. La pre­mière partie est consacrée à l'analyse des facteurs du pouvoir de marché des banques sur les marchés bancaires locaux - coûts de changement de banque, parts de

Michel Dietsch

1993-01-01